original_name,protein_id,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Biological process,Molecular function,Disease involvement,Evidence,HPA evidence,UniProt evidence,NeXtProt evidence,RNA tissue specificity,RNA tissue distribution,RNA tissue specificity score,RNA tissue specific nTPM,RNA single cell type specificity,RNA single cell type distribution,RNA single cell type specificity score,RNA single cell type specific nTPM,RNA cancer specificity,RNA cancer distribution,RNA cancer specificity score,RNA cancer specific FPKM,RNA brain regional specificity,RNA brain regional distribution,RNA brain regional specificity score,RNA brain regional specific nTPM,RNA blood cell specificity,RNA blood cell distribution,RNA blood cell specificity score,RNA blood cell specific nTPM,RNA blood lineage specificity,RNA blood lineage distribution,RNA blood lineage specificity score,RNA blood lineage specific nTPM,RNA cell line specificity,RNA cell line distribution,RNA cell line specificity score,RNA cell line specific nTPM,RNA tissue cell type enrichment,RNA mouse brain regional specificity,RNA mouse brain regional distribution,RNA mouse brain regional specificity score,RNA mouse brain regional specific nTPM,RNA pig brain regional specificity,RNA pig brain regional distribution,RNA pig brain regional specificity score,RNA pig brain regional specific nTPM,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Secretome location,Secretome function,CCD Protein,CCD Transcript,Blood concentration - Conc. blood IM [pg/L],Blood concentration - Conc. blood MS [pg/L],Blood expression cluster,Tissue expression cluster,Brain expression cluster,Cell line expression cluster,Single cell expression cluster,Interactions,Subcellular main location,Subcellular additional location,Antibody RRID,Pathology prognostics - Breast cancer,Pathology prognostics - Cervical cancer,Pathology prognostics - Colorectal cancer,Pathology prognostics - Endometrial cancer,Pathology prognostics - Glioma,Pathology prognostics - Head and neck cancer,Pathology prognostics - Liver cancer,Pathology prognostics - Lung cancer,Pathology prognostics - Melanoma,Pathology prognostics - Ovarian cancer,Pathology prognostics - Pancreatic cancer,Pathology prognostics - Prostate cancer,Pathology prognostics - Renal cancer,Pathology prognostics - Stomach cancer,Pathology prognostics - Testis cancer,Pathology prognostics - Thyroid cancer,Pathology prognostics - Urothelial cancer,sequence
P02768 Albumin 白蛋白,P02768,ALB,,ENSG00000163631,Albumin,4,73397114-73421482,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,136.0,liver: 205952.1,Cell type enriched,Detected in many,4.0,Hepatocytes: 59612.0,Cancer enriched,Detected in many,384.0,liver cancer: 14213.7,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,24.0,liver cancer: 1846.4,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB006262, HPA031024, HPA031025",Enhanced,,Enhanced,"Endoplasmic reticulum,Golgi apparatus",Secreted to blood,Transport,,,40000000000000.0,,,Cluster 31: Liver - Plasma proteins,Cluster 33: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,Golgi apparatus,Endoplasmic reticulum,"CAB006262: AB_425297, HPA031024: AB_2673703, HPA031025: AB_2673704",unprognostic (1.38e-1),unprognostic (8.72e-2),unprognostic (1.73e-1),unprognostic (2.60e-1),unprognostic (4.44e-1),unprognostic (2.46e-1),unprognostic (9.53e-3),unprognostic (2.16e-2),unprognostic (2.40e-1),unprognostic (6.43e-2),unprognostic (3.84e-2),unprognostic (5.37e-2),unprognostic (1.25e-1),prognostic unfavorable (7.87e-4),unprognostic (7.23e-2),unprognostic (1.05e-3),unprognostic (1.02e-2),MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
P01871 （Immunoglobulin heavy constant mu）IGHM 免疫球蛋白重常数,P01871,IGHM,,ENSG00000211899,Immunoglobulin heavy constant mu,14,105851705-105856218,"Disease related genes, Immunoglobulin genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,4.0,intestine: 1279.4;lymphoid tissue: 3116.6,Group enriched,Detected in some,8.0,B-cells: 2732.6;Plasma cells: 9466.1,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in all,16.0,memory B-cell: 4293.6;naive B-cell: 6750.1,Lineage enriched,Detected in all,19.0,B-cells: 6750.1,Cancer enriched,Detected in some,4.0,lymphoma: 1665.3,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,CAB008643,Uncertain,,,,Immunoglobulin genes,Immunity,,,,110000000000.0,Cluster 18: Non-specific - Translation,,Cluster 8: Immune cells - Immune response,Cluster 46: Lymphoma - Humoral immune response,Cluster 77: Plasma cells - Protein processing,,,,CAB008643: AB_1617732,unprognostic (2.91e-3),prognostic favorable (6.49e-4),unprognostic (9.30e-3),unprognostic (9.90e-3),unprognostic (2.05e-1),prognostic favorable (3.70e-6),unprognostic (9.61e-3),unprognostic (1.01e-1),unprognostic (1.52e-2),unprognostic (3.23e-3),unprognostic (2.46e-2),unprognostic (7.13e-2),prognostic unfavorable (5.20e-5),unprognostic (3.01e-1),unprognostic (1.76e-1),unprognostic (3.24e-2),unprognostic (6.28e-3),GSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLGQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTEGEVSADEEGFENLWATASTFIVLFLLSLFYSTTVTLFKVK
P01876 Immunoglobulin heavy constant alpha 1免疫球蛋白重常数,P01876,IGHA1,AL928768.3,ENSG00000211895,Immunoglobulin heavy constant alpha 1,14,105703995-105708665,"Disease related genes, Immunoglobulin genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 7198.9;salivary gland: 4545.3;stomach 1: 6480.0,Cell type enriched,Detected in many,16.0,Plasma cells: 107776.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in many,203.0,memory B-cell: 2579.2;naive B-cell: 1123.4,Lineage enriched,Detected in many,282.0,B-cells: 2579.2,Cancer enriched,Detected in some,20.0,Myeloma: 1517.6,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,"HPA001217, HPA006013",Approved,,,,Immunoglobulin genes,Immunity,,,,130000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,"HPA001217: AB_1079120, HPA006013: AB_1079119",prognostic favorable (8.87e-5),unprognostic (5.36e-3),unprognostic (2.10e-2),unprognostic (1.59e-2),unprognostic (3.75e-2),prognostic favorable (3.81e-5),unprognostic (1.17e-1),unprognostic (3.86e-1),unprognostic (2.62e-1),unprognostic (3.26e-2),unprognostic (1.66e-1),unprognostic (1.34e-1),prognostic unfavorable (1.83e-7),unprognostic (8.10e-2),unprognostic (5.08e-2),unprognostic (1.16e-1),unprognostic (2.99e-2),ASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQDASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLADWQMPPPYVVLDLPQETLEEETPGANLWPTTITFLTLFLLSLFYSTALTVTSVRGPSGNREGPQY
P01877 Immunoglobulin heavy constant alpha 2免疫球蛋白重常数,P01877,IGHA2,,ENSG00000211890,Immunoglobulin heavy constant alpha 2 (A2m marker),14,105583731-105588395,"Immunoglobulin genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,23.0,intestine: 562.7,Cell type enriched,Detected in many,30.0,Plasma cells: 9424.7,Low cancer specificity,Detected in all,,,Not detected,Not detected,,,Group enriched,Detected in some,878.0,memory B-cell: 280.4;naive B-cell: 124.8,Lineage enriched,Detected in single,1215.0,B-cells: 280.4,Cancer enriched,Detected in some,5.0,Myeloma: 47.8,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,"HPA001217, HPA006013",Approved,,,,Immunoglobulin genes,Immunity,,,,67000000000.0,Cluster 17: B-cells - Immunoglobulins,,,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,"HPA001217: AB_1079120, HPA006013: AB_1079119",prognostic favorable (1.98e-9),unprognostic (3.20e-2),unprognostic (2.23e-2),unprognostic (1.53e-2),unprognostic (1.93e-2),prognostic favorable (8.40e-5),unprognostic (4.56e-2),unprognostic (2.59e-1),unprognostic (3.17e-1),unprognostic (3.69e-2),unprognostic (1.20e-1),unprognostic (1.18e-1),prognostic unfavorable (7.50e-6),unprognostic (2.12e-1),unprognostic (3.28e-2),unprognostic (9.70e-2),unprognostic (4.47e-1),ASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNSSQDVTVPCRVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTYAVTSILRVAAEDWKKGETFSCMVGHEALPLAFTQKTIDRMAGSCCVADWQMPPPYVVLDLPQETLEEETPGANLWPTTITFLTLFLLSLFYSTALTVTSVRGPSGKREGPQY
P01857 Immunoglobulin heavy constant gamma 1免疫球蛋白重常数1,P01857,IGHG1,,ENSG00000211896,Immunoglobulin heavy constant gamma 1 (G1m marker),14,105736343-105743071,"Disease related genes, FDA approved drug targets, Immunoglobulin genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,7.0,lymphoid tissue: 5665.1;urinary bladder: 3867.4,Cell type enriched,Detected in many,5.0,Plasma cells: 12047.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Immune cell enriched,Detected in some,6.0,memory B-cell: 768.6,Lineage enriched,Detected in many,122.0,B-cells: 768.6,Cancer enriched,Detected in some,8.0,Myeloma: 1184.5,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,"HPA001245, CAB008642",Supported,,,,Immunoglobulin genes,Immunity,,,,230000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,1.0,,,"CAB008642: AB_1617595, HPA001245: AB_1079121",unprognostic (6.47e-3),unprognostic (4.39e-3),unprognostic (2.91e-2),unprognostic (2.32e-3),unprognostic (1.55e-2),prognostic favorable (2.67e-4),unprognostic (3.90e-2),unprognostic (3.25e-1),unprognostic (7.52e-2),unprognostic (5.36e-3),unprognostic (8.06e-2),unprognostic (1.09e-1),prognostic unfavorable (2.49e-9),unprognostic (3.12e-1),unprognostic (3.52e-1),unprognostic (8.96e-2),unprognostic (7.61e-2),ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQGA
P01859 Immunoglobulin heavy constant gamma 2免疫球蛋白重常数2,P01859,IGHG2,,ENSG00000211893,Immunoglobulin heavy constant gamma 2 (G2m marker),14,105639559-105644790,"FDA approved drug targets, Immunoglobulin genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,FDA approved drug targets,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,lymphoid tissue: 189.5;urinary bladder: 108.3,Cell type enriched,Detected in some,11.0,Plasma cells: 4935.4,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in some,460.0,memory B-cell: 344.6;naive B-cell: 128.5,Lineage enriched,Detected in single,670.0,B-cells: 344.6,Group enriched,Detected in some,9.0,lymphoma: 19.2;Myeloma: 54.1,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA001245,Approved,,,,Immunoglobulin genes,Immunity,,,,250000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,HPA001245: AB_1079121,prognostic favorable (3.53e-4),unprognostic (6.88e-3),unprognostic (2.40e-2),unprognostic (1.55e-2),unprognostic (2.40e-2),prognostic favorable (3.30e-6),unprognostic (1.06e-1),unprognostic (6.67e-2),unprognostic (1.74e-1),unprognostic (7.59e-2),unprognostic (1.80e-1),unprognostic (1.41e-1),prognostic unfavorable (4.30e-8),unprognostic (4.72e-2),unprognostic (3.32e-2),unprognostic (1.05e-1),unprognostic (7.40e-2),ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATITFFKVKWIFSSVVDLKQTIVPDYRNMIRQGA
P01860 Immunoglobulin heavy constant gamma 3免疫球蛋白重常数,P01860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQGA
P01861 Immunoglobulin heavy constant gamma 4免疫球蛋白重常数,P01861,IGHG4,,ENSG00000211892,Immunoglobulin heavy constant gamma 4 (G4m marker),14,105620506-105626066,"FDA approved drug targets, Immunoglobulin genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,FDA approved drug targets,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,4.0,lymphoid tissue: 2402.4,Group enriched,Detected in some,4.0,B-cells: 423.0;Plasma cells: 595.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in some,,,Group enriched,Detected in some,457.0,memory B-cell: 123.0;naive B-cell: 74.3,Lineage enriched,Detected in single,569.0,B-cells: 123.0,Group enriched,Detected in some,43.0,lymphoma: 133.6;Myeloma: 34.1,"Adipose subcutaneous - Plasma cells, Adipose visceral - Mesothelial cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Lung - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells",,,,,,,,,HPA001245,Approved,,,,Immunoglobulin genes,Immunity,,,,170000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 43: Hindbrain - Mixed function,Cluster 46: Lymphoma - Humoral immune response,Cluster 77: Plasma cells - Protein processing,,,,HPA001245: AB_1079121,unprognostic (7.29e-3),unprognostic (5.20e-2),unprognostic (1.32e-2),unprognostic (3.16e-2),unprognostic (1.16e-2),prognostic favorable (1.16e-4),unprognostic (4.58e-1),unprognostic (1.92e-2),unprognostic (3.49e-1),unprognostic (8.63e-2),unprognostic (4.74e-2),unprognostic (6.71e-2),prognostic unfavorable (9.09e-8),unprognostic (2.84e-2),unprognostic (4.23e-1),unprognostic (9.24e-2),unprognostic (7.72e-2),ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIVPDYRNMIRQGA
P0DOY2 Immunoglobulin lambda constant 2免疫球蛋白lambda常数2,P0DOY2,IGLC2,IGLC,ENSG00000211677,Immunoglobulin lambda constant 2,22,22900976-22901437,"Immunoglobulin genes, Predicted intracellular proteins, Predicted secreted proteins","Adaptive immunity, Immunity",Bence-Jones protein,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 9437.0;lymphoid tissue: 19382.3;stomach 1: 10530.9,Cell type enriched,Detected in many,8.0,Plasma cells: 107273.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in all,36.0,memory B-cell: 11410.9;naive B-cell: 10729.1,Lineage enriched,Detected in all,37.0,B-cells: 11410.9,Cancer enriched,Detected in many,10.0,Myeloma: 14457.7,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 20: Myeloma - Immune response,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (5.76e-5),unprognostic (2.29e-2),unprognostic (4.54e-3),unprognostic (1.46e-2),unprognostic (4.02e-2),prognostic favorable (1.14e-4),unprognostic (1.96e-2),unprognostic (7.52e-2),unprognostic (7.15e-2),unprognostic (7.69e-3),unprognostic (2.83e-1),unprognostic (4.41e-2),prognostic unfavorable (4.47e-9),unprognostic (2.00e-1),unprognostic (3.43e-1),unprognostic (1.19e-1),unprognostic (1.45e-1),GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
P0DOY3 Immunoglobulin lambda constant 3免疫球蛋白常数,P0DOY3,IGLC3,IGLC,ENSG00000211679,Immunoglobulin lambda constant 3 (Kern-Oz+ marker),22,22906342-22906803,"Immunoglobulin genes, Predicted intracellular proteins, Predicted secreted proteins","Adaptive immunity, Immunity",Bence-Jones protein,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 3970.7;lymphoid tissue: 7928.0;stomach 1: 4009.5;urinary bladder: 3601.8,Cell type enriched,Detected in many,11.0,Plasma cells: 37474.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in all,34.0,memory B-cell: 7287.2;naive B-cell: 6162.3,Lineage enriched,Detected in all,37.0,B-cells: 7287.2,Cancer enriched,Detected in many,19.0,Myeloma: 12802.2,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,"CAB000050, CAB016533",Supported,,,,Immunoglobulin genes,Immunity,,,,,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,"CAB000050: , CAB016533: AB_629719",prognostic favorable (2.32e-4),unprognostic (1.18e-2),unprognostic (4.35e-3),unprognostic (4.54e-2),unprognostic (8.41e-2),prognostic favorable (3.33e-4),unprognostic (5.45e-2),unprognostic (4.59e-2),unprognostic (8.77e-2),prognostic favorable (4.58e-4),unprognostic (9.71e-2),unprognostic (2.31e-1),prognostic unfavorable (1.04e-9),unprognostic (1.21e-1),unprognostic (2.52e-1),unprognostic (1.37e-1),unprognostic (5.97e-2),GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS
P01619 Immunoglobulin kappa variable 3-20 免疫球蛋白kappa变量3-20,P01619,IGKV3-20,,ENSG00000239951,Immunoglobulin kappa variable 3-20,2,89142574-89143160,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 2965.7;lymphoid tissue: 5079.6,Cell type enriched,Detected in some,120.0,Plasma cells: 38821.5,Low cancer specificity,Detected in all,,,Region enhanced,Detected in many,,spinal cord: 17.6,Group enriched,Detected in many,327.0,memory B-cell: 1609.9;naive B-cell: 1229.8,Lineage enriched,Detected in many,370.0,B-cells: 1609.9,Group enriched,Detected in many,367.0,lymphoma: 353.5;Myeloma: 1322.2,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA047702,Approved,,Approved,Plasma membrane,Immunoglobulin genes,Immunity,,,,20000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 20: Myeloma - Immune response,Cluster 77: Plasma cells - Protein processing,,Plasma membrane,,HPA047702: ,prognostic favorable (1.86e-4),unprognostic (4.16e-2),unprognostic (1.64e-2),unprognostic (1.97e-2),unprognostic (1.13e-1),prognostic favorable (9.01e-4),unprognostic (1.43e-1),unprognostic (3.43e-1),unprognostic (1.37e-1),unprognostic (3.93e-3),unprognostic (8.44e-2),unprognostic (1.97e-1),prognostic unfavorable (1.07e-6),unprognostic (7.35e-2),unprognostic (5.08e-1),unprognostic (6.64e-2),unprognostic (2.70e-2),METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSP
P01766 Immunoglobulin heavy variable 3-13 免疫球蛋白重变量3-13,P01766,IGHV3-13,,ENSG00000211942,Immunoglobulin heavy variable 3-13,14,106129540-106130072,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 65.0;lymphoid tissue: 133.1;urinary bladder: 87.5,Cell type enriched,Detected in some,19.0,Plasma cells: 84.5,Low cancer specificity,Detected in many,,,Not detected,Not detected,,,Group enriched,Detected in some,194.0,memory B-cell: 18.9;naive B-cell: 19.7,Lineage enriched,Detected in single,197.0,B-cells: 19.7,Not detected,Not detected,,,"Adipose visceral - Plasma cells, Breast - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,33000000000.0,Cluster 14: Non-specific - Unknown function,,,Cluster 59: Leukemia - T-cell receptor,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (3.24e-4),unprognostic (7.42e-2),unprognostic (1.96e-2),unprognostic (5.03e-2),,prognostic favorable (6.67e-6),unprognostic (5.44e-2),unprognostic (1.23e-2),unprognostic (1.53e-1),unprognostic (5.31e-2),unprognostic (8.27e-2),unprognostic (2.45e-1),prognostic unfavorable (7.21e-5),unprognostic (6.79e-2),unprognostic (3.21e-1),unprognostic (4.45e-1),unprognostic (7.87e-2),MELGLSWVFLVAILEGVQCEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDPYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCAR
P80748 Immunoglobulin lambda variable 3-21免疫球蛋白变量3-21,P80748,IGLV3-21,,ENSG00000211662,Immunoglobulin lambda variable 3-21,22,22711689-22713203,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,lymphoid tissue: 1760.6;urinary bladder: 747.9,Cell type enriched,Detected in some,118.0,Plasma cells: 5888.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in some,,,Group enriched,Detected in some,337.0,memory B-cell: 433.3;naive B-cell: 225.5,Lineage enriched,Detected in single,444.0,B-cells: 433.3,Cancer enriched,Detected in some,15.0,Myeloma: 691.2,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Testis - Early spermatids, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,4700000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 23: Plasma cells - Humoral immune response,,,,,unprognostic (1.75e-3),unprognostic (6.04e-3),unprognostic (4.21e-2),unprognostic (2.59e-3),unprognostic (4.06e-3),prognostic favorable (3.26e-7),unprognostic (1.63e-1),unprognostic (1.78e-1),unprognostic (1.53e-1),unprognostic (5.30e-2),unprognostic (3.86e-1),unprognostic (2.35e-1),prognostic unfavorable (9.54e-8),unprognostic (7.83e-2),unprognostic (1.88e-1),unprognostic (2.67e-1),unprognostic (7.52e-2),MAWTVLLLGLLSHCTGSVTSYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPT
P01764 Immunoglobulin heavy variable 3-23免疫球蛋白重变量,P01764,IGHV3-23,,ENSG00000211949,Immunoglobulin heavy variable 3-23,14,106268606-106269140,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 1624.0;lymphoid tissue: 2897.8,Cell type enriched,Detected in some,117.0,Plasma cells: 10240.3,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in some,404.0,memory B-cell: 550.6;naive B-cell: 338.3,Lineage enriched,Detected in many,501.0,B-cells: 550.6,Cancer enriched,Detected in some,18.0,Myeloma: 724.1,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,42000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,,unprognostic (1.17e-3),unprognostic (5.43e-2),unprognostic (9.68e-3),unprognostic (3.31e-3),unprognostic (1.34e-2),prognostic favorable (3.85e-4),unprognostic (3.26e-1),unprognostic (4.79e-1),unprognostic (7.26e-2),unprognostic (6.52e-3),unprognostic (1.72e-1),unprognostic (2.45e-1),prognostic unfavorable (1.79e-7),unprognostic (6.22e-2),unprognostic (1.84e-1),unprognostic (1.36e-1),unprognostic (6.42e-2),MEFGLSWLFLVAILKGVQCEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
P06312 Immunoglobulin kappa variable 4-1 免疫球蛋白kappa变量,P06312,IGKV4-1,"B3, IGKV41",ENSG00000211598,Immunoglobulin kappa variable 4-1,2,88885397-88886153,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 1742.2;lymphoid tissue: 3074.1,Cell type enriched,Detected in some,33.0,Plasma cells: 27833.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in many,590.0,memory B-cell: 3048.7;naive B-cell: 3092.7,Lineage enriched,Detected in all,595.0,B-cells: 3092.7,Cancer enriched,Detected in some,11.0,lymphoma: 582.0,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",Not detected,Not detected,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,8500000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 46: Lymphoma - Humoral immune response,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (6.41e-5),unprognostic (9.19e-2),unprognostic (4.29e-3),unprognostic (5.42e-3),unprognostic (2.08e-2),prognostic favorable (8.25e-4),unprognostic (1.79e-2),unprognostic (1.12e-1),unprognostic (3.32e-1),unprognostic (3.71e-3),unprognostic (1.56e-1),unprognostic (3.29e-1),prognostic unfavorable (2.52e-6),unprognostic (1.99e-1),unprognostic (1.01e-1),unprognostic (6.29e-2),unprognostic (1.19e-1),MVLQTQVFISLLLWISGAYGDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTP
P01593 Immunoglobulin kappa variable 1D-33免疫球蛋白变量,P01593,IGKV1D-33,,ENSG00000239975,Immunoglobulin kappa variable 1D-33,2,89913982-89914545,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in some,,gallbladder: 1.9;lymphoid tissue: 2.1;stomach 1: 2.2;urinary bladder: 1.8,Cell type enriched,Detected in some,501.0,Plasma cells: 2537.1,Cancer enhanced,Detected in many,,stomach cancer: 5.0,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,memory B-cell: 2.7,Lineage enriched,Detected in single,27.0,B-cells: 2.7,Cancer enhanced,Detected in single,,lymphoma: 2.4,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA048721,Approved,,,,Immunoglobulin genes,Immunity,,,,4900000000.0,Cluster 23: B-cells - Immunoglobulins,,,Cluster 55: Lymphoma - Immune response,Cluster 23: Plasma cells - Humoral immune response,,,,HPA048721: ,unprognostic (5.10e-3),unprognostic (2.03e-1),unprognostic (2.11e-2),,,unprognostic (2.03e-4),,unprognostic (7.90e-2),,unprognostic (6.50e-2),unprognostic (6.82e-2),,,unprognostic (4.54e-2),unprognostic (4.23e-2),,,MDMRVPAQLLGLLLLWLSGARCDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLP
P01700 Immunoglobulin lambda variable 1-47 免疫球蛋白变量,P01700,IGLV1-47,,ENSG00000211648,Immunoglobulin lambda variable 1-47,22,22357739-22358260,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 683.5;lymphoid tissue: 1747.6,Cell type enriched,Detected in some,10.0,Plasma cells: 8877.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in some,639.0,memory B-cell: 1525.2;naive B-cell: 824.7,Lineage enriched,Detected in many,830.0,B-cells: 1525.2,Cancer enriched,Detected in some,235.0,Myeloma: 3497.7,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,3000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 61: Plasma cells - Immunoglobulins & histones,,,,,unprognostic (5.19e-3),unprognostic (2.69e-2),unprognostic (1.11e-2),unprognostic (1.33e-2),unprognostic (1.26e-1),prognostic favorable (2.66e-4),unprognostic (4.44e-2),unprognostic (1.09e-1),unprognostic (5.69e-2),unprognostic (3.14e-2),unprognostic (2.28e-1),unprognostic (2.64e-1),prognostic unfavorable (5.12e-8),unprognostic (5.00e-3),unprognostic (1.62e-1),unprognostic (7.08e-2),unprognostic (1.15e-2),MAGFPLLLTLLTHCAGSWAQSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSG
P01599 Immunoglobulin kappa variable 1-17免疫球蛋白变量,P01599,IGKV1-17,"A30, IGKV117",ENSG00000240382,Immunoglobulin kappa variable 1-17,2,89117342-89117844,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 361.0;lymphoid tissue: 439.5,Cell type enriched,Detected in some,119.0,Plasma cells: 3624.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in single,,,Group enriched,Detected in some,426.0,memory B-cell: 106.2;naive B-cell: 82.7,Lineage enriched,Detected in single,479.0,B-cells: 106.2,Not detected,Not detected,,,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA048721,Approved,,,,Immunoglobulin genes,Immunity,,,,8400000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 23: Plasma cells - Humoral immune response,,,,HPA048721: ,unprognostic (7.72e-3),unprognostic (1.60e-1),unprognostic (7.37e-3),unprognostic (1.78e-2),unprognostic (5.08e-3),prognostic favorable (4.11e-4),unprognostic (8.04e-2),unprognostic (1.00e-1),unprognostic (9.59e-2),unprognostic (1.76e-2),unprognostic (5.06e-2),unprognostic (2.54e-1),prognostic unfavorable (3.44e-7),unprognostic (3.12e-3),unprognostic (8.83e-2),unprognostic (3.80e-1),unprognostic (7.28e-2),MDMRVPAQLLGLLLLWFPGARCDIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYP
P04433 Immunoglobulin kappa variable 3-11 免疫球蛋白变量,P04433,IGKV3-11,,ENSG00000241351,Immunoglobulin kappa variable 3-11,2,89027171-89027731,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,4.0,intestine: 1323.4;lymphoid tissue: 2723.2;stomach 1: 765.4;urinary bladder: 1760.7,Cell type enriched,Detected in some,94.0,Plasma cells: 16738.2,Low cancer specificity,Detected in all,,,Region enriched,Detected in many,15.0,spinal cord: 34.2,Group enriched,Detected in many,290.0,memory B-cell: 1738.3;naive B-cell: 1408.8,Lineage enriched,Detected in many,321.0,B-cells: 1738.3,Cancer enriched,Detected in some,17.0,Myeloma: 5519.7,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA047702,Approved,,Approved,Plasma membrane,Immunoglobulin genes,Immunity,,,,18000000000.0,Cluster 23: B-cells - Immunoglobulins,,Cluster 7: Non-specific - Ribosome,Cluster 51: Myeloma - Immunoglobulins,Cluster 23: Plasma cells - Humoral immune response,,Plasma membrane,,HPA047702: ,unprognostic (3.97e-3),unprognostic (1.17e-2),unprognostic (3.51e-2),unprognostic (1.91e-2),unprognostic (2.70e-2),prognostic favorable (1.36e-5),unprognostic (2.02e-1),unprognostic (3.20e-1),unprognostic (5.73e-2),unprognostic (2.86e-2),unprognostic (1.70e-1),unprognostic (2.34e-1),prognostic unfavorable (2.26e-8),unprognostic (5.93e-2),unprognostic (2.48e-1),unprognostic (1.22e-1),unprognostic (1.07e-1),MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWP
P01701 Immunoglobulin lambda variable 1-51免疫球蛋白变量,P01701,IGLV1-51,,ENSG00000211644,Immunoglobulin lambda variable 1-51,22,22322472-22322969,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,intestine: 1270.8;lymphoid tissue: 2930.7;urinary bladder: 1531.4,Cell type enriched,Detected in some,262.0,Plasma cells: 14574.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Group enriched,Detected in some,9.0,memory B-cell: 277.1;naive B-cell: 179.3,Lineage enriched,Detected in many,11.0,B-cells: 277.1,Group enriched,Detected in many,52.0,lymphoma: 181.2;Myeloma: 189.3,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,1700000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 37: Neurons - Mixed function,Cluster 55: Lymphoma - Immune response,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (1.85e-4),unprognostic (1.71e-2),unprognostic (3.12e-3),unprognostic (1.76e-3),unprognostic (1.61e-1),prognostic favorable (1.95e-5),unprognostic (3.55e-3),unprognostic (3.78e-2),unprognostic (1.84e-1),unprognostic (1.61e-2),unprognostic (1.41e-1),unprognostic (4.86e-1),prognostic unfavorable (1.40e-5),unprognostic (1.21e-1),unprognostic (5.70e-2),unprognostic (1.89e-1),unprognostic (1.07e-1),MTCSPLLLTLLIHCTGSWAQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSA
P01615 Immunoglobulin kappa variable 2D-28免疫球蛋白变量,P01615,IGKV2D-28,,ENSG00000242534,Immunoglobulin kappa variable 2D-28,2,89959979-89960748,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,esophagus: 87.3;intestine: 106.0;lymphoid tissue: 93.9;salivary gland: 116.8;stomach 1: 98.6,Cell type enriched,Detected in some,177.0,Plasma cells: 2633.1,Low cancer specificity,Detected in many,,,Region enhanced,Detected in single,,medulla oblongata: 1.3,Group enriched,Detected in many,221.0,memory B-cell: 2988.8;naive B-cell: 2094.9,Lineage enriched,Detected in all,260.0,B-cells: 2988.8,Cancer enriched,Detected in single,43.0,lymphoma: 42.9,"Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,3500000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 29: Forebrain - Mixed function,Cluster 46: Lymphoma - Humoral immune response,Cluster 77: Plasma cells - Protein processing,,,,,unprognostic (3.88e-3),unprognostic (2.68e-2),,,,unprognostic (2.51e-3),,unprognostic (1.22e-1),,unprognostic (1.13e-1),unprognostic (4.17e-1),,,unprognostic (1.13e-1),unprognostic (2.66e-1),,,MRLPAQLLGLLMLWVSGSSGDIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTP
B9A064 Immunoglobulin lambda-like polypeptide 5免疫球蛋白 lambda样,B9A064,IGLL5,,ENSG00000254709,Immunoglobulin lambda like polypeptide 5,22,22887780-22896111,"Predicted intracellular proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at transcript level,Evidence at transcript level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 397.1;lymphoid tissue: 656.5;stomach 1: 300.1,Cell type enriched,Detected in some,9.0,Plasma cells: 1531.4,Low cancer specificity,Detected in all,,,Low region specificity,Detected in single,,,Group enriched,Detected in some,227.0,memory B-cell: 517.6;naive B-cell: 619.6,Lineage enriched,Detected in many,247.0,B-cells: 619.6,Cancer enriched,Detected in some,4.0,Myeloma: 1179.4,,,,,,,,,,,,,,,Secreted to blood,No annotated function,,,,53000000000.0,Cluster 23: B-cells - Immunoglobulins,Cluster 70: Lymphoid tissue - Immune response,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (6.10e-4),unprognostic (7.64e-3),unprognostic (4.33e-2),unprognostic (1.51e-3),unprognostic (2.82e-2),prognostic favorable (3.41e-5),unprognostic (1.76e-2),unprognostic (2.18e-1),unprognostic (7.28e-2),unprognostic (1.87e-2),unprognostic (1.01e-1),unprognostic (3.73e-1),prognostic unfavorable (5.94e-8),unprognostic (1.85e-1),unprognostic (4.63e-1),unprognostic (8.52e-2),unprognostic (6.50e-2),MRPKTGQVGCETPEELGPGPRQRWPLLLLGLAMVAHGLLRPMVAPQSGDPDPGASVGSSRSSLRSLWGRLLLQPSPQRADPRCWPRGFWSEPQSLCYVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
P01591 Immunoglobulin J chain 免疫球蛋白J链,P01591,JCHAIN,"IGCJ, IGJ, JCH",ENSG00000132465,Joining chain of multimeric IgA and IgM,4,70655541-70681817,"Plasma proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,breast: 2922.1;intestine: 7701.3;stomach 1: 5747.7,Cell type enriched,Detected in many,13.0,Plasma cells: 78745.1,Low cancer specificity,Detected in all,,,Region enhanced,Detected in many,,spinal cord: 13.1,Group enriched,Detected in all,122.0,memory B-cell: 4194.2;naive B-cell: 2578.5;plasmacytoid DC: 3595.4,Group enriched,Detected in all,137.0,B-cells: 4194.2;dendritic cells: 3595.4,Cancer enriched,Detected in many,10.0,Myeloma: 12971.3,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB034436, HPA044132",Enhanced,,,,Secreted to blood,No annotated function,,,,2200000000.0,Cluster 23: B-cells - Immunoglobulins,Cluster 45: Intestine - Digestion,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,"CAB034436: AB_2233368, HPA044132: AB_2678826",prognostic favorable (1.81e-6),unprognostic (1.45e-3),unprognostic (7.44e-3),unprognostic (1.82e-2),unprognostic (4.23e-2),prognostic favorable (7.56e-7),unprognostic (2.37e-2),unprognostic (2.70e-2),unprognostic (6.30e-2),unprognostic (2.64e-3),unprognostic (3.36e-1),unprognostic (7.34e-2),prognostic unfavorable (1.40e-4),unprognostic (3.43e-1),unprognostic (3.03e-2),unprognostic (2.22e-1),unprognostic (1.96e-1),MKNHLLFWGVLAVFIKAVHVKAQEDERIVLVDNKCKCARITSRIIRSSEDPNEDIVERNIRIIVPLNNRENISDPTSPLRTRFVYHLSDLCKKCDPTEVELDNQIVTATQSNICDEDSATETCYTYDRNKCYTAVVPLVYGGETKMVETALTPDACYPD
P02647 （apoa-1）载脂蛋白,P02647,APOA1,,ENSG00000118137,Apolipoprotein A1,11,116835751-116837622,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",,"Amyloidosis, Atherosclerosis, Cancer-related genes, Disease variant, Neuropathy",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,5.0,liver: 18779.1,Group enriched,Detected in many,13.0,Hepatocytes: 24174.5;Proximal enterocytes: 12804.9,Cancer enriched,Detected in many,48.0,liver cancer: 4515.8,Low region specificity,Detected in some,,,Immune cell enhanced,Detected in single,,plasmacytoid DC: 1.2,Low lineage specificity,Detected in single,,,Group enriched,Detected in some,14.0,Gastric cancer: 176.6;liver cancer: 494.9,"Liver - Hepatocytes, Testis - Sertoli cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB016778, HPA046715",Supported,,Approved,"Vesicles,Cytosol",Secreted to blood,Apolipoprotein,,,1450000000000.0,110000000000.0,,Cluster 83: Liver - Metabolism,Cluster 34: Non-specific - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,10.0,Vesicles,Cytosol,"CAB016778: , HPA046715: AB_2679768",unprognostic (1.88e-3),unprognostic (4.53e-2),unprognostic (7.46e-2),unprognostic (4.00e-3),unprognostic (3.70e-2),unprognostic (1.41e-1),prognostic favorable (5.05e-4),unprognostic (5.40e-2),unprognostic (1.89e-1),unprognostic (9.60e-3),unprognostic (1.59e-3),unprognostic (7.02e-2),prognostic unfavorable (1.67e-8),unprognostic (3.46e-3),unprognostic (1.15e-1),unprognostic (6.24e-2),unprognostic (9.54e-2),MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ
P02649 （APOE）载脂蛋白E,P02649,APOE,AD2,ENSG00000130203,Apolipoprotein E,19,44905791-44909393,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Cholesterol metabolism, Host-virus interaction, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",Heparin-binding,"Alzheimer disease, Amyloidosis, Cancer-related genes, Disease variant, Hyperlipidemia, Neurodegeneration",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in all,4.0,adrenal gland: 3346.3;brain: 2687.4;liver: 6430.8,Cell type enhanced,Detected in many,,Hepatocytes: 8279.7;Hofbauer cells: 5560.9;Leydig cells: 2605.0;Melanocytes: 3267.4;Muller glia cells: 8388.3;Peritubular cells: 4712.6;Proximal tubular cells: 6121.1,Cancer enhanced,Detected in all,,liver cancer: 3183.8,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in all,,liver cancer: 501.2;Rhabdoid: 348.5,"Heart muscle - Fibroblasts, Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Lung - Macrophages, Pancreas - Macrophages, Skeletal muscle - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB008363, HPA065539, HPA068768, CAB069921",Enhanced,,Approved,Vesicles,Secreted to blood,Apolipoprotein,,,51800000000.0,29000000000.0,,Cluster 69: Liver - Oxidoreductase activity,Cluster 19: Astrocytes - Mixed function,Cluster 47: Leukemia - Hemostasis,Cluster 58: Macrophages - Innate immune response,30.0,Vesicles,,"CAB008363: AB_590560, CAB069921: AB_920623, HPA065539: AB_2685509, HPA068768: AB_2686029",unprognostic (8.98e-2),unprognostic (2.32e-2),unprognostic (2.49e-2),unprognostic (5.28e-2),unprognostic (3.77e-2),unprognostic (7.25e-2),unprognostic (5.22e-3),unprognostic (6.13e-2),unprognostic (5.06e-2),unprognostic (4.13e-1),unprognostic (5.78e-2),unprognostic (1.38e-1),unprognostic (1.74e-1),unprognostic (7.76e-2),unprognostic (1.64e-1),unprognostic (1.12e-3),unprognostic (4.13e-2),MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH
P08519 Apolipoprotein(a)载脂蛋白a,P08519,LPA,"LP, Lp(a)",ENSG00000198670,Lipoprotein(a),6,160531482-160664275,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Lipid transport, Transport","Hydrolase, Protease, Serine protease",Atherosclerosis,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,65.0,liver: 74.5,Cell type enriched,Detected in some,6.0,Hepatocytes: 34.5,Cancer enriched,Detected in single,38.0,liver cancer: 3.6,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Kidney - Proximal tubular cells, Liver - Hepatocytes",,,,,,,,,"CAB016072, HPA060604",Supported,,,,Secreted to blood,Transport,,,78800000000.0,1800000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 56: Hypothalamus - Neuropeptide signaling,Cluster 59: Leukemia - T-cell receptor,Cluster 62: Hepatocytes - Metabolism,2.0,,,"CAB016072: AB_2135240, HPA060604: AB_2684330",,unprognostic (2.16e-1),unprognostic (5.10e-1),unprognostic (7.75e-3),unprognostic (6.70e-2),unprognostic (1.60e-1),unprognostic (4.17e-3),unprognostic (1.59e-1),,unprognostic (6.38e-3),unprognostic (3.63e-2),unprognostic (3.18e-1),unprognostic (7.45e-3),unprognostic (2.56e-1),unprognostic (1.80e-1),unprognostic (1.34e-1),unprognostic (3.72e-2),MEHKEVVLLLLLFLKSAAPEQSHVVQDCYHGDGQSYRGTYSTTVTGRTCQAWSSMTPHQHNRTTENYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDPVAAPYCYTRDPSVRWEYCNLTQCSDAEGTAVAPPTITPIPSLEAPSEQAPTEQRPGVQECYHGNGQSYQGTYFITVTGRTCQAWSSMTPHSHSRTPAYYPNAGLIKNYCRNPDPVAAPWCYTTDPSVRWEYCNLTRCSDAEWTAFVPPNVILAPSLEAFFEQALTEETPGVQDCYYHYGQSYRGTYSTTVTGRTCQAWSSMTPHQHSRTPENYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCLVTESSVLATLTVVPDPSTEASSEEAPTEQSPGVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEISPWCYTMDPNVRWEYCNLTQCPVTESSVLATSTAVSEQAPTEQSPTVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCPVMESTLLTTPTVVPVPSTELPSEEAPTENSTGVQDCYRGDGQSYRGTLSTTITGRTCQSWSSMTPHWHRRIPLYYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTRCPVTESSVLTTPTVAPVPSTEAPSEQAPPEKSPVVQDCYHGDGRSYRGISSTTVTGRTCQSWSSMIPHWHQRTPENYPNAGLTENYCRNPDSGKQPWCYTTDPCVRWEYCNLTQCSETESGVLETPTVVPVPSMEAHSEAAPTEQTPVVRQCYHGNGQSYRGTFSTTVTGRTCQSWSSMTPHRHQRTPENYPNDGLTMNYCRNPDADTGPWCFTMDPSIRWEYCNLTRCSDTEGTVVAPPTVIQVPSLGPPSEQDCMFGNGKGYRGKKATTVTGTPCQEWAAQEPHRHSTFIPGTNKWAGLEKNYCRNPDGDINGPWCYTMNPRKLFDYCDIPLCASSSFDCGKPQVEPKKCPGSIVGGCVAHPHSWPWQVSLRTRFGKHFCGGTLISPEWVLTAAHCLKKSSRPSSYKVILGAHQEVNLESHVQEIEVSRLFLEPTQADIALLKLSRPAVITDKVMPACLPSPDYMVTARTECYITGWGETQGTFGTGLLKEAQLLVIENEVCNHYKYICAEHLARGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYARVSRFVTWIEGMMRNN
P02652 APOA2 载脂蛋白A-2,P02652,APOA2,,ENSG00000158874,Apolipoprotein A2,1,161222292-161223631,"Cancer-related genes, Candidate cardiovascular disease genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Host-virus interaction, Lipid transport, Transport",,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,1343.0,liver: 34742.6,Cell type enriched,Detected in some,78.0,Hepatocytes: 51864.9,Cancer enriched,Detected in many,329.0,liver cancer: 11230.1,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,9.0,liver cancer: 2178.7,Liver - Hepatocytes,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB025885, HPA072575",Supported,,,,Secreted to blood,Apolipoprotein,,,115000000000.0,92000000000.0,Cluster 37: Monocytes & Neutrophils - Innate immune response,Cluster 31: Liver - Plasma proteins,Cluster 12: Non-specific - Vasculature,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,15.0,,,"CAB025885: , HPA072575: ",,unprognostic (2.05e-1),unprognostic (4.70e-2),unprognostic (1.12e-1),unprognostic (2.99e-1),,unprognostic (9.82e-2),unprognostic (1.92e-1),unprognostic (3.16e-1),unprognostic (2.79e-1),unprognostic (1.57e-2),,unprognostic (4.40e-3),unprognostic (3.16e-2),unprognostic (2.22e-1),unprognostic (1.60e-1),unprognostic (6.09e-2),MKLLAATVLLLTICSLEGALVRRQAKEPCVESLVSQYFQTVTDYGKDLMEKVKSPELQAEAKSYFEKSKEQLTPLIKKAGTELVNFLSYFVELGTQPATQ
P06727 Apolipoprotein A-IV 载脂蛋白A4,P06727,APOA4,,ENSG00000110244,Apolipoprotein A4,11,116820700-116823304,"Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Lipid transport, Transport",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,12.0,intestine: 3023.3,Cell type enriched,Detected in some,29.0,Proximal enterocytes: 7501.7,Cancer enriched,Detected in some,29.0,liver cancer: 291.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in single,7.0,liver cancer: 3.8,,Not detected,Not detected,,,Not detected,Not detected,,,"HPA001352, HPA002549, CAB068250, CAB068251, CAB068252",Enhanced,,Approved,Vesicles,Secreted to blood,Apolipoprotein,,,61200000000.0,74000000000.0,,Cluster 25: Small intestine - Absorption,,Cluster 34: Testis cancer - Unknown function,Cluster 22: Proximal enterocytes - Digestion,4.0,Vesicles,,"CAB068250: AB_2665657, CAB068251: AB_2665659, CAB068252: AB_2665658, HPA001352: AB_1078179, HPA002549: AB_1078177",,,,,,,unprognostic (8.81e-2),,,,unprognostic (2.12e-2),,,unprognostic (1.75e-2),unprognostic (7.91e-2),,,MFLKAVVLTLALVAVAGARAEVSADQVATVMWDYFSQLSNNAKEAVEHLQKSELTQQLNALFQDKLGEVNTYAGDLQKKLVPFATELHERLAKDSEKLKEEIGKELEELRARLLPHANEVSQKIGDNLRELQQRLEPYADQLRTQVSTQAEQLRRQLTPYAQRMERVLRENADSLQASLRPHADELKAKIDQNVEELKGRLTPYADEFKVKIDQTVEELRRSLAPYAQDTQEKLNHQLEGLTFQMKKNAEELKARISASAEELRQRLAPLAEDVRGNLRGNTEGLQKSLAELGGHLDQQVEEFRRRVEPYGENFNKALVQQMEQLRQKLGPHAGDVEGHLSFLEKDLRDKVNSFFSTFKEKESQDKTLSLPELEQQQEQQQEQQQEQVQMLAPLES
Q6Q788 Apolipoprotein A-V载脂蛋白A5,Q6Q788,APOA5,"APOA-V, RAP3",ENSG00000110243,Apolipoprotein A5,11,116789367-116792420,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Lipid transport, Transport",,Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,218.0,liver: 567.7,Cell type enriched,Detected in some,59.0,Hepatocytes: 1096.0,Cancer enriched,Detected in single,489.0,liver cancer: 112.2,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in single,18.0,liver cancer: 2.7,"Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,Not detected,Not detected,,,,,,,,Secreted to blood,Apolipoprotein,,,114000000.0,21000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,12.0,,,,unprognostic (1.57e-4),,,,,,unprognostic (4.67e-3),unprognostic (5.57e-2),,unprognostic (2.60e-3),,unprognostic (2.40e-1),,unprognostic (2.31e-4),,,,MASMAAVLTWALALLSAFSATQARKGFWDYFSQTSGDKGRVEQIHQQKMAREPATLKDSLEQDLNNMNKFLEKLRPLSGSEAPRLPQDPVGMRRQLQEELEEVKARLQPYMAEAHELVGWNLEGLRQQLKPYTMDLMEQVALRVQELQEQLRVVGEDTKAQLLGGVDEAWALLQGLQSRVVHHTGRFKELFHPYAESLVSGIGRHVQELHRSVAPHAPASPARLSRCVQVLSRKLTLKAKALHARIQQNLDQLREELSRAFAGTGTEEGAGPDPQMLSEEVRQRLQAFRQDTYLQIAAFTRAIDQETEEVQQQLAPPPPGHSAFAPEFQQTDSGKVLSKLQARLDDLWEDITHSLHDQGHSHLGDP
P04114 Apolipoprotein B-100载脂蛋白B,P04114,APOB,,ENSG00000084674,Apolipoprotein B,2,21001429-21044073,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",Heparin-binding,"Atherosclerosis, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in some,143.0,intestine: 296.0;liver: 1155.6,Group enriched,Detected in some,7.0,Hepatocytes: 2290.4;Proximal enterocytes: 1342.2,Cancer enriched,Detected in some,99.0,liver cancer: 295.0,Low region specificity,Detected in some,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,13.0,liver cancer: 178.6,"Adipose subcutaneous - Adipocytes (Subcutaneous), Adipose visceral - Adipocytes (Visceral), Breast - Adipocytes (Breast), Liver - Hepatocytes",Not detected,Not detected,,,Not detected,Not detected,,,"CAB016070, HPA049793, CAB080297, CAB080298, CAB080299",Supported,,Supported,"Vesicles,Cytosol",Secreted to blood,Apolipoprotein,,,1490000000000.0,100000000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,2.0,"Vesicles, Cytosol",,"CAB016070: AB_626690, CAB080297: , CAB080298: , CAB080299: , HPA049793: AB_2680885",unprognostic (1.63e-2),unprognostic (2.71e-2),unprognostic (1.75e-1),unprognostic (1.06e-1),unprognostic (1.04e-2),unprognostic (7.31e-2),unprognostic (1.46e-2),unprognostic (6.53e-3),unprognostic (4.43e-2),unprognostic (8.89e-3),unprognostic (3.01e-1),unprognostic (4.59e-3),unprognostic (3.60e-3),unprognostic (2.89e-2),unprognostic (2.38e-1),unprognostic (2.99e-1),unprognostic (6.23e-2),MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCPKDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKVELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEEFAAAMSRYELKLAIPEGKQVFLYPEKDEPTYILNIKRGIISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVATEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLISSSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMVAQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPKQAEAVLKTLQELKKLTISEQNIQRANLFNKLVTELRGLSDEAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKRVHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRATLYALSHAVNNYHKTNPTGTQELLDIANYLMEQIQDDCTGDEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPSLMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLAAYLMLMRSPSQADINKIVQILPWEQNEQVKNFVASHIANILNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLYKSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAFGFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALYWVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSVEKLIKDLKSKEVPEARAYLRILGEELGFASLHDLQLLGKLLLMGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPTGAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVSVEFVTNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENRQSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDTRLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAEGAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRVNDESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKIKGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGSTVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSDYPKSLHMYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWLQKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLKSDGRVKYTLNKNSLKIEIPLPFGGKSSRDLKMLETVRTPALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLSTNVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVDLLSYNVQGSGETTYDHKNTFTLSCDGSLRHKFLDSNIKFSHVEKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHLFVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNLRFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTASLKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRSEYQADYESLRFFSLLSGSLNSHGLELNADILGTDKINSGAHKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGASMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMILGVDSKNIFNFKVSQEGLKLSNDMMGSYAEMKFDHTNSLNIAGLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNSDLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIYAISSAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAIDMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALWGEHTGQLYSKFLLKAEPLAFTFSHDYKGSTSHHLVSRKSISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYNTKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALEMRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFETLQEYFERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLPQQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIALDDAKINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIANIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNKSGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQNIDIQHLAGKLKQHIEAIDVRVLLDQLGTTISFERINDILEHVKHFVINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMDKLVELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDAVKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDETNDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVYLESLQDTKITLIINWLQEALSSASLAHMKAKFRETLEDTRDRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKNLTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTMPAFEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIKIPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNSELQWPVPDIYLRDLKVEDIPLARITLPDFRLPEIAIPEFIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSILKIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESKLEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEHGSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQLTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIAWTSSGKGSWKWACPRFSDEGTHESQISFTIEGPLTSFGLSNKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGHSVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKNSLFFSAQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSPSAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGEANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEFLKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQSIKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSHDELPRTFQIPGYTVPVVNVEVSPFTIEMSAFGYVFPKAVSMPSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFKELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQSDIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNFKQELNGNTKSKPTVSSSMEFKYDFNSSMLYSTAKGAVDHKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTYLNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRIYSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPWQMSALVQVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRIHSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVYDKSLWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSFSIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPSCKLDFREIQIYKKLRTSSFALNLPTLPEVKFPEVDVLTKYSQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDLNAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQALTARFEVDSPVYNATWSASLKNKADYVETVLDSTCSSTVQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYEEDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTSAASPAVGTVGMDMDEDDDFSKWNFYYSPQSSPDKKLTIFKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATGVLYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQGAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQEGQASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNFPRFQFPGKPGIYTREELCTMFIREVGTVLSQVYSKVHNGSEILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEAQEVFKAIQSLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEMKFTYLINYIQDEINTIFSDYIPYVFKLLKENLCLNLHKFNEFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKYYELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQVEQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQAIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRLIDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELTIIL
P02654 Apolipoprotein C-I 载脂蛋白C1,P02654,APOC1,,ENSG00000130208,Apolipoprotein C1,19,44914247-44919349,"Cancer-related genes, Candidate cardiovascular disease genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Lipid transport, Transport",,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,9.0,liver: 17322.1,Cell type enriched,Detected in many,8.0,Hepatocytes: 34314.8,Cancer enriched,Detected in all,21.0,liver cancer: 3253.7,Low region specificity,Detected in all,,,Immune cell enriched,Detected in single,8.0,myeloid DC: 5.9,Lineage enriched,Detected in single,14.0,dendritic cells: 5.9,Cancer enhanced,Detected in all,,Leukemia: 273.6;liver cancer: 289.3,"Liver - Hepatocytes, Lung - Macrophages, Skin - Sebaceous gland cells",Low region specificity,Detected in all,,,,,,,HPA051518,Supported,,,,Secreted to blood,Apolipoprotein,,,20300000000.0,15000000000.0,Cluster 2: Dendritic cells - Unknown function,Cluster 83: Liver - Metabolism,Cluster 21: Non-specific - Metabolism,Cluster 47: Leukemia - Hemostasis,Cluster 43: Hepatocytes - Metabolism,23.0,,,HPA051518: AB_2681519,unprognostic (3.51e-2),unprognostic (3.31e-3),unprognostic (1.14e-1),unprognostic (2.59e-2),unprognostic (2.06e-1),unprognostic (1.47e-1),prognostic favorable (1.15e-7),unprognostic (9.51e-3),unprognostic (1.30e-1),unprognostic (4.18e-2),unprognostic (1.11e-1),unprognostic (2.52e-1),unprognostic (7.13e-3),unprognostic (3.48e-3),unprognostic (1.65e-1),unprognostic (2.01e-3),unprognostic (1.65e-1),MRLFLSLPVLVVVLSIVLEGPAPAQGTPDVSSALDKLKEFGNTLEDKARELISRIKQSELSAKMREWFSETFQKVKEKLKIDS
P02655 Apolipoprotein C-II 载脂蛋白C2,P02655,APOC2,,ENSG00000234906,Apolipoprotein C2,19,44946035-44949565,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Lipid degradation, Lipid metabolism, Lipid transport, Transport",,"Disease variant, Hyperlipidemia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,130.0,liver: 9320.5,Cell type enriched,Detected in some,23.0,Hepatocytes: 820.6,Cancer enriched,Detected in some,17.0,liver cancer: 49.7,Low region specificity,Detected in all,,,Immune cell enriched,Detected in single,29.0,NK-cell: 3.2,Lineage enriched,Detected in single,29.0,NK-cells: 3.2,Cancer enhanced,Detected in many,,Brain cancer: 55.3;Leukemia: 80.3;liver cancer: 81.2,"Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Pancreas - Macrophages",Not detected,Not detected,,,Not detected,Not detected,,,HPA055877,Supported,,,,Secreted to blood,Apolipoprotein,,,43000000000.0,49000000000.0,Cluster 14: Non-specific - Unknown function,Cluster 31: Liver - Plasma proteins,Cluster 20: Macrophages & Microglia - Immune response,Cluster 70: DU4475 - Unknown function,Cluster 62: Hepatocytes - Metabolism,1.0,,,HPA055877: AB_2682953,unprognostic (4.28e-2),unprognostic (7.73e-3),unprognostic (1.33e-1),unprognostic (3.66e-2),unprognostic (8.91e-2),unprognostic (1.90e-1),unprognostic (2.07e-1),unprognostic (5.41e-2),unprognostic (2.56e-1),unprognostic (1.96e-2),unprognostic (2.86e-1),unprognostic (1.15e-2),unprognostic (5.14e-8),unprognostic (1.32e-1),unprognostic (1.45e-1),unprognostic (1.77e-2),unprognostic (9.80e-3),MGTRLLPALFLVLLVLGFEVQGTQQPQQDEMPSPTFLTQVKESLSSYWESAKTAAQNLYEKTYLPAVDEKLRDLYSKSTAAMSTYTGIFTDQVLSVLKGEE
P02656 Apolipoprotein C-III 载脂蛋白C3,P02656,APOC3,"Apo-C3, Apo-CIII, ApoC-3, ApoC-III, APOCIII",ENSG00000110245,Apolipoprotein C3,11,116829706-116833072,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Lipid degradation, Lipid metabolism, Lipid transport, Transport",,"Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,25.0,liver: 26980.2,Cell type enriched,Detected in some,9.0,Hepatocytes: 87587.5,Cancer enriched,Detected in many,643.0,liver cancer: 4021.9,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,4.0,liver cancer: 40.4,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Low region specificity,Detected in some,,,Not detected,Not detected,,,"HPA065365, HPA073918",Supported,,Approved,"Nucleoplasm,Nucleoli,Cell Junctions",Secreted to blood,Apolipoprotein,,,106000000000.0,45000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,3.0,Nucleoplasm,"Nucleoli, Cell Junctions","HPA065365: AB_2732733, HPA073918: ",,,,,,,prognostic favorable (3.77e-4),,,,unprognostic (2.33e-1),,prognostic unfavorable (6.87e-5),unprognostic (1.60e-2),unprognostic (5.21e-2),,,MQPRVLLVVALLALLASARASEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWDLDPEVRPTSAVAA
P55056 Apolipoprotein C-IV载脂蛋白C4,P55056,APOC4,,ENSG00000267467,Apolipoprotein C4,19,44942237-44945496,"Plasma proteins, Predicted secreted proteins","Lipid transport, Transport",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,505.0,liver: 607.5,Cell type enriched,Detected in single,40.0,Hepatocytes: 15.2,Cancer enriched,Detected in single,15.0,liver cancer: 0.7,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,HPA062671,Approved,,,,Secreted to blood,Apolipoprotein,,,1000000000.0,980000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 31: Liver - Plasma proteins,Cluster 34: Non-specific - Mixed function,Cluster 47: Leukemia - Hemostasis,Cluster 43: Hepatocytes - Metabolism,22.0,,,HPA062671: AB_2684828,,,,,,,unprognostic (1.82e-3),,,,,,,,,,,MSLLRNRLQALPALCLCVLVLACIGACQPEAQEGTLSPPPKLKMSRWSLVRGRMKELLETVVNRTRDGWQWFWSPSTFRGFMQTYYDDHLRDLGPLTKAWFLESKDSLLKKTHSLCPRLVCGDKDQG
O14791 Apolipoprotein L1载脂蛋白L1,O14791,APOL1,APOL,ENSG00000100342,Apolipoprotein L1,22,36253071-36267530,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",,Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,liver: 174.5,Cell type enhanced,Detected in many,,Basal prostatic cells: 107.3;Glandular and luminal cells: 219.4;Hepatocytes: 97.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in many,,,Low lineage specificity,Detected in all,,,Cancer enhanced,Detected in many,,Kidney cancer: 244.0,"Heart muscle - Endothelial cells, Kidney - Endothelial cells",,,,,,,,,"HPA018885, CAB056156",Supported,,,,Secreted to blood,Apolipoprotein,,,1640000000.0,9200000000.0,Cluster 35: Neutrophils - Protein binding,Cluster 11: Liver - Plasma proteins,Cluster 42: Choroid plexus - Mitochondria,Cluster 15: Kidney cancer - Membrane components,Cluster 37: Glandular & Luminal cells - Unknown function,1.0,,,"CAB056156: AB_2665576, HPA018885: AB_1844953",unprognostic (1.05e-2),unprognostic (1.53e-1),unprognostic (1.57e-1),unprognostic (8.98e-3),unprognostic (1.67e-1),unprognostic (8.28e-2),unprognostic (1.41e-2),prognostic unfavorable (5.35e-4),unprognostic (4.41e-2),unprognostic (1.58e-1),unprognostic (4.07e-3),unprognostic (5.15e-2),prognostic unfavorable (7.43e-6),unprognostic (1.93e-1),unprognostic (3.15e-2),unprognostic (5.05e-3),prognostic favorable (2.01e-5),MEGAALLRVSVLCIWMSALFLGVGVRAEEAGARVQQNVPSGTDTGDPQSKPLGDWAAGTMDPESSIFIEDAIKYFKEKVSTQNLLLLLTDNEAWNGFVAAAELPRNEADELRKALDNLARQMIMKDKNWHDKGQQYRNWFLKEFPRLKSELEDNIRRLRALADGVQKVHKGTTIANVVSGSLSISSGILTLVGMGLAPFTEGGSLVLLEPGMELGITAALTGITSSTMDYGKKWWTQAQAHDLVIKSLDKLKEVREFLGENISNFLSLAGNTYQLTRGIGKDIRALRRARANLQSVPHASASRPRVTEPISAESGEQVERVNEPSILEMSRGVKLTDVAPVSFFLVLDVVYLVYESKHLHEGAKSETAEELKKVAQELEEKLNILNNNYKILQADQEL
P05090 Apolipoprotein D载脂蛋白D,P05090,APOD,Apo-D,ENSG00000189058,Apolipoprotein D,3,195568705-195584033,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Transport,,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,breast: 4898.1;choroid plexus: 4317.9,Cell type enhanced,Detected in many,,Fibroblasts: 4290.5;Leydig cells: 1994.7;Melanocytes: 1348.5;Peritubular cells: 1105.2;Serous glandular cells: 920.5,Cancer enriched,Detected in all,4.0,melanoma: 925.2,Low region specificity,Detected in all,,,Immune cell enriched,Detected in single,14.0,memory B-cell: 5.0,Lineage enriched,Detected in single,14.0,B-cells: 5.0,Group enriched,Detected in many,4.0,breast cancer: 117.8;prostate cancer: 92.2;skin cancer: 170.8,Pancreas - Fibroblasts,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA040520,Enhanced,,Approved,Plasma membrane,Secreted to blood,Apolipoprotein,,,98900000000.0,90000000000.0,Cluster 23: B-cells - Immunoglobulins,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 30: White matter - Myelination,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,38.0,Plasma membrane,,HPA040520: AB_2677020,prognostic favorable (5.51e-4),unprognostic (7.62e-3),unprognostic (7.85e-3),unprognostic (3.34e-3),unprognostic (2.20e-1),unprognostic (1.02e-2),unprognostic (3.09e-2),unprognostic (2.06e-3),unprognostic (1.26e-1),unprognostic (3.45e-1),unprognostic (3.38e-1),unprognostic (3.19e-1),unprognostic (6.90e-3),prognostic unfavorable (6.02e-4),unprognostic (1.38e-1),prognostic unfavorable (4.12e-4),unprognostic (1.71e-3),MVMLLLLLSALAGLFGAAEGQAFHLGKCPNPPVQENFDVNKYLGRWYEIEKIPTTFENGRCIQANYSLMENGKIKVLNQELRADGTVNQIEGEATPVNLTEPAKLEVKFSWFMPSAPYWILATDYENYALVYSCTCIIQLFHVDFAWILARNPNLPPETVDSLKNILTSNNIDVKKMTVTDQVNCPKLS
O95445 Apolipoprotein M载脂蛋白M,O95445,APOM,"Apo-M, G3a, NG20",ENSG00000204444,Apolipoprotein M,6,31652416-31658210,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Lipid transport, Transport",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,4.0,liver: 381.2,Group enriched,Detected in many,7.0,Hepatocytes: 703.0;Proximal tubular cells: 402.9,Cancer enriched,Detected in all,13.0,liver cancer: 185.9,Low region specificity,Detected in single,,,Immune cell enhanced,Detected in some,,basophil: 3.0,Low lineage specificity,Detected in many,,,Cancer enhanced,Detected in some,,liver cancer: 6.4,"Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB034086, HPA051006",Approved,,Approved,Golgi apparatus,Secreted to blood,Apolipoprotein,,,7400000000.0,8200000000.0,Cluster 32: Basophils - Transcription,Cluster 1: Liver & Kidney - Metabolism,Cluster 25: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 56: Proximal tubular cells - Amino acid metabolism,,Golgi apparatus,,"CAB034086: AB_1119033, HPA051006: AB_2681307",unprognostic (2.76e-3),unprognostic (1.69e-2),unprognostic (8.66e-2),unprognostic (2.61e-2),unprognostic (1.12e-1),unprognostic (5.28e-2),unprognostic (3.78e-1),unprognostic (1.97e-2),unprognostic (1.80e-1),unprognostic (6.04e-3),unprognostic (2.27e-2),unprognostic (1.48e-1),unprognostic (7.28e-2),unprognostic (5.71e-2),unprognostic (1.96e-1),unprognostic (1.30e-1),unprognostic (3.20e-2),MFHQIWAALLYFYGIILNSIYQCPEHSQLTTLGVDGKEFPEVHLGQWYFIAGAAPTKEELATFDPVDNIVFNMAAGSAPMQLHLRATIRMKDGLCVPRKWIYHLTEGSTDLRTEGRPDMKTELFSSSCPGGIMLNETGQGYQRFLLYNRSPHPPEKCVEEFKSLTSCLDSKAFLLTPRNQEACELSNN
Q13790 Apolipoprotein F载脂蛋白F,Q13790,APOF,,ENSG00000175336,Apolipoprotein F,12,56360568-56362857,"Plasma proteins, Predicted secreted proteins","Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,346.0,liver: 404.0,Cell type enriched,Detected in some,5.0,Hepatocytes: 299.3,Cancer enriched,Detected in some,6.0,liver cancer: 34.8,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,prostate cancer: 1.0,"Liver - Hepatocytes, Prostate - Prostate glandular cells, Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,,,,,,,,,,Secreted to blood,Apolipoprotein,,,18000000000.0,2200000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 48: Non-specific - Mixed function,Cluster 16: Thyroid cancer - Neuronal signaling,Cluster 62: Hepatocytes - Metabolism,,,,,unprognostic (3.55e-2),unprognostic (1.13e-1),unprognostic (1.48e-2),unprognostic (8.99e-3),unprognostic (9.84e-2),unprognostic (3.29e-2),unprognostic (2.08e-3),unprognostic (7.84e-2),unprognostic (4.22e-1),unprognostic (5.69e-2),unprognostic (2.68e-3),unprognostic (8.55e-2),unprognostic (2.42e-2),unprognostic (2.77e-1),unprognostic (5.57e-2),unprognostic (2.87e-1),unprognostic (4.43e-2),MTGLCGYSAPDMRGLRLIMIPVELLLCYLLLHPVDATSYGKQTNVLMHFPLSLESQTPSSDPLSCQFLHPKSLPGFSHMAPLPKFLVSLALRNALEEAGCQADVWALQLQLYRQGGVNATQVLIQHLRGLQKGRSTERNVSVEALASALQLLAREQQSTGRVGRSLPTEDCENEKEQAVHNVVQLLPGVGTFYNLGTALYYATQNCLGKARERGRDGAIDLGYDLLMTMAGMSGGPMGLAISAALKPALRSGVQQLIQYYQDQKDANISQPETTKEGLRAISDVSDLEETTTLASFISEVVSSAPYWGWAIIKSYDLDPGAGSLEI
P04004 (Vitronectin)玻连蛋白,P04004,VTN,VN,ENSG00000109072,Vitronectin,17,28367284-28373091,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins, Transporters",Cell adhesion,Heparin-binding,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,61.0,liver: 5852.0,Cell type enriched,Detected in many,4.0,Hepatocytes: 4354.3,Cancer enriched,Detected in many,85.0,liver cancer: 2216.6,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,liver cancer: 132.3,"Adipose visceral - Mesothelial cells, Liver - Hepatocytes",Low region specificity,Detected in all,,,Low region specificity,Detected in many,,,"CAB016695, CAB016765, HPA060933, HPA068011",Supported,,Supported,"Endoplasmic reticulum,Vesicles",Secreted to blood,Cell adhesion,,,606000000000.0,33000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 15: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,7.0,"Endoplasmic reticulum, Vesicles",,"CAB016695: AB_1624536, CAB016765: , HPA060933: AB_2684389, HPA068011: ",unprognostic (1.19e-1),unprognostic (2.12e-1),unprognostic (2.29e-2),unprognostic (6.13e-2),unprognostic (9.74e-2),unprognostic (8.42e-2),prognostic favorable (3.74e-4),unprognostic (6.20e-2),unprognostic (3.97e-1),unprognostic (8.95e-2),unprognostic (3.24e-3),unprognostic (1.01e-2),prognostic unfavorable (4.10e-11),unprognostic (8.82e-3),unprognostic (2.27e-1),unprognostic (4.86e-3),unprognostic (7.09e-2),MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSAVFEHFAMMQRDSWEDIFELLFWGRTSAGTRQPQFISRDWHGVPGQVDAAMAGRIYISGMAPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRATWLSLFSSEESNLGANNYDDYRMDWLVPATCEPIQSVFFFSGDKYYRVNLRTRRVDTVDPPYPRSIAQYWLGCPAPGHL
P10909 Clusterin丛生蛋白,P10909,CLU,"APOJ, CLI, CLU1, CLU2, KUB1, SGP-2, SP-40, TRPM-2",ENSG00000120885,Clusterin,8,27596917-27614700,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Apoptosis, Complement pathway, Immunity, Innate immunity",Chaperone,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,liver: 9442.3,Cell type enhanced,Detected in all,,Basal prostatic cells: 3199.0;Cholangiocytes: 2558.4;Collecting duct cells: 3117.6;Hepatocytes: 3758.6;Muller glia cells: 6791.7;Secretory cells: 6049.9,Cancer enhanced,Detected in all,,glioma: 1485.6,Low region specificity,Detected in all,,,Immune cell enriched,Detected in many,10.0,basophil: 773.3,Lineage enriched,Detected in all,33.0,granulocytes: 773.3,Low cancer specificity,Detected in all,,,"Liver - Hepatocytes, Lung - Fibroblast_2, Prostate - Smooth muscle cells, Testis - Sertoli cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA000572, CAB016253, HPA075983, CAB080180",Enhanced,,Supported,Cytosol,Secreted to blood,Complement pathway,,,169000000000.0,29000000000.0,Cluster 41: Basophils - Unknown function,Cluster 50: Epididymis - Male reproductive secretion,Cluster 39: Astrocytes - Mixed function,Cluster 72: Neuronal - Signal transduction,Cluster 10: Muller glia cells - Visual perception,8.0,Cytosol,,"CAB016253: AB_673562, CAB080180: , HPA000572: AB_1078539, HPA075983: ",unprognostic (1.10e-2),unprognostic (1.81e-2),unprognostic (1.14e-3),unprognostic (2.74e-2),unprognostic (5.59e-2),unprognostic (4.13e-2),unprognostic (1.76e-2),unprognostic (2.37e-1),unprognostic (1.46e-1),unprognostic (1.05e-1),unprognostic (2.87e-2),unprognostic (1.41e-1),unprognostic (1.80e-2),unprognostic (2.33e-2),unprognostic (1.72e-1),prognostic favorable (7.66e-5),unprognostic (5.29e-2),MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHFSRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNELLKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKFMETVAEKALQEYRKKHREE
P01011 Alpha-1-antichymotrypsin 抗胰凝乳蛋白酶,P01011,SERPINA3,"AACT, ACT",ENSG00000196136,Serpin family A member 3,14,94612384-94624055,"Cancer-related genes, Candidate cardiovascular disease genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Acute phase,"Protease inhibitor, Serine protease inhibitor","Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,5.0,liver: 8942.3;pancreas: 4764.3,Cell type enhanced,Detected in some,,Ductal cells: 21.1;Exocrine glandular cells: 41.9;Fibroblasts: 14.7;Hepatocytes: 11.4;Mucus glandular cells: 36.7;Serous glandular cells: 13.8,Cancer enhanced,Detected in many,,liver cancer: 4.0,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,Bile duct cancer: 142.2;skin cancer: 409.0,"Breast - Breast glandular cells, Prostate - Macrophages, Thyroid - Macrophages",Not detected,Not detected,,,Not detected,Not detected,,,"HPA000893, HPA002560, CAB016647",Enhanced,,,,Secreted to blood,Acute phase,,,697000000000.0,94000000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 69: Skin cancer - ECM organization,Cluster 49: Non-specific - Transcription,6.0,,,"CAB016647: AB_1611882, HPA000893: AB_10794315, HPA002560: AB_1856717",prognostic favorable (8.92e-4),unprognostic (3.33e-3),unprognostic (9.21e-2),unprognostic (1.53e-2),unprognostic (1.05e-1),unprognostic (1.72e-1),unprognostic (2.00e-2),unprognostic (1.00e-2),unprognostic (2.23e-1),unprognostic (9.60e-2),unprognostic (1.20e-2),unprognostic (9.92e-2),unprognostic (3.74e-12),unprognostic (6.47e-2),unprognostic (1.33e-2),,unprognostic (2.02e-2),MERMLPLLALGLLAAGFCPAVLCHPNSPLDEENLTQENQDRGTHVDLGLASANVDFAFSLYKQLVLKAPDKNVIFSPLSISTALAFLSLGAHNTTLTEILKGLKFNLTETSEAEIHQSFQHLLRTLNQSSDELQLSMGNAMFVKEQLSLLDRFTEDAKRLYGSEAFATDFQDSAAAKKLINDYVKNGTRGKITDLIKDLDSQTMMVLVNYIFFKAKWEMPFDPQDTHQSRFYLSKKKWVMVPMMSLHHLTIPYFRDEELSCTVVELKYTGNASALFILPDQDKMEEVEAMLLPETLKRWRDSLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAVSQVVHKAVLDVFEEGTEASAATAVKITLLSALVETRTIVRFNRPFLMIIVPTDTQNIFFMSKVTNPKQA
P00734 Prothrombin 凝血酶原,P00734,F2,,ENSG00000180210,"Coagulation factor II, thrombin",11,46719196-46739506,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Acute phase, Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,1310.0,liver: 1180.6,Cell type enriched,Detected in some,7.0,Hepatocytes: 841.1,Cancer enriched,Detected in some,110.0,liver cancer: 508.2,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,10.0,liver cancer: 64.3,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB016780, HPA051476, HPA054698",Enhanced,,,,Secreted to blood,Blood coagulation,,,108000000000.0,41000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 15: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,1.0,,,"CAB016780: , HPA051476: AB_2681498, HPA054698: AB_2682578",unprognostic (1.98e-1),unprognostic (2.52e-1),unprognostic (2.64e-2),unprognostic (1.85e-1),unprognostic (2.29e-1),unprognostic (2.81e-1),unprognostic (2.23e-2),unprognostic (3.94e-2),,unprognostic (5.79e-2),unprognostic (8.29e-2),unprognostic (4.46e-2),prognostic unfavorable (6.75e-12),unprognostic (5.65e-3),unprognostic (5.80e-2),,unprognostic (1.54e-3),MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE
P06396 Gelsolin 凝胶溶素,P06396,GSN,DKFZp313L0718,ENSG00000148180,Gelsolin,9,121207794-121332843,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Cilium biogenesis/degradation,"Actin capping, Actin-binding","Amyloidosis, Cancer-related genes, Corneal dystrophy, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,heart muscle: 2404.8,Cell type enhanced,Detected in all,,Adipocytes: 1460.5;Fibroblasts: 3746.1,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,eosinophil: 1140.0,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Adipocytes (Breast), Colon - Fibroblasts, Lung - Fibroblast_2, Skin - Fibroblast_2, Thyroid - Fibroblasts",Region enriched,Detected in all,4.0,white matter: 869.4,Low region specificity,Detected in all,,,"CAB010823, CAB016728, CAB036009, HPA054026",Supported,,Supported,Actin filaments,Secreted to blood,Other,,,112000000000.0,240000000000.0,Cluster 29: Non-specific - Unknown function,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 30: White matter - Myelination,Cluster 69: Skin cancer - ECM organization,Cluster 53: Fibroblasts - ECM organization,126.0,Actin filaments,,"CAB010823: , CAB016728: , CAB036009: , HPA054026: AB_2682347",unprognostic (3.25e-2),unprognostic (4.44e-3),unprognostic (1.22e-1),unprognostic (3.10e-3),unprognostic (4.23e-2),unprognostic (4.85e-2),unprognostic (1.21e-1),unprognostic (1.49e-1),unprognostic (1.22e-1),unprognostic (1.20e-1),unprognostic (6.54e-2),unprognostic (6.56e-2),unprognostic (3.06e-2),unprognostic (8.01e-3),unprognostic (4.98e-2),unprognostic (1.23e-2),prognostic unfavorable (1.79e-5),MAPHRPAPALLCALSLALCALSLPVRAATASRGASQAGAPQGRVPEARPNSMVVEHPEFLKAGKEPGLQIWRVEKFDLVPVPTNLYGDFFTGDAYVILKTVQLRNGNLQYDLHYWLGNECSQDESGAAAIFTVQLDDYLNGRAVQHREVQGFESATFLGYFKSGLKYKKGGVASGFKHVVPNEVVVQRLFQVKGRRVVRATEVPVSWESFNNGDCFILDLGNNIHQWCGSNSNRYERLKATQVSKGIRDNERSGRARVHVSEEGTEPEAMLQVLGPKPALPAGTEDTAKEDAANRKLAKLYKVSNGAGTMSVSLVADENPFAQGALKSEDCFILDHGKDGKIFVWKGKQANTEERKAALKTASDFITKMDYPKQTQVSVLPEGGETPLFKQFFKNWRDPDQTDGLGLSYLSSHIANVERVPFDAATLHTSTAMAAQHGMDDDGTGQKQIWRIEGSNKVPVDPATYGQFYGGDSYIILYNYRHGGRQGQIIYNWQGAQSTQDEVAASAILTAQLDEELGGTPVQSRVVQGKEPAHLMSLFGGKPMIIYKGGTSREGGQTAPASTRLFQVRANSAGATRAVEVLPKAGALNSNDAFVLKTPSAAYLWVGTGASEAEKTGAQELLRVLRAQPVQVAEGSEPDGFWEALGGKAAYRTSPRLKDKKMDAHPPRLFACSNKIGRFVIEEVPGELMQEDLATDDVMLLDTWDQVFVWVGKDSQEEEKTEALTSAKRYIETDPANRDRRTPITVVKQGFEPPSFVGWFLGWDDDYWSVDPLDRAMAELAA
P01008 Antithrombin-III 抗凝血酶,P01008,SERPINC1,"AT3, ATIII, MGC22579",ENSG00000117601,Serpin family C member 1,1,173903800-173917327,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Heparin-binding, Protease inhibitor, Serine protease inhibitor","Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,1350.0,liver: 4902.3,Cell type enriched,Detected in some,36.0,Hepatocytes: 2537.3,Cancer enriched,Detected in some,871.0,liver cancer: 1504.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,4.0,Gastric cancer: 1.6;liver cancer: 5.7,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA001816, CAB016790, HPA024007",Supported,,,,Secreted to blood,Blood coagulation,,,,120000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,,,,"CAB016790: , HPA001816: AB_1079926, HPA024007: AB_1856732",unprognostic (1.28e-2),unprognostic (2.22e-1),unprognostic (3.83e-2),unprognostic (5.98e-2),unprognostic (6.91e-2),unprognostic (1.93e-2),prognostic favorable (3.40e-5),unprognostic (1.75e-2),unprognostic (8.67e-2),unprognostic (3.48e-2),unprognostic (4.74e-2),unprognostic (1.91e-1),unprognostic (2.36e-2),unprognostic (5.28e-3),unprognostic (5.80e-2),unprognostic (6.35e-2),unprognostic (8.21e-2),MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK
P12259 Coagulation factor V  凝血因子v,P12259,F5,,ENSG00000198734,Coagulation factor V,1,169511951-169586588,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis",,"Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,6.0,choroid plexus: 79.3;liver: 171.0;placenta: 45.4,Group enriched,Detected in many,7.0,Cholangiocytes: 95.4;Cytotrophoblasts: 83.4;Hepatocytes: 220.7;Syncytiotrophoblasts: 60.4,Cancer enriched,Detected in many,7.0,liver cancer: 69.6,Region enriched,Detected in all,22.0,choroid plexus: 306.3,Group enriched,Detected in some,4.0,classical monocyte: 4.1;eosinophil: 8.1;neutrophil: 7.0;T-reg: 6.2,Group enriched,Detected in many,13.0,granulocytes: 8.1;monocytes: 4.1;T-cells: 6.2,Cancer enhanced,Detected in many,,liver cancer: 17.9,"Breast - Adipocytes (Breast), Kidney - Podocytes, Liver - Hepatocytes, Lung - Neutrophil_2, Prostate - Urothelial cells, Skin - Eccrine sweat gland cells",Group enriched,Detected in many,5.0,basal ganglia: 2.7;hippocampal formation: 6.6;pons and medulla: 4.4;thalamus: 5.5,Group enriched,Detected in all,7.0,amygdala: 53.1;basal ganglia: 46.2;cerebral cortex: 89.3;hippocampal formation: 80.9;olfactory bulb: 37.0,HPA002036,,,Approved,Golgi apparatus,Secreted to blood,Blood coagulation,,,7670000000.0,13000000000.0,Cluster 7: Non-specific - Innate immune response,Cluster 11: Liver - Plasma proteins,Cluster 36: Choroid plexus - Mixed function,Cluster 2: Mucus-secreting cells - Unknown function,Cluster 62: Hepatocytes - Metabolism,,Golgi apparatus,,HPA002036: AB_1078787,unprognostic (3.67e-2),unprognostic (2.77e-4),unprognostic (5.42e-2),unprognostic (2.56e-4),unprognostic (2.03e-1),unprognostic (2.39e-4),unprognostic (3.46e-3),unprognostic (9.25e-3),unprognostic (2.02e-1),unprognostic (8.99e-3),unprognostic (6.55e-3),unprognostic (1.32e-1),unprognostic (2.01e-2),prognostic unfavorable (3.39e-4),unprognostic (7.15e-2),unprognostic (3.41e-1),unprognostic (4.31e-1),MFPGCPRLWVLVVLGTSWVGWGSQGTEAAQLRQFYVAAQGISWSYRPEPTNSSLNLSVTSFKKIVYREYEPYFKKEKPQSTISGLLGPTLYAEVGDIIKVHFKNKADKPLSIHPQGIRYSKLSEGASYLDHTFPAEKMDDAVAPGREYTYEWSISEDSGPTHDDPPCLTHIYYSHENLIEDFNSGLIGPLLICKKGTLTEGGTQKTFDKQIVLLFAVFDESKSWSQSSSLMYTVNGYVNGTMPDITVCAHDHISWHLLGMSSGPELFSIHFNGQVLEQNHHKVSAITLVSATSTTANMTVGPEGKWIISSLTPKHLQAGMQAYIDIKNCPKKTRNLKKITREQRRHMKRWEYFIAAEEVIWDYAPVIPANMDKKYRSQHLDNFSNQIGKHYKKVMYTQYEDESFTKHTVNPNMKEDGILGPIIRAQVRDTLKIVFKNMASRPYSIYPHGVTFSPYEDEVNSSFTSGRNNTMIRAVQPGETYTYKWNILEFDEPTENDAQCLTRPYYSDVDIMRDIASGLIGLLLICKSRSLDRRGIQRAADIEQQAVFAVFDENKSWYLEDNINKFCENPDEVKRDDPKFYESNIMSTINGYVPESITTLGFCFDDTVQWHFCSVGTQNEILTIHFTGHSFIYGKRHEDTLTLFPMRGESVTVTMDNVGTWMLTSMNSSPRSKKLRLKFRDVKCIPDDDEDSYEIFEPPESTVMATRKMHDRLEPEDEESDADYDYQNRLAAALGIRSFRNSSLNQEEEEFNLTALALENGTEFVSSNTDIIVGSNYSSPSNISKFTVNNLAEPQKAPSHQQATTAGSPLRHLIGKNSVLNSSTAEHSSPYSEDPIEDPLQPDVTGIRLLSLGAGEFKSQEHAKHKGPKVERDQAAKHRFSWMKLLAHKVGRHLSQDTGSPSGMRPWEDLPSQDTGSPSRMRPWKDPPSDLLLLKQSNSSKILVGRWHLASEKGSYEIIQDTDEDTAVNNWLISPQNASRAWGESTPLANKPGKQSGHPKFPRVRHKSLQVRQDGGKSRLKKSQFLIKTRKKKKEKHTHHAPLSPRTFHPLRSEAYNTFSERRLKHSLVLHKSNETSLPTDLNQTLPSMDFGWIASLPDHNQNSSNDTGQASCPPGLYQTVPPEEHYQTFPIQDPDQMHSTSDPSHRSSSPELSEMLEYDRSHKSFPTDISQMSPSSEHEVWQTVISPDLSQVTLSPELSQTNLSPDLSHTTLSPELIQRNLSPALGQMPISPDLSHTTLSPDLSHTTLSLDLSQTNLSPELSQTNLSPALGQMPLSPDLSHTTLSLDFSQTNLSPELSHMTLSPELSQTNLSPALGQMPISPDLSHTTLSLDFSQTNLSPELSQTNLSPALGQMPLSPDPSHTTLSLDLSQTNLSPELSQTNLSPDLSEMPLFADLSQIPLTPDLDQMTLSPDLGETDLSPNFGQMSLSPDLSQVTLSPDISDTTLLPDLSQISPPPDLDQIFYPSESSQSLLLQEFNESFPYPDLGQMPSPSSPTLNDTFLSKEFNPLVIVGLSKDGTDYIEIIPKEEVQSSEDDYAEIDYVPYDDPYKTDVRTNINSSRDPDNIAAWYLRSNNGNRRNYYIAAEEISWDYSEFVQRETDIEDSDDIPEDTTYKKVVFRKYLDSTFTKRDPRGEYEEHLGILGPIIRAEVDDVIQVRFKNLASRPYSLHAHGLSYEKSSEGKTYEDDSPEWFKEDNAVQPNSSYTYVWHATERSGPESPGSACRAWAYYSAVNPEKDIHSGLIGPLLICQKGILHKDSNMPMDMREFVLLFMTFDEKKSWYYEKKSRSSWRLTSSEMKKSHEFHAINGMIYSLPGLKMYEQEWVRLHLLNIGGSQDIHVVHFHGQTLLENGNKQHQLGVWPLLPGSFKTLEMKASKPGWWLLNTEVGENQRAGMQTPFLIMDRDCRMPMGLSTGIISDSQIKASEFLGYWEPRLARLNNGGSYNAWSVEKLAAEFASKPWIQVDMQKEVIITGIQTQGAKHYLKSCYTTEFYVAYSSNQINWQIFKGNSTRNVMYFNGNSDASTIKENQFDPPIVARYIRISPTRAYNRPTLRLELQGCEVNGCSTPLGMENGKIENKQITASSFKKSWWGDYWEPFRARLNAQGRVNAWQAKANNNKQWLEIDLLKIKKITAIITQGCKSLSSEMYVKSYTIHYSEQGVEWKPYRLKSSMVDKIFEGNTNTKGHVKNFFNPPIISRFIRVIPKTWNQSIALRLELFGCDIY
P00740 Coagulation factor IX 凝血因子4,P00740,F9,FIX,ENSG00000101981,Coagulation factor IX,X,139530739-139563459,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets, Hemophilia, Thrombophilia",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,2448.0,liver: 683.7,Group enriched,Detected in some,12.0,Hepatocytes: 519.8;Kupffer cells: 161.1,Cancer enriched,Detected in single,1354.0,liver cancer: 67.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,,,,,,Secreted to blood,Blood coagulation,,,,8200000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 10: Ciliated cells - Ion channel activity,Cluster 62: Hepatocytes - Metabolism,,,,,,,,,,,prognostic favorable (6.69e-4),,,,,,,,,,,MQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT
P00742 Coagulation factor X凝血因子X,P00742,F10,,ENSG00000126218,Coagulation factor X,13,113122799-113149529,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,liver: 156.1,Cell type enhanced,Detected in many,,Fibroblasts: 109.1;Hepatocytes: 170.7;Leydig cells: 217.7;Peritubular cells: 232.6;Smooth muscle cells: 57.6,Cancer enriched,Detected in many,11.0,liver cancer: 95.4,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,Adrenocortical cancer: 6.9;liver cancer: 16.8,"Breast - Fibroblasts, Colon - Fibroblasts, Liver - Hepatocytes, Pancreas - Alpha cells, Prostate - Fibroblasts, Skeletal muscle - Fibroblasts, Skin - Fibroblast_1, Skin - Fibroblast_2, Thyroid - Fibroblasts",Not detected,Not detected,,,Low region specificity,Detected in many,,,,,,,,Secreted to blood,Blood coagulation,,,,13000000000.0,,Cluster 83: Liver - Metabolism,Cluster 49: Hindbrain - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 53: Fibroblasts - ECM organization,3.0,,,,unprognostic (4.18e-2),unprognostic (1.07e-1),unprognostic (7.62e-2),unprognostic (9.88e-2),unprognostic (9.44e-2),unprognostic (1.15e-2),unprognostic (4.90e-2),unprognostic (1.02e-2),unprognostic (2.54e-1),unprognostic (1.24e-1),prognostic favorable (1.82e-5),unprognostic (6.39e-2),prognostic unfavorable (5.14e-5),unprognostic (6.60e-2),unprognostic (1.21e-1),unprognostic (3.87e-2),unprognostic (2.23e-3),MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEETCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERRKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK
P03951 Coagulation factor XI 凝血因子XI,P03951,F11,FXI,ENSG00000088926,Coagulation factor XI,4,186266189-186289681,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Heparin-binding, Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,4.0,liver: 235.6,Cell type enriched,Detected in some,7.0,Hepatocytes: 69.2,Cancer enriched,Detected in some,13.0,liver cancer: 16.8,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,liver cancer: 1.8,"Kidney - Ascending Loop of Henle cells, Liver - Hepatocytes, Lung - Alveolar cells type 2",Not detected,Not detected,,,Low region specificity,Detected in all,,,HPA039808,,,Approved,Vesicles,Secreted to blood,Blood coagulation,,,,4400000000.0,,Cluster 83: Liver - Metabolism,Cluster 38: Sub-cortical - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Vesicles,,HPA039808: AB_2676693,,,unprognostic (1.28e-1),,unprognostic (3.15e-1),,prognostic favorable (3.29e-5),unprognostic (1.88e-1),,,unprognostic (2.08e-1),unprognostic (2.11e-1),unprognostic (1.85e-3),unprognostic (2.91e-2),unprognostic (7.65e-2),,,MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV
P00748 Coagulation factor XII凝固因子,P00748,F12,,ENSG00000131187,Coagulation factor XII,5,177402133-177416583,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,311.0,liver: 589.9,Cell type enriched,Detected in many,5.0,Hepatocytes: 375.4,Cancer enriched,Detected in many,21.0,liver cancer: 171.0,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,eosinophil: 1.7,Lineage enhanced,Detected in single,,granulocytes: 1.7,Low cancer specificity,Detected in many,,,"Kidney - Proximal tubular cells, Liver - Hepatocytes, Stomach - Mitotic cells (Stomach)",Low region specificity,Detected in single,,,Not detected,Not detected,,,HPA003825,Approved,,,,Secreted to blood,Blood coagulation,,,1040000.0,7000000000.0,Cluster 19: Eosinophils - Unknown function,Cluster 31: Liver - Plasma proteins,,Cluster 71: Lymphoma - Inflammatory response,Cluster 62: Hepatocytes - Metabolism,1.0,,,HPA003825: AB_1078790,unprognostic (9.75e-2),unprognostic (1.71e-1),unprognostic (2.93e-1),unprognostic (4.47e-2),unprognostic (1.01e-1),unprognostic (2.32e-1),prognostic favorable (4.63e-5),unprognostic (6.97e-2),unprognostic (1.26e-2),unprognostic (3.96e-2),unprognostic (4.41e-1),unprognostic (6.54e-2),prognostic unfavorable (7.09e-4),unprognostic (4.11e-2),unprognostic (3.69e-1),unprognostic (3.40e-6),unprognostic (6.48e-2),MRALLLLGFLLVSLESTLSIPPWEAPKEHKYKAEEHTVVLTVTGEPCHFPFQYHRQLYHKCTHKGRPGPQPWCATTPNFDQDQRWGYCLEPKKVKDHCSKHSPCQKGGTCVNMPSGPHCLCPQHLTGNHCQKEKCFEPQLLRFFHKNEIWYRTEQAAVARCQCKGPDAHCQRLASQACRTNPCLHGGRCLEVEGHRLCHCPVGYTGAFCDVDTKASCYDGRGLSYRGLARTTLSGAPCQPWASEATYRNVTAEQARNWGLGGHAFCRNPDNDIRPWCFVLNRDRLSWEYCDLAQCQTPTQAAPPTPVSPRLHVPLMPAQPAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTRNGPLSCGQRLRKSLSSMTRVVGGLVALRGAHPYIAALYWGHSFCAGSLIAPCWVLTAAHCLQDRPAPEDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAFSPVSYQHDLALLRLQEDADGSCALLSPYVQPVCLPSGAARPSETTLCQVAGWGHQFEGAEEYASFLQEAQVPFLSLERCSAPDVHGSSILPGMLCAGFLEGGTDACQGDSGGPLVCEDQAAERRLTLQGIISWGSGCGDRNKPGVYTDVAYYLAWIREHTVS
P08709 Coagulation factor VII凝固因子,P08709,F7,,ENSG00000057593,Coagulation factor VII,13,113105788-113120685,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,102.0,liver: 156.3,Cell type enriched,Detected in some,7.0,Hepatocytes: 119.3,Cancer enriched,Detected in some,17.0,liver cancer: 41.4,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,breast cancer: 3.0;liver cancer: 8.7,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,HPA004826,,,Approved,Mitochondria,Secreted to blood,Blood coagulation,,,351000000.0,1300000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 1: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,1.0,Mitochondria,,HPA004826: AB_10602805,unprognostic (2.06e-1),unprognostic (2.55e-1),unprognostic (1.03e-1),unprognostic (1.34e-1),unprognostic (3.27e-1),unprognostic (1.91e-1),unprognostic (1.50e-3),unprognostic (3.81e-1),unprognostic (4.36e-3),unprognostic (1.16e-1),unprognostic (4.19e-3),unprognostic (1.15e-1),unprognostic (1.35e-3),unprognostic (3.36e-3),unprognostic (1.09e-1),unprognostic (2.86e-1),unprognostic (1.47e-1),MVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRRANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP
P00488 Coagulation factor XIII A chain 凝血因子,P00488,F13A1,F13A,ENSG00000124491,Coagulation factor XIII A chain,6,6144084-6321013,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Acyltransferase, Transferase","Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,adipose tissue: 224.8;placenta: 473.0,Group enriched,Detected in many,4.0,Hofbauer cells: 791.5;Langerhans cells: 206.4;Macrophages: 321.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,classical monocyte: 141.3;myeloid DC: 179.8,Group enriched,Detected in many,184.0,dendritic cells: 179.8;granulocytes: 50.0;monocytes: 141.3,Cancer enhanced,Detected in some,,cervical cancer: 13.1;Leukemia: 20.7,"Adipose subcutaneous - Macrophages, Adipose visceral - Macrophages, Breast - Macrophages, Colon - Macrophages, Heart muscle - Macrophages, Prostate - Macrophages, Skeletal muscle - Macrophages, Stomach - Macrophages, Testis - Macrophages, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in some,,,"HPA001804, CAB002155",Enhanced,,,,Secreted to blood,Blood coagulation,,,,1400000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 58: Placenta - Pregnancy,Cluster 8: Immune cells - Immune response,Cluster 14: Myeloid leukemia - Innate immune response,Cluster 58: Macrophages - Innate immune response,12.0,,,"CAB002155: AB_564077, HPA001804: AB_1078792",unprognostic (4.44e-1),unprognostic (5.90e-2),unprognostic (2.65e-2),unprognostic (3.93e-2),unprognostic (5.02e-2),unprognostic (3.75e-2),unprognostic (5.27e-2),unprognostic (1.96e-1),unprognostic (2.68e-2),unprognostic (6.84e-3),unprognostic (4.96e-2),unprognostic (1.97e-1),prognostic unfavorable (6.61e-6),unprognostic (2.79e-2),unprognostic (1.52e-1),unprognostic (1.57e-1),unprognostic (2.54e-3),MSETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPRGVNLQEFLNVTSVHLFKERWDTNKVDHHTDKYENNKLIVRRGQSFYVQIDFSRPYDPRRDLFRVEYVIGRYPQENKGTYIPVPIVSELQSGKWGAKIVMREDRSVRLSIQSSPKCIVGKFRMYVAVWTPYGVLRTSRNPETDTYILFNPWCEDDAVYLDNEKEREEYVLNDIGVIFYGEVNDIKTRSWSYGQFEDGILDTCLYVMDRAQMDLSGRGNPIKVSRVGSAMVNAKDDEGVLVGSWDNIYAYGVPPSAWTGSVDILLEYRSSENPVRYGQCWVFAGVFNTFLRCLGIPARIVTNYFSAHDNDANLQMDIFLEEDGNVNSKLTKDSVWNYHCWNEAWMTRPDLPVGFGGWQAVDSTPQENSDGMYRCGPASVQAIKHGHVCFQFDAPFVFAEVNSDLIYITAKKDGTHVVENVDATHIGKLIVTKQIGGDGMMDITDTYKFQEGQEEERLALETALMYGAKKPLNTEGVMKSRSNVDMDFEVENAVLGKDFKLSITFRNNSHNRYTITAYLSANITFYTGVPKAEFKKETFDVTLEPLSFKKEAVLIQAGEYMGQLLEQASLHFFVTARINETRDVLAKQKSTVLTIPEIIIKVRGTQVVGSDMTVTVEFTNPLKETLRNVWVHLDGPGVTRPMKKMFREIRPNSTVQWEEVCRPWVSGHRKLIASMSSDSLRHVYGELDVQIQRRPSM
"P04264 Keratin, type II cytoskeletal 1 角蛋白，II型细胞骨架",P04264,KRT1,"EHK1, KRT1A",ENSG00000167768,Keratin 1,12,52674736-52680407,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,,"Disease variant, Ichthyosis, Palmoplantar keratoderma",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,10.0,skin 1: 12670.5,Cell type enriched,Detected in some,11.0,Suprabasal keratinocytes: 6357.5,Group enriched,Detected in many,5.0,head and neck cancer: 313.8;melanoma: 478.9,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,memory CD4 T-cell: 2.3,Lineage enriched,Detected in single,23.0,T-cells: 2.3,Group enriched,Detected in some,5.0,Bladder cancer: 10.9;Esophageal cancer: 23.0;head and neck cancer: 17.4,Skin - Keratinocyte (other),Low region specificity,Detected in all,,,Not detected,Not detected,,,"CAB002153, HPA017917, HPA062908",Enhanced,,,,,,,,,35000000000.0,Cluster 11: T-cells - Unknown function,Cluster 13: Skin - Cornification,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 12: Squamous epithelial cells - Keratinization,32.0,,,"CAB002153: AB_563790, HPA017917: AB_1852192, HPA062908: AB_2684901",unprognostic (8.05e-2),unprognostic (8.49e-3),unprognostic (5.06e-3),unprognostic (6.44e-2),unprognostic (1.25e-2),unprognostic (1.53e-1),unprognostic (2.07e-1),unprognostic (3.24e-1),unprognostic (1.30e-1),unprognostic (2.16e-1),unprognostic (9.24e-2),unprognostic (6.63e-2),unprognostic (3.23e-4),unprognostic (1.58e-1),unprognostic (3.40e-2),unprognostic (1.36e-1),unprognostic (1.09e-2),MSRQFSSRSGYRSGGGFSSGSAGIINYQRRTTSSSTRRSGGGGGRFSSCGGGGGSFGAGGGFGSRSLVNLGGSKSISISVARGGGRGSGFGGGYGGGGFGGGGFGGGGFGGGGIGGGGFGGFGSGGGGFGGGGFGGGGYGGGYGPVCPPGGIQEVTINQSLLQPLNVEIDPEIQKVKSREREQIKSLNNQFASFIDKVRFLEQQNQVLQTKWELLQQVDTSTRTHNLEPYFESFINNLRRRVDQLKSDQSRLDSELKNMQDMVEDYRNKYEDEINKRTNAENEFVTIKKDVDGAYMTKVDLQAKLDNLQQEIDFLTALYQAELSQMQTQISETNVILSMDNNRSLDLDSIIAEVKAQYEDIAQKSKAEAESLYQSKYEELQITAGRHGDSVRNSKIEISELNRVIQRLRSEIDNVKKQISNLQQSISDAEQRGENALKDAKNKLNDLEDALQQAKEDLARLLRDYQELMNTKLALDLEIATYRTLLEGEESRMSGECAPNVSVSVSTSHTTISGGGSRGGGGGGYGSGGSSYGSGGGSYGSGGGGGGGRGSYGSGGSSYGSGGGSYGSGGGGGGHGSYGSGSSSGGYRGGSGGGGGGSSGGRGSGGGSSGGSIGGRGSSSGGVKSSGGSSSVKFVSTTYSGVTR
"P13645 Keratin, type I cytoskeletal 10  角蛋白，I型细胞骨架",P13645,KRT10,"CK10, K10, KPP",ENSG00000186395,Keratin 10,17,40818117-40822614,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Disease variant, Ichthyosis",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,14.0,skin 1: 15346.8,Cell type enriched,Detected in all,8.0,Suprabasal keratinocytes: 6950.7,Group enriched,Detected in all,4.0,head and neck cancer: 310.0;melanoma: 562.4,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in many,,,Low lineage specificity,Detected in all,,,Cancer enhanced,Detected in all,,Rhabdoid: 214.5,Skin - Keratinocyte (other),Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB000132, HPA012014",Enhanced,,,,Secreted in other tissues,No annotated function,,,,18000000000.0,Cluster 45: Eosinophils - Unknown function,Cluster 13: Skin - Cornification,Cluster 55: Non-specific - Transcription,Cluster 5: Rhabdoid - Unknown function,Cluster 12: Squamous epithelial cells - Keratinization,1.0,,,"CAB000132: , HPA012014: AB_1852195",unprognostic (3.07e-1),unprognostic (5.19e-2),unprognostic (1.71e-1),unprognostic (1.37e-2),unprognostic (2.00e-2),unprognostic (2.60e-1),unprognostic (3.02e-2),unprognostic (1.29e-2),unprognostic (1.09e-1),unprognostic (1.56e-1),unprognostic (1.00e-2),unprognostic (2.14e-1),prognostic unfavorable (9.32e-5),unprognostic (1.64e-1),unprognostic (1.85e-1),unprognostic (1.66e-2),unprognostic (8.10e-2),MSVRYSSSKHYSSSRSGGGGGGGGCGGGGGVSSLRISSSKGSLGGGFSSGGFSGGSFSRGSSGGGCFGGSSGGYGGLGGFGGGSFRGSYGSSSFGGSYGGIFGGGSFGGGSFGGGSFGGGGFGGGGFGGGFGGGFGGDGGLLSGNEKVTMQNLNDRLASYLDKVRALEESNYELEGKIKEWYEKHGNSHQGEPRDYSKYYKTIDDLKNQILNLTTDNANILLQIDNARLAADDFRLKYENEVALRQSVEADINGLRRVLDELTLTKADLEMQIESLTEELAYLKKNHEEEMKDLRNVSTGDVNVEMNAAPGVDLTQLLNNMRSQYEQLAEQNRKDAEAWFNEKSKELTTEIDNNIEQISSYKSEITELRRNVQALEIELQSQLALKQSLEASLAETEGRYCVQLSQIQAQISALEEQLQQIRAETECQNTEYQQLLDIKIRLENEIQTYRSLLEGEGSSGGGGRGGGSFGGGYGGGSSGGGSSGGGHGGGHGGSSGGGYGGGSSGGGSSGGGYGGGSSSGGHGGSSSGGYGGGSSGGGGGGYGGGSSGGGSSSGGGYGGGSSSGGHKSSSSGSVGESSSKGPRY
"P35908 Keratin, type II cytoskeletal 2 epidermal角蛋白，II型细胞骨架表皮",P35908,KRT2,"KRT2A, KRTE",ENSG00000172867,Keratin 2,12,52644558-52652211,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,,"Disease variant, FDA approved drug targets, Ichthyosis",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,57.0,skin 1: 4511.5,Cell type enriched,Detected in some,30.0,Suprabasal keratinocytes: 130.9,Cancer enriched,Detected in some,5.0,melanoma: 23.4,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,naive CD4 T-cell: 1.4,Lineage enriched,Detected in single,14.0,T-cells: 1.4,Not detected,Not detected,,,Skin - Keratinocyte (other),Group enriched,Detected in some,6.0,amygdala: 1.7;hippocampal formation: 2.7,Not detected,Not detected,,,CAB037321,Enhanced,,,,,,,,,9700000000.0,Cluster 43: Non-specific - Transcription & Translation,Cluster 82: Skin - Keratinization,,Cluster 24: Non-specific - Unknown function,Cluster 12: Squamous epithelial cells - Keratinization,11.0,,,CAB037321: ,unprognostic (1.22e-1),unprognostic (1.60e-1),unprognostic (1.34e-1),unprognostic (2.56e-1),unprognostic (8.47e-3),unprognostic (1.69e-2),,unprognostic (1.84e-1),unprognostic (3.59e-1),,unprognostic (2.12e-1),unprognostic (4.76e-2),unprognostic (3.56e-7),unprognostic (6.43e-2),unprognostic (5.98e-3),unprognostic (6.69e-2),unprognostic (3.46e-1),MSCQISCKSRGRGGGGGGFRGFSSGSAVVSGGSRRSTSSFSCLSRHGGGGGGFGGGGFGSRSLVGLGGTKSISISVAGGGGGFGAAGGFGGRGGGFGGGSSFGGGSGFSGGGFGGGGFGGGRFGGFGGPGGVGGLGGPGGFGPGGYPGGIHEVSVNQSLLQPLNVKVDPEIQNVKAQEREQIKTLNNKFASFIDKVRFLEQQNQVLQTKWELLQQMNVGTRPINLEPIFQGYIDSLKRYLDGLTAERTSQNSELNNMQDLVEDYKKKYEDEINKRTAAENDFVTLKKDVDNAYMIKVELQSKVDLLNQEIEFLKVLYDAEISQIHQSVTDTNVILSMDNSRNLDLDSIIAEVKAQYEEIAQRSKEEAEALYHSKYEELQVTVGRHGDSLKEIKIEISELNRVIQRLQGEIAHVKKQCKNVQDAIADAEQRGEHALKDARNKLNDLEEALQQAKEDLARLLRDYQELMNVKLALDVEIATYRKLLEGEECRMSGDLSSNVTVSVTSSTISSNVASKAAFGGSGGRGSSSGGGYSSGSSSYGSGGRQSGSRGGSGGGGSISGGGYGSGGGSGGRYGSGGGSKGGSISGGGYGSGGGKHSSGGGSRGGSSSGGGYGSGGGGSSSVKGSSGEAFGSSVTFSFR
"P35527 Keratin, type I cytoskeletal 9角蛋白，I型细胞骨架",P35527,KRT9,"CK-9, EPPK, K9",ENSG00000171403,Keratin 9,17,41565836-41572059,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,,"Disease variant, Palmoplantar keratoderma",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,5.0,lymphoid tissue: 11.8,Cell type enhanced,Detected in some,,Basal keratinocytes: 2.7;Basal squamous epithelial cells: 1.1;Breast myoepithelial cells: 3.8;Extravillous trophoblasts: 2.9,Cancer enriched,Detected in some,6.0,melanoma: 21.2,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,cervical cancer: 4.2;head and neck cancer: 3.0,"Breast - Breast myoepithelial cells, Testis - Spermatogonia",Region enhanced,Detected in many,,basal ganglia: 25.1,,,,,"HPA007261, CAB037322",Supported,,,,,,,,,24000000000.0,,Cluster 71: Thymus - Adaptive immune response,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 4: Extravillous trophoblasts - Unknown function,,,,"CAB037322: , HPA007261: AB_1079182",unprognostic (2.13e-2),unprognostic (5.08e-2),,unprognostic (4.97e-2),,unprognostic (3.65e-2),,unprognostic (2.89e-3),unprognostic (1.36e-1),unprognostic (1.19e-1),unprognostic (5.92e-7),unprognostic (1.28e-1),,unprognostic (3.02e-2),unprognostic (1.40e-1),,unprognostic (4.15e-2),MSCRQFSSSYLSRSGGGGGGGLGSGGSIRSSYSRFSSSGGGGGGGRFSSSSGYGGGSSRVCGRGGGGSFGYSYGGGSGGGFSASSLGGGFGGGSRGFGGASGGGYSSSGGFGGGFGGGSGGGFGGGYGSGFGGFGGFGGGAGGGDGGILTANEKSTMQELNSRLASYLDKVQALEEANNDLENKIQDWYDKKGPAAIQKNYSPYYNTIDDLKDQIVDLTVGNNKTLLDIDNTRMTLDDFRIKFEMEQNLRQGVDADINGLRQVLDNLTMEKSDLEMQYETLQEELMALKKNHKEEMSQLTGQNSGDVNVEINVAPGKDLTKTLNDMRQEYEQLIAKNRKDIENQYETQITQIEHEVSSSGQEVQSSAKEVTQLRHGVQELEIELQSQLSKKAALEKSLEDTKNRYCGQLQMIQEQISNLEAQITDVRQEIECQNQEYSLLLSIKMRLEKEIETYHNLLEGGQEDFESSGAGKIGLGGRGGSGGSYGRGSRGGSGGSYGGGGSGGGYGGGSGSRGGSGGSYGGGSGSGGGSGGGYGGGSGGGHSGGSGGGHSGGSGGNYGGGSGSGGGSGGGYGGGSGSRGGSGGSHGGGSGFGGESGGSYGGGEEASGSGGGYGGGSGKSSHS
"P02533 Keratin, type I cytoskeletal 14角蛋白，I型细胞骨架",P02533,KRT14,"EBS3, EBS4",ENSG00000186847,Keratin 14,17,41582279-41586895,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,,"Cancer-related genes, Disease variant, Ectodermal dysplasia, Epidermolysis bullosa, Palmoplantar keratoderma",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,5.0,skin 1: 6776.5,Group enriched,Detected in many,6.0,Basal keratinocytes: 28244.3;Suprabasal keratinocytes: 10636.2,Cancer enriched,Detected in many,5.0,head and neck cancer: 5910.5,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,4.0,head and neck cancer: 2098.9,"Breast - Breast myoepithelial cells, Skin - Keratinocyte (other)",Not detected,Not detected,,,Region enhanced,Detected in single,,cerebral cortex: 1.5,"CAB000134, HPA000452, HPA000539, HPA023040",Enhanced,,Enhanced,Intermediate filaments,,,,,,1600000000.0,,Cluster 13: Skin - Cornification,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 12: Squamous epithelial cells - Keratinization,21.0,Intermediate filaments,,"CAB000134: , HPA000452: AB_1079177, HPA000539: , HPA023040: AB_1852201",prognostic favorable (2.66e-4),unprognostic (1.64e-1),unprognostic (1.01e-2),unprognostic (1.42e-2),unprognostic (1.66e-1),unprognostic (1.02e-2),,unprognostic (2.03e-2),unprognostic (2.74e-1),unprognostic (1.35e-1),unprognostic (1.00e-2),unprognostic (5.74e-3),unprognostic (1.49e-8),unprognostic (8.91e-2),unprognostic (2.00e-1),unprognostic (8.80e-3),unprognostic (1.22e-2),MTTCSRQFTSSSSMKGSCGIGGGIGGGSSRISSVLAGGSCRAPSTYGGGLSVSSSRFSSGGACGLGGGYGGGFSSSSSSFGSGFGGGYGGGLGAGLGGGFGGGFAGGDGLLVGSEKVTMQNLNDRLASYLDKVRALEEANADLEVKIRDWYQRQRPAEIKDYSPYFKTIEDLRNKILTATVDNANVLLQIDNARLAADDFRTKYETELNLRMSVEADINGLRRVLDELTLARADLEMQIESLKEELAYLKKNHEEEMNALRGQVGGDVNVEMDAAPGVDLSRILNEMRDQYEKMAEKNRKDAEEWFFTKTEELNREVATNSELVQSGKSEISELRRTMQNLEIELQSQLSMKASLENSLEETKGRYCMQLAQIQEMIGSVEEQLAQLRCEMEQQNQEYKILLDVKTRLEQEIATYRRLLEGEDAHLSSSQFSSGSQSSRDVTSSSRQIRTKVMDVHDGKVVSTHEQVLRTKN
P01009 Alpha-1-antitrypsin抗胰蛋白酶,P01009,SERPINA1,"A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1",ENSG00000197249,Serpin family A member 1,14,94376747-94390693,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Acute phase, Blood coagulation, Hemostasis","Protease inhibitor, Serine protease inhibitor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,45.0,liver: 33156.1,Cell type enriched,Detected in many,7.0,Hepatocytes: 38353.1,Cancer enriched,Detected in all,10.0,liver cancer: 3850.6,Low region specificity,Detected in all,,,Group enriched,Detected in all,5.0,classical monocyte: 2484.3;intermediate monocyte: 3414.0;neutrophil: 2835.2;non-classical monocyte: 4540.7,Group enriched,Detected in all,5.0,granulocytes: 2835.2;monocytes: 4540.7,Cancer enhanced,Detected in many,,Gastric cancer: 303.1;liver cancer: 783.6;lymphoma: 293.1,"Adipose visceral - Neutrophils, Liver - Hepatocytes, Skeletal muscle - Neutrophils",Not detected,Not detected,,,,,,,"HPA000927, HPA001292, CAB013211, CAB016648, CAB073396",Enhanced,,Enhanced,Vesicles,Secreted to blood,Blood coagulation,,,2070000000000.0,140000000000.0,Cluster 37: Monocytes & Neutrophils - Innate immune response,Cluster 83: Liver - Metabolism,Cluster 12: Non-specific - Vasculature,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,4.0,Vesicles,,"CAB013211: , CAB016648: AB_1611888, CAB073396: , HPA000927: AB_1844761, HPA001292: AB_1844762",prognostic favorable (1.61e-5),unprognostic (3.37e-1),prognostic favorable (5.86e-4),unprognostic (1.38e-2),unprognostic (1.98e-2),unprognostic (5.50e-3),unprognostic (3.81e-2),unprognostic (6.78e-2),unprognostic (2.54e-2),unprognostic (7.96e-2),unprognostic (1.08e-1),unprognostic (4.54e-1),unprognostic (1.23e-2),unprognostic (1.89e-1),unprognostic (1.30e-2),unprognostic (1.17e-2),unprognostic (1.96e-1),MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK
P01042 Kininogen-1激肽原,P01042,KNG1,"BDK, BK, HK, HMWK, KNG",ENSG00000113889,Kininogen 1,3,186717348-186744410,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis, Inflammatory response","Protease inhibitor, Thiol protease inhibitor, Vasoactive, Vasodilator",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,7.0,liver: 3097.3,Cell type enriched,Detected in some,6.0,Hepatocytes: 1654.3,Cancer enriched,Detected in some,126.0,liver cancer: 608.6,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,11.0,Gastric cancer: 4.6;liver cancer: 8.0,"Kidney - Ascending Loop of Henle cells, Liver - Hepatocytes, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in single,,,"HPA001616, HPA001645, CAB009809",Enhanced,,,,Secreted to blood,Blood coagulation,,,90000000000.0,47000000000.0,,Cluster 1: Liver & Kidney - Metabolism,Cluster 53: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,,,"CAB009809: AB_2134781, HPA001616: AB_1079216, HPA001645: AB_1079215",unprognostic (3.88e-1),unprognostic (1.63e-1),unprognostic (2.82e-1),unprognostic (3.27e-1),unprognostic (8.30e-3),unprognostic (2.04e-1),prognostic favorable (1.28e-6),unprognostic (1.29e-2),unprognostic (1.10e-1),unprognostic (1.97e-2),unprognostic (9.96e-2),unprognostic (1.65e-1),unprognostic (3.45e-3),unprognostic (5.20e-2),unprognostic (2.46e-1),unprognostic (4.52e-2),,MKLITILFLCSRLLLSLTQESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYRITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQYDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHSSLFMLNEVKRAQRQVVAGLNFRITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIASFSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKLNAENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTESCETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISLMKRPPGFSPFRSSRIGEIKEETTVSPPHTSMAPAQDEERDSGKEQGHTRRHDWGHEKQRKHNLGHGHKHERDQGHGHQRGHGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGHGKHKNKGKKNGKHNGWKTEHLASSSEDSTTPSAQTQEKTEGPTPIPSLAKPGVTVTFSDFQDSDLIATMMPPISPAPIQSDDDWIPDIQIDPNGLSFNPISDFPDTTSPKCPGRPWKSVSEINPTTQMKESYYFDLTDGLS
P01023 Alpha-2-macroglobulin巨球蛋白,P01023,A2M,"CPAMD5, FWP007, S863-7",ENSG00000175899,Alpha-2-macroglobulin,12,9067664-9116229,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",,"Protease inhibitor, Serine protease inhibitor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,liver: 1212.9;lung: 1626.5,Cell type enhanced,Detected in many,,Adipocytes: 1247.2;Cardiomyocytes: 393.1;Endothelial cells: 861.7;Hepatocytes: 654.0;Microglial cells: 339.1;Smooth muscle cells: 471.0,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in single,,gdT-cell: 1.5,Lineage enhanced,Detected in single,,T-cells: 1.5,Cancer enhanced,Detected in many,,Brain cancer: 48.1;liver cancer: 106.6;skin cancer: 72.1,"Adipose subcutaneous - Endothelial cells, Adipose visceral - Endothelial cells, Breast - Endothelial cells, Colon - Endothelial cells, Heart muscle - Macrophages, Kidney - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_1, Prostate - Fibroblasts, Skeletal muscle - Endothelial cells, Thyroid - Endothelial cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA002265, CAB017621",Supported,,,,Secreted to blood,Enzyme inhibitor,,,1630000000000.0,170000000000.0,Cluster 1: T-cells - Unknown function,Cluster 11: Liver - Plasma proteins,Cluster 47: Endothelial cells - Vasculature,Cluster 18: Liver cancer - Metabolism,Cluster 41: Adipocytes & Endothelial cells - Mixed function,51.0,,,"CAB017621: AB_1118894, HPA002265: AB_1078142",unprognostic (1.73e-2),unprognostic (1.05e-3),unprognostic (1.72e-1),unprognostic (2.29e-2),unprognostic (7.36e-2),unprognostic (3.91e-2),unprognostic (7.95e-2),unprognostic (3.65e-2),unprognostic (2.38e-1),unprognostic (7.19e-2),unprognostic (4.71e-2),unprognostic (2.06e-2),unprognostic (1.28e-2),unprognostic (8.04e-3),unprognostic (2.32e-2),unprognostic (8.58e-2),unprognostic (9.03e-3),MGKNKLLHPSLVLLLLVLLPTDASVSGKPQYMVLVPSLLHTETTEKGCVLLSYLNETVTVSASLESVRGNRSLFTDLEAENDVLHCVAFAVPKSSSNEEVMFLTVQVKGPTQEFKKRTTVMVKNEDSLVFVQTDKSIYKPGQTVKFRVVSMDENFHPLNELIPLVYIQDPKGNRIAQWQSFQLEGGLKQFSFPLSSEPFQGSYKVVVQKKSGGRTEHPFTVEEFVLPKFEVQVTVPKIITILEEEMNVSVCGLYTYGKPVPGHVTVSICRKYSDASDCHGEDSQAFCEKFSGQLNSHGCFYQQVKTKVFQLKRKEYEMKLHTEAQIQEEGTVVELTGRQSSEITRTITKLSFVKVDSHFRQGIPFFGQVRLVDGKGVPIPNKVIFIRGNEANYYSNATTDEHGLVQFSINTTNVMGTSLTVRVNYKDRSPCYGYQWVSEEHEEAHHTAYLVFSPSKSFVHLEPMSHELPCGHTQTVQAHYILNGGTLLGLKKLSFYYLIMAKGGIVRTGTHGLLVKQEDMKGHFSISIPVKSDIAPVARLLIYAVLPTGDVIGDSAKYDVENCLANKVDLSFSPSQSLPASHAHLRVTAAPQSVCALRAVDQSVLLMKPDAELSASSVYNLLPEKDLTGFPGPLNDQDNEDCINRHNVYINGITYTPVSSTNEKDMYSFLEDMGLKAFTNSKIRKPKMCPQLQQYEMHGPEGLRVGFYESDVMGRGHARLVHVEEPHTETVRKYFPETWIWDLVVVNSAGVAEVGVTVPDTITEWKAGAFCLSEDAGLGISSTASLRAFQPFFVELTMPYSVIRGEAFTLKATVLNYLPKCIRVSVQLEASPAFLAVPVEKEQAPHCICANGRQTVSWAVTPKSLGNVNFTVSAEALESQELCGTEVPSVPEHGRKDTVIKPLLVEPEGLEKETTFNSLLCPSGGEVSEELSLKLPPNVVEESARASVSVLGDILGSAMQNTQNLLQMPYGCGEQNMVLFAPNIYVLDYLNETQQLTPEIKSKAIGYLNTGYQRQLNYKHYDGSYSTFGERYGRNQGNTWLTAFVLKTFAQARAYIFIDEAHITQALIWLSQRQKDNGCFRSSGSLLNNAIKGGVEDEVTLSAYITIALLEIPLTVTHPVVRNALFCLESAWKTAQEGDHGSHVYTKALLAYAFALAGNQDKRKEVLKSLNEEAVKKDNSVHWERPQKPKAPVGHFYEPQAPSAEVEMTSYVLLAYLTAQPAPTSEDLTSATNIVKWITKQQNAQGGFSSTQDTVVALHALSKYGAATFTRTGKAAQVTIQSSGTFSSKFQVDNNNRLLLQQVSLPELPGEYSMKVTGEGCVYLQTSLKYNILPEKEEFPFALGVQTLPQTCDEPKAHTSFQISLSVSYTGSRSASNMAIVDVKMVSGFIPLKPTVKMLERSNHVSRTEVSSNHVLIYLDKVSNQTLSLFFTVLQDVPVRDLKPAIVKVYDYYETDEFAIAEYNAPCSKDLGNA
P04196 Histidine-rich glycoprotein 富组氨酸糖蛋白,P04196,HRG,"HPRG, HRGP",ENSG00000113905,Histidine rich glycoprotein,3,186660216-186678234,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Angiogenesis, Blood coagulation, Chemotaxis, Fibrinolysis, Hemostasis",Heparin-binding,"Disease variant, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,174.0,liver: 5270.7,Cell type enriched,Detected in some,11.0,Hepatocytes: 396.9,Cancer enriched,Detected in some,262.0,liver cancer: 406.7,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Kidney - Ascending Loop of Henle cells, Liver - Hepatocytes",Not detected,Not detected,,,Not detected,Not detected,,,"HPA050269, HPA054598",Supported,,,,Secreted to blood,Blood coagulation,,,120000000000.0,28000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,2.0,,,"HPA050269: AB_2681068, HPA054598: AB_2682539",,unprognostic (2.67e-1),,unprognostic (1.74e-2),,unprognostic (7.58e-5),prognostic favorable (9.64e-5),unprognostic (1.44e-1),,unprognostic (2.98e-3),unprognostic (2.22e-1),,unprognostic (1.55e-2),unprognostic (1.14e-1),unprognostic (5.50e-2),unprognostic (1.05e-1),unprognostic (1.46e-2),MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK
P02787 Serotransferrin转铁蛋白,P02787,TF,"PRO1557, PRO2086",ENSG00000091513,Transferrin,3,133746040-133796641,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Ion transport, Iron transport, Transport",,"Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,brain: 1466.9;liver: 7278.6;retina: 2358.0,Group enriched,Detected in many,8.0,Hepatocytes: 5785.8;Muller glia cells: 10733.8,Cancer enriched,Detected in many,42.0,liver cancer: 783.0,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,5.0,liver cancer: 221.9,"Adipose subcutaneous - Adipocytes (Subcutaneous), Adipose visceral - Adipocytes (Visceral), Colon - Enteric glia cells, Liver - Hepatocytes, Skin - Sebaceous gland cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001527, HPA005692, CAB009538",Enhanced,,,,Secreted to blood,Transport,,,19800000000000.0,98000000000.0,,Cluster 83: Liver - Metabolism,Cluster 30: White matter - Myelination,Cluster 18: Liver cancer - Metabolism,Cluster 10: Muller glia cells - Visual perception,20.0,,,"CAB009538: AB_793365, HPA001527: AB_1080357, HPA005692: AB_1080354",prognostic favorable (4.05e-4),unprognostic (2.45e-2),unprognostic (1.78e-1),unprognostic (1.50e-1),unprognostic (8.99e-2),unprognostic (5.18e-2),unprognostic (6.63e-2),unprognostic (8.46e-2),unprognostic (2.82e-1),unprognostic (3.08e-1),unprognostic (1.37e-1),unprognostic (7.60e-2),prognostic unfavorable (2.35e-13),unprognostic (2.17e-3),unprognostic (5.49e-2),unprognostic (3.47e-3),unprognostic (9.70e-2),MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVKKASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAIAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP
P02766 Transthyretin 转甲状腺素蛋白,P02766,TTR,"CTS, CTS1, HsT2651, PALB",ENSG00000118271,Transthyretin,18,31557009-31598833,"Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Transport,"Hormone, Thyroid hormone","Amyloidosis, Cancer-related genes, Disease variant, FDA approved drug targets, Neuropathy",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,34.0,choroid plexus: 692067.5,Cell type enriched,Detected in many,7.0,Hepatocytes: 26585.9,Group enriched,Detected in many,28.0,liver cancer: 928.2;pancreatic cancer: 666.0,Region enriched,Detected in all,82.0,choroid plexus: 302089.2,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in many,7.0,Gastric cancer: 130.8;liver cancer: 177.5,"Liver - Hepatocytes, Pancreas - Alpha cells, Testis - Early spermatids",Group enriched,Detected in all,5.0,basal ganglia: 1538.8;hippocampal formation: 4894.4;pons and medulla: 5760.6;thalamus: 3403.0,Region enhanced,Detected in all,,medulla oblongata: 1291.2,"CAB002517, HPA002550, CAB062567, CAB073406",Supported,,Approved,Golgi apparatus,Secreted to blood,Hormone,,,345000000000.0,99000000000.0,,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 36: Choroid plexus - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,56.0,Golgi apparatus,,"CAB002517: AB_563965, CAB062567: AB_2665620, CAB073406: , HPA002550: AB_1080419",unprognostic (6.79e-3),,unprognostic (3.38e-2),unprognostic (4.10e-1),unprognostic (1.74e-1),,unprognostic (1.84e-2),unprognostic (8.15e-2),unprognostic (3.74e-2),,unprognostic (9.66e-3),unprognostic (8.72e-2),unprognostic (1.23e-2),unprognostic (8.35e-3),unprognostic (5.26e-1),,unprognostic (3.52e-2),MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE
P00751 Complement factor B补体因子B,P00751,CFB,"BF, BFD, H2-Bf",ENSG00000243649,Complement factor B,6,31945650-31952086,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Complement alternate pathway, Immunity, Innate immunity","Hydrolase, Protease, Serine protease","Age-related macular degeneration, Disease variant, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,20.0,liver: 2453.1,Cell type enhanced,Detected in many,,Ductal cells: 913.7;Exocrine glandular cells: 569.1;Hepatocytes: 199.3;Mesothelial cells: 453.1;Pancreatic endocrine cells: 368.5,Cancer enhanced,Detected in all,,liver cancer: 78.3,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,5.0,head and neck cancer: 34.6,"Adipose subcutaneous - Adipose progenitor cells, Adipose visceral - Mesothelial cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA000951, HPA001817, HPA001832, CAB016381",Supported,,Approved,"Endoplasmic reticulum,Vesicles,Cell Junctions",Secreted to blood,Immunity,,,879000000.0,120000000000.0,,Cluster 83: Liver - Metabolism,Cluster 12: Non-specific - Vasculature,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 45: Non-specific - Mixed function,,"Endoplasmic reticulum, Vesicles",Cell Junctions,"CAB016381: AB_627562, HPA000951: AB_2797216, HPA001817: AB_1078779, HPA001832: AB_1078778",prognostic favorable (2.76e-5),unprognostic (1.02e-1),unprognostic (1.44e-1),unprognostic (7.94e-2),unprognostic (1.82e-2),unprognostic (8.56e-2),unprognostic (8.08e-3),unprognostic (8.81e-2),unprognostic (3.51e-1),unprognostic (2.26e-2),unprognostic (1.32e-2),unprognostic (6.57e-2),prognostic unfavorable (1.53e-5),unprognostic (1.36e-1),unprognostic (5.13e-2),unprognostic (1.05e-2),unprognostic (3.68e-2),MGSNLSPQLCLMPFILGLLSGGVTTTPWSLARPQGSCSLEGVEIKGGSFRLLQEGQALEYVCPSGFYPYPVQTRTCRSTGSWSTLKTQDQKTVRKAECRAIHCPRPHDFENGEYWPRSPYYNVSDEISFHCYDGYTLRGSANRTCQVNGRWSGQTAICDNGAGYCSNPGIPIGTRKVGSQYRLEDSVTYHCSRGLTLRGSQRRTCQEGGSWSGTEPSCQDSFMYDTPQEVAEAFLSSLTETIEGVDAEDGHGPGEQQKRKIVLDPSGSMNIYLVLDGSDSIGASNFTGAKKCLVNLIEKVASYGVKPRYGLVTYATYPKIWVKVSEADSSNADWVTKQLNEINYEDHKLKSGTNTKKALQAVYSMMSWPDDVPPEGWNRTRHVIILMTDGLHNMGGDPITVIDEIRDLLYIGKDRKNPREDYLDVYVFGVGPLVNQVNINALASKKDNEQHVFKVKDMENLEDVFYQMIDESQSLSLCGMVWEHRKGTDYHKQPWQAKISVIRPSKGHESCMGAVVSEYFVLTAAHCFTVDDKEHSIKVSVGGEKRDLEIEVVLFHPNYNINGKKEAGIPEFYDYDVALIKLKNKLKYGQTIRPICLPCTEGTTRALRLPPTTTCQQQKEELLPAQDIKALFVSEEEKKLTRKEVYIKNGDKKGSCERDAQYAPGYDKVKDISEVVTPRFLCTGGVSPYADPNTCRGDSGGPLIVHKRSRFIQVGVISWGVVDVCKNQKRQKQVPAHARDFHINLFQVLPWLKEKLQDEDLGFL
P01024  (Complement C3)补体蛋白C3,P01024,C3,"ARMD9, C3a, C3b, CPAMD1",ENSG00000125730,Complement C3,19,6677704-6730562,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Fatty acid metabolism, Immunity, Inflammatory response, Innate immunity, Lipid metabolism",,"Age-related macular degeneration, Disease variant, FDA approved drug targets, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,9.0,liver: 5250.9,Cell type enhanced,Detected in many,,Ductal cells: 657.6;Exocrine glandular cells: 845.2;Hepatocytes: 3158.4;Mesothelial cells: 2220.5,Cancer enriched,Detected in all,5.0,liver cancer: 1213.6,Low region specificity,Detected in all,,,Immune cell enriched,Detected in many,5.0,non-classical monocyte: 14.5,Lineage enriched,Detected in many,5.0,monocytes: 14.5,Cancer enhanced,Detected in many,,liver cancer: 255.0,"Liver - Hepatocytes, Lung - Fibroblast_2, Thyroid - Macrophages",Low region specificity,Detected in many,,,Low region specificity,Detected in all,,,"HPA003563, CAB004209, HPA020432",Enhanced,,,,Secreted to blood,Complement pathway,,,1260000000000.0,200000000000.0,Cluster 40: Monocytes - Innate immune response,Cluster 83: Liver - Metabolism,Cluster 20: Macrophages & Microglia - Immune response,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 62: Hepatocytes - Metabolism,9.0,,,"CAB004209: AB_627277, HPA003563: AB_1847117, HPA020432: AB_1847118",unprognostic (3.26e-3),unprognostic (3.91e-1),unprognostic (3.92e-1),unprognostic (5.98e-3),unprognostic (3.31e-1),unprognostic (1.04e-1),prognostic favorable (8.11e-4),unprognostic (1.99e-1),unprognostic (9.26e-2),unprognostic (5.80e-2),unprognostic (8.12e-3),unprognostic (5.48e-2),prognostic unfavorable (1.09e-5),unprognostic (2.63e-2),unprognostic (2.49e-2),unprognostic (6.03e-3),unprognostic (3.88e-1),MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVHDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKVVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSLSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTEKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEVVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKTPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPLSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMDRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGASGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAELQCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEACKKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKEPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVVRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVIVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKEDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTPTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTAYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKDMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMGRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLRSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDAKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSDRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDGKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDEYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSYIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN
P0C0L5 Complement C4-B 补体蛋白C4B,P0C0L5,C4B,"C4B1, C4B3, C4F, CH, CO4, CPAMD3",ENSG00000224389,Complement C4B (Chido blood group),6,32014795-32035418,"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement pathway, Immunity, Inflammatory response, Innate immunity",Blood group antigen,"FDA approved drug targets, Systemic lupus erythematosus",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,5.0,adrenal gland: 214.6;liver: 375.4,Group enriched,Detected in some,5.0,Hepatocytes: 7.1;Mesothelial cells: 13.6,Cancer enhanced,Detected in many,,liver cancer: 33.8,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 6.7;Myeloma: 3.9,Liver - Hepatocytes,,,,,,,,,"HPA046356, HPA048287, HPA050103",Approved,,,,Secreted to blood,Complement pathway,,,,120000000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 70: DU4475 - Unknown function,Cluster 62: Hepatocytes - Metabolism,1.0,,,"HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016",unprognostic (1.29e-1),unprognostic (2.99e-2),unprognostic (5.50e-3),unprognostic (1.30e-1),unprognostic (8.09e-2),unprognostic (6.24e-2),unprognostic (6.09e-2),unprognostic (1.05e-1),unprognostic (4.81e-2),unprognostic (1.12e-1),unprognostic (6.24e-2),unprognostic (6.86e-2),unprognostic (1.04e-1),unprognostic (3.12e-2),unprognostic (1.30e-1),unprognostic (3.99e-3),unprognostic (1.11e-2),MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFSVVPTAATAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRGSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDLSPVIHRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPGKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQGCQV
P0C0L4 Complement C4-A 补体蛋白C4A,P0C0L4,C4A,"C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG",ENSG00000244731,Complement C4A (Rodgers blood group),6,31982057-32002681,"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement pathway, Immunity, Inflammatory response, Innate immunity",Blood group antigen,"Disease variant, FDA approved drug targets, Systemic lupus erythematosus",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adrenal gland: 112.2;liver: 328.2,Group enriched,Detected in some,4.0,Hepatocytes: 6.8;Mesothelial cells: 8.5,Cancer enhanced,Detected in many,,liver cancer: 27.8,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 8.8;Myeloma: 6.7,"Breast - Breast glandular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes",,,,,,,,,"CAB009811, CAB032603, HPA046356, HPA048287, HPA050103",Supported,,,,Secreted to blood,Complement pathway,,,342000000.0,120000000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 70: DU4475 - Unknown function,Cluster 62: Hepatocytes - Metabolism,2.0,,,"CAB009811: AB_2066891, CAB032603: AB_2290613, HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016",unprognostic (2.13e-1),unprognostic (3.02e-2),unprognostic (3.74e-2),unprognostic (3.10e-1),unprognostic (5.29e-2),unprognostic (3.09e-2),unprognostic (2.48e-2),unprognostic (1.02e-1),unprognostic (2.00e-1),unprognostic (1.44e-1),unprognostic (3.70e-1),unprognostic (3.15e-1),unprognostic (4.47e-2),unprognostic (3.20e-2),unprognostic (5.20e-2),unprognostic (3.97e-2),unprognostic (8.63e-2),MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKANSFLGEKASAGLLGAHAAAITAYALTLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPGKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQGCQV
P08603 Complement factor H补体因子H,P08603,CFH,"ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS",ENSG00000000971,Complement factor H,1,196651754-196752476,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Host-virus interaction, Immunity, Innate immunity",,"Age-related macular degeneration, Cancer-related genes, Disease variant, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,6.0,liver: 1645.3,Cell type enhanced,Detected in many,,Fibroblasts: 355.9;Hepatocytes: 834.8;Leydig cells: 285.2;Mesothelial cells: 388.2;Ovarian stromal cells: 208.2,Cancer enriched,Detected in all,9.0,liver cancer: 151.1,Region enhanced,Detected in all,,choroid plexus: 43.6,Immune cell enhanced,Detected in some,,MAIT T-cell: 17.6,Lineage enriched,Detected in single,56.0,T-cells: 17.6,Cancer enhanced,Detected in many,,Gallbladder cancer: 59.2,"Heart muscle - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_2",,,,,,,,,"CAB016385, CAB016769, HPA038922, HPA049176, HPA053326",Supported,,Approved,Vesicles,Secreted to blood,Immunity,,,396000000000.0,100000000000.0,Cluster 1: T-cells - Unknown function,Cluster 83: Liver - Metabolism,Cluster 42: Choroid plexus - Mitochondria,Cluster 71: Lymphoma - Inflammatory response,Cluster 53: Fibroblasts - ECM organization,6.0,Vesicles,,"CAB016385: AB_627572, CAB016769: , HPA038922: AB_2676271, HPA049176: AB_2680663, HPA053326: AB_2682113",unprognostic (2.40e-1),unprognostic (9.86e-2),unprognostic (1.22e-1),unprognostic (8.39e-2),unprognostic (5.40e-3),unprognostic (1.80e-1),unprognostic (3.75e-3),unprognostic (7.40e-2),unprognostic (1.06e-1),unprognostic (1.04e-1),unprognostic (9.08e-2),unprognostic (2.08e-1),prognostic unfavorable (1.92e-6),unprognostic (6.50e-3),unprognostic (4.49e-3),unprognostic (1.73e-1),unprognostic (1.37e-1),MRLLAKIICLMLWAICVAEDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLGNVIMVCRKGEWVALNPLRKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQLLGEINYRECDTDGWTNDIPICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNSGYKIEGDEEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERFQYKCNMGYEYSERGDAVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYPATRGNTAKCTSTGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEHFETPSGSYWDHIHCTQDGWSPAVPCLRKCYFPYLENGYNQNYGRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRVKTCSKSSIDIENGFISESQYTYALKEKAKYQCKLGYVTADGETSGSITCGKDGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLDYECHDGYESNTGSTTGSIVCGYNGWSDLPICYERECELPKIDVHLVPDRKKDQYKVGEVLKFSCKPGFTIVGPNSVQCYHFGLSPDLPICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCNPRFLMKGPNKIQCVDGEWTTLPVCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHRSITCIHGVWTQLPQCVAIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYRCRGKEGWIHTVCINGRWDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYRDGEKVSVLCQENYLIQEGEEITCKDGRWQSIPLCVEKIPCSQPPQIEHGTINSSRSSQESYAHGTKLSYTCEGGFRISEENETTCYMGKWSSPPQCEGLPCKSPPEISHGVVAHMSDSYQYGEEVTYKCFEGFGIDGPAIAKCLGEKWSHPPSCIKTDCLSLPSFENAIPMGEKKDVYKAGEQVTYTCATYYKMDGASNVTCINSRWTGRPTCRDTSCVNPPTVQNAYIVSRQMSKYPSGERVRYQCRSPYEMFGDEEVMCLNGNWTEPPQCKDSTGKCGPPPPIDNGDITSFPLSVYAPASSVEYQCQNLYQLEGNKRITCRNGQWSEPPKCLHPCVISREIMENYNIALRWTAKQKLYSRTGESVEFVCKRGYRLSSRSHTLRTTCWDGKLEYPTCAKR
P00746 Complement factor D补体因子D,P00746,CFD,"ADN, DF, PFD",ENSG00000197766,Complement factor D,19,859453-867884,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Immunity, Innate immunity","Hydrolase, Protease, Serine protease",Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,adipose tissue: 1448.6,Group enriched,Detected in many,9.0,Fibroblasts: 7755.6;Leydig cells: 5061.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in all,,basophil: 1712.8,Lineage enriched,Detected in all,6.0,granulocytes: 1712.8,Cancer enhanced,Detected in all,,Leukemia: 84.8,"Liver - Kupffer cells, Pancreas - Fibroblasts, Prostate - Fibroblasts, Skeletal muscle - Fibroblasts, Skin - Fibroblast_2",Not detected,Not detected,,,Low region specificity,Detected in all,,,,,,,,Secreted to blood,Immunity,,,732000000.0,4400000000.0,Cluster 35: Neutrophils - Protein binding,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 48: Non-specific - Mixed function,Cluster 14: Myeloid leukemia - Innate immune response,Cluster 53: Fibroblasts - ECM organization,,,,,unprognostic (3.00e-2),unprognostic (6.09e-2),unprognostic (2.44e-1),unprognostic (1.22e-3),unprognostic (6.92e-2),unprognostic (5.28e-2),unprognostic (8.11e-3),unprognostic (2.48e-1),unprognostic (1.46e-2),unprognostic (8.10e-2),prognostic favorable (1.77e-4),unprognostic (9.53e-2),prognostic unfavorable (7.09e-4),unprognostic (1.23e-1),unprognostic (4.55e-2),unprognostic (1.92e-2),unprognostic (9.75e-2),MHSWERLAVLVLLGAAACAAPPRGRILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLA
P01031 Complement C5补体C5,P01031,C5,"C5a, C5b, CPAMD4",ENSG00000106804,Complement C5,9,120932987-121075195,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Inflammatory response, Innate immunity",,FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,30.0,liver: 434.4,Cell type enriched,Detected in many,14.0,Hepatocytes: 435.9,Cancer enriched,Detected in many,17.0,liver cancer: 73.0,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,5.0,liver cancer: 21.1,"Liver - Hepatocytes, Thyroid - Fibroblasts",Low region specificity,Detected in single,,,Low region specificity,Detected in many,,,HPA029339,Supported,,,,Secreted to blood,Complement pathway,,,113000000000.0,39000000000.0,,Cluster 83: Liver - Metabolism,Cluster 46: Brainstem - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,17.0,,,HPA029339: AB_10601125,unprognostic (2.51e-1),unprognostic (5.88e-3),unprognostic (2.50e-3),unprognostic (1.57e-2),unprognostic (5.05e-2),unprognostic (9.52e-3),prognostic favorable (9.43e-4),unprognostic (1.83e-1),unprognostic (3.19e-2),unprognostic (1.55e-1),unprognostic (2.35e-2),unprognostic (4.41e-2),unprognostic (1.46e-5),unprognostic (5.91e-2),unprognostic (1.20e-1),unprognostic (3.67e-2),unprognostic (2.75e-1),MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYPDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPITYDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHIGIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGYKNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVTFDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATPLFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASFVLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGEHLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRLLVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWVALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANADDSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLVPRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTVLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFPYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFYVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTAFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEARENSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDKTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLNLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHKGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLKIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLKALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHRPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYAYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIMGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC
P05156 Complement factor I 补体因子1,P05156,CFI,"C3b-INA, FI, IF, KAF",ENSG00000205403,Complement factor I,4,109731008-109802150,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Complement pathway, Host-virus interaction, Immunity, Innate immunity","Hydrolase, Protease, Serine protease","Age-related macular degeneration, Disease variant, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,5.0,liver: 952.1,Cell type enhanced,Detected in many,,Cholangiocytes: 108.7;Hepatocytes: 454.5;Muller glia cells: 114.1;Proximal tubular cells: 195.1,Cancer enhanced,Detected in all,,liver cancer: 90.2,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in many,,,"Adipose subcutaneous - Endothelial cells, Colon - Endothelial cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Skeletal muscle - Endothelial cells, Skin - Endothelial cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA001143, CAB016777, HPA024061",Supported,,,,Secreted to blood,Complement pathway,,,,12000000000.0,,Cluster 1: Liver & Kidney - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 71: Lymphoma - Inflammatory response,Cluster 62: Hepatocytes - Metabolism,1.0,,,"CAB016777: , HPA001143: AB_1078555, HPA024061: AB_1847129",unprognostic (1.04e-1),unprognostic (5.79e-2),unprognostic (1.68e-1),unprognostic (6.32e-2),unprognostic (1.55e-2),unprognostic (8.58e-2),unprognostic (2.95e-2),unprognostic (3.00e-1),unprognostic (2.00e-2),unprognostic (5.42e-3),unprognostic (1.41e-1),unprognostic (3.61e-1),unprognostic (8.63e-2),unprognostic (1.29e-1),unprognostic (3.42e-2),unprognostic (1.74e-1),prognostic unfavorable (6.06e-4),MKLLHVFLLFLCFHLRFCKVTYTSQEDLVEKKCLAKKYTHLSCDKVFCQPWQRCIEGTCVCKLPYQCPKNGTAVCATNRRSFPTYCQQKSLECLHPGTKFLNNGTCTAEGKFSVSLKHGNTDSEGIVEVKLVDQDKTMFICKSSWSMREANVACLDLGFQQGADTQRRFKLSDLSINSTECLHVHCRGLETSLAECTFTKRRTMGYQDFADVVCYTQKADSPMDDFFQCVNGKYISQMKACDGINDCGDQSDELCCKACQGKGFHCKSGVCIPSQYQCNGEVDCITGEDEVGCAGFASVTQEETEILTADMDAERRRIKSLLPKLSCGVKNRMHIRRKRIVGGKRAQLGDLPWQVAIKDASGITCGGIYIGGCWILTAAHCLRASKTHRYQIWTTVVDWIHPDLKRIVIEYVDRIIFHENYNAGTYQNDIALIEMKKDGNKKDCELPRSIPACVPWSPYLFQPNDTCIVSGWGREKDNERVFSLQWGEVKLISNCSKFYGNRFYEKEMECAGTYDGSIDACKGDSGGPLVCMDANNVTYVWGVVSWGENCGKPEFPGVYTKVANYFDWISYHVGRPFISQYNV
P07357 Complement component C8 alpha chain 补体成分c8,P07357,C8A,,ENSG00000157131,Complement C8 alpha chain,1,56854768-56918223,"Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,279.0,liver: 481.7,Cell type enriched,Detected in some,14.0,Hepatocytes: 257.7,Cancer enriched,Detected in single,279.0,liver cancer: 85.3,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,,,,,,Secreted to blood,Complement pathway,,,,6400000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,6.0,,,,,,,,,,unprognostic (3.73e-3),unprognostic (2.44e-1),,,unprognostic (1.28e-1),,,unprognostic (6.40e-2),,unprognostic (9.82e-2),,MFAVVFFILSLMTCQPGVTAQEKVNQRVRRAATPAAVTCQLSNWSEWTDCFPCQDKKYRHRSLLQPNKFGGTICSGDIWDQASCSSSTTCVRQAQCGQDFQCKETGRCLKRHLVCNGDQDCLDGSDEDDCEDVRAIDEDCSQYEPIPGSQKAALGYNILTQEDAQSVYDASYYGGQCETVYNGEWRELRYDSTCERLYYGDDEKYFRKPYNFLKYHFEALADTGISSEFYDNANDLLSKVKKDKSDSFGVTIGIGPAGSPLLVGVGVSHSQDTSFLNELNKYNEKKFIFTRIFTKVQTAHFKMRKDDIMLDEGMLQSLMELPDQYNYGMYAKFINDYGTHYITSGSMGGIYEYILVIDKAKMESLGITSRDITTCFGGSLGIQYEDKINVGGGLSGDHCKKFGGGKTERARKAMAVEDIISRVRGGSSGWSGGLAQNRSTITYRSWGRSLKYNPVVIDFEMQPIHEVLRHTSLGPLEAKRQNLRRALDQYLMEFNACRCGPCFNNGVPILEGTSCRCQCRLGSLGAACEQTQTEGAKADGSWSCWSSWSVCRAGIQERRRECDNPAPQNGGASCPGRKVQTQAC
P07360 Complement component C8 gamma chain 补体成分c8,P07360,C8G,,ENSG00000176919,Complement C8 gamma chain,9,136945185-136946975,"Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,18.0,liver: 550.5,Cell type enriched,Detected in some,9.0,Hepatocytes: 1036.6,Cancer enriched,Detected in all,58.0,liver cancer: 260.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,4.0,Gastric cancer: 6.2;liver cancer: 2.1,,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA046269,Approved,,,,Secreted to blood,Complement pathway,,,,2800000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 57: Stomach & Colon cancer - Digestion,Cluster 62: Hepatocytes - Metabolism,2.0,,,HPA046269: AB_2679606,unprognostic (5.00e-2),unprognostic (4.05e-3),prognostic unfavorable (2.99e-4),unprognostic (3.94e-1),unprognostic (4.53e-1),unprognostic (2.75e-2),unprognostic (1.71e-3),unprognostic (2.79e-1),unprognostic (1.88e-1),unprognostic (3.67e-1),unprognostic (2.96e-2),unprognostic (3.00e-1),unprognostic (5.02e-3),unprognostic (2.16e-1),unprognostic (7.67e-2),unprognostic (1.65e-1),unprognostic (1.05e-2),MLPPGTATLLTLLLAAGSLGQKPQRPRRPASPISTIQPKANFDAQQFAGTWLLVAVGSACRFLQEQGHRAEATTLHVAPQGTAMAVSTFRKLDGICWQVRQLYGDTGVLGRFLLQARDARGAVHVVVAETDYQSFAVLYLERAGQLSVKLYARSLPVSDSVLSGFEQRVQEAHLTEDQIFYFPKYGFCEAADQFHVLDEVRR
P02748 Complement component C9补体成分C9,P02748,C9,,ENSG00000113600,Complement C9,5,39284140-39371324,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,"Age-related macular degeneration, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,264.0,liver: 1268.7,Cell type enriched,Detected in some,10.0,Hepatocytes: 1939.7,Cancer enriched,Detected in single,244.0,liver cancer: 90.4,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in some,,,"CAB002151, HPA029577",Uncertain,,,,Secreted to blood,Complement pathway,,,69600000000.0,64000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 59: Leukemia - T-cell receptor,Cluster 62: Hepatocytes - Metabolism,2.0,,,"CAB002151: AB_563670, HPA029577: AB_10603779",unprognostic (1.00e-1),unprognostic (1.57e-1),unprognostic (1.50e-1),,unprognostic (2.01e-1),unprognostic (6.58e-2),unprognostic (1.30e-1),unprognostic (2.91e-1),unprognostic (5.49e-3),,unprognostic (1.91e-2),unprognostic (1.29e-2),unprognostic (2.19e-2),unprognostic (9.43e-5),unprognostic (1.36e-1),unprognostic (1.80e-1),unprognostic (2.04e-1),MSACRSFAVAICILEISILTAQYTTSYDPELTESSGSASHIDCRMSPWSEWSQCDPCLRQMFRSRSIEVFGQFNGKRCTDAVGDRRQCVPTEPCEDAEDDCGNDFQCSTGRCIKMRLRCNGDNDCGDFSDEDDCESEPRPPCRDRVVEESELARTAGYGINILGMDPLSTPFDNEFYNGLCNRDRDGNTLTYYRRPWNVASLIYETKGEKNFRTEHYEEQIEAFKSIIQEKTSNFNAAISLKFTPTETNKAEQCCEETASSISLHGKGSFRFSYSKNETYQLFLSYSSKKEKMFLHVKGEIHLGRFVMRNRDVVLTTTFVDDIKALPTTYEKGEYFAFLETYGTHYSSSGSLGGLYELIYVLDKASMKRKGVELKDIKRCLGYHLDVSLAFSEISVGAEFNKDDCVKRGEGRAVNITSENLIDDVVSLIRGGTRKYAFELKEKLLRGTVIDVTDFVNWASSINDAPVLISQKLSPIYNLVPVKMKNAHLKKQNLERAIEDYINEFSVRKCHTCQNGGTVILMDGKCLCACPFKFEGIACEISKQKISEGLPALEFPNEK
P07358 Complement component C8 beta chain补体成分C8,P07358,C8B,,ENSG00000021852,Complement C8 beta chain,1,56929207-56974383,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,127.0,liver: 630.0,Cell type enriched,Detected in some,11.0,Hepatocytes: 247.1,Cancer enriched,Detected in some,181.0,liver cancer: 107.0,Not detected,Not detected,,,Immune cell enriched,Detected in single,23.0,basophil: 2.3,Lineage enriched,Detected in single,23.0,granulocytes: 2.3,Cancer enriched,Detected in single,11.0,liver cancer: 1.1,"Liver - Hepatocytes, Testis - Late spermatids",Not detected,Not detected,,,Low region specificity,Detected in all,,,HPA023694,Supported,,,,Secreted to blood,Complement pathway,,,,6700000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,1.0,,,HPA023694: AB_1847128,,,,unprognostic (6.65e-2),,,prognostic favorable (9.31e-5),unprognostic (2.37e-1),,,unprognostic (2.37e-1),,,unprognostic (1.29e-2),unprognostic (6.57e-2),unprognostic (5.12e-3),,MKNSRTWAWRAPVELFLLCAALGCLSLPGSRGERPHSFGSNAVNKSFAKSRQMRSVDVTLMPIDCELSSWSSWTTCDPCQKKRYRYAYLLQPSQFHGEPCNFSDKEVEDCVTNRPCGSQVRCEGFVCAQTGRCVNRRLLCNGDNDCGDQSDEANCRRIYKKCQHEMDQYWGIGSLASGINLFTNSFEGPVLDHRYYAGGCSPHYILNTRFRKPYNVESYTPQTQGKYEFILKEYESYSDFERNVTEKMASKSGFSFGFKIPGIFELGISSQSDRGKHYIRRTKRFSHTKSVFLHARSDLEVAHYKLKPRSLMLHYEFLQRVKRLPLEYSYGEYRDLFRDFGTHYITEAVLGGIYEYTLVMNKEAMERGDYTLNNVHACAKNDFKIGGAIEEVYVSLGVSVGKCRGILNEIKDRNKRDTMVEDLVVLVRGGASEHITTLAYQELPTADLMQEWGDAVQYNPAIIKVKVEPLYELVTATDFAYSSTVRQNMKQALEEFQKEVSSCHCAPCQGNGVPVLKGSRCDCICPVGSQGLACEVSYRKNTPIDGKWNCWSNWSSCSGRRKTRQRQCNNPPPQNGGSPCSGPASETLDCS
P13671 Complement component C6补体成分C6,P13671,C6,,ENSG00000039537,Complement C6,5,41142116-41261438,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters","Complement pathway, Cytolysis, Immunity, Innate immunity",,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,11.0,liver: 610.3,Cell type enhanced,Detected in some,,Cholangiocytes: 125.9;Ciliated cells: 63.9;Hepatocytes: 323.6;Late spermatids: 53.2;Leydig cells: 118.1,Group enriched,Detected in many,7.0,liver cancer: 49.0;pancreatic cancer: 12.5,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,Bone cancer: 1.1,"Breast - Adipocytes (Breast), Liver - Hepatocytes, Lung - Respiratory ciliated cells",Not detected,Not detected,,,Low region specificity,Detected in single,,,"HPA043823, CAB069427",Enhanced,,,,Secreted to blood,Complement pathway,,,45000000000.0,9200000000.0,,Cluster 83: Liver - Metabolism,Cluster 3: Choroid plexus - Cilium,Cluster 44: Connective tissue cells - ECM organization,Cluster 62: Hepatocytes - Metabolism,1.0,,,"CAB069427: AB_1614336, HPA043823: AB_10960262",unprognostic (9.79e-2),unprognostic (1.96e-2),unprognostic (5.94e-3),unprognostic (3.02e-2),unprognostic (1.67e-1),unprognostic (1.18e-1),unprognostic (1.12e-3),unprognostic (4.66e-2),unprognostic (3.72e-2),unprognostic (1.53e-1),unprognostic (2.34e-1),unprognostic (3.04e-3),prognostic favorable (4.31e-4),unprognostic (2.69e-4),unprognostic (1.61e-1),unprognostic (1.40e-2),unprognostic (3.51e-2),MARRSVLYFILLNALINKGQACFCDHYAWTQWTSCSKTCNSGTQSRHRQIVVDKYYQENFCEQICSKQETRECNWQRCPINCLLGDFGPWSDCDPCIEKQSKVRSVLRPSQFGGQPCTAPLVAFQPCIPSKLCKIEEADCKNKFRCDSGRCIARKLECNGENDCGDNSDERDCGRTKAVCTRKYNPIPSVQLMGNGFHFLAGEPRGEVLDNSFTGGICKTVKSSRTSNPYRVPANLENVGFEVQTAEDDLKTDFYKDLTSLGHNENQQGSFSSQGGSSFSVPIFYSSKRSENINHNSAFKQAIQASHKKDSSFIRIHKVMKVLNFTTKAKDLHLSDVFLKALNHLPLEYNSALYSRIFDDFGTHYFTSGSLGGVYDLLYQFSSEELKNSGLTEEEAKHCVRIETKKRVLFAKKTKVEHRCTTNKLSEKHEGSFIQGAEKSISLIRGGRSEYGAALAWEKGSSGLEEKTFSEWLESVKENPAVIDFELAPIVDLVRNIPCAVTKRNNLRKALQEYAAKFDPCQCAPCPNNGRPTLSGTECLCVCQSGTYGENCEKQSPDYKSNAVDGQWGCWSSWSTCDATYKRSRTRECNNPAPQRGGKRCEGEKRQEEDCTFSIMENNGQPCINDDEEMKEVDLPEIEADSGCPQPVPPENGFIRNEKQLYLVGEDVEISCLTGFETVGYQYFRCLPDGTWRQGDVECQRTECIKPVVQEVLTITPFQRLYRIGESIELTCPKGFVVAGPSRYTCQGNSWTPPISNSLTCEKDTLTKLKGHCQLGQKQSGSECICMSPEEDCSHHSEDLCVFDTDSNDYFTSPACKFLAEKCLNNQQLHFLHIGSCQDGRQLEWGLERTRLSSNSTKKESCGYDTCYDWEKCSASTSKCVCLLPPQCFKGGNQLYCVKMGSSTSEKTLNICEVGTIRCANRKMEILHPGKCLA
P10643 Complement component C7补体成分C7,P10643,C7,,ENSG00000112936,Complement C7,5,40909492-41020216,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,"Cancer-related genes, Disease variant",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adrenal gland: 884.6,Group enriched,Detected in many,4.0,Fibroblasts: 729.1;Leydig cells: 1107.4,Cancer enriched,Detected in all,4.0,pancreatic cancer: 73.8,Region enhanced,Detected in many,,choroid plexus: 33.5,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,12.0,Neuroblastoma: 50.9,"Heart muscle - Fibroblasts, Kidney - Fibroblasts, Liver - Hepatic stellate cells, Lung - Fibroblast_2, Pancreas - Fibroblasts, Prostate - Fibroblasts",Not detected,Not detected,,,Region enhanced,Detected in many,,spinal cord: 18.6,HPA001465,Approved,,,,Secreted to blood,Complement pathway,,,,48000000000.0,,Cluster 7: Adipose tissue - Mixed function,Cluster 8: Immune cells - Immune response,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,1.0,,,HPA001465: AB_1078554,unprognostic (5.01e-2),unprognostic (3.74e-2),unprognostic (7.40e-2),unprognostic (4.68e-3),unprognostic (5.35e-2),unprognostic (1.43e-3),prognostic favorable (5.89e-4),unprognostic (6.67e-2),unprognostic (3.45e-1),unprognostic (2.21e-2),unprognostic (1.33e-1),unprognostic (1.93e-3),unprognostic (2.24e-2),unprognostic (6.10e-3),unprognostic (1.12e-1),unprognostic (2.14e-1),unprognostic (2.06e-3),MKVISLFILVGFIGEFQSFSSASSPVNCQWDFYAPWSECNGCTKTQTRRRSVAVYGQYGGQPCVGNAFETQSCEPTRGCPTEEGCGERFRCFSGQCISKSLVCNGDSDCDEDSADEDRCEDSERRPSCDIDKPPPNIELTGNGYNELTGQFRNRVINTKSFGGQCRKVFSGDGKDFYRLSGNVLSYTFQVKINNDFNYEFYNSTWSYVKHTSTEHTSSSRKRSFFRSSSSSSRSYTSHTNEIHKGKSYQLLVVENTVEVAQFINNNPEFLQLAEPFWKELSHLPSLYDYSAYRRLIDQYGTHYLQSGSLGGEYRVLFYVDSEKLKQNDFNSVEEKKCKSSGWHFVVKFSSHGCKELENALKAASGTQNNVLRGEPFIRGGGAGFISGLSYLELDNPAGNKRRYSAWAESVTNLPQVIKQKLTPLYELVKEVPCASVKKLYLKWALEEYLDEFDPCHCRPCQNGGLATVEGTHCLCHCKPYTFGAACEQGVLVGNQAGGVDGGWSCWSSWSPCVQGKKTRSRECNNPPPSGGGRSCVGETTESTQCEDEELEHLRLLEPHCFPLSLVPTEFCPSPPALKDGFVQDEGTMFPVGKNVVYTCNEGYSLIGNPVARCGEDLRWLVGEMHCQKIACVLPVLMDGIQSHPQKPFYTVGEKVTVSCSGGMSLEGPSAFLCGSSLKWSPEMKNARCVQKENPLTQAVPKCQRWEKLQNSRCVCKMPYECGPSLDVCAQDERSKRILPLTVCKMHVLHCQGRNYTLTGRDSCTLPASAEKACGACPLWGKCDAESSKCVCREASECEEEGFSICVEVNGKEQTMSECEAGALRCRGQSISVTSIRPCAAETQ
P09871 Complement C1s subcomponent补体蛋白C1s,P09871,C1S,,ENSG00000182326,Complement C1s,12,6988259-7071032,"Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement pathway, Immunity, Innate immunity","Hydrolase, Protease, Serine protease","Disease variant, Ehlers-Danlos syndrome, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,5.0,liver: 2762.6,Cell type enhanced,Detected in many,,Fibroblasts: 717.8;Hepatocytes: 2248.0;Leydig cells: 1204.3;Mesothelial cells: 578.3;Ovarian stromal cells: 401.7;Peritubular cells: 631.2,Cancer enhanced,Detected in all,,liver cancer: 276.7,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in many,,,"Adipose subcutaneous - Adipose progenitor cells, Adipose visceral - Adipose progenitor cells, Breast - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_2, Skin - Fibroblast_2",Low region specificity,Detected in many,,,Low region specificity,Detected in all,,,"CAB016722, HPA018852",Supported,,Approved,"Nucleoplasm,Cytosol",Secreted to blood,Complement pathway,,,93000000000.0,14000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 39: Astrocytes - Mixed function,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,2.0,Nucleoplasm,Cytosol,"CAB016722: , HPA018852: AB_1847112",unprognostic (2.72e-3),unprognostic (7.31e-2),unprognostic (9.37e-2),unprognostic (1.39e-2),unprognostic (1.05e-2),unprognostic (9.63e-2),prognostic favorable (7.73e-4),unprognostic (6.38e-2),unprognostic (1.16e-1),unprognostic (6.14e-2),unprognostic (1.57e-1),unprognostic (1.85e-2),prognostic unfavorable (7.44e-15),unprognostic (2.02e-2),unprognostic (5.68e-3),unprognostic (1.19e-2),unprognostic (5.39e-2),MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIELSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERFTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVFTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVFVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTPNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCGIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPKCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGNREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVKMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKVEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCGTYGLYTRVKNYVDWIMKTMQENSTPRED
P02745 Complement C1q subcomponent subunit A补体c1q,P02745,C1QA,,ENSG00000173372,Complement C1q A chain,1,22635077-22639678,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement pathway, Host-virus interaction, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,choroid plexus: 621.7;lymphoid tissue: 1066.3,Group enriched,Detected in many,5.0,Hofbauer cells: 1545.9;Kupffer cells: 3931.0;Macrophages: 1776.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Group enriched,Detected in some,38.0,intermediate monocyte: 227.9;non-classical monocyte: 184.6,Lineage enriched,Detected in many,59.0,monocytes: 227.9,Not detected,Not detected,,,"Adipose subcutaneous - Macrophages, Adipose visceral - Macrophages, Breast - Macrophages, Colon - Macrophages, Heart muscle - Macrophages, Kidney - Macrophages, Liver - Kupffer cells, Lung - Macrophages, Pancreas - Macrophages, Prostate - Macrophages, Skeletal muscle - Macrophages, Skin - Macrophages, Stomach - Macrophages, Testis - Macrophages, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA002350, CAB009823",Supported,,,,Secreted to blood,Complement pathway,,,,2700000000.0,Cluster 40: Monocytes - Innate immune response,Cluster 70: Lymphoid tissue - Immune response,Cluster 20: Macrophages & Microglia - Immune response,Cluster 1: Neuronal - Visual perception,Cluster 58: Macrophages - Innate immune response,3.0,,,"CAB009823: AB_2228238, HPA002350: AB_1078552",unprognostic (1.97e-1),unprognostic (1.14e-2),unprognostic (1.98e-3),unprognostic (3.07e-2),unprognostic (6.10e-2),unprognostic (2.60e-1),unprognostic (1.16e-1),unprognostic (2.13e-1),unprognostic (1.67e-2),unprognostic (1.99e-1),unprognostic (4.42e-2),unprognostic (1.86e-1),prognostic unfavorable (1.58e-6),unprognostic (1.54e-1),unprognostic (2.11e-3),unprognostic (2.75e-2),unprognostic (7.30e-2),MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIRTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAIRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSRGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFLIFPSA
P02747 Complement C1q subcomponent subunit C补体C1q,P02747,C1QC,C1QG,ENSG00000159189,Complement C1q C chain,1,22643014-22648110,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement pathway, Immunity, Innate immunity",,Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,lymphoid tissue: 923.4,Group enriched,Detected in many,5.0,Hofbauer cells: 1156.0;Kupffer cells: 1255.6;Macrophages: 969.3,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enriched,Detected in some,6.0,intermediate monocyte: 56.5,Lineage enriched,Detected in single,559.0,monocytes: 56.5,Not detected,Not detected,,,"Adipose subcutaneous - Macrophages, Adipose visceral - Macrophages, Breast - Macrophages, Colon - Macrophages, Heart muscle - Macrophages, Kidney - Macrophages, Liver - Kupffer cells, Lung - Macrophages, Pancreas - Macrophages, Prostate - Macrophages, Skeletal muscle - Macrophages, Skin - Macrophages, Stomach - Macrophages, Testis - Macrophages, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001471, CAB009828",Supported,,,,Secreted to blood,Complement pathway,,,513000000.0,2100000000.0,Cluster 40: Monocytes - Innate immune response,Cluster 70: Lymphoid tissue - Immune response,Cluster 20: Macrophages & Microglia - Immune response,Cluster 14: Myeloid leukemia - Innate immune response,Cluster 58: Macrophages - Innate immune response,3.0,,,"CAB009828: AB_2067541, HPA001471: AB_1078553",unprognostic (2.97e-1),unprognostic (6.80e-2),unprognostic (2.40e-2),unprognostic (1.84e-1),unprognostic (7.40e-2),unprognostic (2.38e-1),unprognostic (1.98e-1),unprognostic (1.40e-1),unprognostic (1.66e-2),unprognostic (7.44e-2),unprognostic (2.75e-2),unprognostic (1.32e-1),prognostic unfavorable (1.17e-5),unprognostic (1.06e-1),unprognostic (1.63e-3),unprognostic (2.21e-2),unprognostic (3.73e-2),MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEPGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQSVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCVLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGFLLFPD
P02746 Complement C1q subcomponent subunit B 补体C1q,P02746,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIFSGFLLFPDMEA
P00736 Complement C1r subcomponent 补体蛋白C1r,P00736,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVFQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDFSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGYELQEDTHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPFDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKLRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQDDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSRESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVFTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRVSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVMEEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAVRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED
Q03591 Complement factor H-related protein 1 补体因子h相关蛋白,Q03591,CFHR1,"CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2",ENSG00000244414,Complement factor H related 1,1,196819731-196837159,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",,,"Cancer-related genes, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,224.0,liver: 2010.5,Cell type enhanced,Detected in some,,Granulosa cells: 65.7;Hepatocytes: 223.4;Kupffer cells: 55.4,Cancer enriched,Detected in single,798.0,liver cancer: 182.4,Region enhanced,Detected in single,,midbrain: 1.7,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,Sarcoma: 3.3;thyroid cancer: 7.0,Liver - Hepatocytes,Not detected,Not detected,,,,,,,"HPA038915, HPA038922, HPA040726",Supported,,Approved,Vesicles,Secreted to blood,Complement pathway,,,,13000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 41: Monoamines - Neurotransmitter signalling,Cluster 16: Thyroid cancer - Neuronal signaling,Cluster 62: Hepatocytes - Metabolism,6.0,Vesicles,,"HPA038915: AB_2676269, HPA038922: AB_2676271, HPA040726: AB_2677101",unprognostic (2.28e-1),unprognostic (3.18e-1),,,unprognostic (3.50e-2),unprognostic (1.88e-2),prognostic favorable (8.71e-6),unprognostic (3.02e-1),unprognostic (3.70e-1),unprognostic (2.50e-1),unprognostic (8.48e-2),,unprognostic (7.21e-4),unprognostic (7.01e-4),unprognostic (1.13e-1),,unprognostic (6.41e-2),MWLLVSVILISRISSVGGEATFCDFPKINHGILYDEEKYKPFSQVPTGEVFYYSCEYNFVSPSKSFWTRITCTEEGWSPTPKCLRLCFFPFVENGHSESSGQTHLEGDTVQIICNTGYRLQNNENNISCVERGWSTPPKCRSTDTSCVNPPTVQNAHILSRQMSKYPSGERVRYECRSPYEMFGDEEVMCLNGNWTEPPQCKDSTGKCGPPPPIDNGDITSFPLSVYAPASSVEYQCQNLYQLEGNKRITCRNGQWSEPPKCLHPCVISREIMENYNIALRWTAKQKLYLRTGESAEFVCKRGYRLSSRSHTLRTTCWDGKLEYPTCAKR
Q9BXR6 Complement factor H-related protein 5 补体因子h相关蛋白,Q9BXR6,CFHR5,"CFHL5, FHR-5, FHR5",ENSG00000134389,Complement factor H related 5,1,196975010-197009678,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Disease variant, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,1620.0,liver: 162.0,Cell type enriched,Detected in some,21.0,Hepatocytes: 95.1,Cancer enriched,Detected in single,396.0,liver cancer: 57.1,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,,,,,,,,,"HPA038915, HPA040726",Supported,,,,Secreted to blood,Complement pathway,,,,1900000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,15.0,,,"HPA038915: AB_2676269, HPA040726: AB_2677101",,,,,,,unprognostic (9.12e-3),,,,,,,,,,,MLLLFSVILISWVSTVGGEGTLCDFPKIHHGFLYDEEDYNPFSQVPTGEVFYYSCEYNFVSPSKSFWTRITCTEEGWSPTPKCLRMCSFPFVKNGHSESSGLIHLEGDTVQIICNTGYSLQNNEKNISCVERGWSTPPICSFTKGECHVPILEANVDAQPKKESYKVGDVLKFSCRKNLIRVGSDSVQCYQFGWSPNFPTCKGQVRSCGPPPQLSNGEVKEIRKEEYGHNEVVEYDCNPNFIINGPKKIQCVDGEWTTLPTCVEQVKTCGYIPELEYGYVQPSVPPYQHGVSVEVNCRNEYAMIGNNMITCINGIWTELPMCVATHQLKRCKIAGVNIKTLLKLSGKEFNHNSRIRYRCSDIFRYRHSVCINGKWNPEVDCTEKREQFCPPPPQIPNAQNMTTTVNYQDGEKVAVLCKENYLLPEAKEIVCKDGRWQSLPRCVESTAYCGPPPSINNGDTTSFPLSVYPPGSTVTYRCQSFYKLQGSVTVTCRNKQWSEPPRCLDPCVVSEENMNKNNIQLKWRNDGKLYAKTGDAVEFQCKFPHKAMISSPPFRAICQEGKFEYPICE
P02671 Fibrinogen alpha chain 纤维蛋白原α链,P02671,FGA,,ENSG00000171560,Fibrinogen alpha chain,4,154583126-154590742,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity",,"Amyloidosis, Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,386.0,liver: 17848.7,Cell type enriched,Detected in many,30.0,Hepatocytes: 13631.3,Cancer enriched,Detected in many,43.0,liver cancer: 2431.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,6.0,liver cancer: 180.5,"Liver - Hepatocytes, Stomach - Parietal cells, Testis - Early spermatids, Testis - Late spermatids",,,,,,,,,"CAB016776, HPA051370, HPA064755",Supported,,Enhanced,Endoplasmic reticulum,Secreted to blood,Blood coagulation,,,407000000.0,140000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,3.0,Endoplasmic reticulum,,"CAB016776: , HPA051370: AB_2681458, HPA064755: AB_2685345",,unprognostic (5.95e-2),unprognostic (6.25e-2),unprognostic (2.02e-1),,unprognostic (5.68e-2),prognostic favorable (7.33e-4),unprognostic (1.29e-3),,,unprognostic (1.84e-1),,prognostic unfavorable (4.23e-6),unprognostic (4.20e-1),unprognostic (1.41e-1),,,MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDWNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSANNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSCRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSSGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTWNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNVSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTKEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFSVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQRGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSHNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENGVVWVSFRGADYSLRAVRMKIRPLVTQ
P02675 Fibrinogen beta chain纤维蛋白原链,P02675,FGB,,ENSG00000171564,Fibrinogen beta chain,4,154563011-154572807,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity",,"Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,372.0,liver: 17393.5,Cell type enriched,Detected in some,8.0,Hepatocytes: 15989.7,Cancer enriched,Detected in many,42.0,liver cancer: 2262.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,8.0,liver cancer: 219.4,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA001900, HPA001901, CAB008624",Enhanced,,Enhanced,Endoplasmic reticulum,Secreted to blood,Blood coagulation,,,,110000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,1.0,Endoplasmic reticulum,,"CAB008624: AB_1615610, HPA001900: AB_1078865, HPA001901: AB_1078864",unprognostic (1.16e-1),unprognostic (3.89e-2),unprognostic (4.65e-2),unprognostic (3.44e-1),,,unprognostic (2.20e-3),unprognostic (1.42e-2),,,unprognostic (1.79e-1),,prognostic unfavorable (5.72e-5),unprognostic (2.48e-2),unprognostic (7.91e-2),,,MKRMVSWSFHKLKTMKHLLLLLLCVFLVKSQGVNDNEEGFFSARGHRPLDKKREEAPSLRPAPPPISGGGYRARPAKAAATQKKVERKAPDAGGCLHADPDLGVLCPTGCQLQEALLQQERPIRNSVDELNNNVEAVSQTSSSSFQYMYLLKDLWQKRQKQVKDNENVVNEYSSELEKHQLYIDETVNSNIPTNLRVLRSILENLRSKIQKLESDVSAQMEYCRTPCTVSCNIPVVSGKECEEIIRKGGETSEMYLIQPDSSVKPYRVYCDMNTENGGWTVIQNRQDGSVDFGRKWDPYKQGFGNVATNTDGKNYCGLPGEYWLGNDKISQLTRMGPTELLIEMEDWKGDKVKAHYGGFTVQNEANKYQISVNKYRGTAGNALMDGASQLMGENRTMTIHNGMFFSTYDRDNDGWLTSDPRKQCSKEDGGGWWYNRCHAANPNGRYYWGGQYTWDMAKHGTDDGVVWMNWKGSWYSMRKMSMKIRPFFPQQ
P02679 Fibrinogen gamma chain 纤维蛋白原γ链,P02679,FGG,,ENSG00000171557,Fibrinogen gamma chain,4,154604134-154612967,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Hemostasis",,"Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,330.0,liver: 16058.1,Cell type enriched,Detected in some,10.0,Hepatocytes: 9849.5,Cancer enriched,Detected in many,19.0,liver cancer: 1503.5,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,6.0,liver cancer: 229.6,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,"HPA027529, CAB033120, HPA074638",Supported,,Approved,Endoplasmic reticulum,Secreted to blood,Blood coagulation,,,267000000000.0,73000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 71: Lymphoma - Inflammatory response,Cluster 62: Hepatocytes - Metabolism,3.0,Endoplasmic reticulum,,"CAB033120: AB_2103818, HPA027529: AB_10601322, HPA074638: ",unprognostic (1.26e-2),,,,unprognostic (4.77e-3),unprognostic (6.33e-3),unprognostic (3.69e-3),unprognostic (2.18e-3),,unprognostic (9.63e-2),unprognostic (7.57e-3),,prognostic unfavorable (1.00e-6),unprognostic (1.75e-3),unprognostic (3.21e-1),,unprognostic (1.14e-1),MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQTKVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIMKYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQDIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEGFGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKYRLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGWWMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTIGEGQQHHLGGAKQVRPEHPAETEYDSLYPEDDL
P08697 Alpha-2-antiplasmin 抗纤维蛋白溶酶,P08697,SERPINF2,"A2AP, AAP, ALPHA-2-PI, alpha2AP, API, PLI",ENSG00000167711,Serpin family F member 2,17,1742836-1755265,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",Acute phase,"Protease inhibitor, Serine protease inhibitor",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,16.0,liver: 1539.8,Cell type enriched,Detected in many,4.0,Hepatocytes: 814.9,Cancer enriched,Detected in all,6.0,liver cancer: 450.6,Region enriched,Detected in all,7.0,choroid plexus: 21.0,Immune cell enriched,Detected in some,4.0,plasmacytoid DC: 44.8,Lineage enriched,Detected in many,23.0,dendritic cells: 44.8,Group enriched,Detected in many,14.0,Gastric cancer: 46.8;liver cancer: 36.6,"Kidney - Proximal tubular cells, Liver - Hepatocytes, Skin - Macrophages",Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA001885, HPA005943, CAB024863",Approved,,Approved,Golgi apparatus,Secreted to blood,Acute phase,,,11900.0,61000000000.0,Cluster 8: Plasmacytoid DCs - Unknown function,Cluster 31: Liver - Plasma proteins,Cluster 36: Choroid plexus - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Golgi apparatus,,"CAB024863: , HPA001885: AB_1079922, HPA005943: ",unprognostic (2.17e-3),unprognostic (2.56e-3),unprognostic (2.48e-1),unprognostic (7.57e-3),unprognostic (3.69e-2),unprognostic (1.45e-2),prognostic favorable (2.26e-5),unprognostic (1.44e-1),unprognostic (2.32e-2),unprognostic (1.38e-1),unprognostic (1.88e-3),unprognostic (2.18e-1),unprognostic (1.09e-3),unprognostic (7.05e-2),unprognostic (2.81e-1),unprognostic (7.68e-3),unprognostic (2.93e-1),MALLWGLLVLSWSCLQGPCSVFSPVSAMEPLGRQLTSGPNQEQVSPLTLLKLGNQEPGGQTALKSPPGVCSRDPTPEQTHRLARAMMAFTADLFSLVAQTSTCPNLILSPLSVALALSHLALGAQNHTLQRLQQVLHAGSGPCLPHLLSRLCQDLGPGAFRLAARMYLQKGFPIKEDFLEQSEQLFGAKPVSLTGKQEDDLANINQWVKEATEGKIQEFLSGLPEDTVLLLLNAIHFQGFWRNKFDPSLTQRDSFHLDEQFTVPVEMMQARTYPLRWFLLEQPEIQVAHFPFKNNMSFVVLVPTHFEWNVSQVLANLSWDTLHPPLVWERPTKVRLPKLYLKHQMDLVATLSQLGLQELFQAPDLRGISEQSLVVSGVQHQSTLELSEVGVEAAAATSIAMSRMSLSSFSVNRPFLFFIFEDTTGLPLFVGSVRNPNPSAPRELKEQQDSPGNKDFLQSLKGFPRGDKLFGPDLKLVPPMEEDYPQFGSPK
P00747 Plasminogen 纤溶酶原,P00747,PLG,,ENSG00000122194,Plasminogen,6,160702194-160754097,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis, Tissue remodeling","Hydrolase, Protease, Serine protease","Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,11.0,liver: 2571.0,Cell type enriched,Detected in some,8.0,Hepatocytes: 1618.7,Cancer enriched,Detected in some,84.0,liver cancer: 180.7,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,liver cancer: 2.6,"Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Lung - Respiratory ciliated cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB000668, CAB016678, HPA021602, HPA048823, HPA053770",Supported,,Approved,Vesicles,Secreted to blood,Blood coagulation,,,140000000000.0,45000000000.0,,Cluster 1: Liver & Kidney - Metabolism,Cluster 14: Neurons - Synaptic function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,2.0,Vesicles,,"CAB000668: , CAB016678: AB_1621208, HPA021602: AB_1855453, HPA048823: AB_2680532, HPA053770: AB_2682256",,unprognostic (1.70e-1),,unprognostic (2.16e-3),unprognostic (2.44e-1),,unprognostic (8.54e-3),unprognostic (1.41e-1),,unprognostic (1.76e-3),unprognostic (6.28e-2),unprognostic (7.25e-2),prognostic favorable (4.22e-4),unprognostic (3.97e-3),unprognostic (5.21e-2),,unprognostic (2.33e-2),MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFTCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEEDCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGGPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN
P02765 Alpha-2-HS-glycoprotein 糖蛋白,P02765,AHSG,"A2HS, FETUA, HSGA",ENSG00000145192,Alpha 2-HS glycoprotein,3,186613060-186621318,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",Mineral balance,,"Cancer-related genes, Disease variant, Hypotrichosis, Intellectual disability",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,4328.0,liver: 5638.7,Cell type enriched,Detected in some,14.0,Hepatocytes: 1120.0,Cancer enriched,Detected in some,284.0,liver cancer: 1231.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,18.0,liver cancer: 479.5,"Liver - Hepatocytes, Testis - Late spermatids",Not detected,Not detected,,,Not detected,Not detected,,,"HPA001524, HPA001525, CAB026209",Enhanced,,Enhanced,Golgi apparatus,Secreted to blood,Other,,,864000000000.0,110000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Golgi apparatus,,"CAB026209: , HPA001524: AB_1078851, HPA001525: AB_1078849",,unprognostic (6.40e-2),unprognostic (1.31e-1),unprognostic (2.03e-2),unprognostic (3.20e-2),unprognostic (1.07e-2),unprognostic (1.16e-2),unprognostic (7.47e-3),unprognostic (3.05e-1),unprognostic (5.27e-2),unprognostic (8.64e-2),,unprognostic (3.99e-7),unprognostic (5.21e-2),unprognostic (5.21e-2),unprognostic (1.04e-1),,MKSLVLLLCLAQLWGCHSAPHGPGLIYRQPNCDDPETEEAALVAIDYINQNLPWGYKHTLNQIDEVKVWPQQPSGELFEIEIDTLETTCHVLDPTPVARCSVRQLKEHAVEGDCDFQLLKLDGKFSVVYAKCDSSPDSAEDVRKVCQDCPLLAPLNDTRVVHAAKAALAAFNAQNNGSNFQLEEISRAQLVPLPPSTYVEFTVSGTDCVAKEATEAAKCNLLAEKQYGFCKATLSEKLGGAEVAVTCMVFQTQPVSSQPQPEGANEAVPTPVVDPDAPPSPPLGAPGLPPAGSPPDSHVLLAAPPGHQLHRAHYDLRHTFMGVVSLGSPSGEVSHPRKTRTVVQPSVGAAAGPVVPPCPGRIRHFKV
P02749 Beta-2-glycoprotein 1 糖蛋白,P02749,APOH,"B2G1, BG",ENSG00000091583,Apolipoprotein H,17,66212033-66256525,"Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,Heparin-binding,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,567.0,liver: 17409.3,Cell type enriched,Detected in some,29.0,Hepatocytes: 7848.6,Cancer enriched,Detected in many,232.0,liver cancer: 2878.9,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,46.0,liver cancer: 154.3,"Kidney - Proximal tubular cells, Liver - Hepatocytes, Lung - Alveolar cells type 2, Pancreas - Alpha cells",Low region specificity,Detected in many,,,Not detected,Not detected,,,"HPA001654, HPA003732, CAB022214",Enhanced,,Supported,Golgi apparatus,Secreted to blood,Apolipoprotein,,,247000000000.0,41000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 53: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,5.0,Golgi apparatus,,"CAB022214: , HPA001654: AB_1078181, HPA003732: AB_1078183",,,unprognostic (2.11e-2),unprognostic (1.87e-1),unprognostic (1.28e-1),,prognostic favorable (2.39e-7),unprognostic (1.26e-1),,unprognostic (5.99e-2),unprognostic (2.88e-3),,prognostic unfavorable (1.10e-6),unprognostic (1.26e-2),unprognostic (5.76e-2),,,MISPVLILFSSFLCHVAIAGRTCPKPDDLPFSTVVPLKTFYEPGEEITYSCKPGYVSRGGMRKFICPLTGLWPINTLKCTPRVCPFAGILENGAVRYTTFEYPNTISFSCNTGFYLNGADSAKCTEEGKWSPELPVCAPIICPPPSIPTFATLRVYKPSAGNNSLYRDTAVFECLPQHAMFGNDTITCTTHGNWTKLPECREVKCPFPSRPDNGFVNYPAKPTLYYKDKATFGCHDGYSLDGPEEIECTKLGNWSAMPSCKASCKVPVKKATVVYQGERVKIQEKFKNGMLHGDKVSFFCKNKEKKCSYTEDAQCIDGTIEVPKCFKEHSSLAFWKTDASDVKPC
P04217 Alpha-1B-glycoprotein糖蛋白,P04217,A1BG,,ENSG00000121410,Alpha-1-B glycoprotein,19,58345178-58353492,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,1513.0,liver: 1194.2,Cell type enhanced,Detected in many,,Hepatocytes: 18.2;Oligodendrocytes: 8.1;Plasma cells: 8.2,Cancer enriched,Detected in single,85.0,liver cancer: 22.3,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,,Not detected,Not detected,,,Low region specificity,Detected in many,,,"CAB016673, HPA044252",Supported,,,,Secreted to blood,No annotated function,,,200000000000.0,51000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 17: Choroid plexus - Cilium,Cluster 18: Liver cancer - Metabolism,Cluster 7: T-cells - T-cell receptor,,,,"CAB016673: AB_1611892, HPA044252: AB_2678876",unprognostic (9.95e-2),unprognostic (5.31e-2),unprognostic (3.67e-2),unprognostic (3.44e-2),unprognostic (1.18e-1),unprognostic (1.66e-2),prognostic favorable (3.97e-4),unprognostic (1.09e-1),unprognostic (2.59e-1),unprognostic (2.10e-1),unprognostic (1.47e-2),unprognostic (1.37e-2),unprognostic (4.19e-5),unprognostic (2.37e-2),unprognostic (1.94e-1),unprognostic (1.72e-1),unprognostic (6.72e-2),MSMLVVFLLLWGVTWGPVTEAAIFYETQPSLWAESESLLKPLANVTLTCQAHLETPDFQLFKNGVAQEPVHLDSPAIKHQFLLTGDTQGRYRCRSGLSTGWTQLSKLLELTGPKSLPAPWLSMAPVSWITPGLKTTAVCRGVLRGVTFLLRREGDHEFLEVPEAQEDVEATFPVHQPGNYSCSYRTDGEGALSEPSATVTIEELAAPPPPVLMHHGESSQVLHPGNKVTLTCVAPLSGVDFQLRRGEKELLVPRSSTSPDRIFFHLNAVALGDGGHYTCRYRLHDNQNGWSGDSAPVELILSDETLPAPEFSPEPESGRALRLRCLAPLEGARFALVREDRGGRRVHRFQSPAGTEALFELHNISVADSANYSCVYVDLKPPFGGSAPSERLELHVDGPPPRPQLRATWSGAVLAGRDAVLRCEGPIPDVTFELLREGETKAVKTVRTPGAAANLELIFVGPQHAGNYRCRYRSWVPHTFESELSDPVELLVAES
P02763 Alpha-1-acid glycoprotein 1 糖蛋白,P02763,ORM1,,ENSG00000229314,Orosomucoid 1,9,114323098-114326479,"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Acute phase, Transport",,"Cancer-related genes, FDA approved drug targets",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,177.0,liver: 41892.9,Cell type enriched,Detected in some,53.0,Hepatocytes: 54806.5,Cancer enriched,Detected in many,16.0,liver cancer: 2506.9,Low region specificity,Detected in single,,,Immune cell enriched,Detected in some,47.0,neutrophil: 201.8,Lineage enriched,Detected in many,47.0,granulocytes: 201.8,Cancer enriched,Detected in many,4.0,liver cancer: 243.4,"Liver - Hepatocytes, Lung - Neutrophil_2",,,,,,,,,"CAB006265, HPA046438, HPA047725, HPA057726",Approved,,Approved,"Golgi apparatus,Vesicles",Secreted to blood,Acute phase,,,945000000000.0,61000000000.0,Cluster 4: Neutrophils - Degranulation,Cluster 31: Liver - Plasma proteins,Cluster 54: Immune cells - T cell receptor,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,Vesicles,Golgi apparatus,"CAB006265: AB_425575, HPA046438: AB_2679666, HPA047725: AB_2680133, HPA057726: AB_2683512",unprognostic (3.85e-1),unprognostic (2.12e-1),unprognostic (1.09e-2),unprognostic (2.16e-2),unprognostic (3.22e-2),unprognostic (1.47e-1),unprognostic (2.29e-1),unprognostic (2.26e-1),,unprognostic (1.16e-1),unprognostic (4.85e-2),unprognostic (1.74e-1),prognostic unfavorable (2.35e-4),unprognostic (2.10e-1),unprognostic (4.38e-2),unprognostic (9.32e-3),unprognostic (4.51e-2),MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDRITGKWFYIASAFRNEEYNKSVQEIQATFFYFTPNKTEDTIFLREYQTRQDQCIYNTTYLNVQRENGTISRYVGGQEHFAHLLILRDTKTYMLAFDVNDEKNWGLSVYADKPETTKEQLGEFYEALDCLRIPKSDVVYTDWKKDKCEPLEKQHEKERKQEEGES
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 胰蛋白酶间抑制剂重链H1,P19827,ITIH1,"H1P, IATIH, ITIH",ENSG00000055957,Inter-alpha-trypsin inhibitor heavy chain 1,3,52777595-52792068,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,"Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,777.0,liver: 1459.7,Cell type enriched,Detected in some,23.0,Hepatocytes: 793.7,Cancer enriched,Detected in some,598.0,liver cancer: 329.1,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Adipose subcutaneous - Smooth muscle cells, Adipose visceral - Smooth muscle cells, Liver - Hepatocytes",Not detected,Not detected,,,Not detected,Not detected,,,"HPA041639, HPA042049",Approved,,Approved,Vesicles,Secreted to blood,Enzyme inhibitor,,,4490000.0,59000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Vesicles,,"HPA041639: AB_10796349, HPA042049: AB_10797379",unprognostic (1.87e-4),unprognostic (1.31e-3),unprognostic (2.38e-1),unprognostic (8.55e-2),unprognostic (1.03e-1),unprognostic (2.64e-3),prognostic favorable (1.89e-5),unprognostic (2.27e-2),unprognostic (1.70e-1),unprognostic (1.30e-1),unprognostic (2.91e-2),unprognostic (8.45e-2),unprognostic (4.53e-4),unprognostic (4.02e-3),unprognostic (5.70e-3),unprognostic (2.08e-1),unprognostic (2.24e-2),MDGAMGPRGLLLCMYLVSLLILQAMPALGSATGRSKSSEKRQAVDTAVDGVFIRSLKVNCKVTSRFAHYVVTSQVVNTANEAREVAFDLEIPKTAFISDFAVTADGNAFIGDIKDKVTAWKQYRKAAISGENAGLVRASGRTMEQFTIHLTVNPQSKVTFQLTYEEVLKRNHMQYEIVIKVKPKQLVHHFEIDVDIFEPQGISKLDAQASFLPKELAAQTIKKSFSGKKGHVLFRPTVSQQQSCPTCSTSLLNGHFKVTYDVSRDKICDLLVANNHFAHFFAPQNLTNMNKNVVFVIDISGSMRGQKVKQTKEALLKILGDMQPGDYFDLVLFGTRVQSWKGSLVQASEANLQAAQDFVRGFSLDEATNLNGGLLRGIEILNQVQESLPELSNHASILIMLTDGDPTEGVTDRSQILKNVRNAIRGRFPLYNLGFGHNVDFNFLEVMSMENNGRAQRIYEDHDATQQLQGFYSQVAKPLLVDVDLQYPQDAVLALTQNHHKQYYEGSEIVVAGRIADNKQSSFKADVQAHGEGQEFSITCLVDEEEMKKLLRERGHMLENHVERLWAYLTIQELLAKRMKVDREERANLSSQALQMSLDYGFVTPLTSMSIRGMADQDGLKPTIDKPSEDSPPLEMLGPRRTFVLSALQPSPTHSSSNTQRLPDRVTGVDTDPHFIIHVPQKEDTLCFNINEEPGVILSLVQDPNTGFSVNGQLIGNKARSPGQHDGTYFGRLGIANPATDFQLEVTPQNITLNPGFGGPVFSWRDQAVLRQDGVVVTINKKRNLVVSVDDGGTFEVVLHRVWKGSSVHQDFLGFYVLDSHRMSARTHGLLGQFFHPIGFEVSDIHPGSDPTKPDATMVVRNRRLTVTRGLQKDYSKDPWHGAEVSCWFIHNNGAGLIDGAYTDYIVPDIF
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 胰蛋白酶间抑制剂重链H2,P19823,ITIH2,H2P,ENSG00000151655,Inter-alpha-trypsin inhibitor heavy chain 2,10,7703316-7749520,"Plasma proteins, Predicted secreted proteins",,"Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,566.0,liver: 2091.1,Cell type enriched,Detected in some,4.0,Hepatocytes: 406.0,Cancer enriched,Detected in many,279.0,liver cancer: 626.9,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,40.0,liver cancer: 147.1,Liver - Hepatocytes,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA059150,Supported,,Approved,Golgi apparatus,Secreted to blood,Enzyme inhibitor,,,,32000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 16: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Golgi apparatus,,HPA059150: AB_2683930,unprognostic (4.82e-2),unprognostic (6.10e-2),unprognostic (2.48e-2),unprognostic (1.21e-2),unprognostic (2.01e-2),unprognostic (2.55e-3),prognostic favorable (1.48e-4),unprognostic (1.37e-1),unprognostic (1.79e-1),unprognostic (1.47e-2),unprognostic (2.28e-1),unprognostic (2.02e-1),unprognostic (2.10e-8),unprognostic (9.91e-3),unprognostic (1.70e-1),unprognostic (2.35e-1),unprognostic (4.46e-4),MKRLTCFFICFFLSEVSGFEIPINGLSEFVDYEDLVELAPGKFQLVAENRRYQRSLPGESEEMMEEVDQVTLYSYKVQSTITSRMATTMIQSKVVNNSPQPQNVVFDVQIPKGAFISNFSMTVDGKTFRSSIKEKTVGRALYAQARAKGKTAGLVRSSALDMENFRTEVNVLPGAKVQFELHYQEVKWRKLGSYEHRIYLQPGRLAKHLEVDVWVIEPQGLRFLHVPDTFEGHFDGVPVISKGQQKAHVSFKPTVAQQRICPNCRETAVDGELVVLYDVKREEKAGELEVFNGYFVHFFAPDNLDPIPKNILFVIDVSGSMWGVKMKQTVEAMKTILDDLRAEDHFSVIDFNQNIRTWRNDLISATKTQVADAKRYIEKIQPSGGTNINEALLRAIFILNEANNLGLLDPNSVSLIILVSDGDPTVGELKLSKIQKNVKENIQDNISLFSLGMGFDVDYDFLKRLSNENHGIAQRIYGNQDTSSQLKKFYNQVSTPLLRNVQFNYPHTSVTDVTQNNFHNYFGGSEIVVAGKFDPAKLDQIESVITATSANTQLVLETLAQMDDLQDFLSKDKHADPDFTRKLWAYLTINQLLAERSLAPTAAAKRRITRSILQMSLDHHIVTPLTSLVIENEAGDERMLADAPPQDPSCCSGALYYGSKVVPDSTPSWANPSPTPVISMLAQGSQVLESTPPPHVMRVENDPHFIIYLPKSQKNICFNIDSEPGKILNLVSDPESGIVVNGQLVGAKKPNNGKLSTYFGKLGFYFQSEDIKIEISTETITLSHGSSTFSLSWSDTAQVTNQRVQISVKKEKVVTITLDKEMSFSVLLHRVWKKHPVNVDFLGIYIPPTNKFSPKAHGLIGQFMQEPKIHIFNERPGKDPEKPEASMEVKGQKLIITRGLQKDYRTDLVFGTDVTCWFVHNSGKGFIDGHYKDYFVPQLYSFLKRP
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 胰蛋白酶间抑制剂重链H3,Q06033,ITIH3,H3P,ENSG00000162267,Inter-alpha-trypsin inhibitor heavy chain 3,3,52794768-52808799,"Plasma proteins, Predicted secreted proteins",,"Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,105.0,liver: 828.4,Group enriched,Detected in some,5.0,Hepatocytes: 920.9;Kupffer cells: 562.7,Cancer enriched,Detected in some,247.0,liver cancer: 273.1,Low region specificity,Detected in some,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in single,12.0,liver cancer: 5.1,"Adipose subcutaneous - Smooth muscle cells, Adipose visceral - Smooth muscle cells, Heart muscle - Smooth muscle cells, Lung - Smooth muscle cells, Skeletal muscle - Smooth muscle cells, Testis - Late spermatids, Thyroid - Smooth muscle cells",Low region specificity,Detected in all,,,Low region specificity,Detected in some,,,HPA017373,Approved,,,,Secreted to blood,Enzyme inhibitor,,,,9100000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 32: Cerebral cortex - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,,,HPA017373: AB_1851954,unprognostic (2.07e-2),unprognostic (5.79e-2),unprognostic (1.89e-1),unprognostic (3.30e-4),unprognostic (4.28e-2),unprognostic (3.26e-2),unprognostic (5.97e-2),unprognostic (6.07e-2),unprognostic (1.49e-1),unprognostic (7.05e-2),unprognostic (1.04e-1),unprognostic (3.19e-1),prognostic unfavorable (4.49e-8),unprognostic (2.09e-4),unprognostic (1.70e-1),unprognostic (2.55e-2),unprognostic (9.31e-2),MAFAWWPCLILALLSSLAASGFPRSPFRLLGKRSLPEGVANGIEVYSTKINSKVTSRFAHNVVTMRAVNRADTAKEVSFDVELPKTAFITNFTLTIDGVTYPGNVKEKEVAKKQYEKAVSQGKTAGLVKASGRKLEKFTVSVNVAAGSKVTFELTYEELLKRHKGKYEMYLKVQPKQLVKHFEIEVDIFEPQGISMLDAEASFITNDLLGSALTKSFSGKKGHVSFKPSLDQQRSCPTCTDSLLNGDFTITYDVNRESPGNVQIVNGYFVHFFAPQGLPVVPKNVAFVIDISGSMAGRKLEQTKEALLRILEDMQEEDYLNFILFSGDVSTWKEHLVQATPENLQEARTFVKSMEDKGMTNINDGLLRGISMLNKAREEHRIPERSTSIVIMLTDGDANVGESRPEKIQENVRNAIGGKFPLYNLGFGNNLNYNFLENMALENHGFARRIYEDSDADLQLQGFYEEVANPLLTGVEMEYPENAILDLTQNTYQHFYDGSEIVVAGRLVDEDMNSFKADVKGHGATNDLTFTEEVDMKEMEKALQERDYIFGNYIERLWAYLTIEQLLEKRKNAHGEEKENLTARALDLSLKYHFVTPLTSMVVTKPEDNEDERAIADKPGEDAEATPVSPAMSYLTSYQPPQNPYYYVDGDPHFIIQIPEKDDALCFNIDEAPGTVLRLIQDAVTGLTVNGQITGDKRGSPDSKTRKTYFGKLGIANAQMDFQVEVTTEKITLWNRAVPSTFSWLDTVTVTQDGLSMMINRKNMVVSFGDGVTFVVVLHQVWKKHPVHRDFLGFYVVDSHRMSAQTHGLLGQFFQPFDFKVSDIRPGSDPTKPDATLVVKNHQLIVTRGSQKDYRKDASIGTKVVCWFVHNNGEGLIDGVHTDYIVPNLF
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 胰蛋白酶间抑制剂重链H4,Q14624,ITIH4,"H4P, IHRP, ITIHL1",ENSG00000055955,Inter-alpha-trypsin inhibitor heavy chain 4,3,52812962-52830688,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Acute phase,"Protease inhibitor, Serine protease inhibitor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,38.0,liver: 1807.4,Group enriched,Detected in many,4.0,Early spermatids: 68.4;Hepatocytes: 91.9;Late spermatids: 159.0,Cancer enriched,Detected in single,27.0,liver cancer: 7.4,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,liver cancer: 1.4,"Adipose subcutaneous - Smooth muscle cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA001835, HPA003948, CAB072872",Enhanced,,Approved,Vesicles,Secreted to blood,Acute phase,,,3060000.0,58000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 32: Cerebral cortex - Mixed function,Cluster 59: Leukemia - T-cell receptor,Cluster 62: Hepatocytes - Metabolism,,Vesicles,,"CAB072872: AB_2665724, HPA001835: AB_1079432, HPA003948: AB_1079433",unprognostic (6.08e-2),unprognostic (4.45e-2),unprognostic (1.67e-1),unprognostic (2.69e-1),unprognostic (2.64e-1),unprognostic (1.96e-1),unprognostic (5.86e-2),unprognostic (1.98e-2),unprognostic (5.64e-2),unprognostic (1.02e-1),unprognostic (2.47e-2),unprognostic (1.52e-1),unprognostic (1.10e-14),unprognostic (1.71e-3),unprognostic (2.96e-2),unprognostic (1.52e-1),unprognostic (4.21e-5),MKPPRPVRTCSKVLVLLSLLAIHQTTTAEKNGIDIYSLTVDSRVSSRFAHTVVTSRVVNRANTVQEATFQMELPKKAFITNFSMIIDGMTYPGIIKEKAEAQAQYSAAVAKGKSAGLVKATGRNMEQFQVSVSVAPNAKITFELVYEELLKRRLGVYELLLKVRPQQLVKHLQMDIHIFEPQGISFLETESTFMTNQLVDALTTWQNKTKAHIRFKPTLSQQQKSPEQQETVLDGNLIIRYDVDRAISGGSIQIENGYFVHYFAPEGLTTMPKNVVFVIDKSGSMSGRKIQQTREALIKILDDLSPRDQFNLIVFSTEATQWRPSLVPASAENVNKARSFAAGIQALGGTNINDAMLMAVQLLDSSNQEERLPEGSVSLIILLTDGDPTVGETNPRSIQNNVREAVSGRYSLFCLGFGFDVSYAFLEKLALDNGGLARRIHEDSDSALQLQDFYQEVANPLLTAVTFEYPSNAVEEVTQNNFRLLFKGSEMVVAGKLQDRGPDVLTATVSGKLPTQNITFQTESSVAEQEAEFQSPKYIFHNFMERLWAYLTIQQLLEQTVSASDADQQALRNQALNLSLAYSFVTPLTSMVVTKPDDQEQSQVAEKPMEGESRNRNVHSGSTFFKYYLQGAKIPKPEASFSPRRGWNRQAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPFRRLAILPASAPPATSNPDPAVSRVMNMKIEETTMTTQTPAPIQAPSAILPLPGQSVERLCVDPRHRQGPVNLLSDPEQGVEVTGQYEREKAGFSWIEVTFKNPLVWVHASPEHVVVTRNRRSSAYKWKETLFSVMPGLKMTMDKTGLLLLSDPDKVTIGLLFWDGRGEGLRLLLRDTDRFSSHVGGTLGQFYQEVLWGSPAASDDGRRTLRVQGNDHSATRERRLDYQEGPPGVEISCWSVEL
P68871 (Hemoglobin subunit beta )血红蛋白亚单位,P68871,HBB,"beta-globin, CD113t-C",ENSG00000244734,Hemoglobin subunit beta,11,5225464-5229395,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Oxygen transport, Transport","Hypotensive agent, Vasoactive","Congenital dyserythropoietic anemia, Disease variant, FDA approved drug targets, Hereditary hemolytic anemia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,11.0,bone marrow: 131241.6,Cell type enriched,Detected in many,216.0,Erythroid cells: 265225.8,Group enriched,Detected in all,4.0,cervical cancer: 66.4;glioma: 244.6;renal cancer: 65.1,Low region specificity,Detected in all,,,Group enriched,Detected in all,5.0,neutrophil: 662.1;plasmacytoid DC: 380.8,Group enriched,Detected in all,11.0,dendritic cells: 380.8;granulocytes: 662.1,Cancer enriched,Detected in many,5.0,Leukemia: 132.1,Liver - Erythroid cells,,,,,,,,,"CAB009526, HPA043234",Enhanced,,,,,,,,,10000000000.0,Cluster 35: Neutrophils - Protein binding,Cluster 77: Bone marrow - Cell proliferation,Cluster 42: Choroid plexus - Mitochondria,Cluster 47: Leukemia - Hemostasis,Cluster 1: Erythroid cells - Oxygen transport,5.0,,,"CAB009526: AB_2143058, HPA043234: AB_2678378",unprognostic (2.41e-1),unprognostic (8.55e-2),unprognostic (2.40e-1),unprognostic (4.40e-2),unprognostic (1.14e-1),unprognostic (3.22e-1),unprognostic (4.88e-2),unprognostic (7.46e-2),unprognostic (2.91e-2),unprognostic (1.76e-1),unprognostic (1.91e-1),unprognostic (8.11e-3),unprognostic (2.40e-2),unprognostic (5.81e-2),unprognostic (1.42e-1),unprognostic (8.87e-3),unprognostic (6.41e-2),MVHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH
P04003 C4b-binding protein alpha chain c4b结合蛋白α链,P04003,C4BPA,C4BP,ENSG00000123838,Complement component 4 binding protein alpha,1,207104233-207144972,"Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement pathway, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,11.0,liver: 1860.6,Group enriched,Detected in some,4.0,Alveolar cells type 2: 321.7;Hepatocytes: 852.2,Cancer enriched,Detected in many,7.0,liver cancer: 434.8,Low region specificity,Detected in many,,,Immune cell enriched,Detected in single,137.0,neutrophil: 29.6,Lineage enriched,Detected in single,137.0,granulocytes: 29.6,Cancer enhanced,Detected in some,,liver cancer: 7.4;lung cancer: 3.9,"Liver - Hepatocytes, Lung - Alveolar cells type 2",Not detected,Not detected,,,Region enhanced,Detected in single,,midbrain: 1.6,"HPA000926, HPA001578",Enhanced,,,,Secreted to blood,Complement pathway,,,30800000000.0,28000000000.0,Cluster 4: Neutrophils - Degranulation,Cluster 83: Liver - Metabolism,Cluster 26: Oligodendrocytes - Mixed function,Cluster 72: Neuronal - Signal transduction,Cluster 62: Hepatocytes - Metabolism,,,,"HPA000926: AB_1078355, HPA001578: AB_1078354",unprognostic (3.85e-4),unprognostic (9.07e-2),unprognostic (2.06e-1),prognostic favorable (6.37e-5),unprognostic (3.58e-2),unprognostic (2.41e-1),prognostic favorable (2.24e-4),unprognostic (3.64e-2),unprognostic (1.94e-1),unprognostic (5.90e-4),unprognostic (4.47e-2),unprognostic (2.58e-1),unprognostic (5.51e-7),unprognostic (9.74e-2),unprognostic (2.52e-2),unprognostic (6.92e-2),unprognostic (2.66e-1),MHPPKTPSGALHRKRKMAAWPFSRLWKVSDPILFQMTLIAALLPAVLGNCGPPPTLSFAAPMDITLTETRFKTGTTLKYTCLPGYVRSHSTQTLTCNSDGEWVYNTFCIYKRCRHPGELRNGQVEIKTDLSFGSQIEFSCSEGFFLIGSTTSRCEVQDRGVGWSHPLPQCEIVKCKPPPDIRNGRHSGEENFYAYGFSVTYSCDPRFSLLGHASISCTVENETIGVWRPSPPTCEKITCRKPDVSHGEMVSGFGPIYNYKDTIVFKCQKGFVLRGSSVIHCDADSKWNPSPPACEPNSCINLPDIPHASWETYPRPTKEDVYVVGTVLRYRCHPGYKPTTDEPTTVICQKNLRWTPYQGCEALCCPEPKLNNGEITQHRKSRPANHCVYFYGDEISFSCHETSRFSAICQGDGTWSPRTPSCGDICNFPPKIAHGHYKQSSSYSFFKEEIIYECDKGYILVGQAKLSCSYSHWSAPAPQCKALCRKPELVNGRLSVDKDQYVEPENVTIQCDSGYGVVGPQSITCSGNRTWYPEVPKCEWETPEGCEQVLTGKRLMQCLPNPEDVKMALEVYKLSLEIEQLELQRDSARQSTLDKEL
P02774 Vitamin D-binding protein维生素D,P02774,GC,"DBP, hDBP, VDBP",ENSG00000145321,GC vitamin D binding protein,4,71741696-71804041,"Metabolic proteins, Plasma proteins, Predicted secreted proteins",Transport,Actin-binding,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,17.0,liver: 8007.3,Group enriched,Detected in some,9.0,Cholangiocytes: 1684.6;Hepatocytes: 2766.0,Cancer enriched,Detected in many,18.0,liver cancer: 1016.1,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,17.0,liver cancer: 29.9,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,"HPA001526, CAB008596, HPA019855",Supported,,,,Secreted to blood,Transport,,,143000000000.0,73000000000.0,,Cluster 83: Liver - Metabolism,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,,,"CAB008596: AB_1622398, HPA001526: AB_1078959, HPA019855: AB_1849545",,,,,,,prognostic favorable (8.08e-4),,,,unprognostic (1.06e-3),,prognostic unfavorable (5.81e-5),unprognostic (1.55e-1),unprognostic (2.15e-1),,,MKRVLVLLLAVAFGHALERGRDYEKNKVCKEFSHLGKEDFTSLSLVLYSRKFPSGTFEQVSQLVKEVVSLTEACCAEGADPDCYDTRTSALSAKSCESNSPFPVHPGTAECCTKEGLERKLCMAALKHQPQEFPTYVEPTNDEICEAFRKDPKEYANQFMWEYSTNYGQAPLSLLVSYTKSYLSMVGSCCTSASPTVCFLKERLQLKHLSLLTTLSNRVCSQYAAYGEKKSRLSNLIKLAQKVPTADLEDVLPLAEDITNILSKCCESASEDCMAKELPEHTVKLCDNLSTKNSKFEDCCQEKTAMDVFVCTYFMPAAQLPELPDVELPTNKDVCDPGNTKVMDKYTFELSRRTHLPEVFLSKVLEPTLKSLGECCDVEDSTTCFNAKGPLLKKELSSFIDKGQELCADYSENTFTEYKKKLAERLKAKLPDATPTELAKLVNKHSDFASNCCSINSPPLYCDSEIDAELKNIL
P69905 Hemoglobin subunit alpha血红蛋白亚单位,P69905,HBA2,HBA-T2,ENSG00000188536,Hemoglobin subunit alpha 2,16,172876-173710,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Oxygen transport, Transport",,"Disease variant, FDA approved drug targets, Hereditary hemolytic anemia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,5.0,bone marrow: 37617.4,Cell type enriched,Detected in many,96.0,Erythroid cells: 55683.9,Cancer enhanced,Detected in all,,glioma: 59.7,Low region specificity,Detected in all,,,Group enriched,Detected in all,5.0,eosinophil: 316.7;neutrophil: 961.9;plasmacytoid DC: 488.2,Group enriched,Detected in all,7.0,dendritic cells: 488.2;granulocytes: 961.9,Cancer enriched,Detected in many,34.0,Leukemia: 1053.9,Liver - Erythroid cells,,,,,,,,,"CAB038417, HPA043780",Enhanced,,,,,,,,,14000000000.0,Cluster 22: Eosinophils - Transcription,Cluster 77: Bone marrow - Cell proliferation,Cluster 42: Choroid plexus - Mitochondria,Cluster 47: Leukemia - Hemostasis,Cluster 1: Erythroid cells - Oxygen transport,13.0,,,"CAB038417: , HPA043780: AB_2678667",unprognostic (1.57e-1),unprognostic (7.02e-2),unprognostic (2.59e-2),unprognostic (2.13e-1),unprognostic (3.59e-1),unprognostic (3.18e-1),unprognostic (3.39e-2),unprognostic (2.12e-1),unprognostic (4.99e-2),unprognostic (4.43e-1),unprognostic (1.09e-2),unprognostic (1.19e-2),unprognostic (1.72e-3),unprognostic (1.36e-1),unprognostic (2.11e-1),unprognostic (4.73e-2),unprognostic (8.92e-2),MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR
P69905 Hemoglobin subunit alpha血红蛋白亚单位,P69905,HBA1,HBA-T3,ENSG00000206172,Hemoglobin subunit alpha 1,16,176680-177522,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Oxygen transport, Transport",,"Disease variant, FDA approved drug targets, Hereditary hemolytic anemia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,4.0,bone marrow: 23966.1,Cell type enriched,Detected in many,105.0,Erythroid cells: 56964.9,Group enriched,Detected in many,4.0,endometrial cancer: 2.6;glioma: 6.3;ovarian cancer: 2.6;stomach cancer: 2.6,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,neutrophil: 143.5;plasmacytoid DC: 101.4,Group enriched,Detected in all,5.0,dendritic cells: 101.4;granulocytes: 143.5,Cancer enriched,Detected in many,55.0,Leukemia: 983.6,Liver - Erythroid cells,,,,,,,,,"CAB032534, HPA043780",Enhanced,,,,,,,,,14000000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 77: Bone marrow - Cell proliferation,Cluster 42: Choroid plexus - Mitochondria,Cluster 47: Leukemia - Hemostasis,Cluster 1: Erythroid cells - Oxygen transport,13.0,,,"CAB032534: AB_2294993, HPA043780: AB_2678667",unprognostic (1.16e-1),unprognostic (1.45e-2),unprognostic (8.87e-2),unprognostic (9.78e-3),unprognostic (3.02e-1),unprognostic (1.44e-1),unprognostic (1.67e-1),unprognostic (1.35e-1),unprognostic (6.21e-3),unprognostic (1.92e-2),unprognostic (1.64e-1),unprognostic (1.02e-2),unprognostic (3.59e-2),unprognostic (3.79e-1),unprognostic (6.61e-2),unprognostic (2.67e-2),unprognostic (9.56e-2),MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR
P02760 Protein AMBP,P02760,AMBP,"EDC1, HCP, HI30, IATIL, ITI, ITIL, ITILC, UTI",ENSG00000106927,Alpha-1-microglobulin/bikunin precursor,9,114060127-114078328,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Host-virus interaction,"Oxidoreductase, Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,68.0,liver: 10607.0,Group enriched,Detected in many,23.0,Cholangiocytes: 2459.2;Hepatocytes: 9092.4,Cancer enriched,Detected in many,115.0,liver cancer: 2620.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,8.0,liver cancer: 556.5,"Breast - Breast glandular cells, Liver - Hepatocytes, Testis - Late spermatids",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA001497, CAB069436, HPA075585",Approved,,Approved,"Golgi apparatus,Vesicles,Cytosol",Secreted to blood,Enzyme,,,,47000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,2.0,Vesicles,"Golgi apparatus, Cytosol","CAB069436: AB_1611916, HPA001497: AB_1078144, HPA075585: ",unprognostic (6.92e-2),unprognostic (3.61e-1),unprognostic (4.95e-3),prognostic favorable (1.20e-4),unprognostic (9.79e-2),unprognostic (2.90e-1),unprognostic (1.04e-3),unprognostic (7.59e-2),unprognostic (2.83e-2),unprognostic (2.04e-1),unprognostic (2.14e-1),unprognostic (7.84e-2),unprognostic (4.36e-2),unprognostic (2.89e-3),unprognostic (4.66e-2),unprognostic (2.97e-3),unprognostic (9.45e-3),MRSLGALLLLLSACLAVSAGPVPTPPDNIQVQENFNISRIYGKWYNLAIGSTCPWLKKIMDRMTVSTLVLGEGATEAEISMTSTRWRKGVCEETSGAYEKTDTDGKFLYHKSKWNITMESYVVHTNYDEYAIFLTKKFSRHHGPTITAKLYGRAPQLRETLLQDFRVVAQGVGIPEDSIFTMADRGECVPGEQEPEPILIPRVRRAVLPQEEEGSGGGQLVTEVTKKEDSCQLGYSAGPCMGMTSRYFYNGTSMACETFQYGGCMGNGNNFVTEKECLQTCRTVAACNLPIVRGPCRAFIQLWAFDAVKGKCVLFPYGGCQGNGNKFYSEKECREYCGVPGDGDEELLRFSN
P02790 Hemopexin  血液结合素,P02790,HPX,,ENSG00000110169,Hemopexin,11,6431049-6442617,"Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Host-virus interaction, Transport",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,886.0,liver: 5126.7,Cell type enriched,Detected in some,23.0,Hepatocytes: 4942.9,Cancer enriched,Detected in many,79.0,liver cancer: 571.1,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 9.0,"Breast - Breast glandular cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB016725, HPA065318, HPA068847",Approved,,,,Secreted to blood,Transport,,,425000000000.0,190000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 15: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,,,"CAB016725: , HPA065318: , HPA068847: ",unprognostic (3.39e-2),unprognostic (9.26e-2),unprognostic (3.88e-1),unprognostic (6.19e-4),unprognostic (2.05e-2),unprognostic (2.41e-1),prognostic favorable (2.26e-4),unprognostic (6.33e-2),unprognostic (5.67e-3),unprognostic (3.88e-1),unprognostic (5.08e-3),unprognostic (2.78e-2),unprognostic (5.82e-12),unprognostic (2.01e-1),unprognostic (4.48e-1),unprognostic (1.84e-2),unprognostic (2.14e-2),MARVLGAPVALGLWSLCWSLAIATPLPPTSAHGNVAEGETKPDPDVTERCSDGWSFDATTLDDNGTMLFFKGEFVWKSHKWDRELISERWKNFPSPVDAAFRQGHNSVFLIKGDKVWVYPPEKKEKGYPKLLQDEFPGIPSPLDAAVECHRGECQAEGVLFFQGDREWFWDLATGTMKERSWPAVGNCSSALRWLGRYYCFQGNQFLRFDPVRGEVPPRYPRDVRDYFMPCPGRGHGHRNGTGHGNSTHHGPEYMRCSPHLVLSALTSDNHGATYAFSGTHYWRLDTSRDGWHSWPIAHQWPQGPSAVDAAFSWEEKLYLVQGTQVYVFLTKGGYTLVSGYPKRLEKEVGTPHGIILDSVDAAFICPGSSRLHIMAGRRLWWLDLKSGAQATWTELPWPHEKVDGALCMEKSLGPNSCSANGPGLYLIHGPNLYCYSDVEKLNAAKALPQPQNVTSLLGCTH
P07996 (Thrombospondin-1) 血小板反应蛋白,P07996,THBS1,"THBS, THBS-1, TSP, TSP-1, TSP1",ENSG00000137801,Thrombospondin 1,15,39581079-39599466,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Angiogenesis, Apoptosis, Cell adhesion, Inflammatory response, Unfolded protein response",Heparin-binding,Cancer-related genes,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in many,,,Cell type enhanced,Detected in many,,Macrophages: 678.5;monocytes: 1951.1;Mucus glandular cells: 699.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in some,,eosinophil: 15.8,Low lineage specificity,Detected in many,,,Low cancer specificity,Detected in all,,,Colon - Neutrophils,Low region specificity,Detected in many,,,Region enhanced,Detected in many,,spinal cord: 27.1,"CAB033678, HPA059756",Approved,,Approved,Plasma membrane,Secreted to extracellular matrix,Cell adhesion,,,16000000000.0,1400000000.0,Cluster 7: Non-specific - Innate immune response,Cluster 62: Connective tissue - ECM organization,Cluster 44: Non-specific - Mixed function,Cluster 64: Connective tissue cells - ECM organization,Cluster 29: Monocytes - Innate immune response,2.0,Plasma membrane,,"CAB033678: AB_793044, HPA059756: AB_2684121",unprognostic (1.72e-2),unprognostic (9.55e-3),unprognostic (7.49e-2),unprognostic (3.31e-1),unprognostic (4.34e-2),unprognostic (1.03e-3),unprognostic (3.60e-1),unprognostic (1.53e-2),unprognostic (1.22e-1),unprognostic (2.07e-1),unprognostic (6.40e-2),unprognostic (9.16e-2),prognostic unfavorable (8.47e-5),prognostic unfavorable (8.50e-4),unprognostic (1.00e-1),unprognostic (9.25e-3),unprognostic (1.48e-3),MGLAWGLGVLFLMHVCGTNRIPESGGDNSVFDIFELTGAARKGSGRRLVKGPDPSSPAFRIEDANLIPPVPDDKFQDLVDAVRAEKGFLLLASLRQMKKTRGTLLALERKDHSGQVFSVVSNGKAGTLDLSLTVQGKQHVVSVEEALLATGQWKSITLFVQEDRAQLYIDCEKMENAELDVPIQSVFTRDLASIARLRIAKGGVNDNFQGVLQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGSSPAIRTNYIGHKTKDLQAICGISCDELSSMVLELRGLRTIVTTLQDSIRKVTEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQNSVTICKKVSCPIMPCSNATVPDGECCPRCWPSDSADDGWSPWSEWTSCSTSCGNGIQQRGRSCDSLNNRCEGSSVQTRTCHIQECDKRFKQDGGWSHWSPWSSCSVTCGDGVITRIRLCNSPSPQMNGKPCEGEARETKACKKDACPINGGWGPWSPWDICSVTCGGGVQKRSRLCNNPTPQFGGKDCVGDVTENQICNKQDCPIDGCLSNPCFAGVKCTSYPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDACFNHNGEHRCENTDPGYNCLPCPPRFTGSQPFGQGVEHATANKQVCKPRNPCTDGTHDCNKNAKCNYLGHYSDPMYRCECKPGYAGNGIICGEDTDLDGWPNENLVCVANATYHCKKDNCPNLPNSGQEDYDKDGIGDACDDDDDNDKIPDDRDNCPFHYNPAQYDYDRDDVGDRCDNCPYNHNPDQADTDNNGEGDACAADIDGDGILNERDNCQYVYNVDQRDTDMDGVGDQCDNCPLEHNPDQLDSDSDRIGDTCDNNQDIDEDGHQNNLDNCPYVPNANQADHDKDGKGDACDHDDDNDGIPDDKDNCRLVPNPDQKDSDGDGRGDACKDDFDHDSVPDIDDICPENVDISETDFRRFQMIPLDPKGTSQNDPNWVVRHQGKELVQTVNCDPGLAVGYDEFNAVDFSGTFFINTERDDDYAGFVFGYQSSSRFYVVMWKQVTQSYWDTNPTRAQGYSGLSVKVVNSTTGPGEHLRNALWHTGNTPGQVRTLWHDPRHIGWKDFTAYRWRLSHRPKTGFIRVVMYEGKKIMADSGPIYDKTYAGGRLGLFVFSQEMVFFSDLKYECRDP
P05155 Plasma protease C1 inhibitor 血浆蛋白酶C1抑制剂,P05155,SERPING1,"C1-INH, C1IN, C1INH, C1NH, HAE1, HAE2",ENSG00000149131,Serpin family G member 1,11,57597387-57619171,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Complement pathway, Fibrinolysis, Hemostasis, Immunity, Innate immunity","Protease inhibitor, Serine protease inhibitor",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,liver: 2545.7,Cell type enhanced,Detected in many,,Cholangiocytes: 662.0;Ductal cells: 686.0;Fibroblasts: 846.6;Hepatocytes: 2176.6;Leydig cells: 740.9;Mesothelial cells: 1959.4,Cancer enhanced,Detected in all,,liver cancer: 609.9,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,neutrophil: 65.5;plasmacytoid DC: 60.7,Group enriched,Detected in many,231.0,dendritic cells: 60.7;granulocytes: 65.5;monocytes: 25.7,Cancer enhanced,Detected in many,,liver cancer: 37.5;testis cancer: 38.7,"Heart muscle - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_1, Prostate - Fibroblasts",Low region specificity,Detected in all,,,Region enhanced,Detected in all,,spinal cord: 255.7,"CAB026161, HPA048738",Supported,,,,Secreted to blood,Blood coagulation,,,,28000000000.0,Cluster 2: Dendritic cells - Unknown function,Cluster 83: Liver - Metabolism,Cluster 8: Immune cells - Immune response,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,2.0,,,"CAB026161: , HPA048738: AB_2680505",unprognostic (1.35e-2),unprognostic (2.24e-1),prognostic unfavorable (9.96e-4),unprognostic (4.26e-2),unprognostic (4.38e-2),unprognostic (2.32e-1),unprognostic (4.12e-3),unprognostic (2.13e-1),unprognostic (8.95e-2),prognostic favorable (8.03e-4),unprognostic (5.92e-3),unprognostic (3.76e-2),prognostic unfavorable (1.55e-4),unprognostic (2.60e-2),unprognostic (4.14e-2),unprognostic (2.56e-1),unprognostic (1.17e-1),MASRLTLLTLLLLLLAGDRASSNPNATSSSSQDPESLQDRGEGKVATTVISKMLFVEPILEVSSLPTTNSTTNSATKITANTTDEPTTQPTTEPTTQPTIQPTQPTTQLPTDSPTQPTTGSFCPGPVTLCSDLESHSTEAVLGDALVDFSLKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYPKDFTCVHQALKGFTTKGVTSVSQIFHSPDLAIRDTFVNASRTLYSSSPRVLSNNSDANLELINTWVAKNTNNKISRLLDSLPSDTRLVLLNAIYLSAKWKTTFDPKKTRMEPFHFKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVILVPQNLKHRLEDMEQALSPSVFKAIMEKLEMSKFQPTLLTLPRIKVTTSQDMLSIMEKLEFFDFSYDLNLCGLTEDPDLQVSAMQHQTVLELTETGVEAAAASAISVARTLLVFEVQQPFLFVLWDQQHKFPVFMGRVYDPRA
P00738 Haptoglobin 触珠蛋白,P00738,HP,,ENSG00000257017,Haptoglobin,16,72054505-72061055,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Acute phase, Immunity","Antibiotic, Antimicrobial, Antioxidant, Serine protease homolog","Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,85.0,liver: 54575.6,Group enriched,Detected in many,45.0,Hepatocytes: 52816.7;Mesothelial cells: 16337.1,Cancer enriched,Detected in many,81.0,liver cancer: 1297.4,Region enhanced,Detected in all,,medulla oblongata: 56.4,Group enriched,Detected in many,5.0,classical monocyte: 49.5;eosinophil: 80.5,Group enriched,Detected in many,7.0,granulocytes: 80.5;monocytes: 49.5,Group enriched,Detected in some,12.0,Gastric cancer: 6.6;Leukemia: 4.1;liver cancer: 15.7,Liver - Hepatocytes,,,,,,,,,"CAB003787, HPA047750, HPA066795",Enhanced,,Approved,Vesicles,Secreted to blood,Acute phase,,,998000000000.0,100000000000.0,Cluster 36: Eosinophils - Protein ubiquitination,Cluster 31: Liver - Plasma proteins,Cluster 12: Non-specific - Vasculature,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,3.0,Vesicles,,"CAB003787: , HPA047750: AB_2680146, HPA066795: ",unprognostic (6.38e-3),unprognostic (7.73e-3),unprognostic (1.23e-1),unprognostic (2.41e-2),unprognostic (2.34e-3),unprognostic (2.07e-1),unprognostic (7.79e-3),unprognostic (1.37e-1),unprognostic (2.31e-1),unprognostic (1.84e-1),unprognostic (6.30e-2),unprognostic (8.18e-2),prognostic unfavorable (6.94e-13),unprognostic (4.34e-4),unprognostic (1.80e-1),unprognostic (6.61e-2),unprognostic (2.49e-2),MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN
P02751 Fibronectin 纤连蛋白,P02751,FN1,"CIG, FINC, GFND2, LETS, MSF",ENSG00000115414,Fibronectin 1,2,215360440-215436073,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Acute phase, Angiogenesis, Cell adhesion, Cell shape",Heparin-binding,"Cancer-related genes, Disease variant, Dwarfism, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,liver: 1674.5;placenta: 2828.8,Cell type enhanced,Detected in many,,Extravillous trophoblasts: 3161.0;Fibroblasts: 697.7;Hepatocytes: 800.2;Pancreatic endocrine cells: 517.9;Smooth muscle cells: 482.6,Cancer enhanced,Detected in all,,thyroid cancer: 833.9,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in all,,testis cancer: 4284.8;thyroid cancer: 4456.7,"Adipose subcutaneous - Adipose progenitor cells, Breast - Fibroblasts, Colon - Smooth muscle cells, Prostate - Smooth muscle cells, Skeletal muscle - Fibroblasts, Skin - Fibroblast_2",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB000126, HPA027066",Enhanced,,,,Secreted to blood,Acute phase,,,227000000000.0,47000000000.0,,Cluster 11: Liver - Plasma proteins,Cluster 12: Non-specific - Vasculature,Cluster 64: Connective tissue cells - ECM organization,Cluster 32: Smooth muscle cells - Muscle contraction,21.0,,,"CAB000126: , HPA027066: AB_10602500",unprognostic (8.08e-2),unprognostic (1.09e-3),unprognostic (2.20e-2),unprognostic (3.45e-3),unprognostic (1.82e-2),unprognostic (3.47e-3),unprognostic (3.36e-2),unprognostic (5.91e-3),unprognostic (2.96e-2),unprognostic (2.91e-3),unprognostic (1.41e-2),unprognostic (2.84e-1),prognostic unfavorable (3.44e-8),prognostic unfavorable (8.82e-5),unprognostic (7.88e-2),unprognostic (7.74e-2),prognostic unfavorable (3.33e-4),MLRGPGPGLLLLAVQCLGTAVPSTGASKSKRQAQQMVQPQSPVAVSQSKPGCYDNGKHYQINQQWERTYLGNALVCTCYGGSRGFNCESKPEAEETCFDKYTGNTYRVGDTYERPKDSMIWDCTCIGAGRGRISCTIANRCHEGGQSYKIGDTWRRPHETGGYMLECVCLGNGKGEWTCKPIAEKCFDHAAGTSYVVGETWEKPYQGWMMVDCTCLGEGSGRITCTSRNRCNDQDTRTSYRIGDTWSKKDNRGNLLQCICTGNGRGEWKCERHTSVQTTSSGSGPFTDVRAAVYQPQPHPQPPPYGHCVTDSGVVYSVGMQWLKTQGNKQMLCTCLGNGVSCQETAVTQTYGGNSNGEPCVLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHTVLVQTRGGNSNGALCHFPFLYNNHNYTDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTTNEGVMYRIGDQWDKQHDMGHMMRCTCVGNGRGEWTCIAYSQLRDQCIVDDITYNVNDTFHKRHEEGHMLNCTCFGQGRGRWKCDPVDQCQDSETGTFYQIGDSWEKYVHGVRYQCYCYGRGIGEWHCQPLQTYPSSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTPVTSNTVTGETTPFSPLVATSESVTEITASSFVVSWVSASDTVSGFRVEYELSEEGDEPQYLDLPSTATSVNIPDLLPGRKYIVNVYQISEDGEQSLILSTSQTTAPDAPPDTTVDQVDDTSIVVRWSRPQAPITGYRIVYSPSVEGSSTELNLPETANSVTLSDLQPGVQYNITIYAVEENQESTPVVIQQETTGTPRSDTVPSPRDLQFVEVTDVKVTIMWTPPESAVTGYRVDVIPVNLPGEHGQRLPISRNTFAEVTGLSPGVTYYFKVFAVSHGRESKPLTAQQTTKLDAPTNLQFVNETDSTVLVRWTPPRAQITGYRLTVGLTRRGQPRQYNVGPSVSKYPLRNLQPASEYTVSLVAIKGNQESPKATGVFTTLQPGSSIPPYNTEVTETTIVITWTPAPRIGFKLGVRPSQGGEAPREVTSDSGSIVVSGLTPGVEYVYTIQVLRDGQERDAPIVNKVVTPLSPPTNLHLEANPDTGVLTVSWERSTTPDITGYRITTTPTNGQQGNSLEEVVHADQSSCTFDNLSPGLEYNVSVYTVKDDKESVPISDTIIPEVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSVGYYTVTGLEPGIDYDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKNEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTGLDSPTGIDFSDITANSFTVHWIAPRATITGYRIRHHPEHFSGRPREDRVPHSRNSITLTNLTPGTEYVVSIVALNGREESPLLIGQQSTVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKTKTAGPDQTEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTNIDRPKGLAFTDVDVDSIKIAWESPQGQVSRYRVTYSSPEDGIHELFPAPDGEEDTAELQGLRPGSEYTVSVVALHDDMESQPLIGTQSTAIPAPTDLKFTQVTPTSLSAQWTPPNVQLTGYRVRVTPKEKTGPMKEINLAPDSSSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVSPPRRARVTDATETTITISWRTKTETITGFQVDAVPANGQTPIQRTIKPDVRSYTITGLQPGTDYKIYLYTLNDNARSSPVVIDASTAIDAPSNLRFLATTPNSLLVSWQPPRARITGYIIKYEKPGSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTDELPQLVTLPHPNLHGPEILDVPSTVQKTPFVTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFRRTTPPTTATPIRHRPRPYPPNVGEEIQIGHIPREDVDYHLYPHGPGLNPNASTGQEALSQTTISWAPFQDTSEYIISCHPVGTDEEPLQFRVPGTSTSATLTGLTRGATYNVIVEALKDQQRHKVREEVVTVGNSVNEGLNQPTDDSCFDPYTVSHYAVGDEWERMSESGFKLLCQCLGFGSGHFRCDSSRWCHDNGVNYKIGEKWDRQGENGQMMSCTCLGNGKGEFKCDPHEATCYDDGKTYHVGEQWQKEYLGAICSCTCFGGQRGWRCDNCRRPGGEPSPEGTTGQSYNQYSQRYHQRTNTNVNCPIECFMPLDVQADREDSRE
P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH,P04406,GAPDH,GAPD,ENSG00000111640,Glyceraldehyde-3-phosphate dehydrogenase,12,6534512-6538374,"Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins","Apoptosis, Glycolysis, Immunity, Innate immunity, Translation regulation","Oxidoreductase, Transferase",FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in all,4.0,skeletal muscle: 26611.3;tongue: 18150.7,Cell type enhanced,Detected in all,,Extravillous trophoblasts: 11520.0,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Skeletal muscle - Skeletal myocytes,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB005197, CAB016392, HPA040067, HPA061280, CAB079968",Supported,,Enhanced,"Nuclear membrane,Vesicles,Plasma membrane,Cytosol",,,No,No,,1400000000.0,Cluster 26: Monocytes - Plasma membrane proteins,Cluster 14: Skeletal muscle - Muscle contraction,Cluster 27: Non-specific - Mixed function,Cluster 38: Non-specific - Transcription,Cluster 45: Non-specific - Mixed function,28.0,"Plasma membrane, Cytosol","Nuclear membrane, Vesicles","CAB005197: AB_641107, CAB016392: AB_627678, CAB079968: , HPA040067: AB_10965903, HPA061280: AB_2684463",unprognostic (3.03e-1),unprognostic (2.62e-3),unprognostic (3.58e-2),unprognostic (4.20e-1),unprognostic (9.73e-3),unprognostic (1.77e-3),prognostic unfavorable (1.79e-6),unprognostic (2.89e-3),unprognostic (2.86e-1),unprognostic (2.06e-2),unprognostic (9.50e-3),unprognostic (4.52e-1),prognostic unfavorable (6.25e-10),unprognostic (2.33e-1),unprognostic (4.28e-1),unprognostic (1.40e-1),unprognostic (1.26e-2),MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDNEFGYSNRVVDLMAHMASKE
P00739 Haptoglobin-related protein 结合珠蛋白相关蛋白质,P00739,HPR,,ENSG00000261701,Haptoglobin-related protein,16,72063148-72077246,"Enzymes, Plasma proteins, Predicted secreted proteins",,Serine protease homolog,,Evidence at protein level,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Tissue enriched,Detected in many,6.0,liver: 786.9,Cell type enriched,Detected in some,7.0,Hepatocytes: 205.7,Cancer enriched,Detected in some,53.0,liver cancer: 185.1,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,4.0,liver cancer: 2.3;prostate cancer: 3.5,Liver - Hepatocytes,,,,,,,,,HPA047750,Supported,,Approved,Vesicles,Secreted to blood,Other,,,49000000000.0,55000000000.0,,Cluster 83: Liver - Metabolism,Cluster 19: Astrocytes - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 15: Non-specific - Mixed function,,Vesicles,,HPA047750: AB_2680146,unprognostic (2.43e-1),,unprognostic (4.69e-2),unprognostic (5.97e-3),unprognostic (2.42e-1),,unprognostic (2.32e-3),unprognostic (2.36e-1),,unprognostic (1.66e-1),unprognostic (8.21e-2),unprognostic (2.30e-1),unprognostic (3.44e-6),unprognostic (2.09e-2),unprognostic (1.45e-1),unprognostic (1.29e-1),,MSDLGAVISLLLWGRQLFALYSGNDVTDISDDRFPKPPEIANGYVEHLFRYQCKNYYRLRTEGDGVYTLNDKKQWINKAVGDKLPECEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYHQVDIGLIKLKQKVLVNERVMPICLPSKNYAEVGRVGYVSGWGQSDNFKLTDHLKYVMLPVADQYDCITHYEGSTCPKWKAPKSPVGVQPILNEHTFCVGMSKYQEDTCYGDAGSAFAVHDLEEDTWYAAGILSFDKSCAVAEYGVYVKVTSIQHWVQKTIAEN
P07225 Vitamin K-dependent protein S维生素k,P07225,PROS1,PROS,ENSG00000184500,Protein S,3,93873051-93980003,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis",,"Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,choroid plexus: 137.3;liver: 274.9,Cell type enhanced,Detected in many,,Hepatocytes: 261.3;Mesothelial cells: 85.9,Cancer enhanced,Detected in all,,thyroid cancer: 64.8,Region enriched,Detected in all,34.0,choroid plexus: 214.4,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,skin cancer: 46.7,"Breast - Fibroblasts, Liver - Hepatocytes",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA007724, HPA023974, CAB032610",Approved,,,,Secreted to blood,Blood coagulation,,,22500000000.0,5000000000.0,,Cluster 83: Liver - Metabolism,Cluster 36: Choroid plexus - Mixed function,Cluster 15: Kidney cancer - Membrane components,Cluster 53: Fibroblasts - ECM organization,4.0,,,"CAB032610: AB_2237647, HPA007724: AB_1079688, HPA023974: AB_1855738",unprognostic (2.00e-2),unprognostic (2.81e-2),unprognostic (9.21e-2),unprognostic (8.03e-3),unprognostic (3.35e-2),unprognostic (2.41e-1),unprognostic (6.48e-2),unprognostic (3.07e-1),unprognostic (5.18e-2),unprognostic (3.12e-1),unprognostic (1.10e-1),unprognostic (1.91e-1),unprognostic (1.10e-1),prognostic unfavorable (8.35e-4),unprognostic (4.90e-2),unprognostic (1.05e-2),prognostic unfavorable (4.42e-5),MRVLGGRCGALLACLLLVLPVSEANFLSKQQASQVLVRKRRANSLLEETKQGNLERECIEELCNKEEAREVFENDPETDYFYPKYLVCLRSFQTGLFTAARQSTNAYPDLRSCVNAIPDQCSPLPCNEDGYMSCKDGKASFTCTCKPGWQGEKCEFDINECKDPSNINGGCSQICDNTPGSYHCSCKNGFVMLSNKKDCKDVDECSLKPSICGTAVCKNIPGDFECECPEGYRYNLKSKSCEDIDECSENMCAQLCVNYPGGYTCYCDGKKGFKLAQDQKSCEVVSVCLPLNLDTKYELLYLAEQFAGVVLYLKFRLPEISRFSAEFDFRTYDSEGVILYAESIDHSAWLLIALRGGKIEVQLKNEHTSKITTGGDVINNGLWNMVSVEELEHSISIKIAKEAVMDINKPGPLFKPENGLLETKVYFAGFPRKVESELIKPINPRLDGCIRSWNLMKQGASGIKEIIQEKQNKHCLVTVEKGSYYPGSGIAQFHIDYNNVSSAEGWHVNVTLNIRPSTGTGVMLALVSGNNTVPFAVSLVDSTSEKSQDILLSVENTVIYRIQALSLCSDQQSHLEFRVNRNNLELSTPLKIETISHEDLQRQLAVLDKAMKAKVATYLGGLPDVPFSATPVNAFYNGCMEVNINGVQLDLDEAISKHNDIRAHSCPSVWKKTKNS
P05154 Plasma serine protease inhibitor血浆丝氨酸蛋白酶抑制剂,P05154,SERPINA5,"PAI3, PCI, PLANH3, PROCI",ENSG00000188488,Serpin family A member 5,14,94561442-94593118,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Fertilization, Lipid transport, Transport","Heparin-binding, Protease inhibitor, Serine protease inhibitor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adrenal gland: 469.3;liver: 761.5;testis: 419.6,Cell type enhanced,Detected in many,,Basal prostatic cells: 239.3;Cholangiocytes: 360.6;Glandular and luminal cells: 330.8;Hepatocytes: 174.8;Late spermatids: 271.4;Peritubular cells: 139.8;Sertoli cells: 356.3,Cancer enhanced,Detected in many,,liver cancer: 121.1,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,Gastric cancer: 27.3;liver cancer: 67.0,"Liver - Hepatocytes, Pancreas - Macrophages, Skin - Fibroblast_2, Testis - Sertoli cells",Not detected,Not detected,,,Not detected,Not detected,,,HPA078846,Enhanced,,,,Secreted to blood,Transport,,,,2100000000.0,,Cluster 78: Testis - Transcription,Cluster 44: Non-specific - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 37: Glandular & Luminal cells - Unknown function,1.0,,,HPA078846: ,unprognostic (5.94e-3),unprognostic (2.64e-4),unprognostic (1.13e-1),prognostic favorable (7.72e-4),unprognostic (3.34e-3),unprognostic (6.10e-3),unprognostic (3.94e-2),unprognostic (1.39e-3),unprognostic (5.36e-1),unprognostic (1.50e-1),unprognostic (6.16e-2),unprognostic (1.87e-2),unprognostic (8.39e-3),unprognostic (3.38e-3),unprognostic (9.92e-2),unprognostic (8.08e-2),unprognostic (3.23e-1),MQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAAPSQSIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQPRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQTKGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSREDQYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLELYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGTRAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP
"P60709 Actin, cytoplasmic 1 肌动蛋白，细胞质1",P60709,ACTB,,ENSG00000075624,Actin beta,7,5526409-5563902,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,Hydrolase,"Deafness, Disease variant, Dystonia, Intellectual disability",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Extravillous trophoblasts: 13764.8;Hofbauer cells: 15165.3,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Smooth muscle cells, Colon - Smooth muscle cells, Prostate - Smooth muscle cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB002621, HPA041264, HPA041271",Supported,,,,,,,,,5800000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 29: Squamous epithelium - Innate immune response,Cluster 27: Non-specific - Mixed function,Cluster 67: Non-specific - Unknown function,Cluster 14: Langerhans cells - Innate immune response,25.0,,,"CAB002621: , HPA041264: AB_2677383, HPA041271: AB_2677386",unprognostic (1.66e-1),unprognostic (1.15e-1),unprognostic (4.20e-2),unprognostic (1.15e-2),unprognostic (1.01e-2),prognostic unfavorable (4.51e-4),unprognostic (9.80e-3),unprognostic (1.57e-3),unprognostic (1.73e-1),unprognostic (5.99e-2),unprognostic (3.33e-2),unprognostic (3.77e-1),prognostic unfavorable (3.78e-5),unprognostic (2.68e-2),unprognostic (3.20e-1),unprognostic (1.50e-1),unprognostic (4.88e-3),MDDDIAALVVDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQEYDESGPSIVHRKCF
P03952 Plasma kallikrein 血浆激肽释放酶,P03952,KLKB1,KLK3,ENSG00000164344,Kallikrein B1,4,186226438-186258471,"Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis, Inflammatory response","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,28.0,liver: 318.1,Cell type enriched,Detected in many,4.0,Hepatocytes: 223.6,Cancer enriched,Detected in some,17.0,liver cancer: 27.6,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in many,,,,,,,,Secreted to blood,Blood coagulation,,,28900000000.0,5300000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 23: Choroid plexus - Mixed function,Cluster 12: Bone cancer - Neuronal signaling,Cluster 62: Hepatocytes - Metabolism,8.0,,,,unprognostic (4.80e-2),unprognostic (4.53e-3),unprognostic (4.36e-2),unprognostic (4.17e-2),unprognostic (5.93e-2),unprognostic (1.90e-2),unprognostic (1.15e-2),unprognostic (2.83e-1),unprognostic (8.14e-2),unprognostic (1.35e-1),unprognostic (1.38e-2),unprognostic (1.15e-1),unprognostic (1.45e-2),unprognostic (6.01e-2),unprognostic (7.30e-2),unprognostic (1.20e-1),unprognostic (1.59e-2),MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA
P05546 Heparin cofactor 2 肝素辅助因子2,P05546,SERPIND1,"D22S673, HC-II, HC2, HCF2, HLS2",ENSG00000099937,Serpin family D member 1,22,20774113-20787720,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Chemotaxis, Hemostasis","Heparin-binding, Protease inhibitor, Serine protease inhibitor","Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,5.0,liver: 1214.6,Cell type enriched,Detected in some,13.0,Hepatocytes: 238.0,Cancer enriched,Detected in many,80.0,liver cancer: 334.4,Region enriched,Detected in all,21.0,choroid plexus: 191.0,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in many,15.0,liver cancer: 30.6;ovarian cancer: 66.9,"Liver - Hepatocytes, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in some,,,"CAB008639, HPA055767",Supported,,Approved,Vesicles,Secreted to blood,Blood coagulation,,,,50000000000.0,Cluster 30: Non-specific - DNA binding,Cluster 31: Liver - Plasma proteins,Cluster 36: Choroid plexus - Mixed function,Cluster 66: Non-specific - Mitochondria,Cluster 62: Hepatocytes - Metabolism,,Vesicles,,"CAB008639: AB_1618010, HPA055767: AB_2682912",unprognostic (1.68e-1),unprognostic (8.27e-2),unprognostic (4.40e-2),prognostic favorable (4.09e-4),unprognostic (5.42e-2),unprognostic (1.23e-1),unprognostic (1.12e-3),unprognostic (1.56e-1),unprognostic (1.13e-1),unprognostic (1.74e-1),unprognostic (1.21e-2),unprognostic (2.88e-1),unprognostic (3.94e-9),unprognostic (2.01e-1),unprognostic (4.66e-2),unprognostic (8.36e-3),unprognostic (1.46e-1),MKHSLNALLIFLIITSAWGGSKGPLDQLEKGGETAQSADPQWEQLNNKNLSMPLLPADFHKENTVTNDWIPEGEEDDDYLDLEKIFSEDDDYIDIVDSLSVSPTDSDVSAGNILQLFHGKSRIQRLNILNAKFAFNLYRVLKDQVNTFDNIFIAPVGISTAMGMISLGLKGETHEQVHSILHFKDFVNASSKYEITTIHNLFRKLTHRLFRRNFGYTLRSVNDLYIQKQFPILLDFKTKVREYYFAEAQIADFSDPAFISKTNNHIMKLTKGLIKDALENIDPATQMMILNCIYFKGSWVNKFPVEMTHNHNFRLNEREVVKVSMMQTKGNFLAANDQELDCDILQLEYVGGISMLIVVPHKMSGMKTLEAQLTPRVVERWQKSMTNRTREVLLPKFKLEKNYNLVESLKLMGIRMLFDKNGNMAGISDQRIAIDLFKHQGTITVNEEGTQATTVTTVGFMPLSTQVRFTVDRPFLFLIYEHRTSCLLFMGRVANPSRS
P27169 Serum paraoxonase/arylesterase 1 血清对氧磷酶,P27169,PON1,"ESA, PON",ENSG00000005421,Paraoxonase 1,7,95297676-95324532,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters",,Hydrolase,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,103.0,liver: 516.3,Cell type enriched,Detected in some,13.0,Hepatocytes: 428.5,Cancer enriched,Detected in some,78.0,liver cancer: 97.8,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 1.0;prostate cancer: 2.4,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,HPA001610,Approved,,,,Secreted to blood,Enzyme,,,96000000000.0,17000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 10: Cerebellum - Nucleic acid binding,Cluster 59: Leukemia - T-cell receptor,Cluster 43: Hepatocytes - Metabolism,,,,HPA001610: AB_1079656,unprognostic (2.02e-2),unprognostic (2.41e-2),unprognostic (3.04e-1),unprognostic (3.54e-2),unprognostic (2.70e-1),,prognostic favorable (7.24e-7),unprognostic (2.24e-1),unprognostic (1.95e-1),unprognostic (9.02e-3),unprognostic (1.76e-3),unprognostic (3.97e-2),unprognostic (6.74e-9),unprognostic (1.09e-3),unprognostic (2.29e-2),unprognostic (2.07e-1),unprognostic (5.54e-3),MAKLIALTLLGMGLALFRNHQSSYQTRLNALREVQPVELPNCNLVKGIETGSEDLEILPNGLAFISSGLKYPGIKSFNPNSPGKILLMDLNEEDPTVLELGITGSKFDVSSFNPHGISTFTDEDNAMYLLVVNHPDAKSTVELFKFQEEEKSLLHLKTIRHKLLPNLNDIVAVGPEHFYGTNDHYFLDPYLQSWEMYLGLAWSYVVYYSPSEVRVVAEGFDFANGINISPDGKYVYIAELLAHKIHVYEKHANWTLTPLKSLDFNTLVDNISVDPETGDLWVGCHPNGMKIFFYDSENPPASEVLRIQNILTEEPKVTQVYAENGTVLQGSTVASVYKGKLLIGTVFHKALYCEL
P01019 Angiotensinogen 血管紧张肽原,P01019,AGT,SERPINA8,ENSG00000135744,Angiotensinogen,1,230690776-230745576,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins",,"Vasoactive, Vasoconstrictor",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,6.0,liver: 1563.6,Group enriched,Detected in many,4.0,Cholangiocytes: 984.4;Hepatocytes: 1899.1,Cancer enriched,Detected in all,4.0,liver cancer: 1163.4,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,6.0,liver cancer: 204.0,"Kidney - Proximal tubular cells, Liver - Hepatocytes, Testis - Late spermatids",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,CAB025798,Supported,,,,Secreted to blood,Other,,,5940000.0,65000000000.0,,Cluster 83: Liver - Metabolism,Cluster 44: Non-specific - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,8.0,,,CAB025798: ,unprognostic (7.77e-2),unprognostic (4.46e-1),unprognostic (2.15e-2),unprognostic (2.07e-2),unprognostic (2.67e-1),unprognostic (3.61e-2),unprognostic (5.75e-2),unprognostic (2.50e-1),unprognostic (2.20e-2),unprognostic (4.46e-2),unprognostic (4.32e-3),unprognostic (6.70e-2),unprognostic (9.28e-2),unprognostic (4.42e-3),unprognostic (2.17e-1),unprognostic (3.89e-1),unprognostic (1.38e-1),MAPAGVSLRATILCLLAWAGLAAGDRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNSTSVSVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNSIFFELEADEREPTESTQQLNKPEVLEVTLNRPFLFAVYDQSATALHFLGRVANPLSTA
P35542 Serum amyloid A-4 protein 血清淀粉样蛋白4,P35542,SAA4,"C-SAA, CSAA",ENSG00000148965,"Serum amyloid A4, constitutive",11,18231355-18236802,"Plasma proteins, Predicted secreted proteins",Acute phase,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,125.0,liver: 1879.5,Cell type enriched,Detected in some,34.0,Hepatocytes: 1673.3,Cancer enriched,Detected in many,141.0,liver cancer: 118.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,Bile duct cancer: 4.4;head and neck cancer: 6.3;liver cancer: 5.5,"Adipose visceral - Adipocytes (Visceral), Liver - Hepatocytes, Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,,,,,"CAB026061, HPA060139",Supported,,,,Secreted to blood,Acute phase,,,65000000000.0,33000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,,,"CAB026061: , HPA060139: AB_2684210",unprognostic (4.70e-4),unprognostic (1.17e-1),unprognostic (1.17e-1),unprognostic (4.83e-1),unprognostic (4.15e-2),unprognostic (6.05e-2),unprognostic (3.63e-3),unprognostic (5.94e-2),,unprognostic (2.40e-2),unprognostic (1.41e-1),unprognostic (7.35e-2),unprognostic (2.54e-8),unprognostic (2.49e-1),,,unprognostic (6.46e-2),MRLFTGIVFCSLVMGVTSESWRSFFKEALQGVGDMGRAYWDIMISNHQNSNRYLYARGNYDAAQRGPGGVWAAKLISRSRVYLQGLIDCYLFGNSSTVLEDSKSNEKAEEWGRSGKDPDRFRPDGLPKKY
Q14520 Hyaluronan-binding protein 2透明质酸结合蛋白,Q14520,HABP2,"FSAP, HABP, HGFAL, PHBP",ENSG00000148702,Hyaluronan binding protein 2,10,113550837-113589602,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",,"Hydrolase, Protease, Serine protease",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,12.0,liver: 424.0,Cell type enhanced,Detected in some,,Cholangiocytes: 120.2;Ductal cells: 38.7;Hepatocytes: 185.7;Kupffer cells: 33.7;Oocytes: 85.3,Cancer enriched,Detected in many,5.0,liver cancer: 92.4,Region enhanced,Detected in some,,cerebral cortex: 2.3,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,5.0,Kidney cancer: 14.7;liver cancer: 19.4,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,HPA019518,Uncertain,,,,Secreted to blood,Enzyme,,,20200000000.0,4400000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 53: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,,,HPA019518: AB_1850467,unprognostic (3.89e-2),unprognostic (6.15e-2),unprognostic (1.33e-1),unprognostic (1.24e-1),unprognostic (1.45e-1),unprognostic (6.92e-2),unprognostic (1.01e-1),unprognostic (5.86e-3),unprognostic (1.67e-1),unprognostic (9.78e-2),unprognostic (5.10e-2),unprognostic (4.77e-2),unprognostic (9.18e-3),unprognostic (2.62e-3),unprognostic (2.11e-1),unprognostic (3.22e-1),unprognostic (9.05e-3),MFARMSDLHVLLLMALVGKTACGFSLMSLLESLDPDWTPDQYDYSYEDYNQEENTSSTLTHAENPDWYYTEDQADPCQPNPCEHGGDCLVHGSTFTCSCLAPFSGNKCQKVQNTCKDNPCGRGQCLITQSPPYYRCVCKHPYTGPSCSQVVPVCRPNPCQNGATCSRHKRRSKFTCACPDQFKGKFCEIGSDDCYVGDGYSYRGKMNRTVNQHACLYWNSHLLLQENYNMFMEDAETHGIGEHNFCRNPDADEKPWCFIKVTNDKVKWEYCDVSACSAQDVAYPEESPTEPSTKLPGFDSCGKTEIAERKIKRIYGGFKSTAGKHPWQASLQSSLPLTISMPQGHFCGGALIHPCWVLTAAHCTDIKTRHLKVVLGDQDLKKEEFHEQSFRVEKIFKYSHYNERDEIPHNDIALLKLKPVDGHCALESKYVKTVCLPDGSFPSGSECHISGWGVTETGKGSRQLLDAKVKLIANTLCNSRQLYDHMIDDSMICAGNLQKPGQDTCQGDSGGPLTCEKDGTYYVYGIVSWGLECGKRPGVYTQVTKFLNWIKATIKSESGF
P02743 Serum amyloid P-component 血清淀粉样P成分,P02743,APCS,"MGC88159, PTX2, SAP",ENSG00000132703,"Amyloid P component, serum",1,159587826-159588865,"Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,76.0,liver: 3515.6,Cell type enriched,Detected in some,10.0,Hepatocytes: 4133.8,Cancer enriched,Detected in some,25.0,liver cancer: 826.2,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,10.0,liver cancer: 14.2,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB007817, HPA053294",Supported,,,,Secreted to blood,No annotated function,,,27700000000.0,39000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 7: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,3.0,,,"CAB007817: AB_598185, HPA053294: AB_2682104",,,,,,,unprognostic (3.19e-3),,,,unprognostic (2.30e-2),,,,,,,MNKPLLWISVLTSLLEAFAHTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYSDLSRAYSLFSYNTQGRDNELLVYKERVGEYSLYIGRHKVTSKVIEKFPAPVHICVSWESSSGIAEFWINGTPLVKKGLRQGYFVEAQPKIVLGQEQDSYGGKFDRSQSFVGEIGDLYMWDSVLPPENILSAYQGTPLPANILDWQALNYEIRGYVIIKPLVWV
P49908 Selenoprotein P 硒蛋白P,P49908,SELENOP,"SELP, SeP, SEPP, SEPP1",ENSG00000250722,Selenoprotein P,5,42799880-42887392,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in all,4.0,intestine: 2030.1;liver: 6077.3,Cell type enhanced,Detected in many,,Hepatocytes: 3136.6;Proximal enterocytes: 5404.0,Cancer enriched,Detected in all,4.0,liver cancer: 116.7,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,liver cancer: 182.2,"Liver - Hepatocytes, Liver - Hepatocytes, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,,,,,HPA036287,Approved,,Uncertain,"Nucleoplasm,Golgi apparatus",Secreted to blood,No annotated function,,,2220000000.0,1800000000.0,Cluster 12: Non-specific - Mitochondrial translation,Cluster 83: Liver - Metabolism,Cluster 30: White matter - Myelination,Cluster 18: Liver cancer - Metabolism,Cluster 22: Proximal enterocytes - Digestion,1.0,"Nucleoplasm, Golgi apparatus",,HPA036287: AB_10794618,unprognostic (7.96e-2),unprognostic (2.10e-1),unprognostic (4.28e-3),unprognostic (1.19e-3),unprognostic (6.67e-2),unprognostic (6.37e-2),unprognostic (9.22e-2),unprognostic (2.19e-2),unprognostic (1.44e-2),unprognostic (2.88e-1),unprognostic (2.07e-2),unprognostic (1.05e-1),prognostic favorable (6.97e-6),unprognostic (1.35e-2),unprognostic (4.19e-2),unprognostic (2.89e-1),unprognostic (1.42e-1),MWRSLGLALALCLLPSGGTESQDQSSLCKQPPAWSIRDQDPMLNSNGSVTVVALLQASUYLCILQASKLEDLRVKLKKEGYSNISYIVVNHQGISSRLKYTHLKNKVSEHIPVYQQEENQTDVWTLLNGSKDDFLIYDRCGRLVYHLGLPFSFLTFPYVEEAIKIAYCEKKCGNCSLTTLKDEDFCKRVSLATVDKTVETPSPHYHHEHHHNHGHQHLGSSELSENQQPGAPNAPTHPAPPGLHHHHKHKGQHRQGHPENRDMPASEDLQDLQKKLCRKRCINQLLCKLPTDSELAPRSUCCHCRHLIFEKTGSAITUQCKENLPSLCSUQGLRAEENITESCQURLPPAAUQISQQLIPTEASASURUKNQAKKUEUPSN
O43866 CD5 antigen-like CD5抗原,O43866,CD5L,"API6, Spalpha",ENSG00000073754,CD5 molecule like,1,157830911-157898256,"Plasma proteins, Predicted secreted proteins","Apoptosis, Immunity, Inflammatory response",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,5.0,lymphoid tissue: 558.4,Group enriched,Detected in some,29.0,Hofbauer cells: 226.6;Kupffer cells: 624.6,Cancer enriched,Detected in some,5.0,liver cancer: 4.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Kupffer cells,Not detected,Not detected,,,Not detected,Not detected,,,"HPA065686, HPA068384",Enhanced,,,,Secreted to blood,Immunity,,,4030000000.0,4300000000.0,,Cluster 47: Spleen - Immune response,,Cluster 51: Myeloma - Immunoglobulins,Cluster 58: Macrophages - Innate immune response,,,,"HPA065686: AB_2685532, HPA068384: AB_2685979",,unprognostic (2.96e-1),,unprognostic (2.90e-1),unprognostic (1.08e-1),unprognostic (1.94e-1),prognostic favorable (8.88e-5),unprognostic (1.73e-2),unprognostic (4.51e-2),unprognostic (1.89e-1),unprognostic (1.56e-1),,unprognostic (5.95e-3),unprognostic (2.26e-1),unprognostic (1.06e-1),unprognostic (3.63e-1),,MALLFSLILAICTRPGFLASPSGVRLVGGLHRCEGRVEVEQKGQWGTVCDDGWDIKDVAVLCRELGCGAASGTPSGILYEPPAEKEQKVLIQSVSCTGTEDTLAQCEQEEVYDCSHDEDAGASCENPESSFSPVPEGVRLADGPGHCKGRVEVKHQNQWYTVCQTGWSLRAAKVVCRQLGCGRAVLTQKRCNKHAYGRKPIWLSQMSCSGREATLQDCPSGPWGKNTCNHDEDTWVECEDPFDLRLVGGDNLCSGRLEVLHKGVWGSVCDDNWGEKEDQVVCKQLGCGKSLSPSFRDRKCYGPGVGRIWLDNVRCSGEEQSLEQCQHRFWGFHDCTHQEDVAVICSG
P18428 Lipopolysaccharide-binding protein 脂多糖结合蛋白,P18428,LBP,BPIFD2,ENSG00000129988,Lipopolysaccharide binding protein,20,38346482-38377013,"Plasma proteins, Predicted secreted proteins, Transporters","Immunity, Innate immunity, Lipid transport, Transport","Antibiotic, Antimicrobial",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,23.0,liver: 1304.6,Cell type enriched,Detected in some,14.0,Hepatocytes: 388.2,Cancer enriched,Detected in many,20.0,liver cancer: 356.7,Region enhanced,Detected in single,,medulla oblongata: 2.2,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,8.0,Brain cancer: 6.7;breast cancer: 2.7;liver cancer: 2.3;lymphoma: 1.8;thyroid cancer: 2.9,"Breast - Adipocytes (Breast), Kidney - Proximal tubular cells, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001508, CAB025905",Approved,,,,Secreted to blood,Transport,,,25000000000.0,1300000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 39: Astrocytes - Mixed function,Cluster 71: Lymphoma - Inflammatory response,Cluster 62: Hepatocytes - Metabolism,1.0,,,"CAB025905: , HPA001508: AB_1079241",unprognostic (4.20e-2),prognostic unfavorable (5.56e-4),unprognostic (4.54e-2),unprognostic (2.47e-1),unprognostic (3.80e-2),unprognostic (2.53e-2),unprognostic (5.50e-2),unprognostic (2.48e-3),unprognostic (6.15e-2),unprognostic (2.12e-1),unprognostic (7.93e-2),unprognostic (2.62e-1),prognostic unfavorable (3.62e-12),prognostic unfavorable (5.76e-4),unprognostic (1.69e-1),unprognostic (1.22e-1),unprognostic (1.67e-1),MGALARALPSILLALLLTSTPEALGANPGLVARITDKGLQYAAQEGLLALQSELLRITLPDFTGDLRIPHVGRGRYEFHSLNIHSCELLHSALRPVPGQGLSLSISDSSIRVQGRWKVRKSFFKLQGSFDVSVKGISISVNLLLGSESSGRPTVTASSCSSDIADVEVDMSGDLGWLLNLFHNQIESKFQKVLESRICEMIQKSVSSDLQPYLQTLPVTTEIDSFADIDYSLVEAPRATAQMLEVMFKGEIFHRNHRSPVTLLAAVMSLPEEHNKMVYFAISDYVFNTASLVYHEEGYLNFSITDDMIPPDSNIRLTTKSFRPFVPRLARLYPNMNLELQGSVPSAPLLNFSPGNLSVDPYMEIDAFVLLPSSSKEPVFRLSVATNVSATLTFNTSKITGFLKPGKVKVELKESKVGLFNAELLEALLNYYILNTFYPKFNDKLAEGFPLPLLKRVQLYDLGLQIHKDFLFLGANVQYMRV
Q92954 Proteoglycan 4 粘蛋白,Q92954,PRG4,"bG174L6.2, CACP, FLJ32635, HAPO, JCAP, MSF, SZP",ENSG00000116690,Proteoglycan 4,1,186296279-186314567,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,4.0,adipose tissue: 90.2;liver: 180.2,Cell type enriched,Detected in some,11.0,Mesothelial cells: 3614.7,Cancer enriched,Detected in many,10.0,liver cancer: 28.4,Region enriched,Detected in some,8.0,hypothalamus: 66.4,Immune cell enriched,Detected in single,5.0,T-reg: 1.2,Lineage enriched,Detected in single,12.0,T-cells: 1.2,Cancer enriched,Detected in some,18.0,Rhabdoid: 33.0,"Adipose visceral - Mesothelial cells, Liver - Hepatocytes",Low region specificity,Detected in many,,,Low region specificity,Detected in some,,,CAB054258,Supported,,,,Secreted to extracellular matrix,No annotated function,,,,4300000000.0,Cluster 16: Non-specific - Cell proliferation,Cluster 83: Liver - Metabolism,Cluster 56: Hypothalamus - Neuropeptide signaling,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,,,,CAB054258: ,unprognostic (8.67e-2),unprognostic (2.28e-1),unprognostic (1.82e-3),unprognostic (1.98e-1),unprognostic (1.77e-1),unprognostic (7.87e-2),unprognostic (7.33e-2),unprognostic (1.78e-1),unprognostic (1.28e-1),unprognostic (1.53e-1),unprognostic (5.03e-2),unprognostic (4.11e-1),unprognostic (1.91e-13),unprognostic (1.40e-2),unprognostic (2.60e-1),unprognostic (1.60e-3),unprognostic (7.05e-3),MAWKTLPIYLLLLLSVFVIQQVSSQDLSSCAGRCGEGYSRDATCNCDYNCQHYMECCPDFKRVCTAELSCKGRCFESFERGRECDCDAQCKKYDKCCPDYESFCAEVHNPTSPPSSKKAPPPSGASQTIKSTTKRSPKPPNKKKTKKVIESEEITEEHSVSENQESSSSSSSSSSSSTIRKIKSSKNSAANRELQKKLKVKDNKKNRTKKKPTPKPPVVDEAGSGLDNGDFKVTTPDTSTTQHNKVSTSPKITTAKPINPRPSLPPNSDTSKETSLTVNKETTVETKETTTTNKQTSTDGKEKTTSAKETQSIEKTSAKDLAPTSKVLAKPTPKAETTTKGPALTTPKEPTPTTPKEPASTTPKEPTPTTIKSAPTTPKEPAPTTTKSAPTTPKEPAPTTTKEPAPTTPKEPAPTTTKEPAPTTTKSAPTTPKEPAPTTPKKPAPTTPKEPAPTTPKEPTPTTPKEPAPTTKEPAPTTPKEPAPTAPKKPAPTTPKEPAPTTPKEPAPTTTKEPSPTTPKEPAPTTTKSAPTTTKEPAPTTTKSAPTTPKEPSPTTTKEPAPTTPKEPAPTTPKKPAPTTPKEPAPTTPKEPAPTTTKKPAPTTPKEPAPTTPKETAPTTPKKLTPTTPEKLAPTTPEKPAPTTPEELAPTTPEEPTPTTPEEPAPTTPKAAAPNTPKEPAPTTPKEPAPTTPKEPAPTTPKETAPTTPKGTAPTTLKEPAPTTPKKPAPKELAPTTTKEPTSTTSDKPAPTTPKGTAPTTPKEPAPTTPKEPAPTTPKGTAPTTLKEPAPTTPKKPAPKELAPTTTKGPTSTTSDKPAPTTPKETAPTTPKEPAPTTPKKPAPTTPETPPPTTSEVSTPTTTKEPTTIHKSPDESTPELSAEPTPKALENSPKEPGVPTTKTPAATKPEMTTTAKDKTTERDLRTTPETTTAAPKMTKETATTTEKTTESKITATTTQVTSTTTQDTTPFKITTLKTTTLAPKVTTTKKTITTTEIMNKPEETAKPKDRATNSKATTPKPQKPTKAPKKPTSTKKPKTMPRVRKPKTTPTPRKMTSTMPELNPTSRIAEAMLQTTTRPNQTPNSKLVEVNPKSEDAGGAEGETPHMLLRPHVFMPEVTPDMDYLPRVPNQGIIINPMLSDETNICNGKPVDGLTTLRNGTLVAFRGHYFWMLSPFSPPSPARRITEVWGIPSPIDTVFTRCNCEGKTFFFKDSQYWRFTNDIKDAGYPKPIFKGFGGLTGQIVAALSTAKYKNWPESVYFFKRGGSIQQYIYKQEPVQKCPGRRPALNYPVYGETTQVRRRRFERAIGPSQTHTIRIQYSPARLAYQDKGVLHNEVKVSILWRGLPNVVTSAISLPNIRKPDGYDYYAFSKDQYYNIDVPSRTARAITTRSGQTLSKVWYNCP
P02776 Platelet factor 4 血小板因子4,P02776,PF4,"CXCL4, SCYB4",ENSG00000163737,Platelet factor 4,4,73980811-73982027,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Chemotaxis,"Cytokine, Heparin-binding",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in some,11.0,bone marrow: 29.2;lung: 10.2;lymphoid tissue: 30.8,Cell type enhanced,Detected in some,,B-cells: 6.3;Ductal cells: 5.9;Enteroendocrine cells: 9.3;Granulosa cells: 30.8;NK-cells: 24.9,Cancer enhanced,Detected in some,,colorectal cancer: 4.4,Region enhanced,Detected in single,,cerebral cortex: 1.9,Immune cell enriched,Detected in single,5.0,neutrophil: 2.0,Lineage enriched,Detected in single,9.0,granulocytes: 2.0,Not detected,Not detected,,,,,,,,,,,,"CAB026008, HPA052485",Enhanced,,,,Secreted to blood,Cytokine,,,7700000.0,,Cluster 4: Neutrophils - Degranulation,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 23: Choroid plexus - Mixed function,Cluster 47: Leukemia - Hemostasis,Cluster 57: Platelets - Hemostasis,20.0,,,"CAB026008: , HPA052485: AB_2681847",,unprognostic (4.14e-4),unprognostic (1.00e-2),unprognostic (2.49e-1),unprognostic (1.96e-4),unprognostic (7.58e-2),unprognostic (1.42e-1),unprognostic (7.55e-2),unprognostic (2.04e-1),unprognostic (9.02e-3),unprognostic (1.84e-2),unprognostic (3.03e-2),unprognostic (9.54e-5),unprognostic (2.55e-1),unprognostic (8.77e-2),unprognostic (9.69e-2),unprognostic (4.81e-2),MSSAAGFCASRPGLLFLGLLLLPLVVAFASAEAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES
P0DJI8 Serum amyloid A-1 protein 血清淀粉样蛋白A-1,P0DJI8,SAA1,"PIG4, SAA, TP53I4",ENSG00000173432,Serum amyloid A1,11,18266260-18269977,"Disease related genes, Predicted secreted proteins",Acute phase,Heparin-binding,Amyloidosis,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,20.0,liver: 46934.0,Cell type enriched,Detected in many,9.0,Hepatocytes: 88360.6,Cancer enriched,Detected in many,16.0,liver cancer: 1249.6,Group enriched,Detected in many,5.0,choroid plexus: 3.7;pons: 8.3;thalamus: 14.1,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,head and neck cancer: 445.5,"Adipose visceral - Adipocytes (Visceral), Breast - Adipocytes (Breast)",,,,,,,,,,,,,,Secreted to blood,Acute phase,,,300000000.0,11000000000.0,,Cluster 83: Liver - Metabolism,Cluster 12: Non-specific - Vasculature,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 62: Hepatocytes - Metabolism,,,,,unprognostic (2.86e-3),unprognostic (1.41e-1),unprognostic (2.82e-1),unprognostic (1.50e-1),unprognostic (4.54e-3),unprognostic (1.79e-2),unprognostic (1.63e-2),unprognostic (7.04e-2),unprognostic (1.54e-1),unprognostic (1.08e-2),unprognostic (8.95e-2),unprognostic (1.90e-2),prognostic unfavorable (4.57e-12),unprognostic (5.15e-2),unprognostic (9.78e-2),unprognostic (9.23e-3),unprognostic (1.64e-1),MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNYDAAKRGPGGAWAAEVITDARENIQRFFGHGAEDSLADQAANEWGRSGKDPNHFRPAGLPEKY
P04070 Vitamin K-dependent protein C维生素k,P04070,PROC,,ENSG00000115718,"Protein C, inactivator of coagulation factors Va and VIIIa",2,127418427-127429242,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,40.0,liver: 584.1,Cell type enriched,Detected in some,4.0,Hepatocytes: 339.4,Cancer enriched,Detected in many,22.0,liver cancer: 118.3,Low region specificity,Detected in many,,,Immune cell enriched,Detected in some,9.0,plasmacytoid DC: 59.8,Lineage enriched,Detected in many,9.0,dendritic cells: 59.8,Cancer enriched,Detected in many,6.0,liver cancer: 28.4,"Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Skin - Outer root sheath cells",,,,,Not detected,Not detected,,,"HPA005550, CAB016721, CAB016792",Approved,,,,Secreted to blood,Blood coagulation,,,,5200000000.0,Cluster 8: Plasmacytoid DCs - Unknown function,Cluster 31: Liver - Plasma proteins,Cluster 26: Oligodendrocytes - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,,,"CAB016721: , CAB016792: , HPA005550: AB_1079687",unprognostic (2.46e-2),unprognostic (1.08e-1),unprognostic (1.38e-1),unprognostic (1.58e-1),unprognostic (6.64e-2),unprognostic (3.13e-2),unprognostic (4.90e-3),unprognostic (2.63e-1),unprognostic (1.67e-1),unprognostic (3.29e-1),unprognostic (3.74e-3),unprognostic (2.56e-2),unprognostic (8.12e-3),unprognostic (2.01e-2),unprognostic (1.71e-1),unprognostic (4.60e-3),unprognostic (8.06e-2),MWQLTSLLLFVATWGISGTPAPLDSVFSSSERAHQVLRIRKRANSFLEELRHSSLERECIEEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP
Q13103 Secreted phosphoprotein 24 分泌磷酸化蛋白24,Q13103,SPP2,SPP24,ENSG00000072080,Secreted phosphoprotein 2,2,234050679-234077134,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,4403.0,liver: 502.9,Cell type enriched,Detected in some,28.0,Hepatocytes: 246.6,Cancer enriched,Detected in some,112.0,liver cancer: 65.3,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Low region specificity,Detected in some,,,Low region specificity,Detected in all,,,,,,,,Secreted to blood,No annotated function,,,,480000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 5: Rhabdoid - Unknown function,Cluster 43: Hepatocytes - Metabolism,,,,,,,,,,,prognostic favorable (2.33e-6),unprognostic (7.02e-3),,unprognostic (9.62e-3),,,,,,,,MISRMEKMTMMMKILIMFALGMNYWSCSGFPVYDYDPSSLRDALSASVVKVNSQSLSPYLFRAFRSSLKRVEVLDENNLVMNLEFSIRETTCRKDSGEDPATCAFQRDYYVSTAVCRSTVKVSAQQVQGVHARCSWSSSTSESYSSEEMIFGDMLGSHKWRNNYLFGLISDESISEQFYDRSLGIMRRVLPPGNRRYPNHRHRARINTDFE
Q9UK55 Protein Z-dependent protease inhibitor 蛋白z依赖性蛋白酶抑制剂,Q9UK55,SERPINA10,"PZI, ZPI",ENSG00000140093,Serpin family A member 10,14,94280460-94293268,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Heparin-binding, Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,113.0,liver: 338.3,Cell type enriched,Detected in some,17.0,Hepatocytes: 217.4,Cancer enriched,Detected in some,51.0,liver cancer: 40.6,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in many,,,"Breast - Breast glandular cells, Liver - Hepatocytes, Pancreas - Alpha cells, Stomach - Gastric enteroendocrine cells",Not detected,Not detected,,,,,,,HPA048739,,,Approved,"Nucleoplasm,Cytosol",Secreted to blood,Blood coagulation,,,3960000000.0,4700000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 9: Non-specific - Receptor signaling,Cluster 10: Ciliated cells - Ion channel activity,Cluster 62: Hepatocytes - Metabolism,2.0,Nucleoplasm,Cytosol,HPA048739: AB_2797237,unprognostic (7.14e-2),unprognostic (2.03e-1),unprognostic (2.69e-2),unprognostic (2.01e-1),unprognostic (1.21e-1),unprognostic (1.45e-1),prognostic favorable (9.00e-4),unprognostic (6.11e-2),,unprognostic (2.81e-4),unprognostic (2.31e-4),unprognostic (2.77e-2),unprognostic (2.91e-3),unprognostic (1.38e-1),unprognostic (1.58e-1),unprognostic (1.11e-1),unprognostic (7.93e-3),MKVVPSLLLSVLLAQVWLVPGLAPSPQSPETPAPQNQTSRVVQAPKEEEEDEQEASEEKASEEEKAWLMASRQQLAKETSNFGFSLLRKISMRHDGNMVFSPFGMSLAMTGLMLGATGPTETQIKRGLHLQALKPTKPGLLPSLFKGLRETLSRNLELGLTQGSFAFIHKDFDVKETFFNLSKRYFDTECVPMNFRNASQAKRLMNHYINKETRGKIPKLFDEINPETKLILVDYILFKGKWLTPFDPVFTEVDTFHLDKYKTIKVPMMYGAGKFASTFDKNFRCHVLKLPYQGNATMLVVLMEKMGDHLALEDYLTTDLVETWLRNMKTRNMEVFFPKFKLDQKYEMHELLRQMGIRRIFSPFADLSELSATGRNLQVSRVLQRTVIEVDERGTEAVAGILSEITAYSMPPVIKVDRPFHFMIYEETSGMLLFLGRVVNPTLL
Q96IY4 Carboxypeptidase B2 羧肽酶B2,Q96IY4,CPB2,"CPU, PCPB, TAFI",ENSG00000080618,Carboxypeptidase B2,13,46053186-46105033,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis","Carboxypeptidase, Hydrolase, Metalloprotease, Protease",FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,84.0,liver: 1439.0,Cell type enriched,Detected in some,5.0,Hepatocytes: 1226.7,Cancer enriched,Detected in some,112.0,liver cancer: 268.4,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,6.0,liver cancer: 11.2,"Liver - Hepatocytes, Lung - Alveolar cells type 2",Not detected,Not detected,,,Low region specificity,Detected in some,,,HPA004146,Approved,,,,Secreted to blood,Blood coagulation,,,,8500000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 28: Oligodendrocytes - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,,,,HPA004146: AB_1078397,unprognostic (3.44e-2),unprognostic (1.25e-1),unprognostic (2.94e-2),unprognostic (1.89e-2),unprognostic (7.69e-2),unprognostic (1.17e-2),prognostic favorable (2.06e-4),unprognostic (1.89e-1),unprognostic (2.74e-1),unprognostic (2.48e-1),unprognostic (3.17e-2),unprognostic (4.83e-2),unprognostic (3.20e-3),unprognostic (1.34e-1),unprognostic (7.10e-2),unprognostic (3.34e-2),unprognostic (9.61e-2),MKLCSLAVLVPIVLFCEQHVFAFQSGQVLAALPRTSRQVQVLQNLTTTYEIVLWQPVTADLIVKKKQVHFFVNASDVDNVKAHLNVSGIPCSVLLADVEDLIQQQISNDTVSPRASASYYEQYHSLNEIYSWIEFITERHPDMLTKIHIGSSFEKYPLYVLKVSGKEQAAKNAIWIDCGIHAREWISPAFCLWFIGHITQFYGIIGQYTNLLRLVDFYVMPVVNVDGYDYSWKKNRMWRKNRSFYANNHCIGTDLNRNFASKHWCEEGASSSSCSETYCGLYPESEPEVKAVASFLRRNINQIKAYISMHSYSQHIVFPYSYTRSKSKDHEELSLVASEAVRAIEKISKNTRYTHGHGSETLYLAPGGGDDWIYDLGIKYSFTIELRDTGTYGFLLPERYIKPTCREAFAAVSKIAWHVIRNV
P27918 Properdin 血清灭菌蛋白,P27918,CFP,PFC,ENSG00000126759,Complement factor properdin,X,47623172-47630305,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Immunity, Innate immunity",,Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,6.0,bone marrow: 83.0;lymphoid tissue: 57.0,Cell type enhanced,Detected in some,,Kupffer cells: 8.4;Langerhans cells: 21.9;Macrophages: 43.6;monocytes: 11.1,Low cancer specificity,Detected in many,,,Low region specificity,Detected in many,,,Group enriched,Detected in all,8.0,classical monocyte: 1169.0;intermediate monocyte: 1275.0;myeloid DC: 995.2;neutrophil: 733.0;non-classical monocyte: 872.6,Group enriched,Detected in all,46.0,dendritic cells: 995.2;granulocytes: 733.0;monocytes: 1275.0,Cancer enriched,Detected in some,9.0,Leukemia: 12.2,"Adipose subcutaneous - Macrophages, Breast - Macrophages, Colon - Macrophages, Lung - Neutrophil_2, Skeletal muscle - Macrophages, Stomach - Macrophages",Low region specificity,Detected in many,,,Low region specificity,Detected in some,,,HPA072644,,,Approved,Vesicles,Secreted to blood,Immunity,,,,6200000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 15: Non-specific - Transcription,Cluster 14: Myeloid leukemia - Innate immune response,Cluster 29: Monocytes - Innate immune response,22.0,Vesicles,,HPA072644: ,unprognostic (2.77e-3),unprognostic (2.21e-3),unprognostic (1.00e-1),unprognostic (2.15e-2),unprognostic (4.15e-2),unprognostic (9.66e-5),unprognostic (9.90e-3),unprognostic (1.30e-2),unprognostic (5.37e-2),unprognostic (1.20e-1),unprognostic (1.08e-2),unprognostic (2.70e-1),unprognostic (1.97e-2),unprognostic (2.58e-1),unprognostic (1.32e-1),unprognostic (4.62e-2),unprognostic (2.17e-1),MITEGAQAPRLLLPPLLLLLTLPATGSDPVLCFTQYEESSGKCKGLLGGGVSVEDCCLNTAFAYQKRSGGLCQPCRSPRWSLWSTWAPCSVTCSEGSQLRYRRCVGWNGQCSGKVAPGTLEWQLQACEDQQCCPEMGGWSGWGPWEPCSVTCSKGTRTRRRACNHPAPKCGGHCPGQAQESEACDTQQVCPTHGAWATWGPWTPCSASCHGGPHEPKETRSRKCSAPEPSQKPPGKPCPGLAYEQRRCTGLPPCPVAGGWGPWGPVSPCPVTCGLGQTMEQRTCNHPVPQHGGPFCAGDATRTHICNTAVPCPVDGEWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRCAGQQQDIRHCYSIQHCPLKGSWSEWSTWGLCMPPCGPNPTRARQRLCTPLLPKYPPTVSMVEGQGEKNVTFWGRPLPRCEELQGQKLVVEEKRPCLHVPACKDPEEEEL
P05452 Tetranectin 四连接素,P05452,CLEC3B,"TN, TNA",ENSG00000163815,C-type lectin domain family 3 member B,3,45001548-45036071,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adipose tissue: 406.8,Cell type enhanced,Detected in some,,Adipocytes: 37.5;Endothelial cells: 35.2;Fibroblasts: 79.6;Leydig cells: 17.6;Microglial cells: 66.2;Smooth muscle cells: 21.6,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,Sarcoma: 16.1,"Liver - Sinusoid Endothelial cells, Liver - Vascular Endothelial cells, Skin - Fibroblast_1, Skin - Fibroblast_2, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB002582, HPA034794",Approved,,,,Secreted to blood,No annotated function,,,6540000000.0,25000000000.0,,Cluster 7: Adipose tissue - Mixed function,Cluster 19: Astrocytes - Mixed function,Cluster 64: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,,,,"CAB002582: AB_564027, HPA034794: AB_2674332",unprognostic (2.04e-1),unprognostic (1.80e-3),unprognostic (2.58e-1),unprognostic (4.57e-2),unprognostic (7.75e-2),prognostic favorable (1.53e-4),prognostic favorable (9.99e-9),unprognostic (1.75e-2),unprognostic (2.25e-1),unprognostic (4.02e-1),prognostic favorable (5.68e-4),unprognostic (9.33e-2),unprognostic (2.39e-2),unprognostic (7.46e-2),unprognostic (1.39e-1),unprognostic (5.54e-2),unprognostic (4.21e-2),MELWGAYLLLCLFSLLTQVTTEPPTQKPKKIVNAKKDVVNTKMFEELKSRLDTLAQEVALLKEQQALQTVCLKGTKVHMKCFLAFTQTKTFHEASEDCISRGGTLGTPQTGSENDALYEYLRQSVGNEAEIWLGLNDMAAEGTWVDMTGARIAYKNWETEITAQPDGGKTENCAVLSGAANGKWFDKRCRDQLPYICQFGIV
P20851 C4b-binding protein beta chain c4b结合蛋白链,P20851,C4BPB,C4BP,ENSG00000123843,Complement component 4 binding protein beta,1,207088860-207099993,"Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement pathway, Immunity, Innate immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,13.0,liver: 458.6,Cell type enriched,Detected in many,12.0,Hepatocytes: 654.1,Cancer enriched,Detected in many,19.0,liver cancer: 83.7,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,plasmacytoid DC: 1.1,Low lineage specificity,Detected in single,,,Cancer enhanced,Detected in many,,Bile duct cancer: 39.5,"Adipose subcutaneous - Macrophages, Testis - Late spermatids",,,,,Not detected,Not detected,,,"HPA000925, HPA051620",Approved,,Uncertain,Golgi apparatus,Secreted to blood,Complement pathway,,,265000000000.0,1100000000.0,Cluster 30: Non-specific - DNA binding,Cluster 31: Liver - Plasma proteins,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 43: Hepatocytes - Metabolism,,Golgi apparatus,,"HPA000925: , HPA051620: AB_2681554",unprognostic (1.73e-1),unprognostic (2.62e-1),unprognostic (3.26e-1),unprognostic (2.07e-3),unprognostic (1.72e-1),unprognostic (2.54e-2),unprognostic (4.58e-3),unprognostic (9.49e-2),unprognostic (1.37e-1),unprognostic (4.25e-1),unprognostic (6.39e-2),unprognostic (2.64e-2),unprognostic (1.21e-2),unprognostic (1.55e-1),unprognostic (1.03e-1),unprognostic (1.05e-2),unprognostic (8.25e-2),MFFWCACCLMVAWRVSASDAEHCPELPPVDNSIFVAKEVEGQILGTYVCIKGYHLVGKKTLFCNASKEWDNTTTECRLGHCPDPVLVNGEFSSSGPVNVSDKITFMCNDHYILKGSNRSQCLEDHTWAPPFPICKSRDCDPPGNPVHGYFEGNNFTLGSTISYYCEDRYYLVGVQEQQCVDGEWSSALPVCKLIQEAPKPECEKALLAFQESKNLCEAMENFMQQLKESGMTMEELKYSLELKKAELKAKLL
P02775 Platelet basic protein 血小板碱性蛋白,P02775,PPBP,"b-TG1, Beta-TG, CTAP3, CTAPIII, CXCL7, LA-PF4, LDGF, MDGF, NAP-2, NAP-2-L1, PBP, SCYB7, TGB, TGB1, THBGB1",ENSG00000163736,Pro-platelet basic protein,4,73986439-73988190,"Plasma proteins, Predicted secreted proteins",Chemotaxis,"Antibiotic, Antimicrobial, Cytokine, Growth factor, Mitogen",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in some,,bone marrow: 82.3;lymphoid tissue: 52.4,Cell type enhanced,Detected in some,,B-cells: 9.1;dendritic cells: 12.6;Kupffer cells: 10.5;Macrophages: 25.2;NK-cells: 39.3;T-cells: 7.3,Cancer enriched,Detected in many,7.0,colorectal cancer: 86.8,Low region specificity,Detected in some,,,Group enriched,Detected in many,15.0,basophil: 287.2;neutrophil: 86.7,Lineage enriched,Detected in all,23.0,granulocytes: 287.2,Group enriched,Detected in some,6.0,colorectal cancer: 8.4;lung cancer: 3.5,,Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA008354, CAB017624",Supported,,,,Secreted to blood,Cytokine,,,24500000.0,2900000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 12: Non-specific - Vasculature,Cluster 57: Stomach & Colon cancer - Digestion,Cluster 57: Platelets - Hemostasis,4.0,,,"CAB017624: AB_1127132, HPA008354: AB_1847353",unprognostic (2.13e-1),prognostic unfavorable (6.17e-4),unprognostic (7.69e-2),unprognostic (1.67e-1),unprognostic (4.37e-2),unprognostic (3.13e-1),unprognostic (2.79e-1),unprognostic (6.98e-3),unprognostic (2.58e-1),unprognostic (4.21e-2),unprognostic (1.81e-1),unprognostic (2.88e-1),unprognostic (2.38e-3),unprognostic (1.49e-1),unprognostic (2.90e-1),unprognostic (2.15e-3),unprognostic (2.59e-2),MSLRLDTTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRNLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDESAD
P02741 C-reactive proteinC反应蛋白,P02741,CRP,PTX1,ENSG00000132693,C-reactive protein,1,159712289-159714589,"Cancer-related genes, Candidate cardiovascular disease genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Acute phase,,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,80.0,liver: 9151.6,Group enriched,Detected in some,7.0,Ductal cells: 1316.9;Hepatocytes: 3016.1,Cancer enriched,Detected in some,13.0,liver cancer: 1010.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,Gastric cancer: 1.1,,Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB005036, HPA027367, HPA027396",Supported,,Approved,"Nucleoplasm,Vesicles,Intermediate filaments",Secreted to blood,Acute phase,,,2920000000.0,5200000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 51: Myeloma - Immunoglobulins,Cluster 62: Hepatocytes - Metabolism,7.0,"Nucleoplasm, Vesicles",Intermediate filaments,"CAB005036: AB_562362, HPA027367: AB_1847216, HPA027396: AB_1847217",unprognostic (3.74e-1),unprognostic (5.31e-2),,,,unprognostic (2.97e-2),unprognostic (1.27e-1),unprognostic (3.57e-2),,,unprognostic (1.33e-2),unprognostic (3.13e-1),prognostic unfavorable (4.17e-10),unprognostic (3.39e-2),unprognostic (3.48e-1),unprognostic (5.60e-2),unprognostic (6.61e-2),MEKLLCFLVLTSLSHAFGQTDMSRKAFVFPKESDTSYVSLKAPLTKPLKAFTVCLHFYTELSSTRGYSIFSYATKRQDNEILIFWSKDIGYSFTVGGSEILFEVPEVTVAPVHICTSWESASGIVEFWVDGKPRVRKSLKKGYTVGAEASIILGQEQDSFGGNFEGSQSLVGDIGNVNMWDFVLSPDEINTIYLGGPFSPNVLNWRALKYEVQGEVFTKPQLWP
P35579 Myosin-9 肌浆球蛋白,P35579,MYH9,"DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA",ENSG00000100345,Myosin heavy chain 9,22,36281280-36388010,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins","Cell adhesion, Cell shape","Actin-binding, Calmodulin-binding, Motor protein, Myosin","Alport syndrome, Cancer-related genes, Cataract, Deafness, Disease variant, Non-syndromic deafness",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in many,,Alveolar cells type 1: 471.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Adipose subcutaneous - Endothelial cells, Testis - Endothelial cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001644, CAB015386, HPA064783",Enhanced,,Supported,"Nuclear bodies,Plasma membrane,Actin filaments,Cytosol",,,No,No,,410000000.0,Cluster 36: Eosinophils - Protein ubiquitination,Cluster 7: Adipose tissue - Mixed function,Cluster 47: Endothelial cells - Vasculature,Cluster 15: Kidney cancer - Membrane components,Cluster 32: Smooth muscle cells - Muscle contraction,11.0,"Plasma membrane, Actin filaments","Nuclear bodies, Cytosol","CAB015386: AB_784698, HPA001644: AB_1079439, HPA064783: AB_2732721",unprognostic (1.38e-1),unprognostic (9.12e-2),unprognostic (4.21e-2),unprognostic (6.34e-2),unprognostic (1.49e-1),unprognostic (3.90e-2),unprognostic (9.56e-2),unprognostic (8.28e-2),unprognostic (5.50e-2),unprognostic (6.38e-2),unprognostic (1.93e-2),unprognostic (1.61e-1),unprognostic (7.98e-2),unprognostic (9.48e-2),unprognostic (1.64e-1),unprognostic (1.62e-1),unprognostic (2.59e-2),MAQQAADKYLYVDKNFINNPLAQADWAAKKLVWVPSDKSGFEPASLKEEVGEEAIVELVENGKKVKVNKDDIQKMNPPKFSKVEDMAELTCLNEASVLHNLKERYYSGLIYTYSGLFCVVINPYKNLPIYSEEIVEMYKGKKRHEMPPHIYAITDTAYRSMMQDREDQSILCTGESGAGKTENTKKVIQYLAYVASSHKSKKDQGELERQLLQANPILEAFGNAKTVKNDNSSRFGKFIRINFDVNGYIVGANIETYLLEKSRAIRQAKEERTFHIFYYLLSGAGEHLKTDLLLEPYNKYRFLSNGHVTIPGQQDKDMFQETMEAMRIMGIPEEEQMGLLRVISGVLQLGNIVFKKERNTDQASMPDNTAAQKVSHLLGINVTDFTRGILTPRIKVGRDYVQKAQTKEQADFAIEALAKATYERMFRWLVLRINKALDKTKRQGASFIGILDIAGFEIFDLNSFEQLCINYTNEKLQQLFNHTMFILEQEEYQREGIEWNFIDFGLDLQPCIDLIEKPAGPPGILALLDEECWFPKATDKSFVEKVMQEQGTHPKFQKPKQLKDKADFCIIHYAGKVDYKADEWLMKNMDPLNDNIATLLHQSSDKFVSELWKDVDRIIGLDQVAGMSETALPGAFKTRKGMFRTVGQLYKEQLAKLMATLRNTNPNFVRCIIPNHEKKAGKLDPHLVLDQLRCNGVLEGIRICRQGFPNRVVFQEFRQRYEILTPNSIPKGFMDGKQACVLMIKALELDSNLYRIGQSKVFFRAGVLAHLEEERDLKITDVIIGFQACCRGYLARKAFAKRQQQLTAMKVLQRNCAAYLKLRNWQWWRLFTKVKPLLQVSRQEEEMMAKEEELVKVREKQLAAENRLTEMETLQSQLMAEKLQLQEQLQAETELCAEAEELRARLTAKKQELEEICHDLEARVEEEEERCQHLQAEKKKMQQNIQELEEQLEEEESARQKLQLEKVTTEAKLKKLEEEQIILEDQNCKLAKEKKLLEDRIAEFTTNLTEEEEKSKSLAKLKNKHEAMITDLEERLRREEKQRQELEKTRRKLEGDSTDLSDQIAELQAQIAELKMQLAKKEEELQAALARVEEEAAQKNMALKKIRELESQISELQEDLESERASRNKAEKQKRDLGEELEALKTELEDTLDSTAAQQELRSKREQEVNILKKTLEEEAKTHEAQIQEMRQKHSQAVEELAEQLEQTKRVKANLEKAKQTLENERGELANEVKVLLQGKGDSEHKRKKVEAQLQELQVKFNEGERVRTELADKVTKLQVELDNVTGLLSQSDSKSSKLTKDFSALESQLQDTQELLQEENRQKLSLSTKLKQVEDEKNSFREQLEEEEEAKHNLEKQIATLHAQVADMKKKMEDSVGCLETAEEVKRKLQKDLEGLSQRHEEKVAAYDKLEKTKTRLQQELDDLLVDLDHQRQSACNLEKKQKKFDQLLAEEKTISAKYAEERDRAEAEAREKETKALSLARALEEAMEQKAELERLNKQFRTEMEDLMSSKDDVGKSVHELEKSKRALEQQVEEMKTQLEELEDELQATEDAKLRLEVNLQAMKAQFERDLQGRDEQSEEKKKQLVRQVREMEAELEDERKQRSMAVAARKKLEMDLKDLEAHIDSANKNRDEAIKQLRKLQAQMKDCMRELDDTRASREEILAQAKENEKKLKSMEAEMIQLQEELAAAERAKRQAQQERDELADEIANSSGKGALALEEKRRLEARIAQLEEELEEEQGNTELINDRLKKANLQIDQINTDLNLERSHAQKNENARQQLERQNKELKVKLQEMEGTVKSKYKASITALEAKIAQLEEQLDNETKERQAACKQVRRTEKKLKDVLLQVDDERRNAEQYKDQADKASTRLKQLKRQLEEAEEEAQRANASRRKLQRELEDATETADAMNREVSSLKNKLRRGDLPFVVPRRMARKGAGDGSDEEVDGKADGAEAKPAE
P15169 Carboxypeptidase N catalytic chain羧基肽酶N催化链,P15169,CPN1,,ENSG00000120054,Carboxypeptidase N subunit 1,10,100042193-100081869,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",,"Carboxypeptidase, Hydrolase, Metalloprotease, Protease",Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,55.0,liver: 79.5,Cell type enriched,Detected in some,4.0,Hepatocytes: 35.4,Group enriched,Detected in some,12.0,liver cancer: 26.6;melanoma: 7.9,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,6.0,skin cancer: 35.3,Liver - Hepatocytes,Low region specificity,Detected in some,,,Not detected,Not detected,,,,,,,,Secreted to blood,Enzyme,,,,13000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 69: Skin cancer - ECM organization,Cluster 62: Hepatocytes - Metabolism,4.0,,,,,,unprognostic (2.97e-2),unprognostic (2.23e-2),,,unprognostic (3.93e-2),,unprognostic (1.64e-1),,unprognostic (6.75e-2),,unprognostic (2.93e-2),unprognostic (5.26e-2),unprognostic (2.63e-1),,,MSDLLSVFLHLLLLFKLVAPVTFRHHRYDDLVRTLYKVQNECPGITRVYSIGRSVEGRHLYVLEFSDHPGIHEPLEPEVKYVGNMHGNEALGRELMLQLSEFLCEEFRNRNQRIVQLIQDTRIHILPSMNPDGYEVAAAQGPNKPGYLVGRNNANGVDLNRNFPDLNTYIYYNEKYGGPNHHLPLPDNWKSQVEPETRAVIRWMHSFNFVLSANLHGGAVVANYPYDKSFEHRVRGVRRTASTPTPDDKLFQKLAKVYSYAHGWMFQGWNCGDYFPDGITNGASWYSLSKGMQDFNYLHTNCFEITLELSCDKFPPEEELQREWLGNREALIQFLEQVHQGIKGMVLDENYNNLANAVISVSGINHDVTSGDHGDYFRLLLPGIYTVSATAPGYDPETVTVTVGPAEPTLVNFHLKRSIPQVSPVRRAPSRRHGVRAKVQPQARKKEMEMRQLQRGPA
P49747 Cartilage oligomeric matrix protein软骨寡聚基质蛋白,P49747,COMP,"EDM1, EPD1, MED, PSACH, THBS5",ENSG00000105664,Cartilage oligomeric matrix protein,19,18782773-18791305,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Apoptosis, Cell adhesion",Heparin-binding,"Disease variant, Dwarfism",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adipose tissue: 75.1;heart muscle: 63.2;skin 1: 78.0,Cell type enhanced,Detected in some,,Basal respiratory cells: 15.9;Early spermatids: 35.1;Fibroblasts: 46.5;Glandular and luminal cells: 38.2;Late spermatids: 73.6;Smooth muscle cells: 31.6,Low cancer specificity,Detected in many,,,Region enhanced,Detected in single,,cerebellum: 2.8,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,6.0,Bladder cancer: 6.7;Gastric cancer: 4.2;ovarian cancer: 12.3;Rhabdoid: 5.1,"Testis - Early spermatids, Testis - Late spermatids",Low region specificity,Detected in single,,,Low region specificity,Detected in single,,,HPA077555,,,Approved,Golgi apparatus,Secreted to extracellular matrix,Cell adhesion,,,,1500000000.0,,Cluster 21: Testis - Unknown function,Cluster 35: Non-specific - DNA binding,Cluster 64: Connective tissue cells - ECM organization,Cluster 32: Smooth muscle cells - Muscle contraction,7.0,Golgi apparatus,,HPA077555: ,unprognostic (1.26e-1),unprognostic (7.22e-2),prognostic unfavorable (9.08e-5),prognostic unfavorable (2.04e-4),unprognostic (8.05e-2),unprognostic (8.45e-2),unprognostic (3.62e-2),unprognostic (5.12e-2),unprognostic (1.65e-1),unprognostic (1.55e-2),unprognostic (2.18e-2),unprognostic (3.85e-1),prognostic unfavorable (1.52e-6),unprognostic (5.96e-3),unprognostic (1.44e-1),unprognostic (2.87e-2),prognostic unfavorable (6.95e-4),MVPDTACVLLLTLAALGASGQGQSPLGSDLGPQMLRELQETNAALQDVRELLRQQVREITFLKNTVMECDACGMQQSVRTGLPSVRPLLHCAPGFCFPGVACIQTESGARCGPCPAGFTGNGSHCTDVNECNAHPCFPRVRCINTSPGFRCEACPPGYSGPTHQGVGLAFAKANKQVCTDINECETGQHNCVPNSVCINTRGSFQCGPCQPGFVGDQASGCQRRAQRFCPDGSPSECHEHADCVLERDGSRSCVCAVGWAGNGILCGRDTDLDGFPDEKLRCPERQCRKDNCVTVPNSGQEDVDRDGIGDACDPDADGDGVPNEKDNCPLVRNPDQRNTDEDKWGDACDNCRSQKNDDQKDTDQDGRGDACDDDIDGDRIRNQADNCPRVPNSDQKDSDGDGIGDACDNCPQKSNPDQADVDHDFVGDACDSDQDQDGDGHQDSRDNCPTVPNSAQEDSDHDGQGDACDDDDDNDGVPDSRDNCRLVPNPGQEDADRDGVGDVCQDDFDADKVVDKIDVCPENAEVTLTDFRAFQTVVLDPEGDAQIDPNWVVLNQGREIVQTMNSDPGLAVGYTAFNGVDFEGTFHVNTVTDDDYAGFIFGYQDSSSFYVVMWKQMEQTYWQANPFRAVAEPGIQLKAVKSSTGPGEQLRNALWHTGDTESQVRLLWKDPRNVGWKDKKSYRWFLQHRPQVGYIRVRFYEGPELVADSNVVLDTTMRGGRLGVFCFSQENIIWANLRYRCNDTIPEDYETHQLRQA
P36955 Pigment epithelium-derived factor色素上皮来源因子,P36955,SERPINF1,"EPC-1, PEDF, PIG35",ENSG00000132386,Serpin family F member 1,17,1762029-1777565,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Cancer-related genes, Dwarfism, Osteogenesis imperfecta",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,5.0,choroid plexus: 4719.0,Cell type enhanced,Detected in many,,Basal respiratory cells: 665.9;Cytotrophoblasts: 799.4;Fibroblasts: 881.9;Hepatocytes: 714.4;Leydig cells: 1843.9;Peritubular cells: 1051.8,Cancer enhanced,Detected in all,,liver cancer: 245.2,Region enriched,Detected in all,20.0,choroid plexus: 3985.5,Immune cell enriched,Detected in many,18.0,plasmacytoid DC: 1458.3,Lineage enriched,Detected in all,121.0,dendritic cells: 1458.3,Cancer enhanced,Detected in many,,Rhabdoid: 156.0,"Adipose visceral - Macrophages, Heart muscle - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_2, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA005825,Uncertain,,,,Secreted to blood,No annotated function,,,9290000000.0,44000000000.0,Cluster 8: Plasmacytoid DCs - Unknown function,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 36: Choroid plexus - Mixed function,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,3.0,,,HPA005825: AB_1079921,unprognostic (3.85e-1),prognostic favorable (5.49e-4),unprognostic (9.44e-2),unprognostic (2.32e-2),unprognostic (2.96e-2),unprognostic (2.09e-1),unprognostic (3.32e-3),unprognostic (2.33e-1),unprognostic (7.88e-2),unprognostic (5.92e-2),unprognostic (1.69e-1),unprognostic (4.18e-2),prognostic unfavorable (1.40e-8),unprognostic (2.11e-3),unprognostic (2.82e-1),unprognostic (4.53e-3),unprognostic (1.25e-3),MQALVLLLCIGALLGHSSCQNPASPPEEGSPDPDSTGALVEEEDPFFKVPVNKLAAAVSNFGYDLYRVRSSTSPTTNVLLSPLSVATALSALSLGAEQRTESIIHRALYYDLISSPDIHGTYKELLDTVTAPQKNLKSASRIVFEKKLRIKSSFVAPLEKSYGTRPRVLTGNPRLDLQEINNWVQAQMKGKLARSTKEIPDEISILLLGVAHFKGQWVTKFDSRKTSLEDFYLDEERTVRVPMMSDPKAVLRYGLDSDLSCKIAQLPLTGSMSIIFFLPLKVTQNLTLIEESLTSEFIHDIDRELKTVQAVLTVPKLKLSYEGEVTKSLQEMKLQSLFDSPDFSKITGKPIKLTQVEHRAGFEWNEDGAGTTPSPGLQPAHLTFPLDYHLNQPFIFVLRDTDTGALLFIGKILDPRGP
P19652 Alpha-1-acid glycoprotein 2酸性糖蛋白2抗体,P19652,ORM2,"AGP-B, AGP-B', AGP2",ENSG00000228278,Orosomucoid 2,9,114329869-114333251,"FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Acute phase, Transport",,FDA approved drug targets,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,297.0,liver: 8652.9,Cell type enriched,Detected in some,44.0,Hepatocytes: 9678.3,Cancer enriched,Detected in many,34.0,liver cancer: 873.1,Low region specificity,Detected in some,,,Immune cell enriched,Detected in single,39.0,neutrophil: 13.2,Lineage enriched,Detected in single,39.0,granulocytes: 13.2,Cancer enriched,Detected in some,27.0,liver cancer: 95.6,"Liver - Hepatocytes, Testis - Late spermatids",,,,,,,,,"HPA046438, HPA047725, HPA057726",Approved,,Approved,"Golgi apparatus,Vesicles",Secreted to blood,Acute phase,,,422000000.0,41000000000.0,Cluster 4: Neutrophils - Degranulation,Cluster 31: Liver - Plasma proteins,Cluster 33: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,,Vesicles,Golgi apparatus,"HPA046438: AB_2679666, HPA047725: AB_2680133, HPA057726: AB_2683512",unprognostic (6.77e-2),unprognostic (8.00e-2),unprognostic (1.19e-1),unprognostic (4.44e-3),unprognostic (1.18e-1),unprognostic (5.61e-2),unprognostic (5.66e-2),unprognostic (9.70e-2),unprognostic (3.05e-1),unprognostic (1.48e-1),unprognostic (1.99e-2),unprognostic (5.76e-2),prognostic unfavorable (1.23e-9),unprognostic (3.23e-1),unprognostic (6.80e-2),unprognostic (7.62e-2),unprognostic (9.15e-4),MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDRITGKWFYIASAFRNEEYNKSVQEIQATFFYFTPNKTEDTIFLREYQTRQNQCFYNSSYLNVQRENGTVSRYEGGREHVAHLLFLRDTKTLMFGSYLDDEKNWGLSFYADKPETTKEQLGEFYEALDCLCIPRSDVMYTDWKKDKCEPLEKQHEKERKQEEGES
P07737 Profilin-1 抑制蛋白,P07737,PFN1,,ENSG00000108518,Profilin 1,17,4945652-4949061,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,Actin-binding,"Amyotrophic lateral sclerosis, Disease variant, Neurodegeneration",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Extravillous trophoblasts: 5808.0;Hofbauer cells: 4235.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Colon - Smooth muscle cells, Prostate - Smooth muscle cells, Skeletal muscle - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in single,,,"CAB037134, CAB037140",Enhanced,,Approved,Cytosol,,,,,,660000000.0,Cluster 29: Non-specific - Unknown function,Cluster 70: Lymphoid tissue - Immune response,Cluster 27: Non-specific - Mixed function,Cluster 42: Non-specific - Unknown function,Cluster 14: Langerhans cells - Innate immune response,2.0,Cytosol,,"CAB037134: AB_1079599, CAB037140: AB_1079598",unprognostic (1.07e-1),unprognostic (3.57e-1),unprognostic (1.60e-1),unprognostic (5.45e-3),unprognostic (1.65e-1),unprognostic (7.54e-2),unprognostic (4.01e-3),unprognostic (7.83e-3),unprognostic (3.38e-1),unprognostic (1.09e-3),unprognostic (2.17e-1),unprognostic (3.40e-2),prognostic unfavorable (1.06e-4),unprognostic (3.62e-1),unprognostic (8.17e-2),unprognostic (1.02e-2),unprognostic (1.28e-1),MAGWNAYIDNLMADGTCQDAAIVGYKDSPSVWAAVPGKTFVNITPAEVGVLVGKDRSSFYVNGLTLGGQKCSVIRDSLLQDGEFSMDLRTKSTGGAPTFNVTVTKTDKTLVLLMGKEGVHGGLINKKCYEMASHLRRSQY
P22891 Vitamin K-dependent protein Z维生素k,P22891,PROZ,PZ,ENSG00000126231,"Protein Z, vitamin K dependent plasma glycoprotein",13,113158648-113172386,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis",Serine protease homolog,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,8.0,liver: 106.6,Cell type enriched,Detected in some,7.0,Hepatocytes: 63.9,Cancer enriched,Detected in single,27.0,liver cancer: 12.1,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in some,,,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Not detected,Not detected,,,,,,,HPA052006,Supported,,,,Secreted to blood,Blood coagulation,,,1720000000.0,650000000.0,,Cluster 1: Liver & Kidney - Metabolism,Cluster 5: Non-specific - Mixed function,Cluster 59: Leukemia - T-cell receptor,Cluster 62: Hepatocytes - Metabolism,1.0,,,HPA052006: AB_2681691,unprognostic (5.03e-2),unprognostic (4.05e-2),unprognostic (1.11e-1),unprognostic (2.36e-1),unprognostic (6.48e-2),unprognostic (1.39e-1),prognostic favorable (3.46e-4),unprognostic (4.10e-1),unprognostic (2.21e-1),unprognostic (2.50e-1),unprognostic (5.20e-2),unprognostic (2.87e-1),unprognostic (9.83e-2),unprognostic (5.63e-2),unprognostic (1.41e-1),unprognostic (9.99e-2),unprognostic (2.51e-4),MAGCVPLLQGLVLVLALHRVEPSVFLPASKANDVLVRWKRAGSYLLEELFEGNLEKECYEEICVYEEAREVFENEVVTDEFWRRYKGGSPCISQPCLHNGSCQDSIWGYTCTCSPGYEGSNCELAKNECHPERTDGCQHFCLPGQESYTCSCAQGYRLGEDHKQCVPHDQCACGVLTSEKRAPDLQDLPWQVKLTNSEGKDFCGGVIIRENFVLTTAKCSLLHRNITVKTYFNRTSQDPLMIKITHVHVHMRYDADAGENDLSLLELEWPIQCPGAGLPVCTPEKDFAEHLLIPRTRGLLSGWARNGTDLGNSLTTRPVTLVEGEECGQVLNVTVTTRTYCERSSVAAMHWMDGSVVTREHRGSWFLTGVLGSQPVGGQAHMVLVTKVSRYSLWFKQIMN
P08514 Integrin alpha-Iib 整合素,P08514,ITGA2B,"CD41, CD41B, GP2B, PPP1R93",ENSG00000005961,Integrin subunit alpha 2b,17,44372180-44389649,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Cell adhesion,"Integrin, Receptor","Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,bone marrow: 16.4;epididymis: 10.4;lymphoid tissue: 10.9,Cell type enhanced,Detected in many,,Erythroid cells: 38.7;Late spermatids: 26.7;Lymphatic endothelial cells: 8.9;Oligodendrocyte precursor cells: 9.0,Cancer enhanced,Detected in some,,testis cancer: 2.1,Low region specificity,Detected in all,,,Immune cell enriched,Detected in some,14.0,basophil: 65.1,Lineage enriched,Detected in single,75.0,granulocytes: 65.1,Cancer enriched,Detected in some,59.0,Leukemia: 83.1,Testis - Late spermatids,Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB018611, HPA031168, HPA031169, HPA031170, HPA031171",Enhanced,,Approved,Plasma membrane,,,,,,90000000.0,Cluster 41: Basophils - Unknown function,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 48: Non-specific - Mixed function,Cluster 47: Leukemia - Hemostasis,Cluster 57: Platelets - Hemostasis,1.0,Plasma membrane,,"CAB018611: AB_2265153, HPA031168: AB_10664706, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773",unprognostic (6.11e-2),unprognostic (3.23e-2),unprognostic (1.23e-1),unprognostic (4.85e-2),unprognostic (1.59e-2),unprognostic (3.98e-3),unprognostic (4.23e-5),unprognostic (1.25e-1),unprognostic (1.33e-2),unprognostic (7.22e-2),unprognostic (2.97e-3),unprognostic (1.30e-1),unprognostic (8.83e-9),unprognostic (7.82e-2),unprognostic (1.85e-1),unprognostic (1.95e-1),unprognostic (2.25e-1),MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE
Q04756 Hepatocyte growth factor activator肝细胞生长因子激活物,Q04756,HGFAC,"HGFA, HGFAP",ENSG00000109758,HGF activator,4,3441968-3449486,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",,"Hydrolase, Protease, Serine protease",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,57.0,liver: 211.9,Group enriched,Detected in some,5.0,Early spermatids: 75.5;Hepatocytes: 55.8;Late spermatids: 163.2,Cancer enriched,Detected in some,22.0,liver cancer: 26.7,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,thyroid cancer: 1.1,,Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA058279, HPA059076",Enhanced,,,,Secreted to blood,Enzyme,,,7590000.0,9300000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 48: Non-specific - Mixed function,Cluster 16: Thyroid cancer - Neuronal signaling,Cluster 11: Late spermatids - Unknown function,4.0,,,"HPA058279: AB_2683665, HPA059076: AB_2683898",unprognostic (2.70e-2),unprognostic (8.20e-2),unprognostic (1.57e-1),unprognostic (1.86e-1),unprognostic (1.36e-1),unprognostic (1.39e-2),unprognostic (2.85e-3),unprognostic (5.37e-3),unprognostic (5.90e-2),unprognostic (1.81e-1),unprognostic (8.54e-3),unprognostic (5.52e-2),prognostic unfavorable (9.31e-4),unprognostic (2.87e-1),unprognostic (2.24e-1),unprognostic (9.49e-2),unprognostic (3.74e-4),MGRWAWVPSPWPPPGLGPFLLLLLLLLLLPRGFQPQPGGNRTESPEPNATATPAIPTILVTSVTSETPATSAPEAEGPQSGGLPPPPRAVPSSSSPQAQALTEDGRPCRFPFRYGGRMLHACTSEGSAHRKWCATTHNYDRDRAWGYCVEATPPPGGPAALDPCASGPCLNGGSCSNTQDPQSYHCSCPRAFTGKDCGTEKCFDETRYEYLEGGDRWARVRQGHVEQCECFGGRTWCEGTRHTACLSSPCLNGGTCHLIVATGTTVCACPPGFAGRLCNIEPDERCFLGNGTGYRGVASTSASGLSCLAWNSDLLYQELHVDSVGAAALLGLGPHAYCRNPDNDERPWCYVVKDSALSWEYCRLEACESLTRVQLSPDLLATLPEPASPGRQACGRRHKKRTFLRPRIIGGSSSLPGSHPWLAAIYIGDSFCAGSLVHTCWVVSAAHCFSHSPPRDSVSVVLGQHFFNRTTDVTQTFGIEKYIPYTLYSVFNPSDHDLVLIRLKKKGDRCATRSQFVQPICLPEPGSTFPAGHKCQIAGWGHLDENVSGYSSSLREALVPLVADHKCSSPEVYGADISPNMLCAGYFDCKSDACQGDSGGPLACEKNGVAYLYGIISWGDGCGRLHKPGVYTRVANYVDWINDRIRPPRRLVAPS
P06733 Alpha-enolase烯醇酶,P06733,ENO1,"ENO1L1, MBP-1, MPB1, PPH",ENSG00000074800,Enolase 1,1,8861000-8879190,"Cancer-related genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins","Glycolysis, Plasminogen activation, Transcription, Transcription regulation","DNA-binding, Lyase, Repressor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Ductal cells: 2000.6;Extravillous trophoblasts: 2170.5;Muller glia cells: 2541.6,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB018614, HPA068284, HPA068721, CAB069394, CAB080034",Supported,,Enhanced,"Plasma membrane,Cytosol",,,,,,310000000.0,Cluster 33: Non-specific - ATP binding,Cluster 17: Neuronal - Synaptic function,Cluster 21: Non-specific - Metabolism,Cluster 15: Kidney cancer - Membrane components,Cluster 39: Non-specific - Basic cellular processes,4.0,"Plasma membrane, Cytosol",,"CAB018614: AB_2099061, CAB069394: , CAB080034: , HPA068284: , HPA068721: AB_2732119",unprognostic (6.51e-3),unprognostic (9.50e-3),unprognostic (3.56e-2),unprognostic (1.86e-1),prognostic unfavorable (2.71e-4),unprognostic (1.82e-2),prognostic unfavorable (1.30e-8),unprognostic (2.37e-2),unprognostic (5.58e-2),unprognostic (9.72e-2),unprognostic (1.67e-2),unprognostic (1.46e-1),unprognostic (7.53e-2),unprognostic (6.20e-2),unprognostic (1.97e-1),unprognostic (2.22e-1),unprognostic (1.36e-3),MSILKIHAREIFDSRGNPTVEVDLFTSKGLFRAAVPSGASTGIYEALELRDNDKTRYMGKGVSKAVEHINKTIAPALVSKKLNVTEQEKIDKLMIEMDGTENKSKFGANAILGVSLAVCKAGAVEKGVPLYRHIADLAGNSEVILPVPAFNVINGGSHAGNKLAMQEFMILPVGAANFREAMRIGAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNILENKEGLELLKTAIGKAGYTDKVVIGMDVAASEFFRSGKYDLDFKSPDDPSRYISPDQLADLYKSFIKDYPVVSIEDPFDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKSCNCLLLKVNQIGSVTESLQACKLAQANGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLLRIEEELGSKAKFAGRNFRNPLAK
P23528 Cofilin-1人肌动蛋白素,P23528,CFL1,CFL,ENSG00000172757,Cofilin 1,11,65823022-65862026,"Plasma proteins, Predicted intracellular proteins",Host-virus interaction,Actin-binding,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Low cell type specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,,Low region specificity,Detected in all,,,,,,,"CAB033687, CAB037077, HPA053761, HPA077782",Approved,,Supported,Plasma membrane,,,,,,290000000.0,Cluster 29: Non-specific - Unknown function,Cluster 25: Small intestine - Absorption,Cluster 14: Neurons - Synaptic function,Cluster 24: Non-specific - Unknown function,Cluster 45: Non-specific - Mixed function,12.0,Plasma membrane,,"CAB033687: AB_1121774, CAB037077: AB_1078547, HPA053761: AB_2682251, HPA077782: ",unprognostic (1.14e-1),unprognostic (2.37e-2),unprognostic (7.69e-3),unprognostic (4.32e-3),unprognostic (3.14e-2),unprognostic (2.09e-2),prognostic unfavorable (1.73e-5),unprognostic (1.59e-3),unprognostic (2.52e-1),unprognostic (5.88e-3),unprognostic (6.57e-3),unprognostic (2.09e-1),unprognostic (6.19e-3),unprognostic (1.72e-2),unprognostic (1.82e-1),unprognostic (1.49e-1),unprognostic (2.06e-1),MASGVAVSDGVIKVFNDMKVRKSSTPEEVKKRKKAVLFCLSEDKKNIILEEGKEILVGDVGQTVDDPYATFVKMLPDKDCRYALYDATYETKESKKEDLVFIFWAPESAPLKSKMIYASSKDAIKKKLTGIKHELQANCYEEVKDRCTLAEKLGGSAVISLEGKPL
P63104 14-3-3 protein zeta/delta,P63104,YWHAZ,"14-3-3-zeta, KCIP-1, YWHAD",ENSG00000164924,Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta,8,100916523-100953388,"Plasma proteins, Predicted intracellular proteins, Transporters",,,Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Late spermatids: 2282.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Skin - Keratinocyte (other), Thyroid - Thyroid glandular cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,CAB005065,Approved,,,,,,,,,320000000.0,Cluster 40: Monocytes - Innate immune response,Cluster 29: Squamous epithelium - Innate immune response,Cluster 14: Neurons - Synaptic function,Cluster 40: Non-specific - Unknown function,Cluster 45: Non-specific - Mixed function,128.0,,,CAB005065: AB_2218378,unprognostic (4.70e-3),unprognostic (7.38e-3),unprognostic (8.09e-2),prognostic unfavorable (3.91e-4),unprognostic (1.83e-3),unprognostic (2.00e-2),prognostic unfavorable (2.28e-5),prognostic unfavorable (3.93e-4),unprognostic (1.65e-1),unprognostic (3.72e-1),prognostic unfavorable (1.20e-5),unprognostic (1.09e-1),prognostic unfavorable (2.03e-6),unprognostic (1.02e-1),unprognostic (1.69e-1),unprognostic (1.20e-1),unprognostic (1.49e-1),MDKNELVQKAKLAEQAERYDDMAACMKSVTEQGAELSNEERNLLSVAYKNVVGARRSSWRVVSSIEQKTEGAEKKQQMAREYREKIETELRDICNDVLSLLEKFLIPNASQAESKVFYLKMKGDYYRYLAEVAAGDDKKGIVDQSQQAYQEAFEISKKEMQPTHPIRLGLALNFSVFYYEILNSPEKACSLAKTAFDEAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDTQGDEAEAGEGGEN
P35858 Insulin-like growth factor-binding protein complex acid labile subunit 胰岛素样生长因子结合蛋白复合物酸不稳定亚基,P35858,IGFALS,ALS,ENSG00000099769,Insulin like growth factor binding protein acid labile subunit,16,1790413-1794971,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Cell adhesion,,Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,11.0,liver: 113.8,Cell type enriched,Detected in some,6.0,Hepatocytes: 65.5,Cancer enhanced,Detected in many,,liver cancer: 11.1,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in single,,,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA040692, HPA040948",Supported,,,,Secreted to blood,Cell adhesion,,,14700000000.0,26000000000.0,,Cluster 83: Liver - Metabolism,Cluster 6: Non-specific - Immune response,Cluster 15: Kidney cancer - Membrane components,Cluster 43: Hepatocytes - Metabolism,,,,"HPA040692: AB_10794067, HPA040948: AB_10794999",unprognostic (2.74e-3),unprognostic (1.95e-1),unprognostic (9.13e-2),prognostic unfavorable (6.06e-4),unprognostic (2.54e-1),unprognostic (1.37e-2),prognostic favorable (5.97e-4),unprognostic (5.54e-4),unprognostic (3.00e-1),unprognostic (1.17e-1),unprognostic (9.06e-2),unprognostic (1.05e-2),unprognostic (1.10e-1),unprognostic (1.49e-1),unprognostic (1.23e-1),unprognostic (4.39e-1),unprognostic (5.51e-2),MALRKGGLALALLLLSWVALGPRSLEGADPGTPGEAEGPACPAACVCSYDDDADELSVFCSSRNLTRLPDGVPGGTQALWLDGNNLSSVPPAAFQNLSSLGFLNLQGGQLGSLEPQALLGLENLCHLHLERNQLRSLALGTFAHTPALASLGLSNNRLSRLEDGLFEGLGSLWDLNLGWNSLAVLPDAAFRGLGSLRELVLAGNRLAYLQPALFSGLAELRELDLSRNALRAIKANVFVQLPRLQKLYLDRNLIAAVAPGAFLGLKALRWLDLSHNRVAGLLEDTFPGLLGLRVLRLSHNAIASLRPRTFKDLHFLEELQLGHNRIRQLAERSFEGLGQLEVLTLDHNQLQEVKAGAFLGLTNVAVMNLSGNCLRNLPEQVFRGLGKLHSLHLEGSCLGRIRPHTFTGLSGLRRLFLKDNGLVGIEEQSLWGLAELLELDLTSNQLTHLPHRLFQGLGKLEYLLLSRNRLAELPADALGPLQRAFWLDVSHNRLEALPNSLLAPLGRLRYLSLRNNSLRTFTPQPPGLERLWLEGNPWDCGCPLKALRDFALQNPSAVPRFVQAICEGDDCQPPAYTYNNITCASPPEVVGLDLRDLSEAHFAPC
P18065 Insulin-like growth factor-binding protein 2胰岛素样生长因子结合蛋白2,P18065,IGFBP2,IBP2,ENSG00000115457,Insulin like growth factor binding protein 2,2,216632828-216664436,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Growth regulation,Growth factor binding,Cancer-related genes,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,pancreas: 926.0,Cell type enhanced,Detected in many,,Breast myoepithelial cells: 656.1;Endometrial stromal cells: 1446.9;Granulosa cells: 948.5;Hepatocytes: 527.2,Low cancer specificity,Detected in all,,,Region enriched,Detected in all,8.0,choroid plexus: 238.7,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in all,,,"Pancreas - Exocrine glandular cells, Stomach - Parietal cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA077723,,,Approved,Endoplasmic reticulum,Secreted to blood,Other,,,303000000.0,810000000.0,,Cluster 68: Non-specific - Protein processing,Cluster 23: Choroid plexus - Mixed function,Cluster 49: HMC-1 - Innate immune response,Cluster 9: Endometrial stromal cells - Transcription,1.0,Endoplasmic reticulum,,HPA077723: AB_2686853,unprognostic (2.58e-1),unprognostic (5.95e-2),unprognostic (1.94e-1),unprognostic (3.32e-3),unprognostic (9.50e-3),unprognostic (2.36e-2),unprognostic (2.06e-1),unprognostic (9.11e-3),prognostic unfavorable (2.43e-4),unprognostic (2.34e-1),unprognostic (1.63e-3),unprognostic (1.82e-1),prognostic unfavorable (2.22e-5),unprognostic (5.04e-2),unprognostic (1.07e-1),unprognostic (5.83e-2),unprognostic (1.22e-1),MLPRVGCPALPLPPPPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ
P17936 Insulin-like growth factor-binding protein 3胰岛素样,P17936,IGFBP3,"BP-53, IBP3",ENSG00000146674,Insulin like growth factor binding protein 3,7,45912245-45921874,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Apoptosis,Growth factor binding,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,liver: 693.4;placenta: 1799.7,Cell type enhanced,Detected in many,,Basal respiratory cells: 815.8;Club cells: 408.7;Extravillous trophoblasts: 2449.9;Ionocytes: 425.9,Cancer enhanced,Detected in all,,renal cancer: 377.7,Low region specificity,Detected in all,,,Immune cell enriched,Detected in many,5.0,plasmacytoid DC: 48.9,Lineage enriched,Detected in many,5.0,dendritic cells: 48.9,Cancer enriched,Detected in all,5.0,Kidney cancer: 3358.0,"Liver - Hepatic stellate cells, Testis - Endothelial cells",Low region specificity,Detected in all,,,Low region specificity,Detected in many,,,CAB010360,,,Uncertain,Vesicles,Secreted to blood,Other,,,3250000000.0,3600000000.0,Cluster 8: Plasmacytoid DCs - Unknown function,Cluster 58: Placenta - Pregnancy,Cluster 49: Hindbrain - Mixed function,Cluster 15: Kidney cancer - Membrane components,Cluster 50: Connective tissue cells - ECM organization,5.0,Vesicles,,CAB010360: AB_2233528,unprognostic (4.46e-3),unprognostic (4.84e-2),prognostic unfavorable (1.08e-4),unprognostic (2.30e-1),unprognostic (1.15e-1),unprognostic (6.54e-2),prognostic unfavorable (1.64e-4),unprognostic (8.14e-3),unprognostic (3.31e-2),unprognostic (2.03e-1),unprognostic (9.67e-3),unprognostic (2.80e-1),prognostic unfavorable (5.07e-7),unprognostic (2.36e-2),unprognostic (4.14e-2),unprognostic (2.37e-3),unprognostic (2.63e-1),MQRARPTLWAAALTLLVLLRGPPVARAGASSAGLGPVVRCEPCDARALAQCAPPPAVCAELVREPGCGCCLTCALSEGQPCGIYTERCGSGLRCQPSPDEARPLQALLDGRGLCVNASAVSRLRAYLLPAPPAPGNASESEEDRSAGSVESPSVSSTHRVSDPKFHPLHSKIIIIKKGHAKDSQRYKVDYESQSTDTQNFSSESKRETEYGPCRREMEDTLNHLKFLNVLSPRGVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYTTKGKEDVHCYSMQSK
Q86UX7 Fermitin family homolog 3费米廷家族同源物,Q86UX7,FERMT3,"KIND3, MGC10966, MIG2B, UNC112C, URP2",ENSG00000149781,FERM domain containing kindlin 3,11,64205926-64223896,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",Cell adhesion,,Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,bone marrow: 100.1;lymphoid tissue: 127.0,Cell type enhanced,Detected in many,,dendritic cells: 141.5;Hofbauer cells: 200.8;Kupffer cells: 85.8;Langerhans cells: 108.4;Macrophages: 126.9;monocytes: 117.9;NK-cells: 77.3;T-cells: 73.1,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Cancer enhanced,Detected in many,,Leukemia: 126.8;lymphoma: 93.3;Myeloma: 55.6,"Adipose subcutaneous - Macrophages, Adipose visceral - Macrophages, Breast - Macrophages, Colon - Macrophages, Heart muscle - Macrophages, Skeletal muscle - Macrophages, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in many,,,HPA065231,,,Approved,Vesicles,,,,,,160000000.0,Cluster 10: Non-specific - Membrane trafficking,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 20: Macrophages & Microglia - Immune response,Cluster 35: RS4;11 - Unknown function,Cluster 57: Platelets - Hemostasis,,Vesicles,,HPA065231: AB_2685439,unprognostic (1.96e-2),unprognostic (1.07e-2),unprognostic (3.38e-3),prognostic favorable (9.89e-4),unprognostic (8.77e-2),unprognostic (1.83e-2),unprognostic (3.56e-2),unprognostic (2.46e-1),unprognostic (4.20e-1),unprognostic (3.98e-1),unprognostic (2.70e-1),unprognostic (3.88e-1),prognostic unfavorable (2.12e-5),unprognostic (3.08e-3),unprognostic (5.25e-2),unprognostic (4.97e-2),unprognostic (1.75e-1),MAGMKTASGDYIDSSWELRVFVGEEDPEAESVTLRVTGESHIGGVLLKIVEQINRKQDWSDHAIWWEQKRQWLLQTHWTLDKYGILADARLFFGPQHRPVILRLPNRRALRLRASFSQPLFQAVAAICRLLSIRHPEELSLLRAPEKKEKKKKEKEPEEELYDLSKVVLAGGVAPALFRGMPAHFSDSAQTEACYHMLSRPQPPPDPLLLQRLPRPSSLSDKTQLHSRWLDSSRCLMQQGIKAGDALWLRFKYYSFFDLDPKTDPVRLTQLYEQARWDLLLEEIDCTEEEMMVFAALQYHINKLSQSGEVGEPAGTDPGLDDLDVALSNLEVKLEGSAPTDVLDSLTTIPELKDHLRIFRIPRRPRKLTLKGYRQHWVVFKETTLSYYKSQDEAPGDPIQQLNLKGCEVVPDVNVSGQKFCIKLLVPSPEGMSEIYLRCQDEQQYARWMAGCRLASKGRTMADSSYTSEVQAILAFLSLQRTGSGGPGNHPHGPDASAEGLNPYGLVAPRFQRKFKAKQLTPRILEAHQNVAQLSLAEAQLRFIQAWQSLPDFGISYVMVRFKGSRKDEILGIANNRLIRIDLAVGDVVKTWRFSNMRQWNVNWDIRQVAIEFDEHINVAFSCVSASCRIVHEYIGGYIFLSTRERARGEELDEDLFLQLTGGHEAF
P02753 Retinol-binding protein 4视黄醇结合蛋白,P02753,RBP4,,ENSG00000138207,Retinol binding protein 4,10,93591687-93601744,"Cancer-related genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Sensory transduction, Transport, Vision",,"Cancer-related genes, Disease variant, Microphthalmia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,19.0,liver: 10726.7,Cell type enriched,Detected in many,13.0,Hepatocytes: 12476.9,Cancer enriched,Detected in all,27.0,liver cancer: 3135.4,Region enriched,Detected in all,4.0,hypothalamus: 204.5,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,4.0,liver cancer: 195.7,"Adipose subcutaneous - Adipocytes (Subcutaneous), Adipose visceral - Adipocytes (Visceral), Breast - Adipocytes (Breast), Liver - Hepatocytes, Lung - Macrophages, Pancreas - Beta cells, Skin - Adipocytes (Skin), Testis - Spermatogonia",Low region specificity,Detected in all,,,Low region specificity,Detected in many,,,"HPA001641, CAB004555",Supported,,,,Secreted to blood,Transport,,,46100000000.0,210000000000.0,,Cluster 83: Liver - Metabolism,Cluster 56: Hypothalamus - Neuropeptide signaling,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,,,"CAB004555: AB_670938, HPA001641: AB_1079795",unprognostic (9.42e-3),unprognostic (3.40e-2),unprognostic (1.90e-1),prognostic unfavorable (1.50e-4),unprognostic (2.60e-2),unprognostic (6.69e-4),prognostic favorable (1.74e-8),unprognostic (2.39e-1),unprognostic (5.76e-2),unprognostic (3.26e-2),unprognostic (3.26e-1),unprognostic (3.44e-1),unprognostic (7.14e-3),unprognostic (9.88e-3),unprognostic (2.31e-1),unprognostic (1.03e-1),unprognostic (8.60e-2),MKWVWALLLLAALGSGRAERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNLL
Q5TB80 Centrosomal protein of 162 kDa 中心体蛋白162 kDa,Q5TB80,CEP162,"C6orf84, KIAA1009, QN1",ENSG00000135315,Centrosomal protein 162,6,84124241-84227643,"Plasma proteins, Predicted intracellular proteins",Cilium biogenesis/degradation,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Early spermatids: 180.2;Late spermatids: 62.3;Oligodendrocytes: 59.6,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in all,,,Testis - Early spermatids,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA030170, HPA030171, HPA030172, HPA030173",Supported,,Approved,"Nucleoplasm,Centriolar satellite,Cytosol",,,,,,,Cluster 29: Non-specific - Unknown function,Cluster 16: Non-specific - Transcription,Cluster 46: Brainstem - Mixed function,Cluster 28: Non-specific - Nuclear processes,Cluster 18: Early spermatids - Unknown function,3.0,"Nucleoplasm, Cytosol",Centriolar satellite,"HPA030170: AB_10611113, HPA030171: AB_10601567, HPA030172: AB_10602414, HPA030173: AB_10602206",unprognostic (1.75e-1),unprognostic (1.46e-2),unprognostic (1.64e-1),unprognostic (1.26e-2),unprognostic (1.06e-1),unprognostic (1.63e-3),unprognostic (2.95e-4),unprognostic (1.03e-1),unprognostic (6.73e-2),unprognostic (1.21e-3),unprognostic (1.57e-3),unprognostic (3.98e-2),unprognostic (2.87e-3),unprognostic (3.27e-2),unprognostic (6.32e-2),unprognostic (3.58e-1),unprognostic (1.44e-3),MANCSQEELDEEFEQFMKELSDDSFENSDKTARQSKKEMKKKDTVPWWITEDDFKDDGLLGTNVSYLKTKKTSQPVMEIEEESAEKIQFLKSSGTSLLSTDSLETNELVVSELNHSSLGVGLDTLEEQEEKEQFFARLEKGLTSSIDYSRLNKELDSNDSTHFKALHSNQANAELTDDEHENESKHEELAENYSDDFEDEYVGAPLTTKDEEMPSKENSKSEKISVPKQEEEKTGMLANVVLLDSLDSVAEVNLDEQDKITPKPRCLPEMTENEMTGTGVSYGQSSSDVEALHQAYCHIAHSLGDEDKQKIESNTVEDIKSSVKGHPQENEENSKNISTMESDLPTVEELMKPIRIDSFGISGFDLQPVSSEKVAERKETEFFSSLPLKMNPNILSQDSQHVNLFFDKNDENVILQKTTNESMENSCPQVTEVTATEEHVDKMYLNILRKKITVNSSSLSQDDKINKTYRSQLSSEEEGAVMGKQVPYKKARSAPPLLKRKPQSGLYASVRSSGYGKPSSPLKMFSTLEKKTSEDIIKSKNLRSISTSNQPRKKEILSGTKLIKPAALDKPAHKTESCLSTRKKSENPTETDSCIQFQTDSLGYCGENKEKKLLMFKRVQEAEDKWRGAQALIEQIKATFSEKEKELENKLEELKKQQEKELFKLNQDNYILQAKLSSFEETNKKQRWLHFGEAADPVTGEKLKQIQKEIQEQETLLQGYQQENERLYNQVKDLQEQNKKNEERMFKENQSLFSEVASLKEQMHKSRFLSQVVEDSEPTRNQNFTDLLAELRMAQKEKDSLLEDIKRLKQDKQALEVDFEKMKKERDQAKDQIAYVTGEKLYEIKILEETHKQEISRLQKRLQWYAENQELLDKDALRLREANEEIEKLKLEIEKLKAESGNPSIRQKIRLKDKAADAKKIQDLERQVKEMEGILKRRYPNSLPALILAASAAGDTVDKNTVEFMEKRIKKLEADLEGKDEDAKKSLRTMEQQFQKMKIQYEQRLEQQEQLLACKLNQHDSPRIKALEKELDDIKEAHQITVRNLEAEIDVLKHQNAELDVKKNDKDDEDFQSIEFQVEQAHAKAKLVRLNEELAAKKREIQDLSKTVERLQKDRRMMLSNQNSKGREEMSAKRAKKDVLHSSKGNANSFPGTLDSKLYQPHTFTDSHVSEVLQENYRLKNELEGLISEKNELKMKSEAVMNQFENSMRRVKEDTAAHIASLKASHQREIEKLLCQNAVENSSSKVAELNRKIATQEVLIRHFQSQVNELQSKQESLVVSEVREEILQKEITKLLEELREAKENHTPEMKHFVGLEKKIKQMEMRHAQREQELQQIIQQTHQVVETEQNKEVEKWKRLAQLKNRELEKFRTELDSILDVLRELHRQGVVVPVAFADEMNAPEY
P22352 Glutathione peroxidase 3血浆型谷胱甘肽过氧化物酶,P22352,GPX3,,ENSG00000211445,Glutathione peroxidase 3,5,151020591-151028988,"Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,"Oxidoreductase, Peroxidase",,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,kidney: 10840.5,Group enriched,Detected in many,5.0,Muller glia cells: 4288.3;Proximal tubular cells: 16878.3,Cancer enhanced,Detected in all,,renal cancer: 605.6;thyroid cancer: 856.0,Group enriched,Detected in all,4.0,choroid plexus: 1127.5;medulla oblongata: 588.7,Immune cell enriched,Detected in some,5.0,neutrophil: 20.8,Lineage enriched,Detected in many,5.0,granulocytes: 20.8,Cancer enhanced,Detected in all,,ovarian cancer: 198.7;thyroid cancer: 178.6,"Adipose subcutaneous - Adipocytes (Subcutaneous), Breast - Adipocytes (Breast), Kidney - Proximal tubular cells, Kidney - Proximal tubular cells",Region enhanced,Detected in all,,hypothalamus: 239.6,Low region specificity,Detected in all,,,CAB069456,Approved,,,,Secreted to blood,Enzyme,,,5090000000.0,6200000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 52: Kidney - Transmembrane transport,Cluster 44: Non-specific - Mixed function,Cluster 44: Connective tissue cells - ECM organization,Cluster 38: Proximal tubular cells - Transmembrane transport,,,,CAB069456: AB_1616682,unprognostic (4.03e-1),unprognostic (7.35e-2),unprognostic (5.05e-3),unprognostic (9.01e-2),unprognostic (1.41e-2),unprognostic (8.13e-2),unprognostic (1.39e-2),unprognostic (1.62e-1),unprognostic (5.75e-3),unprognostic (2.70e-3),unprognostic (8.17e-3),unprognostic (1.14e-2),unprognostic (2.95e-1),prognostic unfavorable (1.65e-4),unprognostic (2.14e-1),unprognostic (5.11e-2),unprognostic (1.26e-1),MARLLQASCLLSLLLAGFVSQSRGQEKSKMDCHGGISGTIYEYGALTIDGEEYIPFKQYAGKYVLFVNVASYUGLTGQYIELNALQEELAPFGLVILGFPCNQFGKQEPGENSEILPTLKYVRPGGGFVPNFQLFEKGDVNGEKEQKFYTFLKNSCPPTSELLGTSDRLFWEPMKVHDIRWNFEKFLVGPDGIPIMRWHHRTTVSNVKMDILSYMRRQAALGVKRK
P35443 Thrombospondin-4血小板反应蛋白,P35443,THBS4,,ENSG00000113296,Thrombospondin 4,5,79991311-80083287,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Cell adhesion, Tissue remodeling, Unfolded protein response","Growth factor, Mitogen",Cancer-related genes,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adipose tissue: 209.2;heart muscle: 162.0;smooth muscle: 243.3;tongue: 206.3,Cell type enhanced,Detected in many,,Adipocytes: 40.7;Cone photoreceptor cells: 52.7;Early spermatids: 50.7;Fibroblasts: 71.4;Oligodendrocyte precursor cells: 56.6;Peritubular cells: 42.2;Prostatic glandular cells: 46.7;Sertoli cells: 182.2;Smooth muscle cells: 56.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enriched,Detected in single,46.0,eosinophil: 4.6,Lineage enriched,Detected in single,46.0,granulocytes: 4.6,Low cancer specificity,Detected in many,,,Skeletal muscle - Fibroblasts,Region enriched,Detected in many,8.0,white matter: 85.8,Region enriched,Detected in many,29.0,spinal cord: 117.4,"CAB004597, HPA042426",Approved,,Approved,Vesicles,Secreted to extracellular matrix,Growth factor,,,,510000000.0,Cluster 22: Eosinophils - Transcription,Cluster 7: Adipose tissue - Mixed function,Cluster 41: Monoamines - Neurotransmitter signalling,Cluster 64: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,,Vesicles,,"CAB004597: AB_628352, HPA042426: AB_2677992",unprognostic (1.41e-1),unprognostic (5.33e-2),unprognostic (4.26e-3),unprognostic (3.64e-2),unprognostic (9.94e-2),unprognostic (8.10e-2),unprognostic (5.64e-2),unprognostic (7.12e-2),unprognostic (1.66e-1),unprognostic (2.25e-1),unprognostic (2.06e-1),unprognostic (2.14e-1),unprognostic (1.96e-3),unprognostic (2.74e-2),unprognostic (3.98e-2),unprognostic (1.76e-3),prognostic unfavorable (3.33e-4),MLAPRGAAVLLLHLVLQRWLAAGAQATPQVFDLLPSSSQRLNPGALLPVLTDPALNDLYVISTFKLQTKSSATIFGLYSSTDNSKYFEFTVMGRLNKAILRYLKNDGKVHLVVFNNLQLADGRRHRILLRLSNLQRGAGSLELYLDCIQVDSVHNLPRAFAGPSQKPETIELRTFQRKPQDFLEELKLVVRGSLFQVASLQDCFLQQSEPLAATGTGDFNRQFLGQMTQLNQLLGEVKDLLRQQVKETSFLRNTIAECQACGPLKFQSPTPSTVVPPAPPAPPTRPPRRCDSNPCFRGVQCTDSRDGFQCGPCPEGYTGNGITCIDVDECKYHPCYPGVHCINLSPGFRCDACPVGFTGPMVQGVGISFAKSNKQVCTDIDECRNGACVPNSICVNTLGSYRCGPCKPGYTGDQIRGCKAERNCRNPELNPCSVNAQCIEERQGDVTCVCGVGWAGDGYICGKDVDIDSYPDEELPCSARNCKKDNCKYVPNSGQEDADRDGIGDACDEDADGDGILNEQDNCVLIHNVDQRNSDKDIFGDACDNCLSVLNNDQKDTDGDGRGDACDDDMDGDGIKNILDNCPKFPNRDQRDKDGDGVGDACDSCPDVSNPNQSDVDNDLVGDSCDTNQDSDGDGHQDSTDNCPTVINSAQLDTDKDGIGDECDDDDDNDGIPDLVPPGPDNCRLVPNPAQEDSNSDGVGDICESDFDQDQVIDRIDVCPENAEVTLTDFRAYQTVVLDPEGDAQIDPNWVVLNQGMEIVQTMNSDPGLAVGYTAFNGVDFEGTFHVNTQTDDDYAGFIFGYQDSSSFYVVMWKQTEQTYWQATPFRAVAEPGIQLKAVKSKTGPGEHLRNSLWHTGDTSDQVRLLWKDSRNVGWKDKVSYRWFLQHRPQVGYIRVRFYEGSELVADSGVTIDTTMRGGRLGVFCFSQENIIWSNLKYRCNDTIPEDFQEFQTQNFDRFDN
P62937 Peptidyl-prolyl cis-trans isomerase A 肽基脯氨酸顺反异构酶A,P62937,PPIA,CYPA,ENSG00000196262,Peptidylprolyl isomerase A,7,44796680-44824564,"Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Apoptosis, Host-virus interaction","Isomerase, Rotamase",FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Low cell type specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,,,,,,,,,,"CAB004655, HPA058345",Uncertain,,,,Secreted to blood,Enzyme,,,,230000000.0,Cluster 13: Non-specific - Mitochondria,Cluster 33: Brain - Neuronal signaling,Cluster 14: Neurons - Synaptic function,Cluster 67: Non-specific - Unknown function,Cluster 49: Non-specific - Transcription,10.0,,,"CAB004655: AB_425607, HPA058345: AB_2683685",unprognostic (3.10e-1),unprognostic (2.28e-1),unprognostic (1.27e-1),unprognostic (7.86e-2),unprognostic (9.27e-2),unprognostic (2.19e-2),prognostic unfavorable (2.27e-6),unprognostic (1.12e-3),unprognostic (3.30e-2),unprognostic (3.92e-2),unprognostic (8.68e-3),unprognostic (2.52e-1),unprognostic (6.35e-3),unprognostic (2.77e-1),unprognostic (1.24e-1),unprognostic (7.84e-2),unprognostic (1.16e-1),MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE
P10720 Platelet factor 4 variant血小板因子4变体,P10720,PF4V1,"CXCL4L1, CXCL4V1, SCYB4V1",ENSG00000109272,Platelet factor 4 variant 1,4,73853296-73854483,"Plasma proteins, Predicted secreted proteins",,"Cytokine, Heparin-binding",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in some,,intestine: 1.6;lymphoid tissue: 2.3,Cell type enhanced,Detected in some,,Cholangiocytes: 17.2;Club cells: 10.7;Enteroendocrine cells: 16.0;Hepatocytes: 4.0,Cancer enhanced,Detected in some,,renal cancer: 3.4,Not detected,Not detected,,,Group enriched,Detected in some,42.0,basophil: 12.5;neutrophil: 9.2,Lineage enriched,Detected in single,48.0,granulocytes: 12.5,Cancer enhanced,Detected in single,,thyroid cancer: 1.2,,,,,,,,,,HPA052485,Supported,,,,Secreted to blood,Cytokine,,,,,Cluster 4: Neutrophils - Degranulation,Cluster 25: Small intestine - Absorption,,Cluster 64: Connective tissue cells - ECM organization,Cluster 57: Platelets - Hemostasis,1.0,,,HPA052485: AB_2681847,,unprognostic (4.95e-1),unprognostic (5.68e-2),unprognostic (1.54e-1),unprognostic (1.16e-3),unprognostic (9.88e-2),unprognostic (1.72e-2),unprognostic (1.68e-3),,unprognostic (2.66e-1),unprognostic (6.02e-2),unprognostic (2.65e-1),unprognostic (1.95e-3),unprognostic (1.39e-2),,,unprognostic (2.11e-1),MSSAARSRLTRATRQEMLFLALLLLPVVVAFARAEAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQALLYKKIIKEHLES
P48740 Mannan-binding lectin serine protease 1 甘露聚糖结合凝集素丝氨酸蛋白酶,P48740,MASP1,"CRARF, MAP-1, Map44, MASP, MASP-3, PRSS5",ENSG00000127241,MBL associated serine protease 1,3,187217282-187291980,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Complement activation lectin pathway, Immunity, Innate immunity","Hydrolase, Protease, Serine protease",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,cervix: 116.0;heart muscle: 111.9;liver: 178.0,Cell type enhanced,Detected in some,,Astrocytes: 26.6;Cardiomyocytes: 29.0;Cholangiocytes: 26.7;Endometrial stromal cells: 29.6;Fibroblasts: 16.5;Hepatocytes: 57.4,Group enriched,Detected in some,9.0,glioma: 6.8;liver cancer: 7.7;prostate cancer: 3.0;renal cancer: 3.9,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 11.8;Rhabdoid: 14.6,"Breast - Fibroblasts, Pancreas - Fibroblasts, Prostate - Smooth muscle cells, Skin - Fibroblast_1, Skin - Fibroblast_2",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001617, HPA009641",Supported,,Enhanced,"Nucleoplasm,Cytosol",Secreted to blood,Immunity,No,,8670000000.0,1900000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 64: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,2.0,"Nucleoplasm, Cytosol",,"HPA001617: AB_1079314, HPA009641: AB_1079313",unprognostic (1.67e-1),unprognostic (1.02e-2),unprognostic (1.99e-1),unprognostic (5.20e-2),unprognostic (1.02e-2),unprognostic (1.25e-6),prognostic favorable (2.20e-4),unprognostic (9.92e-2),unprognostic (3.22e-1),unprognostic (2.29e-1),unprognostic (4.18e-1),unprognostic (1.29e-1),unprognostic (2.82e-3),unprognostic (3.56e-3),unprognostic (1.97e-1),unprognostic (7.85e-2),unprognostic (4.29e-1),MRWLLLYYALCFSLSKASAHTVELNNMFGQIQSPGYPDSYPSDSEVTWNITVPDGFRIKLYFMHFNLESSYLCEYDYVKVETEDQVLATFCGRETTDTEQTPGQEVVLSPGSFMSITFRSDFSNEERFTGFDAHYMAVDVDECKEREDEELSCDHYCHNYIGGYYCSCRFGYILHTDNRTCRVECSDNLFTQRTGVITSPDFPNPYPKSSECLYTIELEEGFMVNLQFEDIFDIEDHPEVPCPYDYIKIKVGPKVLGPFCGEKAPEPISTQSHSVLILFHSDNSGENRGWRLSYRAAGNECPELQPPVHGKIEPSQAKYFFKDQVLVSCDTGYKVLKDNVEMDTFQIECLKDGTWSNKIPTCKIVDCRAPGELEHGLITFSTRNNLTTYKSEIKYSCQEPYYKMLNNNTGIYTCSAQGVWMNKVLGRSLPTCLPVCGLPKFSRKLMARIFNGRPAQKGTTPWIAMLSHLNGQPFCGGSLLGSSWIVTAAHCLHQSLDPEDPTLRDSDLLSPSDFKIILGKHWRLRSDENEQHLGVKHTTLHPQYDPNTFENDVALVELLESPVLNAFVMPICLPEGPQQEGAMVIVSGWGKQFLQRFPETLMEIEIPIVDHSTCQKAYAPLKKKVTRDMICAGEKEGGKDACAGDSGGPMVTLNRERGQWYLVGTVSWGDDCGKKDRYGVYSYIHHNKDWIQRVTGVRN
P25311 Zinc-alpha-2-glycoprotein锌糖蛋白,P25311,AZGP1,"ZA2G, ZAG",ENSG00000160862,"Alpha-2-glycoprotein 1, zinc-binding",7,99966720-99976042,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,liver: 2718.3;salivary gland: 3732.5,Cell type enhanced,Detected in many,,Breast glandular cells: 1494.4;Hepatocytes: 4213.4;Mucus glandular cells: 2188.5;Prostatic glandular cells: 4198.4;Serous glandular cells: 4020.8,Group enriched,Detected in many,12.0,breast cancer: 412.6;liver cancer: 273.6;prostate cancer: 469.5,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,breast cancer: 226.3;prostate cancer: 78.4,"Adipose subcutaneous - Adipocytes (Subcutaneous), Adipose visceral - Adipocytes (Visceral), Breast - Breast glandular cells, Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Liver - Hepatocytes, Prostate - Prostate glandular cells, Stomach - Chief cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA012582, HPA012876, CAB016087, CAB032276",Enhanced,,Approved,"Nucleoplasm,Vesicles",Secreted to blood,No annotated function,,,55200000000.0,74000000000.0,,Cluster 68: Non-specific - Protein processing,Cluster 26: Oligodendrocytes - Mixed function,Cluster 2: Mucus-secreting cells - Unknown function,Cluster 75: Serous glandular cells - Salivary secretion,2.0,Vesicles,Nucleoplasm,"CAB016087: AB_667849, CAB032276: AB_2062580, HPA012582: AB_1845226, HPA012876: ",unprognostic (8.14e-2),unprognostic (1.50e-1),unprognostic (3.41e-1),unprognostic (5.42e-3),unprognostic (4.98e-2),unprognostic (5.74e-3),prognostic favorable (2.90e-4),unprognostic (1.50e-1),unprognostic (1.85e-1),unprognostic (2.19e-1),unprognostic (2.35e-2),unprognostic (1.79e-1),prognostic favorable (1.53e-4),unprognostic (2.18e-1),unprognostic (2.08e-2),unprognostic (9.80e-2),unprognostic (3.51e-3),MVRMVPVLLSLLLLLGPAVPQENQDGRYSLTYIYTGLSKHVEDVPAFQALGSLNDLQFFRYNSKDRKSQPMGLWRQVEGMEDWKQDSQLQKAREDIFMETLKDIVEYYNDSNGSHVLQGRFGCEIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQKWEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVVVTSHQAPGEKKKLKCLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNGNGTYQSWVVVAVPPQDTAPYSCHVQHSSLAQPLVVPWEAS
P43652 Afamin,P43652,AFM,"ALB2, ALBA",ENSG00000079557,Afamin,4,73481745-73504001,"Plasma proteins, Predicted secreted proteins","Protein transport, Transport",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,12.0,liver: 932.0,Cell type enriched,Detected in some,8.0,Hepatocytes: 294.0,Cancer enriched,Detected in single,167.0,liver cancer: 62.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA017006, HPA052437",Enhanced,,Uncertain,Plasma membrane,Secreted to blood,Transport,,,54900000000.0,8700000000.0,,Cluster 1: Liver & Kidney - Metabolism,,Cluster 55: Lymphoma - Immune response,Cluster 43: Hepatocytes - Metabolism,1.0,Plasma membrane,,"HPA017006: AB_1844635, HPA052437: AB_2732575",,,,,,,prognostic favorable (1.80e-4),,,,unprognostic (5.73e-2),,unprognostic (4.24e-2),,,,,MKLLKLTGFIFFLFFLTESLTLPTQPRDIENFNSTQKFIEDNIEYITIIAFAQYVQEATFEEMEKLVKDMVEYKDRCMADKTLPECSKLPNNVLQEKICAMEGLPQKHNFSHCCSKVDAQRRLCFFYNKKSDVGFLPPFPTLDPEEKCQAYESNRESLLNHFLYEVARRNPFVFAPTLLTVAVHFEEVAKSCCEEQNKVNCLQTRAIPVTQYLKAFSSYQKHVCGALLKFGTKVVHFIYIAILSQKFPKIEFKELISLVEDVSSNYDGCCEGDVVQCIRDTSKVMNHICSKQDSISSKIKECCEKKIPERGQCIINSNKDDRPKDLSLREGKFTDSENVCQERDADPDTFFAKFTFEYSRRHPDLSIPELLRIVQIYKDLLRNCCNTENPPGCYRYAEDKFNETTEKSLKMVQQECKHFQNLGKDGLKYHYLIRLTKIAPQLSTEELVSLGEKMVTAFTTCCTLSEEFACVDNLADLVFGELCGVNENRTINPAVDHCCKTNFAFRRPCFESLKADKTYVPPPFSQDLFTFHADMCQSQNEELQRKTDRFLVNLVKLKHELTDEELQSLFTNFANVVDKCCKAESPEVCFNEESPKIGN
Q9Y490 Talin-1踝蛋白,Q9Y490,TLN1,"ILWEQ, TLN",ENSG00000137076,Talin 1,9,35696948-35732195,"Plasma proteins, Predicted intracellular proteins",Host-virus interaction,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,monocytes: 372.9,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Colon - Smooth muscle cells, Prostate - Smooth muscle cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB002006, HPA004748",Supported,,Supported,"Plasma membrane,Focal adhesion sites,Centriolar satellite,Cytosol",,,,,,1300000000.0,Cluster 25: Non-specific - Unknown function,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 20: Macrophages & Microglia - Immune response,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 32: Smooth muscle cells - Muscle contraction,4.0,"Focal adhesion sites, Cytosol","Plasma membrane, Centriolar satellite","CAB002006: , HPA004748: AB_1857760",unprognostic (9.71e-2),unprognostic (2.02e-2),prognostic unfavorable (5.56e-4),unprognostic (1.96e-1),unprognostic (5.55e-2),unprognostic (2.52e-1),unprognostic (3.18e-2),unprognostic (5.07e-2),unprognostic (1.94e-1),unprognostic (6.46e-2),unprognostic (1.82e-1),unprognostic (1.27e-1),prognostic favorable (7.21e-4),unprognostic (1.36e-1),unprognostic (2.71e-2),unprognostic (7.83e-2),unprognostic (8.83e-3),MVALSLKISIGNVVKTMQFEPSTMVYDACRIIRERIPEAPAGPPSDFGLFLSDDDPKKGIWLEAGKALDYYMLRNGDTMEYRKKQRPLKIRMLDGTVKTIMVDDSKTVTDMLMTICARIGITNHDEYSLVRELMEEKKEEITGTLRKDKTLLRDEKKMEKLKQKLHTDDELNWLDHGRTLREQGVEEHETLLLRRKFFYSDQNVDSRDPVQLNLLYVQARDDILNGSHPVSFDKACEFAGFQCQIQFGPHNEQKHKAGFLDLKDFLPKEYVKQKGERKIFQAHKNCGQMSEIEAKVRYVKLARSLKTYGVSFFLVKEKMKGKNKLVPRLLGITKECVMRVDEKTKEVIQEWNLTNIKRWAASPKSFTLDFGDYQDGYYSVQTTEGEQIAQLIAGYIDIILKKKKSKDHFGLEGDEESTMLEDSVSPKKSTVLQQQYNRVGKVEHGSVALPAIMRSGASGPENFQVGSMPPAQQQITSGQMHRGHMPPLTSAQQALTGTINSSMQAVQAAQATLDDFDTLPPLGQDAASKAWRKNKMDESKHEIHSQVDAITAGTASVVNLTAGDPAETDYTAVGCAVTTISSNLTEMSRGVKLLAALLEDEGGSGRPLLQAAKGLAGAVSELLRSAQPASAEPRQNLLQAAGNVGQASGELLQQIGESDTDPHFQDALMQLAKAVASAAAALVLKAKSVAQRTEDSGLQTQVIAAATQCALSTSQLVACTKVVAPTISSPVCQEQLVEAGRLVAKAVEGCVSASQAATEDGQLLRGVGAAATAVTQALNELLQHVKAHATGAGPAGRYDQATDTILTVTENIFSSMGDAGEMVRQARILAQATSDLVNAIKADAEGESDLENSRKLLSAAKILADATAKMVEAAKGAAAHPDSEEQQQRLREAAEGLRMATNAAAQNAIKKKLVQRLEHAAKQAAASATQTIAAAQHAASTPKASAGPQPLLVQSCKAVAEQIPLLVQGVRGSQAQPDSPSAQLALIAASQSFLQPGGKMVAAAKASVPTIQDQASAMQLSQCAKNLGTALAELRTAAQKAQEACGPLEMDSALSVVQNLEKDLQEVKAAARDGKLKPLPGETMEKCTQDLGNSTKAVSSAIAQLLGEVAQGNENYAGIAARDVAGGLRSLAQAARGVAALTSDPAVQAIVLDTASDVLDKASSLIEEAKKAAGHPGDPESQQRLAQVAKAVTQALNRCVSCLPGQRDVDNALRAVGDASKRLLSDSLPPSTGTFQEAQSRLNEAAAGLNQAATELVQASRGTPQDLARASGRFGQDFSTFLEAGVEMAGQAPSQEDRAQVVSNLKGISMSSSKLLLAAKALSTDPAAPNLKSQLAAAARAVTDSINQLITMCTQQAPGQKECDNALRELETVRELLENPVQPINDMSYFGCLDSVMENSKVLGEAMTGISQNAKNGNLPEFGDAISTASKALCGFTEAAAQAAYLVGVSDPNSQAGQQGLVEPTQFARANQAIQMACQSLGEPGCTQAQVLSAATIVAKHTSALCNSCRLASARTTNPTAKRQFVQSAKEVANSTANLVKTIKALDGAFTEENRAQCRAATAPLLEAVDNLSAFASNPEFSSIPAQISPEGRAAMEPIVISAKTMLESAGGLIQTARALAVNPRDPPSWSVLAGHSRTVSDSIKKLITSMRDKAPGQLECETAIAALNSCLRDLDQASLAAVSQQLAPREGISQEALHTQMLTAVQEISHLIEPLANAARAEASQLGHKVSQMAQYFEPLTLAAVGAASKTLSHPQQMALLDQTKTLAESALQLLYTAKEAGGNPKQAAHTQEALEEAVQMMTEAVEDLTTTLNEAASAAGVVGGMVDSITQAINQLDEGPMGEPEGSFVDYQTTMVRTAKAIAVTVQEMVTKSNTSPEELGPLANQLTSDYGRLASEAKPAAVAAENEEIGSHIKHRVQELGHGCAALVTKAGALQCSPSDAYTKKELIECARRVSEKVSHVLAALQAGNRGTQACITAASAVSGIIADLDTTIMFATAGTLNREGTETFADHREGILKTAKVLVEDTKVLVQNAAGSQEKLAQAAQSSVATITRLADVVKLGAASLGAEDPETQVVLINAVKDVAKALGDLISATKAAAGKVGDDPAVWQLKNSAKVMVTNVTSLLKTVKAVEDEATKGTRALEATTEHIRQELAVFCSPEPPAKTSTPEDFIRMTKGITMATAKAVAAGNSCRQEDVIATANLSRRAIADMLRACKEAAYHPEVAPDVRLRALHYGRECANGYLELLDHVLLTLQKPSPELKQQLTGHSKRVAGSVTELIQAAEAMKGTEWVDPEDPTVIAENELLGAAAAIEAAAKKLEQLKPRAKPKEADESLNFEEQILEAAKSIAAATSALVKAASAAQRELVAQGKVGAIPANALDDGQWSQGLISAARMVAAATNNLCEAANAAVQGHASQEKLISSAKQVAASTAQLLVACKVKADQDSEAMKRLQAAGNAVKRASDNLVKAAQKAAAFEEQENETVVVKEKMVGGIAQIIAAQEEMLRKERELEEARKKLAQIRQQQYKFLPSELRDEH
P05106 Integrin beta-3整合素,P05106,ITGB3,"CD61, GP3A, GPIIIa",ENSG00000259207,Integrin subunit beta 3,17,47253827-47313743,"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Cell adhesion, Host-virus interaction","Host cell receptor for virus entry, Integrin, Receptor","Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,thyroid gland: 54.6,Cell type enhanced,Detected in many,,Collecting duct cells: 9.7;Pancreatic endocrine cells: 10.2;Proximal tubular cells: 19.4;Salivary duct cells: 14.8;Sertoli cells: 13.6,Group enriched,Detected in many,6.0,melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5,Low region specificity,Detected in all,,,Group enriched,Detected in some,17.0,basophil: 5.6;neutrophil: 3.0,Lineage enriched,Detected in single,22.0,granulocytes: 5.6,Cancer enhanced,Detected in many,,Kidney cancer: 99.0;skin cancer: 125.1,"Liver - Vascular Endothelial cells, Prostate - Smooth muscle cells, Testis - Spermatogonia",Low region specificity,Detected in many,,,Low region specificity,Detected in all,,,HPA027852,Approved,,Supported,"Nucleoplasm,Plasma membrane",Intracellular and membrane,Receptor,,,,38000000.0,Cluster 35: Neutrophils - Protein binding,Cluster 51: Thyroid gland - Unknown function,Cluster 12: Non-specific - Vasculature,Cluster 69: Skin cancer - ECM organization,Cluster 57: Platelets - Hemostasis,9.0,Plasma membrane,Nucleoplasm,HPA027852: AB_10601760,unprognostic (1.13e-2),unprognostic (1.97e-3),unprognostic (2.47e-1),unprognostic (3.00e-2),unprognostic (1.91e-2),unprognostic (6.04e-3),unprognostic (3.70e-1),unprognostic (3.00e-1),unprognostic (1.44e-1),unprognostic (3.85e-1),unprognostic (6.35e-2),unprognostic (7.22e-2),unprognostic (1.36e-1),unprognostic (1.03e-2),unprognostic (2.72e-2),unprognostic (1.48e-1),unprognostic (1.17e-3),MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT
P18206 Vinculin黏着斑蛋白,P18206,VCL,,ENSG00000035403,Vinculin,10,73995193-74121363,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",Cell adhesion,Actin-binding,"Cardiomyopathy, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Alveolar cells type 1: 232.0;Cardiomyocytes: 345.3,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Smooth muscle cells, Colon - Smooth muscle cells, Prostate - Smooth muscle cells, Thyroid - Smooth muscle cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA002131, CAB002453, HPA063777",Enhanced,,Enhanced,Focal adhesion sites,,,,,,750000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 42: Choroid plexus - Mitochondria,Cluster 52: Non-specific - Mitochondria,Cluster 32: Smooth muscle cells - Muscle contraction,4.0,Focal adhesion sites,,"CAB002453: AB_564057, HPA002131: AB_1080570, HPA063777: AB_2685121",unprognostic (8.49e-2),unprognostic (1.61e-2),unprognostic (3.14e-1),unprognostic (6.31e-2),unprognostic (3.34e-1),unprognostic (9.62e-3),unprognostic (2.72e-3),unprognostic (2.67e-3),unprognostic (3.42e-2),unprognostic (1.46e-1),prognostic unfavorable (2.75e-4),unprognostic (1.29e-1),unprognostic (3.68e-2),unprognostic (4.03e-2),unprognostic (4.02e-2),unprognostic (1.89e-1),unprognostic (1.37e-3),MPVFHTRTIESILEPVAQQISHLVIMHEEGEVDGKAIPDLTAPVAAVQAAVSNLVRVGKETVQTTEDQILKRDMPPAFIKVENACTKLVQAAQMLQSDPYSVPARDYLIDGSRGILSGTSDLLLTFDEAEVRKIIRVCKGILEYLTVAEVVETMEDLVTYTKNLGPGMTKMAKMIDERQQELTHQEHRVMLVNSMNTVKELLPVLISAMKIFVTTKNSKNQGIEEALKNRNFTVEKMSAEINEIIRVLQLTSWDEDAWASKDTEAMKRALASIDSKLNQAKGWLRDPSASPGDAGEQAIRQILDEAGKVGELCAGKERREILGTCKMLGQMTDQVADLRARGQGSSPVAMQKAQQVSQGLDVLTAKVENAARKLEAMTNSKQSIAKKIDAAQNWLADPNGGPEGEEQIRGALAEARKIAELCDDPKERDDILRSLGEISALTSKLADLRRQGKGDSPEARALAKQVATALQNLQTKTNRAVANSRPAKAAVHLEGKIEQAQRWIDNPTVDDRGVGQAAIRGLVAEGHRLANVMMGPYRQDLLAKCDRVDQLTAQLADLAARGEGESPQARALASQLQDSLKDLKARMQEAMTQEVSDVFSDTTTPIKLLAVAATAPPDAPNREEVFDERAANFENHSGKLGATAEKAAAVGTANKSTVEGIQASVKTARELTPQVVSAARILLRNPGNQAAYEHFETMKNQWIDNVEKMTGLVDEAIDTKSLLDASEEAIKKDLDKCKVAMANIQPQMLVAGATSIARRANRILLVAKREVENSEDPKFREAVKAASDELSKTISPMVMDAKAVAGNISDPGLQKSFLDSGYRILGAVAKVREAFQPQEPDFPPPPPDLEQLRLTDELAPPKPPLPEGEVPPPRPPPPEEKDEEFPEQKAGEVINQPMMMAARQLHDEARKWSSKPGIPAAEVGIGVVAEADAADAAGFPVPPDMEDDYEPELLLMPSNQPVNQPILAAAQSLHREATKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKETVREAEAASIKIRTDAGFTLRWVRKTPWYQ
P02788 Lactotransferrin乳运铁蛋白,P02788,LTF,HLF2,ENSG00000012223,Lactotransferrin,3,46435645-46485234,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Immunity, Ion transport, Iron transport, Osteogenesis, Transcription, Transcription regulation, Transport","Antibiotic, Antimicrobial, DNA-binding, Heparin-binding, Hydrolase, Protease, Serine protease",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,4.0,bone marrow: 4212.2;salivary gland: 1128.6,Group enriched,Detected in many,5.0,Breast glandular cells: 1470.5;Club cells: 393.9;Mucus glandular cells: 1389.1;Serous glandular cells: 1532.1,Group enriched,Detected in all,5.0,breast cancer: 239.0;endometrial cancer: 170.3;glioma: 152.6;prostate cancer: 195.2,Low region specificity,Detected in all,,,Group enriched,Detected in some,23.0,neutrophil: 5.4;non-classical monocyte: 17.0,Group enriched,Detected in many,23.0,granulocytes: 5.4;monocytes: 17.0,Cancer enhanced,Detected in some,,Myeloma: 2.9,Lung - Neutrophil_1,Not detected,Not detected,,,Low region specificity,Detected in many,,,"CAB008646, CAB016201, HPA057177, HPA059976",Enhanced,,,,Secreted to blood,Transport,,,,350000000.0,Cluster 37: Monocytes & Neutrophils - Innate immune response,Cluster 6: Bone marrow - Innate immune response,Cluster 46: Brainstem - Mixed function,Cluster 51: Myeloma - Immunoglobulins,Cluster 17: Breast glandular cells - Lactation,,,,"CAB008646: AB_1618695, CAB016201: AB_629860, HPA057177: AB_2683361, HPA059976: AB_2684185",unprognostic (7.24e-3),unprognostic (2.43e-1),unprognostic (5.94e-2),unprognostic (3.41e-2),unprognostic (7.14e-3),unprognostic (3.45e-2),unprognostic (6.43e-3),unprognostic (2.52e-1),unprognostic (1.92e-1),unprognostic (4.21e-2),unprognostic (3.43e-1),unprognostic (1.04e-1),prognostic favorable (6.30e-5),unprognostic (1.66e-2),unprognostic (3.53e-1),unprognostic (2.05e-1),unprognostic (9.09e-3),MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCVPNSNERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK
P06702 Protein S100-A9钙结合蛋白S100A,P06702,S100A9,"60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP-14, MRP14, NIF, P14, S100-A9",ENSG00000163220,S100 calcium binding protein A9,1,153357854-153361023,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Apoptosis, Autophagy, Chemotaxis, Immunity, Inflammatory response, Innate immunity","Antimicrobial, Antioxidant",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,bone marrow: 31844.0;esophagus: 29726.6;vagina: 13605.6,Cell type enriched,Detected in many,4.0,Suprabasal keratinocytes: 51199.6,Cancer enhanced,Detected in all,,cervical cancer: 5468.0;head and neck cancer: 6692.8,Region enhanced,Detected in all,,cerebral cortex: 97.1,Group enriched,Detected in all,6.0,classical monocyte: 24645.2;neutrophil: 33874.3,Group enriched,Detected in all,6.0,granulocytes: 33874.3;monocytes: 24645.2,Cancer enhanced,Detected in many,,breast cancer: 536.0;head and neck cancer: 1157.4,"Breast - Macrophages, Colon - Neutrophils, Liver - Neutrophils, Lung - Neutrophil_2, Skeletal muscle - Neutrophils, Thyroid - Neutrophils",Low region specificity,Detected in many,,,Not detected,Not detected,,,"HPA004193, CAB009441, CAB080262",Enhanced,,Supported,"Plasma membrane,Intermediate filaments,Cytosol",Secreted to blood,Immunity,,,10600000.0,1200000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 77: Bone marrow - Cell proliferation,Cluster 12: Non-specific - Vasculature,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 59: Suprabasal keratinocytes - Cornification,8.0,"Plasma membrane, Intermediate filaments, Cytosol",,"CAB009441: AB_2184420, CAB080262: , HPA004193: AB_1856537",unprognostic (1.72e-1),unprognostic (3.33e-2),unprognostic (2.40e-1),unprognostic (3.94e-3),unprognostic (1.36e-2),unprognostic (5.45e-3),prognostic unfavorable (1.13e-6),unprognostic (1.10e-2),unprognostic (4.31e-1),unprognostic (3.06e-1),unprognostic (1.35e-2),unprognostic (5.59e-2),prognostic unfavorable (8.10e-4),unprognostic (1.48e-1),unprognostic (7.52e-2),unprognostic (5.39e-2),unprognostic (1.75e-2),MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRKDLQNFLKKENKNEKVIEHIMEDLDTNADKQLSFEEFIMLMARLTWASHEKMHEGDEGPGHHHKPGLGEGTP
Q96PD5 N-acetylmuramoyl-L-alanine amidase 乙酰胞壁酰基丙氨酸酰,Q96PD5,PGLYRP2,"PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like",ENSG00000161031,Peptidoglycan recognition protein 2,19,15468645-15498956,"Enzymes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Immunity,Hydrolase,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,45.0,liver: 250.7,Cell type enriched,Detected in some,8.0,Hepatocytes: 132.3,Cancer enriched,Detected in some,16.0,liver cancer: 42.9,Not detected,Not detected,,,Low immune cell specificity,Detected in many,,,Group enriched,Detected in many,7.0,granulocytes: 3.4;monocytes: 5.1;T-cells: 2.3,Group enriched,Detected in some,4.0,Bone cancer: 4.9;breast cancer: 5.8,"Breast - Breast glandular cells, Breast - Breast glandular cells, Liver - Hepatocytes, Testis - Sertoli cells",Not detected,Not detected,,,Not detected,Not detected,,,"CAB033468, HPA046311, HPA075237",Supported,,Approved,Cell Junctions,Secreted to blood,Immunity,,,,87000000000.0,Cluster 37: Monocytes & Neutrophils - Innate immune response,Cluster 31: Liver - Plasma proteins,,Cluster 27: Breast cancer - Unknown function,Cluster 43: Hepatocytes - Metabolism,,Cell Junctions,,"CAB033468: AB_1127187, HPA046311: AB_2679621, HPA075237: AB_2686739",unprognostic (7.39e-3),unprognostic (1.52e-2),unprognostic (5.22e-2),unprognostic (8.79e-2),unprognostic (3.97e-1),unprognostic (4.88e-4),unprognostic (5.93e-3),unprognostic (6.48e-2),unprognostic (1.99e-1),unprognostic (1.18e-2),unprognostic (3.15e-2),unprognostic (2.40e-1),unprognostic (6.66e-16),unprognostic (6.35e-3),unprognostic (2.80e-1),unprognostic (2.45e-2),unprognostic (2.81e-4),MAQGVLWILLGLLLWSDPGTASLPLLMDSVIQALAELEQKVPAAKTRHTASAWLMSAPNSGPHNRLYHFLLGAWSLNATELDPCPLSPELLGLTKEVARHDVREGKEYGVVLAPDGSTVAVEPLLAGLEAGLQGRRVINLPLDSMAAPWETGDTFPDVVAIAPDVRATSSPGLRDGSPDVTTADIGANTPDATKGCPDVQASLPDAKAKSPPTMVDSLLAVTLAGNLGLTFLRGSQTQSHPDLGTEGCWDQLSAPRTFTLLDPKASLLTMAFLNGALDGVILGDYLSRTPEPRPSLSHLLSQYYGAGVARDPGFRSNFRRQNGAALTSASILAQQVWGTLVLLQRLEPVHLQLQCMSQEQLAQVAANATKEFTEAFLGCPAIHPRCRWGAAPYRGRPKLLQLPLGFLYVHHTYVPAPPCTDFTRCAANMRSMQRYHQDTQGWGDIGYSFVVGSDGYVYEGRGWHWVGAHTLGHNSRGFGVAIVGNYTAALPTEAALRTVRDTLPSCAVRAGLLRPDYALLGHRQLVRTDCPGDALFDLLRTWPHFTATVKPRPARSVSKRSRREPPPRTLPATDLQ
Q9UGM5 Fetuin-B 胎球蛋白,Q9UGM5,FETUB,,ENSG00000090512,Fetuin B,3,186635969-186653141,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Fertilization,"Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,27.0,liver: 227.3,Cell type enriched,Detected in some,6.0,Hepatocytes: 46.2,Cancer enriched,Detected in some,12.0,liver cancer: 44.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Kidney - Ascending Loop of Henle cells, Liver - Hepatocytes, Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,Not detected,Not detected,,,"HPA035132, HPA035133",Supported,,Approved,Vesicles,Secreted to blood,Enzyme inhibitor,,,47500000000.0,3600000000.0,,Cluster 83: Liver - Metabolism,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 43: Hepatocytes - Metabolism,6.0,Vesicles,,"HPA035132: AB_10601650, HPA035133: ",,unprognostic (9.01e-2),,unprognostic (1.95e-1),unprognostic (4.62e-1),unprognostic (8.74e-2),unprognostic (6.28e-3),unprognostic (1.24e-2),unprognostic (7.55e-2),unprognostic (9.78e-2),unprognostic (1.73e-2),,,unprognostic (9.18e-2),unprognostic (1.79e-1),unprognostic (8.39e-2),,MGLLLPLALCILVLCCGAMSPPQLALNPSALLSRGCNDSDVLAVAGFALRDINKDRKDGYVLRLNRVNDAQEYRRGGLGSLFYLTLDVLETDCHVLRKKAWQDCGMRIFFESVYGQCKAIFYMNNPSRVLYLAAYNCTLRPVSKKKIYMTCPDCPSSIPTDSSNHQVLEAATESLAKYNNENTSKQYSLFKVTRASSQWVVGPSYFVEYLIKESPCTKSQASSCSLQSSDSVPVGLCKGSLTRTHWEKFVSVTCDFFESQAPATGSENSAVNQKPTNLPKVEESQQKNTPPTDSPSKAGPRGSVQYLPDLDDKNSQEKGPQEAFPVHLDLTTNPQGETLDISFLFLEPMEEKLVVLPFPKEKARTAECPGPAQNASPLVLPP
O00391 Sulfhydryl oxidase 1巯基氧化酶,O00391,QSOX1,QSCN6,ENSG00000116260,Quiescin sulfhydryl oxidase 1,1,180154869-180204030,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",,Oxidoreductase,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enriched,Detected in many,8.0,Extravillous trophoblasts: 1872.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Prostate - Fibroblasts,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA056243,,,Supported,"Golgi apparatus,Vesicles",Secreted to extracellular matrix,Enzyme,,,,2600000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 20: Macrophages & Microglia - Immune response,Cluster 64: Connective tissue cells - ECM organization,Cluster 4: Extravillous trophoblasts - Unknown function,,Golgi apparatus,Vesicles,HPA056243: AB_2683077,unprognostic (1.13e-1),unprognostic (2.62e-3),unprognostic (2.46e-1),unprognostic (2.49e-2),unprognostic (2.00e-2),unprognostic (2.73e-1),unprognostic (5.47e-2),unprognostic (2.22e-1),unprognostic (3.94e-1),unprognostic (3.12e-2),unprognostic (5.07e-2),unprognostic (2.80e-3),prognostic unfavorable (1.86e-5),unprognostic (3.25e-1),unprognostic (2.14e-1),unprognostic (3.53e-2),unprognostic (1.40e-1),MRRCNSGSGPPPSLLLLLLWLLAVPGANAAPRSALYSPSDPLTLLQADTVRGAVLGSRSAWAVEFFASWCGHCIAFAPTWKALAEDVKAWRPALYLAALDCAEETNSAVCRDFNIPGFPTVRFFKAFTKNGSGAVFPVAGADVQTLRERLIDALESHHDTWPPACPPLEPAKLEEIDGFFARNNEEYLALIFEKGGSYLGREVALDLSQHKGVAVRRVLNTEANVVRKFGVTDFPSCYLLFRNGSVSRVPVLMESRSFYTAYLQRLSGLTREAAQTTVAPTTANKIAPTVWKLADRSKIYMADLESALHYILRIEVGRFPVLEGQRLVALKKFVAVLAKYFPGRPLVQNFLHSVNEWLKRQKRNKIPYSFFKTALDDRKEGAVLAKKVNWIGCQGSEPHFRGFPCSLWVLFHFLTVQAARQNVDHSQEAAKAKEVLPAIRGYVHYFFGCRDCASHFEQMAAASMHRVGSPNAAVLWLWSSHNRVNARLAGAPSEDPQFPKVQWPPRELCSACHNERLDVPVWDVEATLNFLKAHFSPSNIILDFPAAGSAARRDVQNVAAAPELAMGALELESRNSTLDPGKPEMMKSPTNTTPHVPAEGPEASRPPKLHPGLRAAPGQEPPEHMAELQRNEQEQPLGQWHLSKRDTGAALLAESRAEKNRLWGPLEVRRVGRSSKQLVDIPEGQLEARAGRGRGQWLQVLGGGFSYLDISLCVGLYSLSFMGLLAMYTYFQAKIRALKGHAGHPAA
P11142 Heat shock cognate 71 kDa protein热休克,P11142,HSPA8,"HSC70, HSC71, HSP73, HSPA10",ENSG00000109971,Heat shock protein family A (Hsp70) member 8,11,123057489-123063230,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Autophagy, Host-virus interaction, mRNA processing, mRNA splicing, Stress response, Transcription, Transcription regulation","Chaperone, Hydrolase, Repressor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Low cell type specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Adipocytes (Breast), Testis - Spermatogonia",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB002056, HPA052504",Uncertain,,Approved,"Nucleoplasm,Vesicles",,,,Yes,,140000000.0,Cluster 9: T-regs - Cell cycle regulation,Cluster 23: Non-specific - Cellular respiration,Cluster 21: Non-specific - Metabolism,Cluster 22: Non-specific - mRNA splicing & Cell cycle,Cluster 80: Non-specific - Transcription,35.0,Nucleoplasm,Vesicles,"CAB002056: , HPA052504: AB_2681854",unprognostic (2.28e-3),unprognostic (1.19e-3),prognostic favorable (6.14e-6),unprognostic (1.75e-1),unprognostic (1.84e-2),unprognostic (5.70e-2),prognostic unfavorable (1.93e-4),unprognostic (9.65e-3),unprognostic (3.82e-1),unprognostic (9.64e-2),unprognostic (2.93e-1),unprognostic (3.22e-1),prognostic favorable (3.81e-4),unprognostic (2.53e-1),unprognostic (1.83e-1),unprognostic (2.74e-1),unprognostic (7.16e-2),MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD
P14618 Pyruvate kinase PKM丙酮酸激酶,P14618,PKM,"OIP3, PK3, PKM2, THBP1",ENSG00000067225,Pyruvate kinase M1/2,15,72199029-72231819,"Cancer-related genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins","Glycolysis, Translation regulation","Allosteric enzyme, Kinase, Transferase",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,skeletal muscle: 3889.6;tongue: 2564.9,Cell type enhanced,Detected in all,,Basal respiratory cells: 1894.9;Cone photoreceptor cells: 1779.0;Extravillous trophoblasts: 1559.9;Late spermatids: 1768.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Adipose subcutaneous - Adipose progenitor cells, Skeletal muscle - Skeletal myocytes",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB019421, HPA029501",Uncertain,,Enhanced,Cytosol,,,No,No,,310000000.0,Cluster 26: Monocytes - Plasma membrane proteins,Cluster 14: Skeletal muscle - Muscle contraction,Cluster 45: Non-specific - Mixed function,Cluster 15: Kidney cancer - Membrane components,Cluster 45: Non-specific - Mixed function,11.0,Cytosol,,"CAB019421: AB_2252325, HPA029501: AB_10602118",unprognostic (8.73e-3),unprognostic (4.63e-3),unprognostic (1.68e-2),unprognostic (3.09e-1),unprognostic (6.51e-2),prognostic unfavorable (1.30e-4),prognostic unfavorable (2.74e-6),prognostic unfavorable (2.85e-4),unprognostic (9.51e-2),unprognostic (1.17e-2),prognostic unfavorable (5.17e-5),unprognostic (3.16e-1),unprognostic (3.22e-1),unprognostic (7.85e-2),unprognostic (3.17e-2),unprognostic (1.44e-1),unprognostic (1.25e-2),MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP
P23142 Fibulin-1腓骨蛋白,P23142,FBLN1,FBLN,ENSG00000077942,Fibulin 1,22,45502238-45601135,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Host-virus interaction,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,choroid plexus: 1826.9,Cell type enhanced,Detected in many,,Cytotrophoblasts: 636.6;Endometrial stromal cells: 611.2;Extravillous trophoblasts: 720.8;Fibroblasts: 1354.1;Syncytiotrophoblasts: 1303.4,Cancer enhanced,Detected in all,,endometrial cancer: 199.6,Region enriched,Detected in all,13.0,choroid plexus: 1731.1,Immune cell enhanced,Detected in some,,non-classical monocyte: 2.5,Low lineage specificity,Detected in many,,,Low cancer specificity,Detected in all,,,"Adipose subcutaneous - Adipose progenitor cells, Adipose visceral - Adipose progenitor cells, Breast - Fibroblasts, Colon - Fibroblasts, Heart muscle - Fibroblasts, Kidney - Fibroblasts, Liver - Hepatic stellate cells, Lung - Fibroblast_2, Pancreas - Fibroblasts, Prostate - Fibroblasts, Skeletal muscle - Fibroblasts, Skin - Fibroblast_2, Stomach - Fibroblasts, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001612, HPA001613, CAB004393, CAB068187",Enhanced,,Approved,Endoplasmic reticulum,Secreted to extracellular matrix,Other,,,,21000000000.0,Cluster 10: Non-specific - Membrane trafficking,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 36: Choroid plexus - Mixed function,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,2.0,Endoplasmic reticulum,,"CAB004393: AB_671972, CAB068187: AB_2665634, HPA001612: AB_1078825, HPA001613: AB_1078824",unprognostic (6.62e-2),unprognostic (2.47e-2),unprognostic (1.64e-1),prognostic favorable (9.28e-4),unprognostic (1.26e-3),unprognostic (4.82e-2),unprognostic (9.79e-3),unprognostic (2.49e-1),unprognostic (6.30e-2),unprognostic (3.86e-2),unprognostic (2.84e-2),unprognostic (3.30e-2),prognostic unfavorable (3.02e-10),unprognostic (1.08e-3),unprognostic (1.46e-1),unprognostic (1.29e-2),unprognostic (3.64e-2),MERAAPSRRVPLPLLLLGGLALLAAGVDADVLLEACCADGHRMATHQKDCSLPYATESKECRMVQEQCCHSQLEELHCATGISLANEQDRCATPHGDNASLEATFVKRCCHCCLLGRAAQAQGQSCEYSLMVGYQCGQVFQACCVKSQETGDLDVGGLQETDKIIEVEEEQEDPYLNDRCRGGGPCKQQCRDTGDEVVCSCFVGYQLLSDGVSCEDVNECITGSHSCRLGESCINTVGSFRCQRDSSCGTGYELTEDNSCKDIDECESGIHNCLPDFICQNTLGSFRCRPKLQCKSGFIQDALGNCIDINECLSISAPCPIGHTCINTEGSYTCQKNVPNCGRGYHLNEEGTRCVDVDECAPPAEPCGKGHRCVNSPGSFRCECKTGYYFDGISRMCVDVNECQRYPGRLCGHKCENTLGSYLCSCSVGFRLSVDGRSCEDINECSSSPCSQECANVYGSYQCYCRRGYQLSDVDGVTCEDIDECALPTGGHICSYRCINIPGSFQCSCPSSGYRLAPNGRNCQDIDECVTGIHNCSINETCFNIQGGFRCLAFECPENYRRSAATLQQEKTDTVRCIKSCRPNDVTCVFDPVHTISHTVISLPTFREFTRPEEIIFLRAITPPHPASQANIIFDITEGNLRDSFDIIKRYMDGMTVGVVRQVRPIVGPFHAVLKLEMNYVVGGVVSHRNVVNVHIFVSEYWF
P68366 Tubulin alpha-4A chain微管蛋白α - 4a链,P68366,TUBA4A,"FLJ30169, H2-ALPHA, TUBA1",ENSG00000127824,Tubulin alpha 4a,2,219249710-219277902,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,Hydrolase,"Amyotrophic lateral sclerosis, FDA approved drug targets, Neurodegeneration",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,skeletal muscle: 351.6;tongue: 256.2,Cell type enhanced,Detected in many,,Late spermatids: 899.2;Suprabasal keratinocytes: 645.1,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in many,,,Testis - Late spermatids,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB004621, CAB005887, HPA039247, HPA043684, HPA063394",Approved,,Enhanced,Microtubules,,,,,,130000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 14: Skeletal muscle - Muscle contraction,Cluster 52: Neurons & Synapses - Synaptic function,Cluster 7: Liver cancer - Metabolism,Cluster 57: Platelets - Hemostasis,4.0,Microtubules,,"CAB004621: AB_628411, CAB005887: AB_2288001, HPA039247: AB_2676410, HPA043684: AB_2678617, HPA063394: AB_2685003",unprognostic (8.08e-2),unprognostic (2.31e-1),unprognostic (4.03e-2),unprognostic (2.56e-2),unprognostic (5.18e-3),unprognostic (3.99e-2),prognostic unfavorable (4.54e-6),unprognostic (1.52e-3),unprognostic (4.47e-1),unprognostic (8.85e-2),unprognostic (1.49e-2),unprognostic (5.27e-2),unprognostic (1.94e-1),unprognostic (2.70e-1),unprognostic (2.36e-1),unprognostic (7.38e-3),unprognostic (9.32e-2),MRECISVHVGQAGVQMGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFTTFFCETGAGKHVPRAVFVDLEPTVIDEIRNGPYRQLFHPEQLITGKEDAANNYARGHYTIGKEIIDPVLDRIRKLSDQCTGLQGFLVFHSFGGGTGSGFTSLLMERLSVDYGKKSKLEFSIYPAPQVSTAVVEPYNSILTTHTTLEHSDCAFMVDNEAIYDICRRNLDIERPTYTNLNRLISQIVSSITASLRFDGALNVDLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVAEITNACFEPANQMVKCDPRHGKYMACCLLYRGDVVPKDVNAAIAAIKTKRSIQFVDWCPTGFKVGINYQPPTVVPGGDLAKVQRAVCMLSNTTAIAEAWARLDHKFDLMYAKRAFVHWYVGEGMEEGEFSEAREDMAALEKDYEEVGIDSYEDEDEGEE
P12814 Alpha-actinin-1辅肌动蛋白,P12814,ACTN1,,ENSG00000072110,Actinin alpha 1,14,68874128-68979440,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,Actin-binding,"Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,smooth muscle: 515.0,Cell type enhanced,Detected in many,,Extravillous trophoblasts: 369.9;Pancreatic endocrine cells: 336.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,neutrophil: 346.0,Low lineage specificity,Detected in many,,,Cancer enhanced,Detected in all,,Adrenocortical cancer: 1086.0,"Colon - Smooth muscle cells, Lung - Smooth muscle cells, Prostate - Smooth muscle cells, Skin - Outer root sheath cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB004303, HPA006035",Approved,,Approved,"Plasma membrane,Actin filaments,Focal adhesion sites,Cytosol",,,,,,210000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 23: Choroid plexus - Mixed function,Cluster 30: Non-specific - Gene expression regulation,Cluster 32: Smooth muscle cells - Muscle contraction,26.0,"Actin filaments, Focal adhesion sites","Plasma membrane, Cytosol","CAB004303: AB_626633, HPA006035: AB_1078095",unprognostic (4.40e-2),unprognostic (1.03e-3),unprognostic (2.49e-2),unprognostic (1.96e-1),unprognostic (1.19e-1),prognostic unfavorable (2.49e-4),unprognostic (6.19e-3),prognostic unfavorable (7.63e-5),unprognostic (3.62e-1),unprognostic (3.23e-2),unprognostic (3.16e-2),unprognostic (1.71e-1),prognostic unfavorable (9.08e-10),unprognostic (2.87e-2),unprognostic (2.00e-1),unprognostic (6.05e-3),prognostic unfavorable (8.00e-4),MDHYDSQQTNDYMQPEEDWDRDLLLDPAWEKQQRKTFTAWCNSHLRKAGTQIENIEEDFRDGLKLMLLLEVISGERLAKPERGKMRVHKISNVNKALDFIASKGVKLVSIGAEEIVDGNVKMTLGMIWTIILRFAIQDISVEETSAKEGLLLWCQRKTAPYKNVNIQNFHISWKDGLGFCALIHRHRPELIDYGKLRKDDPLTNLNTAFDVAEKYLDIPKMLDAEDIVGTARPDEKAIMTYVSSFYHAFSGAQKAETAANRICKVLAVNQENEQLMEDYEKLASDLLEWIRRTIPWLENRVPENTMHAMQQKLEDFRDYRRLHKPPKVQEKCQLEINFNTLQTKLRLSNRPAFMPSEGRMVSDINNAWGCLEQVEKGYEEWLLNEIRRLERLDHLAEKFRQKASIHEAWTDGKEAMLRQKDYETATLSEIKALLKKHEAFESDLAAHQDRVEQIAAIAQELNELDYYDSPSVNARCQKICDQWDNLGALTQKRREALERTEKLLETIDQLYLEYAKRAAPFNNWMEGAMEDLQDTFIVHTIEEIQGLTTAHEQFKATLPDADKERLAILGIHNEVSKIVQTYHVNMAGTNPYTTITPQEINGKWDHVRQLVPRRDQALTEEHARQQHNERLRKQFGAQANVIGPWIQTKMEEIGRISIEMHGTLEDQLSHLRQYEKSIVNYKPKIDQLEGDHQLIQEALIFDNKHTNYTMEHIRVGWEQLLTTIARTINEVENQILTRDAKGISQEQMNEFRASFNHFDRDHSGTLGPEEFKACLISLGYDIGNDPQGEAEFARIMSIVDPNRLGVVTFQAFIDFMSRETADTDTADQVMASFKILAGDKNYITMDELRRELPPDQAEYCIARMAPYTGPDSVPGALDYMSFSTALYGESDL
P61224 Ras-related protein Rap-1b,P61224,RAP1B,"DKFZp586H0723, K-REV, RAL1B",ENSG00000127314,"RAP1B, member of RAS oncogene family",12,68610855-68671901,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",,Hydrolase,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,monocytes: 1030.1;NK-cells: 597.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Endothelial cells, Heart muscle - Endothelial cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,,,,,,,,,,,,Cluster 28: Neutrophils - Unknown function,Cluster 77: Bone marrow - Cell proliferation,Cluster 55: Non-specific - Transcription,Cluster 5: Rhabdoid - Unknown function,Cluster 57: Platelets - Hemostasis,6.0,,,,unprognostic (1.20e-1),unprognostic (1.47e-3),unprognostic (1.11e-1),unprognostic (1.20e-1),unprognostic (4.15e-2),unprognostic (7.23e-2),unprognostic (1.60e-3),unprognostic (1.48e-1),unprognostic (5.83e-2),unprognostic (1.80e-1),unprognostic (2.01e-2),unprognostic (2.86e-1),prognostic unfavorable (8.08e-4),unprognostic (1.08e-1),unprognostic (8.86e-2),unprognostic (7.86e-2),unprognostic (3.22e-1),MREYKLVVLGSGGVGKSALTVQFVQGIFVEKYDPTIEDSYRKQVEVDAQQCMLEILDTAGTEQFTAMRDLYMKNGQGFALVYSITAQSTFNDLQDLREQILRVKDTDDVPMILVGNKCDLEDERVVGKEQGQNLARQWNNCAFLESSAKSKINVNEIFYDLVRQINRKTPVPGKARKKSSCQLL
Q13201 Multimerin-1多聚蛋白,Q13201,MMRN1,"ECM, EMILIN4, GPIa*, MMRN",ENSG00000138722,Multimerin 1,4,89879532-89954629,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in many,,,Cell type enriched,Detected in many,7.0,Lymphatic endothelial cells: 1678.6,Low cancer specificity,Detected in many,,,Low region specificity,Detected in many,,,Group enriched,Detected in some,9.0,NK-cell: 6.3;plasmacytoid DC: 2.2,Group enriched,Detected in many,9.0,dendritic cells: 2.2;NK-cells: 6.3,Cancer enhanced,Detected in some,,Leukemia: 17.0;Rhabdoid: 13.3,"Liver - Vascular Endothelial cells, Prostate - Endothelial cells, Skin - Macrophages, Testis - Early spermatids",Not detected,Not detected,,,Not detected,Not detected,,,HPA035769,Enhanced,,Approved,Endoplasmic reticulum,Secreted to extracellular matrix,No annotated function,,,,200000000.0,Cluster 14: Non-specific - Unknown function,Cluster 62: Connective tissue - ECM organization,Cluster 44: Non-specific - Mixed function,Cluster 48: Adipocytes & Endothelial cells - Angiogenesis,Cluster 54: Lymphatic endothelial cells - Lymph vessel development,,Endoplasmic reticulum,,HPA035769: AB_10696511,unprognostic (1.15e-1),unprognostic (1.81e-2),unprognostic (1.23e-1),unprognostic (2.41e-1),unprognostic (2.11e-1),unprognostic (7.05e-3),unprognostic (1.62e-3),unprognostic (1.91e-1),unprognostic (1.88e-1),unprognostic (2.12e-1),unprognostic (9.71e-3),unprognostic (1.18e-1),prognostic unfavorable (1.77e-4),prognostic unfavorable (5.46e-4),unprognostic (2.14e-1),unprognostic (1.36e-1),unprognostic (2.23e-2),MKGARLFVLLSSLWSGGIGLNNSKHSWTIPEDGNSQKTMPSASVPPNKIQSLQILPTTRVMSAEIATTPEARTSEDSLLKSTLPPSETSAPAEGVRNQTLTSTEKAEGVVKLQNLTLPTNASIKFNPGAESVVLSNSTLKFLQSFARKSNEQATSLNTVGGTGGIGGVGGTGGVGNRAPRETYLSRGDSSSSQRTDYQKSNFETTRGKNWCAYVHTRLSPTVILDNQVTYVPGGKGPCGWTGGSCPQRSQKISNPVYRMQHKIVTSLDWRCCPGYSGPKCQLRAQEQQSLIHTNQAESHTAVGRGVAEQQQQQGCGDPEVMQKMTDQVNYQAMKLTLLQKKIDNISLTVNDVRNTYSSLEGKVSEDKSREFQSLLKGLKSKSINVLIRDIVREQFKIFQNDMQETVAQLFKTVSSLSEDLESTRQIIQKVNESVVSIAAQQKFVLVQENRPTLTDIVELRNHIVNVRQEMTLTCEKPIKELEVKQTHLEGALEQEHSRSILYYESLNKTLSKLKEVHEQLLSTEQVSDQKNAPAAESVSNNVTEYMSTLHENIKKQSLMMLQMFEDLHIQESKINNLTVSLEMEKESLRGECEDMLSKCRNDFKFQLKDTEENLHVLNQTLAEVLFPMDNKMDKMSEQLNDLTYDMEILQPLLEQGASLRQTMTYEQPKEAIVIRKKIENLTSAVNSLNFIIKELTKRHNLLRNEVQGRDDALERRINEYALEMEDGLNKTMTIINNAIDFIQDNYALKETLSTIKDNSEIHHKCTSDMETILTFIPQFHRLNDSIQTLVNDNQRYNFVLQVAKTLAGIPRDEKLNQSNFQKMYQMFNETTSQVRKYQQNMSHLEEKLLLTTKISKNFETRLQDIESKVTQTLIPYYISVKKGSVVTNERDQALQLQVLNSRFKALEAKSIHLSINFFSLNKTLHEVLTMCHNASTSVSELNATIPKWIKHSLPDIQLLQKGLTEFVEPIIQIKTQAALSNLTCCIDRSLPGSLANVVKSQKQVKSLPKKINALKKPTVNLTTVLIGRTQRNTDNIIYPEEYSSCSRHPCQNGGTCINGRTSFTCACRHPFTGDNCTIKLVEENALAPDFSKGSYRYAPMVAFFASHTYGMTIPGPILFNNLDVNYGASYTPRTGKFRIPYLGVYVFKYTIESFSAHISGFLVVDGIDKLAFESENINSEIHCDRVLTGDALLELNYGQEVWLRLAKGTIPAKFPPVTTFSGYLLYRT
P67936 Tropomyosin alpha-4 chain原肌球蛋白-4链,P67936,TPM4,,ENSG00000167460,Tropomyosin 4,19,16067021-16103002,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",,"Actin-binding, Muscle protein",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Low cell type specificity,Detected in many,,,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Breast - Smooth muscle cells,Low region specificity,Detected in all,,,,,,,"CAB004685, HPA047089, HPA053624",Approved,,Approved,"Actin filaments,Cytosol",,,,,,370000000.0,Cluster 33: Non-specific - ATP binding,Cluster 62: Connective tissue - ECM organization,Cluster 25: Non-specific - Transcription,Cluster 64: Connective tissue cells - ECM organization,Cluster 45: Non-specific - Mixed function,3.0,Actin filaments,Cytosol,"CAB004685: AB_425723, HPA047089: AB_2679928, HPA053624: AB_2682210",unprognostic (1.27e-1),unprognostic (1.53e-2),unprognostic (3.62e-3),unprognostic (7.38e-3),unprognostic (3.80e-1),unprognostic (2.40e-2),unprognostic (3.11e-2),unprognostic (2.75e-3),unprognostic (1.38e-2),unprognostic (3.61e-1),prognostic unfavorable (3.07e-4),unprognostic (1.03e-1),prognostic unfavorable (1.26e-10),unprognostic (3.85e-2),unprognostic (2.25e-1),unprognostic (1.48e-1),unprognostic (1.78e-1),MAGLNSLEAVKRKIQALQQQADEAEDRAQGLQRELDGERERREKAEGDVAALNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIENRAMKDEEKMEIQEMQLKEAKHIAEEADRKYEEVARKLVILEGELERAEERAEVSELKCGDLEEELKNVTNNLKSLEAASEKYSEKEDKYEEEIKLLSDKLKEAETRAEFAERTVAKLEKTIDDLEEKLAQAKEENVGLHQTLDQTLNELNCI
P01034 Cystatin-C胱抑素,P01034,CST3,,ENSG00000101439,Cystatin C,20,23626706-23638473,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",,"Protease inhibitor, Thiol protease inhibitor","Age-related macular degeneration, Amyloidosis, Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,brain: 4419.8;choroid plexus: 4010.9,Cell type enhanced,Detected in all,,Langerhans cells: 22281.6;Schwann cells: 10946.4,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Group enriched,Detected in all,7.0,classical monocyte: 4979.2;intermediate monocyte: 6434.2;myeloid DC: 7977.6;non-classical monocyte: 4321.2;plasmacytoid DC: 4438.0,Group enriched,Detected in all,9.0,dendritic cells: 7977.6;monocytes: 6434.2,Low cancer specificity,Detected in all,,,"Kidney - Fibroblasts, Skin - Fibroblast_2, Stomach - Fibroblasts, Testis - Sertoli cells, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB000118, HPA013143",Enhanced,,Supported,"Golgi apparatus,Vesicles",Secreted to blood,Enzyme inhibitor,,,1040000000.0,2800000000.0,Cluster 10: Non-specific - Membrane trafficking,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 39: Astrocytes - Mixed function,Cluster 2: Mucus-secreting cells - Unknown function,Cluster 28: Dendritic cells - Antigen presentation,1.0,"Golgi apparatus, Vesicles",,"CAB000118: , HPA013143: AB_1847417",unprognostic (3.89e-2),unprognostic (1.63e-1),unprognostic (1.45e-1),prognostic favorable (1.83e-4),unprognostic (8.53e-2),unprognostic (4.06e-2),unprognostic (2.10e-2),unprognostic (2.18e-2),unprognostic (3.46e-2),unprognostic (3.72e-1),unprognostic (2.29e-3),unprognostic (3.51e-2),unprognostic (1.85e-1),unprognostic (1.16e-1),unprognostic (2.97e-1),unprognostic (5.01e-2),prognostic favorable (8.77e-4),MAGPLRAPLLLLAILAVALAVSPAAGSSPGKPPRLVGGPMDASVEEEGVRRALDFAVGEYNKASNDMYHSRALQVVRARKQIVAGVNYFLDVELGRTTCTKTQPNLDNCPFHDQPHLKRKAFCSFQIYAVPWQGTMTLSKSTCQDA
P81605 Dermcidin皮离蛋白,P81605,DCD,"AIDD, DCD-1, DSEP, HCAP, PIF",ENSG00000161634,Dermcidin,12,54644589-54648493,"Plasma proteins, Predicted secreted proteins, Transporters",,"Antibiotic, Antimicrobial, Fungicide, Hydrolase, Protease",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,7.0,skin 1: 2396.9,Cell type enriched,Detected in some,26.0,Melanocytes: 5710.1,Cancer enriched,Detected in some,9.0,breast cancer: 91.2,Low region specificity,Detected in many,,,Low immune cell specificity,Detected in some,,,Low lineage specificity,Detected in single,,,Group enriched,Detected in some,5.0,Bone cancer: 1.0;breast cancer: 3.9,Skin - Eccrine sweat gland cells,,,,,,,,,HPA063967,Enhanced,,,,Secreted in other tissues,Enzyme,,,,410000000.0,Cluster 15: NK-cells - Unknown function,Cluster 13: Skin - Cornification,Cluster 9: Non-specific - Receptor signaling,Cluster 27: Breast cancer - Unknown function,Cluster 26: Schwann cells & Melanocytes - Mixed function,2.0,,,HPA063967: AB_2685163,unprognostic (3.55e-2),,,,,,,,,,,,,unprognostic (1.61e-1),,,,MRFMTLLFLTALAGALVCAYDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL
P11226 Mannose-binding protein C甘露糖结合蛋白C,P11226,MBL2,"COLEC1, MBL, MBP, MBP-C, MBP1",ENSG00000165471,Mannose binding lectin 2,10,52765380-52772784,"Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement activation lectin pathway, Complement pathway, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,2727.0,liver: 272.6,Cell type enriched,Detected in some,98.0,Hepatocytes: 230.9,Cancer enriched,Detected in single,275.0,liver cancer: 22.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in single,5.0,liver cancer: 1.0,Liver - Hepatocytes,Not detected,Not detected,,,Region enriched,Detected in single,13.0,basal ganglia: 1.3,"HPA002027, CAB016782",Enhanced,,,,Secreted to blood,Complement pathway,,,1220000000.0,1900000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,9.0,,,"CAB016782: , HPA002027: AB_1079324",,,,,,,unprognostic (1.72e-2),,unprognostic (3.03e-1),,,,,,,,,MSLFPSLPLLLLSMVAASYSETVTCEDAQKTCPAVIACSSPGINGFPGKDGRDGTKGEKGEPGQGLRGLQGPPGKLGPPGNPGPSGSPGPKGQKGDPGKSPDGDSSLAASERKALQTEMARIKKWLTFSLGKQVGNKFFLTNGEIMTFEKVKALCVKFQASVATPRNAAENGAIQNLIKEEAFLGITDEKTEGQFVDLTGNRLTYTNWNEGEPNNAGSDEDCVLLLKNGQWNDVPCSTSHLAVCEFPI
P39039 · MBL1_MOUSEMannose-binding protein A甘露糖结合蛋白A,P39039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MLLLPLLPVLLCVVSVSSSGSQTCEDTLKTCSVIACGRDGRDGPKGEKGEPGQGLRGLQGPPGKLGPPGSVGSPGSPGPKGQKGDHGDNRAIEEKLANMEAEIRILKSKLQLTNKLHAFSMGKKSGKKLFVTNHEKMPFSKVKSLCTELQGTVAIPRNAEENKAIQEVATGIAFLGITDEATEGQFMYVTGGRLTYSNWKKDEPNNHGSGEDCVIILDNGLWNDISCQASFKAVCEFPA
